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Abstract 
 
The DNA cleavage activity of several vanadium complexes (VC) was studied. The focus 
was on vanadium acetylacetonate, V
IV
O(acac)2, 1, and several β-diketonate 
oxidovanadium(IV/V) derivatives: V
IV
O(hd)2 (2, hd = 3,5-heptanedione), V
IV
O(Cl-acac) 2, (3, 
Cl-acac = 3-chloro-2,4-pentanedione), V
IV
O(Et-acac)2 (4, Et-acac = 3-ethyl- 2,4- 
pentanedione) and V
IV
O(Me-acac)2 (5, Me-acac = 3-methyl-2,4-pentanedione), 
V
V
2O4(acac)2 (6), V
V
O2(acac)(phen) (7, phen = 1,10-phenanthroline) and 
V
V
O(OH)(OMe)(acac) (8). The nuclease activity of 28 additional vanadium, copper and 
nickel complexes was also analysed and compared.  
The experimental techniques involved digestion of plasmid DNA (pDNA) followed by 
agarose gel electrophoreses to evaluate nuclease efficiency. pDNA was prepared and 
purified to assure the absence of interference from EDTA (ethylenediaminetetraacetic 
acid) and Tris present in commercial pDNA. The stability of complexes in aqueous solutions 
was studied by UV/vis spectroscopy and electroanalytical techniques, cyclic (CV) and 
square wave voltammetry (SWV). The nature of DNA cleavage mechanisms was assayed 
using fluorescent probes and 
1
H and 
51
V NMR spectroscopy. 
V
IV
O(acac)2 was found to be efficient in cleaving pDNA. The extent of this pDNA cleavage is 
dependent on buffer media. In organic buffers (Tris, HEPES MOPS) no significant changes 
are observed, whereas in phosphate medium the nuclease activity is remarkable. The 
activity of the different complexes follows the order 3>1≥2>>4~5. The V(V) derivatives, 6-8, 
do not show any significant activity, except in the presence of an oxidant activating agent. 
CV results show that 1-3 have a quasi-reversible electrochemical behaviour, while of 4 and 
5 have an irreversible one, similar to 6. 
The DNA cleavage by these complexes takes place through an oxidative mechanism. 
Complex 1 also cleaves DNA hydrolytically, however the reaction is too slow to compete 
with the radical mechanism. 
In conclusion, phosphate buffer potentiates the DNA cleavage by V
IV
O(acac)2 derivatives 
through a species which presents a quasi-reversible redox behaviour and facilitates the 
formation of ROS, probably a mixed V(IV)-V(V)-acac-phosphate complex. 
Keywords: Inorganic nucleases, DNA cleavage, Vanadyl acetylacetonate, Oxidovanadium 
(IV/V) complexes, Phosphate, ROS, Agarose Gel Electrophoresis. 
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Resumo 
 
Este trabalho estuda a interação de complexos de vanádio com ADN, em particular a 
atividade nuclease do acetilacetonato de oxovánadio(IV), V
IV
O(acac)2, 1, e alguns dos seus 
derivados: VO(hd)2 (2, hd = 3,5-heptanodiona), VO(Cl-acac)2, (3, Cl-acac = 3-cloro-2,4-
pentanodiona), VO(Et-acac)2 (4, Et-acac = 3-etil-2,4-pentanodiona) e VO(Me-acac)2 (5, Me-
acac = 3-metil-2,4-pentanodiona), V2O4(acac)2 (6), VO2(acac)(phen) (7, phen = 1,10-
fenantrolina) and VO(OH)(OMe)(acac) (8). O objetivo inicial foi identificar a(s) espécie(s) 
metálicas presentes em solução responsáveis pela degradação do ADN. 
A atividade nuclease de seis compostos de vanádio e três compostos de cobre contendo 
aminoácidos e 1,10-fenantrolina e/ou 2,2‟-bipiridina como co-ligandos, 10-36, foi também 
analisada. 
A eficiência da clivagem do ADN pelos complexos metálicos em soluções tamponizadas a 
pH 7 foi determinada por electroforese em gel de agarose. Comparou-se o efeito de 
diferentes tampões de pH sobre a atividade. A estabilidade dos complexos em solução 
aquosa foi estudada por espectroscopia de absorção molecular no UV-Vis e por técnicas 
electroanalíticas (voltametria cíclica e voltametria de onda quadrada). A natureza radicalar 
ou hidrolítica dos mecanismos de clivagem foi averiguada recorrendo a compostos modelo 
e usando técnicas de fluorescência molecular e de ressonância magnética nuclear. 
O VO(acac)2 mostrou ser extremamente eficiente na clivagem de ADN (pADN), em 
particular em soluções tamponizadas com fosfato. Não requer agentes ativadores, ar ou 
fotoirradiação para degradar o pADN. A clivagem de uma cadeia simples (“nicking”) 
observa-se na presença de concentrações de metal na ordem dos 1,2 µM (correspondendo 
a ri = 0,08, onde ri é a razão da concentração de metal para a concentração do ADN, em 
pares de bases). A extensão da clivagem aumenta à medida que a concentração de 1 
aumenta, e para concentrações de metal da ordem dos 10 µM (ri = 0,7) observa-se a 
clivagem da dupla cadeia. Quando ri = 1,7 observa-se a degradação completa da forma 
superenrolada (Sc) do pADN. 
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Todos os complexos estudados apresentam atividade nuclease, dependente da 
concentração. O complexo 2 é uma nuclease um pouco menos eficiente do que 1, 
atingindo a degradação completa da forma Sc para ri = 3,3. O complexo 3 é muito pouco 
solúvel em solução aquosa, mas ainda assim demonstra uma atividade nuclease razoável, 
sugerindo ser mais eficiente do que os anteriores. Os complexos 4 e 5 têm atividades 
semelhantes e muito inferiores a 1, não chegado a linearizar o pADN excepto para ri > 6,7. 
Os complexos 4 e 5 promovem a clivagem simples de uma cadeia a ri = 1,7. 
O VOSO4 é frequentemente considerado um controlo negativo em ensaios de atividade 
nuclease de compostos de vanádio. Neste estudo verificou-se que o VOSO4 (9) tem um 
comportamento pouco reprodutível, nalguns ensaios apresenta uma atividade nuclease 
dependente da concentração tão forte como 1, enquanto noutros não apresenta qualquer 
atividade. É possível que esta falta de reprodutibilidade seja devida nalguns casos 
precipitação do oxovanádio como hidróxido. A precipitação resulta em pouca ou nenhuma 
atividade observada. Caso as condições da precipitação e a sua extensão sejam 
irreprodutíveis, a atividade observada resulta também irreprodutível. 
A estabilidade em solução aquosa dos complexos 1–5 e 9 foi avaliada por espectroscopia 
de absorção molecular no UV/Vis. Verificou-se que 1 e 2 são razoavelmente estáveis nas 
primeiras 24 h em tampão fosfato, havendo apenas pequenas alterações no espectro ao 
fim de 2-4 h. Os complexos 4 e 5 têm um comportamento totalmente diferente, 
observando-se uma hidrólise significativa em menos de 1 h. O mesmo sucede com o 
complexo 9. O complexo 3 não é suficientemente solúvel em água, mas é muito estável em 
DMSO. 
A diferente atividade dos complexos relaciona-se com a sua estabilidade em solução 
aquosa, seguindo a ordem 1≥2>>4~5. As nucleases fracas (4 e 5) são complexos instáveis 
que são rapidamente oxidados e hidrolisados a complexos de V(V) durante a primeira hora 
após dissolução numa solução tamponizada a pH 7. Esta observação é confirmada pelos 
resultados de voltametria cíclica: 1-3 apresentam um comportamento semelhante entre si, 
e muito diferente de 4 e 5. O comportamento electroquímico dos primeiros é quase-
reversível, enquanto o dos segundos é claramente irreversível com um voltamograma 
semelhante ao do derivado de oxovanádio(V) (6).  
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Estudos de atividade nuclease dos complexos na presença de excesso de ligando mostram 
que deve ser outra espécie que não V
IV
OL2 a responsável pela atividade. A adição de 
excesso de ligando favorece a formação desta espécie em solução, relativamente ao metal 
livre e ao complexo V
IV
OL
+
. Ao adicionar excesso de acac a 1, observa-se uma diminuição 
progressiva da atividade à medida que a razão ligando/metal aumenta de 80 para 160.  
O efeito da presença de agentes redutores e de agentes oxidantes foi testada juntando 
oxona ou ácido mercaptopropiónico (MPA) à mistura reacional. Observou-se que a oxona 
favorece a eficiência da clivagem por 1. Por outro lado, o MPA reduz a atividade nuclease 
destes compostos, mas não totalmente. Estes efeitos são observados tanto quando a 
digestão é feita ao ar como em atmosfera de azoto.  
A presença de H2O2 favorece fortemente a clivagem. O aumento da concentração de H2O2 
tem um efeito muito menos significativo na degração do pADN do que o aumento da 
concentração de complexo. 
A atividade nuclease dos derivados de oxidovanádio(V), 6-8, faz-se notar apenas na 
presença de oxona e em tampão fosfato. É improvável que o monovanadato (V1), o produto 
mais comum da hidrólise e oxidação do vanádio(IV) em solução aquosa, seja a espécie 
responsável pela atividade nuclease de 1. Por si só, o V1 não exerce efeitos no pADN. 
Embora na presença de oxona possa causar clivagem da cadeia simples, é muito menos 
eficiente do que 1. 
A natureza e a concentração do tampão de pH são determinantes para a atividade 
nuclease. Demonstra-se que a extensão da clivagem do pADN causada por 1 depende 
grandemente do meio tampão, sendo maior em tampão fosfato do que em tampões 
orgânicos como HEPES, Tris e MOPS. A reação é sempre inibida na presença de MOPS, 
mesmo quando existe excesso de fosfato em solução, mas progride até à linearização do 
pADN na ausência daquele. O efeito do tampão foi estudado por electroforese em gel de 
agarose, espectroscopia de UV-Vis, voltametria cíclica e voltametria de onda quadrada e 
RMN de 
1
H e 
51
V. 
Os resultados apontam para que as espécies responsáveis pela degradação observada no 
ADN em tampão fosfato sejam provavelmente espécies mistas contendo V(IV) e V(V), e os 
ligandos acac e fosfato, apresentando um comportamento redox quase reversível. Os 
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resultados de voltametria de onda quadrada indicam a formação de pelo menos três 
espécies diferentes, possivelmente: VO(acac)2(H2PO4)
-
, VO(acac)(H2PO4 )2
-
 e VO(H2PO4)2. 
A clivagem do ADN ocorre através de um mecanismo radicalar. A formação de radicais OH 
foi observada em ensaios de hidroxilação do ácido tereftálico (TPA), um método muito 
sensível para a sua detecção. Observa-se um aumento notável na intensidade de 
fluorescência, devida à formação de ácido hidroxitereftálico, ao misturar TPA com soluções 
aquosas de 1. Na presença de H2O2 a intensidade de fluorescência torna-se muito mais 
alta do que na sua ausência, confirmando a libertação de OH. No entanto é possível que o 
radical superóxido ou radicais ligados ao complexo metálico sejam de fato as ROS que 
causam a clivagem oxidativa observada na ausência de agentes oxidantes. 
Estudos por RMN de 
1
H e 
51
V, com modelos da ligação fosfodiéster mostram que o 
VO(acac)2 é capaz de clivar e promover a clivagem hidrolítica do ADN, e que as espécies 
responsáveis são provavelmente tetravanadatos. No entanto, esta hidrólise é demasiado 
lenta (>24 h a 50 ºC) para competir com a reação radicalar que ocorre no tempo de 
incubação típico de 1 h a 37ºC.  
A atividade nuclease de outros complexos de oxidovanádio(IV) e alguns complexos de 
cobre foi também avaliada e discutida. 
Os complexos VO(acac-Naf)2 (10, acac-Naf = acetonaftalina), VO(tmh)2 (11, tmh = 2,2,6,6-
tetrametil-3,5-heptanodiona), VO(pbd)2 (12, pbd = 1-Fenil-1,3-butadiona)), VO(acac-NH2)2 
(13, acac-NH2 = acetoacetamida), VO(acac-NMe2)2 (14, N,N-dimetilacetoacetamida) são 
outros derivados de 1 que foram estudados neste trabalho. Com a excepção de 10, que 
não induz qualquer clivaegem do ADN, 11-14 promovem a clivagem simples da dupla 
cadeia. 
Cu(acac)2 (15) e Ni(acac)2 (16) foram testados como complexos com uma estrutura 
quadrangular plana, com coordenação semelhante a 1. Ao contrário de 16, que não 
apresenta qualquer atividade nuclease, 15 induz “nicking”, mas aparentemente não 
dependente da concentração de complexo. A adição de agentes ativadores aumenta 
significativamente a atividade nuclease de 15, especialmente na presença de MPA, 
situação em que se observa a destruição completa do pADN. Este efeito do MP sugere um 
xii 
 
mecanismo radicalar desencadeado pela redução do Cu(II) a Cu(I) pelo MPA. O complexo 
16 também não apresenta efeitos sobre o ADN na presença de MPA. 
Outro grupo de complexos estudados contém ácido picolínico na sua estrutura: VO(MPA)2 
(17, MPA = ácido 6-metil-2-picolínico), VO(dmpp)2 (18, dmpp = 1-(3,4-dimetil-fenil)-
piperazina) e VO(PA)2 (19, PA = ácido picolínico). O complexo 19 é o mais ativo, seguido 
de 17 e 18. Tanto as bandas Nck como Lin aparecem para concentações de 25, 50 e 
100 µM (ri 1.67, 3,3 e 6,7, respetivamente). 
VO(oda) (20), VO(oda)phen (21) e VO(oda)bipy (23), onde “oda” é o ligando oxodiacetato e 
phen denota fenantrolina, são outros exemplos de nucleases eficientes. VO(phen)2 (22) foi 
estudado como termo de comparação. Os quatro complexos interagem prontamente com o 
pADN, causando clivagem simples e dupla. 
VO(morin)2 (24), VO(chrysin)2 (25), VO(clor) (26), e VO(silibinin)2 (27), complexos que 
demonstaram efeitos antitumurais, não promovem qualquer clivagem significativa, mesmo 
quando ativados com oxona ou MPA. 
 
Palavras-Chave: nucleases, Clivagem do ADN, acetilacetonato de vanádio, complexos de 
oxidovanadio(IV), fosfato, ROS, electroforese em gel de agarose. 
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I. Introduction 
 Objectives I.1
Current interest in biochemistry of vanadium-containing compounds (VC) falls into four 
fields: (1) study of its natural occurrence in biological system; (2) insulin-enhancing 
properties in the treatment of diabetes mellitus [1-4]; (3) potent artificial enzymes in 
gene manipulation procedures; (4) antitumor effect in cancer therapy [5,6].  
When considering the therapeutic applications of VC many questions arise, namely 
whether and how VC can enter cells. Considering they do, an important question must 
be addressed: will they interact with DNA and, if so, how harmful (or beneficial, in case 
of anticancer drugs) will this interaction be? The effects over DNA may be dramatic 
(resulting in cytotoxicity) or subtle, and may not be detected within the timeframe of 
traditional clinical trials. A thorough understanding of these possible effects is essential 
to assure the safety of metallodrugs. 
The central aim of this work is to evaluate the nuclease activity of vanadium 
compounds, and to establish which is/are the active species in the DNA cleavage.  
Our particular focus are oxidovanadium(IV) complexes containing acetylacetonate 
ligands, primarily VIVO(acac)2, which have been considered as good candidates for the 
anti-diabetic drugs. Many diverse studies have been conducted with this family of 
compounds, however, little is known about its structure and chemistry in an aqueous 
solution at biologically relevant concentrations capable of cleaving DNA.  
The main objective of this work is to understand how VC can cleave DNA, and which 
are the most active species involved. With this in mind, the work is divided into: (a) the 
synthesis and characterization of VC, (b) aqueous solution speciation via 
electrochemical and stability studies, (c) understanding of the role of buffer media and 
(d) determination of the mechanism of DNA cleavage action. 
Along this work the following compounds were studied:
I. INTRODUCTION 
2 
 
 
 
I. INTRODUCTION 
3 
 
I. INTRODUCTION 
4 
I. INTRODUCTION 
5 
 General concerns on vanadium chemistry I.2
 Chemical and physical properties  I.2.1
Vanadium is a transition metal, member of the first transition series of group 5 (VB),  
d-block of the periodic table. The atomic number and mass are 23 and 50.9415, 
respectively, and symbol is V. The ground state electron configuration is [Ar] 3d3 4s2, 
and the main oxidation states are +2, +3, +4 and +5. Oxovandium(V) is diamagnetic d0, 
metal can be present in tetrahedral (VO4), pentahedral (VO5) and octahedral (VO6) 
coordination environment and tends to form polyoxoanions [7]. Oxidovanadium(IV) (d1, 
paramagnetic) is also stable and mostly present in square pyramidal or pseudo-
octahedral coordination as an isolated cation. Other oxidation states such as 
oxidovanadium(III) (d2, paramagnetic) and oxidovanadium(II) (d3) are less stable and 
only present under reducing conditions [8,9].  
 
 History, isolation and application  I.2.2
Discovered in Mexican lead ore in 1801 by Spanish-Mexican mineralogist A. M. del Rio, 
vanadium was initially named panchromium, meaning "all colours”. The element was re-
named later to erythronium (erytho- means "red") as most of its alkaline salts became 
red upon heating (forming V2O5) or treating with acids (decavanadates, namely 
[H4V4O28]
4−). Del Rio‟s claim of the new element was rejected in 1805 by French 
chemist H.V. Collet-Descotils, who erroneously concluded that “the new element” was 
nothing but impure chromium. The element was re-discovered nearly 30 years later 
(1830) by Swedish chemist N. G. Sefström, who named it vanadium in honour of the 
goddess of beauty and fertility, Vanadis (old Norse name for Freya in Scandinavian 
mythology) [9]. Until 1869, when English chemist H.E. Roscoe obtained for the first time 
pure (metallic) vanadium by reduction of VCl2 with hydrogen, it was used in the form of 
V2O5. The first major synthesis of pure vanadium (99.9%) was carried out in 1927 by the 
Westinghouse Lamp Co by heating a mixture of oxidovanadium(III), Ca and CaCl2 at 
760 ºC.  
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Most of the pure vanadium metal produced these days is obtained by reduction of V2O5 
with calcium in a pressure vessel using iodide process (thermolysis of VI3, van Arkel-de 
Boer process) [9]. The metal is relatively inert toward oxygen, nitrogen, and hydrogen at 
room temperature. However, when heated in air at different temperatures, it oxidizes to 
a brownish black trioxide, a blue black tetraoxide, or a reddish orange pentoxide. It 
reacts with chlorine at fairly low temperatures (180 ºC) forming vanadium tetrachloride; 
with carbon and nitrogen at high temperatures forming respectively VC and VN. The 
most common commercially available vanadium compounds are V2O5, VOSO4, NaVO3, 
Na3VO4, NH4VO3.  
Industrially, almost 80% of the annual world production of vanadium (~38 000 tons) is 
used in ferrovanadium alloy (reduction of the crude vanadium and iron oxides with coal, 
~1:1) for fabrication of particularly strong and durable steels as it makes steel shock- 
rust- and vibration-resistant. For this reason vanadium is considered a strategic metal, 
since a part of the steel production goes into the weapon manufactory. Vanadium alloys 
are used in aerospace industry also, e.g. titanium–aluminium–vanadium alloys for aero-
engine gas turbines and undercarriages of planes. Vanadium finds use in nuclear 
applications because of its low fission neutron cross section; as well as in ceramics, 
electronics, dyes for textiles and leather [7], vanadium redox batteries [10]. 
Certain vanadium compounds have a specific use in industry. Vanadium sulphate and 
vanadium tetrachloride, for example, are used as mordants in the dyeing industry. 
Vanadium silicates are used as catalysts. Vanadium dioxide and vanadium trioxide are 
employed in metallurgy. However, the most significant compounds in terms of industrial 
health hazards are vanadium pentoxide and ammonium metavanadate [11]. 
 
 Occurrence I.2.3
Vanadium is a trace element, the most abundant in marine environment (after 
molybdenum), where it exists as monomeric vanadate, vanadate oxoanion, and most 
commonly, in the form of ion pairs Na
+
H2VO4
 
 at the average concentration of ca. 
0.03 µM. Its amount in the fresh waters is significantly higher than in the ocean [12]. The 
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cosmic abundance (0.0001%) is similar to that of zinc and copper. In the earth's crust, it 
is the 18th most abundant element (0.0019% w/w) [13], similar to zinc and nickel 
(~0.008%). Vanadium is found in about 152 minerals, among which the important 
sources are vanadinite, carnotite, roscoelite and patronite. In most minerals vanadium is 
present at II, IV and V oxidation states in the form of oxide and seldom in as metal 
cation. Shales are especially rich in vanadium, contain 0.012% w/w [9]. Vanadium is 
also present in phosphate rock, certain iron ores, some crude oils in the form of organic 
complexes, e.g. V–porphyrin complexes [14]. The major sources of vanadium are 
titaniferrous magnetite ores from mines in Australia, China, Russia and South Africa 
(98% world‟s production) [7,15]. 
 
 Aqueous oxidovanadium chemistry I.2.4
Water is a constituent essential for the processes of life, participates in all essential 
reaction in biological system, act as a solvent, reaction medium and reactant. When 
studying physiological action of transition metals, solution chemistry recognition is of 
high importance. Understanding the behaviour of metal compound in aqueous 
environment allows predicting possible redox reactions and forming species in order to 
assure a successful implementation in vivo. 
The aqueous oxidovanadium chemistry is very complex. With a variety of oxidation 
states, +2 (VII), +3 (VIII), +4 (VIV) and +5 (VV), the metal can undergo hydrolytic, acid-
base, condensation and redox reactions. These reactions are highly affected by the pH 
of a solution (Figure I.1), and the presence of potential ligands, which upon coordination 
with vanadium, can form stable complexes with different coordination geometries [12].  
Depending on the oxidation state, vanadium acidic solutions have different colouring: 
V2+ (violet), V3+ (green), VIVO2+ (blue) and V
V
O4
2-
 (yellow). Except the last one, all ions 
exist in the form of cations. Vanadium(II) compounds are reducing agents, whereas 
those of vanadium(V) are oxidizing. Vanadium(IV) compounds often exist as 
oxidovanadium derivatives which contain the VO2+ center. Biological relevance is found 
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for all four oxidation states, i.e., II/III/IV (nitrogenases), III/IV (ascidians), IV (amavadin), 
IV/V (bacterial respiration), V (haloperoxidases) [9,13]. 
 
 
Figure I.1. The Pourbaix diagram of vanadium, expressing the vanadium speciation as a 
function of pH and potential at 25°ºC and an ionic strength of 1 M [16]. 
 
Due to the rapid oxidation of vanadium(II) and (III) in aqua media, unless prevented by 
complexation with sufficiently reducing ligands, the studies of aqueous vanadium 
chemistry are mainly focused on vanadium(IV) and (V). Much is known about the redox 
properties and reactions of both vanadium(IV) and (V) in organic solvents, however, 
little knowledge is obtained in aqueous system [12,17]. The chemistry of these two 
oxidation states, in the forms of oxidovanadium(IV) and (V) (VIVOSO4, vanadate(V), 
peroxidovanadates(V)), is particularly relevant since these compounds are typically 
employed in classical treatment of diabetic animals and seldom in humans [13,18]. 
However, biological studies with vanadium are complicated by the aqueous chemistry of 
vanadium(IV) and (V), and the facility with which these oxidation states convert in aqua 
media.  
In the physiological pH range, vanadate(V) is readily dissolved in water and is more 
stable as free vanadate, (~90% [H2VO4]
− + 10% [HVO4]
2− hereinafter referred to as Vi, 
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monomeric vanadate ion). Vi readily undergoes condensation reactions with many 
nucleophilic ligands, including other vanadium derivatives. In solution containing 
millimolar and higher vanadate concentrations, at pH 3 to 6 the major condensed 
species is V10O28
6-
/ HV10O28
5-
 (V10 decavanadate), which forms yellow-orange solutions. 
At pH 6 to 10, the major oligomers include a dimer H2V2O7
2-
 HV2O7
3-
 (V2, divanadate), 
cyclic tetramer V4O  
 -
 (V4, tetravanadate) and cyclic pentamer V5O12
5-
 (V5, 
pentavanadate) which are colourless. At neutral pH all vanadium(V) species present in 
water are anionic, below pH 3 and above pH 10 respectively, the cationic and anionic 
monomers are the major species. The cationic VO3+ and VO2
+
 exist only when stabilised 
by ligands which prevent precipitation of hydroxides. Due to a hydrolytic resistance of 
V10, usually heating is necessary to convert it to colourless oligomeric species. 
Oxidovanadium(IV) is rapidly oxidized by molecular oxygen [19] or precipitated in the 
form of insoluble hydroxides In the latter case, the concentration of VO2+ is between 
micromolar and nanomolar range regardless of the amount of oxidovanadium(IV) 
compound dissolved in solution [9,12,13].  
 
In vivo, under aerobic conditions, VV is stable whereas, in anoxic environments (e.g., in 
cytoplasm), reducing agents such as ascorbate, glutathione and NADH readily reduce 
V
V
O2
+
 to V
IV
O
2+
. In the form of Vi, V
V is less likely to be reduced. The reduction of 
V
IV
O
2+
 to V3+ does not occur under common conditions. These redox reactions are well 
described by Rehder [9] and are based on the redox potentials of these inorganic 
vanadium species at pH 7 ( 
Table I.1). 
Solution chemistry of vanadium compounds has been explored by electronic and 
vibrational spectroscopies. Diamagnetic oxidovanadium(V) is often studied by nuclear 
magnetic resonance (NMR) spectroscopy whereas, oxidovanadium(IV) is examined by 
electron absorption (UV-Vis) and electron paramagnetic resonance (EPR) 
spectroscopy, and less commonly, electron spin echo envelope modulation (ESEEM) 
and hyperfine sublevel correlation (HYSCORE) spectroscopies [12]. 
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The speciation in the aqueous vanadophosphate [20] and peroxovanadate system [21], 
vanadate-ligand and peroxovanadate-ligand system [22], H+/H2VO4
-
/H2O2/citrate [23] 
and H+/H2VO4
-
/H2O2/phosphate system [24,25] has been thoroughly studied by 
Petterssons‟ group, employing a combination of proton potentiometry and 51V NMR 
spectroscopy. T. Kiss [26-28] and D. Crans [19,29-31] studies vanadium(IV/V) 
speciation of complexes with variety of ligands mostly by H+ potentiometry, UV-Vis and 
EPR spectroscopy. J. Costa Pessoa and T. Kiss explored the speciation of vanadium in 
human serum [32,33]. Many other studies have been conducted regarding the redox 
reactions of vanadium complexes in aqueous media [34-36] using and aforementioned 
techniques.  
 
Table I.1. Redox potentials for inorganic vanadium species.E (V) vs. normal hydrogen electron 
(NHE) [9]. 
Species E0 EpH=7 
VO2+/V3+ (VIV/VIII) +0.359 -0.462 
[H2VO4]
-/VO2+ (VV/VIV) +1.31 -0.34 
NAD+/NADH  -0.315 
Pyruvate/Lactate  -0.185 
1/2(GS)2GSH  -0.10 
Dehydroascorbate/ascorbate  +0.06 
VO2
+/VO2+(VV/VIV) +1.016 +0.19 
O2/H2O2 +0.695 +0.295 
1O2/H2O +1.23 +0.815 
 
Many aspects of aqueous vanadium chemistry remain unclear, as a consequence, the 
lack of proper interpretation of the results in vivo studies. Rapid conversion between the 
vanadium(IV) and (V) oxidation states makes it difficult to even specify the oxidation 
state of the active vanadium species.   
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 Vanadium in biology I.3
Table I.2 lists most important dates in the history of vanadium‟s biological chemistry 
[16,37-41]. 
Table I.2. Milestones in the history of development of vanadium biology and chemistry. 
1830 Discovery of vanadium (N. Sefström). 
1899 First report of vanadium salts as probes of metallotherapeutics (B. Lyonnet and co-workers). 
1911 First report of high levels of vanadium in tunicates (Ascidiacea Phallusia mamillata) (M. Henze). 
1933-36 Discovery of the role of vanadium in nitrogen fixation (H. Bortels). 
1972 Isolation of amavadin from the fly agaric (E. Bayer). 
1977 Discovery of the role of vanadate as an efficient inhibitor of Na+, K+-ATPases (L. J. Cantley). 
1980- Development of vanadium compounds for the treatment of diabetes mellitus. 
1983 Isolation of the first vanadium enzyme, vanadate-dependent bromoperoxidase, in the marine alga 
Ascophyllum nodosum (H. Vilter). 
Discovery of the affinity of vanadium for transport proteins (Chasteen and co-workers). 
1986 Isolation of a vanadium nitrogenase from Azotobacter ninelandii (Sussex Nitrogen Fixation Group). 
1993 Discovery of high levels of vanadium in fan worms Pseudopotamilla occelata (T. Ishii and co-workers). 
1997- Discovery and development of vanadium-binding proteins (vanabins) in Ascidia sydneiensis samea 
(Michibata and co-workers). 
1998 First report on isolation of vanadium-containing (molybdenum-free nitrate reductase) enzyme from 
Pseudomonas isachenkovii and Thioalkalivibrio nitratireducens (Antipov and co-workers). 
2003 Phase I of clinical trials of a designed vanadium-based pharmaceutical agent 
(bis(ethylmaltolato)oxidovanadium(IV), BEOV) (C. Orvig and K. Thompson). 
2010 Discovery of the ability of vanadium nitrogenase from Azotobacter vinelandii to catalyze the reduction of 
CO (W. Ribbe and co-workers). 
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 Vanadium in biological systems I.3.1
Vanadium‟s essentiality was determined in the 1970s through studies in rats [83]. The 
beneficial and essential role in humans is still uncertain and yet to be discovered. To 
animals and humans vanadium is mostly supplied via food and drinking water and is 
chiefly accumulated in bones, kidneys and liver. The concentration level in blood and 
tissue, respectively, is ca. 0.2 and 6 µM, respectively. Vanadium can enter the food 
chain via soil and water, where it is transferred to plants (beans, beets, barley, and 
wheat etc.) accumulated in roots and seeds. Most food has naturally occurring low 
concentrations of vanadium (average ca. 30 µg/kg) [13]. Common sources of vanadium 
in food are dill seeds, black pepper, garlic, parsley, cereals, seafood, meat, fish, 
mushrooms, olives, grains, vegetable oils, and fats [42]. Since vanadium is the second 
most abundant element in marine environment, seafood is richer in vanadium than meat 
from land animals.  
 
 Absorption  I.3.2
Vanadium‟s absorption rate is still unclear. When administered orally, the absorption in 
the gastrointestinal tract is minimal (i.e., ~2% in humans and 40% in some animals). As 
vanadium is poorly absorbed, ingested vanadium compounds mainly in the form of VO2+ 
hydroxides are eliminated with faeces. When applied intravenously, vanadium is rapidly 
distributed in body via blood circulation. The accumulation begins in kidneys, liver and 
spleen, excreted with urine probably in the form of VIV bound to iron-containing 
complexes such as albumin, transferrin or ferritin [33,43]. Bones and muscles retain 
with vanadium the longest. A biological half-life of vanadium is 20-100 h [44]. 
 
 Vanadium in living organisms and life processes I.3.3
Vanadium has been proven to be a necessary part of the diet of rats and chickens, but 
only in very small amounts. Deficiencies of vanadium causes reduced growth and 
impair reproduction. Vanadyl sulfate and sodium metavanadate have been used in 
dietary supplements for athletes and body builders [31,45].  
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Vanadium is certainly essential for some living organisms, which either accumulate 
(ascidians, fly agaric and fan worms) or employ vanadium in life processes (bacterial 
respiration, vanadium-dependent haloperoxidases, nitrogenases and nitrate 
reductases). 
Ascidians1, known as marine tunicates or sea squirts, contain high levels of vanadium. 
They accumulate vanadium from sea water, where it is present at the average 
concentration of 0.03 µM, but may vary increasing up to 107.  
In 1911, Henze discovered extraordinary levels of vanadium in the blood cells (coelomic 
cell, named vanadocytes) of Phallusia mamillata. Since then much interest has been 
developed towards the redox mechanism and possible physiological roles of vanadium 
in tunicates. It is worth mentioning, that in the early findings there was an assumption on 
the respiratory importance of vanadium and vanadium compound(s) present in 
vanadocytes of ascidians in terms of oxygen transport. These compound(s) were called 
„haemovanadin‟, however such function was refuted because no parallelism to iron-
based haemoglobins and the copper-based haemocyanins exist [9].  
Vanadate is assumed to enter the organism of these marine creatures via phosphate 
and sulphate channels. It is then reduced, presumably by tunichromes2 (blood 
pigments) to VO2+ and V3+ [46]. Depending on the species of tunicates, vanadium(III) is 
accumulated in the form of aqua-sulfato complexes (V(H2O)4(OH)(HSO4)
+) in tunic, 
mantle, branchial, serum and mainly in vanadocytes at concentrations up to 0.3 M 
(350 mM V(III), 500 mM SO4
2-
 at pH 1.9). The lower the pH is, the more vanadium 
appears to be accumulated [9]. Michibata‟s group has extensively studied ascidians 
[47,48]. One of their most significant contributions is development of vanadium-binding 
protein, vanabins. They suggested that the accumulated metal ions may be a source of 
oxidizing energy for redox reactions in vanadocytes or in other tissues. Recent studies 
                                            
1
 Ascidians are marine animals, knows as filter feeders. They are sessile animals (remain firmly attached to 
substratum such as rocks and shells) that found all over the world, usually in shallow water with salinity over 2.5%. 
Tunicates are phylogenically classified into the phylum Chordata between Invertebrata and Vertebrata, while the adult 
individuals do not contain a vertebral column, the juvenile larvae show features in common with vertebrates [9,48]. 
These animals feature a tunic. The main constituents of this tough outer mantle are a mucopolysaccharide–protein 
substance, contain blood cells and tunicin fibres which contain cellulose. 
2
 Tunichromes are small tri- or dipeptides, referred to a class of DOPA (3,4-dihydroxyphenylalanine) and hydroxyl-
Dopa-containing peptides. The theory about tunichromes being associated with vanadocytes, was turned down [9]. 
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of vanadium-rich species have shown that vanadium accumulation in ascidians is 
associated with enhanced capacity of metabolize glucose-6-phosphate via pentose 
phosphate pathway [49]. 
 
Amanita muscaria3, A. regalis and A. velatipes are three species of the genus Amanita 
(poisonous mushrooms), that were found to accumulate amavadin, a vanadium-
containing anion. This anion is an octa-coordinated VIV non-oxo complex, which bonded 
with two tetradentate ligands derived from N-hydroxyimino-2,2'-dipropionic acid. This 
complex was discovered in 1931 but isolated and identified only in 1972 by Kneifel and 
Bayer. Although, muscarin, the poisonous part of this mushroom, is not in any known 
relationship with amavadin, the latter may serve as a toxin for protection of the 
mushroom [50]. The concentration of vanadium in A. muscaria was found to be 
approximately 400 times higher than that in plants. The element is not evenly distributed 
since the bulb accumulates the most, up to 1000 mg/kg dry weight, and the lamellae up 
to 400 mg/kg, whereas spores contained only 1-2% of the lamellar vanadium. 
Interestingly, the amount of vanadium in these mushrooms is independent of the 
vanadium content in soil [9].  
The biological function of amavadin is still unknown. Its reversible one-electron redox 
properties have been related to the possible role in biology as a one-electron redox 
mediator. Studies have shown that amavadin can catalyze thiol oxidation in the absence 
of H2O2 [51] and in the presence of hydrogen peroxide, it can perform halogenation, 
hydroxylation, and oxygenation of alkyl and aromatic substrates [52]. Fraústo Silva et al. 
have found that amavadin electro-catalyze the oxidation of some thiols to the 
corresponding disulfides [53] and that amavadin could convert methane into acetic acid 
in the presence of peroxodisulfate salt and trifluoroacetic acid [54]. Hubregtse et al. 
suggested that amavadin may acts as peroxidase via the reaction with H2O2 for the 
regeneration of damaged tissues [55].  
 
                                            
3
 A. muscaria is commonly known as fly agaric or toadstool 
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Fan worms4 are the second marine organisms which in 1993 were reported to contain 
high levels of vanadium [37]. Vanadium content is 320-1350 µg/g dry weight of the 
whole body. About 90% of the overall vanadium is found in the branchial crown as 
(V(H2O)5(HSO4)
2-). This speciation is similar to that of vanadocytes in ascidians [9].  
To date, the role of vanadium in ascidians, fan worms and amanita remains unclear.  
 
Vanadate-dependent haloperoxidases (VHPO) form a group of enzymes that have 
been isolated from seaweeds, fungi and lichen. These enzymes catalyse the oxidation 
of a halide (X-) by hydrogen peroxide to corresponding hypohalous acid (HOX) 
according to the following scheme [31]: 
 
-
        
    
→        - ike intermediates 
 
 
 
 
VHPOs is the first specific vanadate-dependent enzyme. In 1983, Vilter isolated the first 
representative of the large family of VHPO, vanadium bromoperoxidase (VBrPO) from 
brown alga Ascophyllum nodosum (knobbed wrack), where it is widely distributed. 
VHPOs are also found in red (such as Corallina pilulifera and Cor. officinalis), and green 
alga (Halimeda sp.), the fungi (Curvularia inaequalis and Botrytis cinerea) and in the 
terrestrial lichen Xanthoria parietina [9]. With the discovery VHPOs, there are now three 
distinguished classes of peroxidases: non-metallo haloperoxidases, Fe-Haeme 
haloperoxidases and vanadate-dependent haloperoxidases.  
                                            
4
 Pseudopotamilla occelata is a class Polychetes (bristle worms), belong to phylum Annelida  
Organic H2O2 
(i.e., HOX, X2 X3
-
, Enz-X) 
X-organic  1O2 + X
- 
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In all of the VHPOs the active centre is hydrogen vanadate (H2VO4
-
  which does not 
change its redox state during catalysis. The metal most probably functions as Lewis 
acid coordinating and activating the substrates in such a way that catalysis occurs.  
VHPOs are divided into two related groups which are alga bromo/iodo peroxidases and 
fungal chloroperoxidases. The enzymes are termed iodo-, bromo- or chloroperoxidases. 
Iodoperoxidases (VIPO) can oxidise only iodide, bromoperoxidases (VBrPO) iodide and 
bromide, while chloroperoxidases (VClPO) are able to oxidise all three halides  VHPOs 
are very chemo- and thermostable enzymes, remains active at high temperatures 
(~70 ºC). Unlike haeme haloperoxidades, VHPOs are resistant to excess of H2O2, 
organic solvents and hypohalous acid. These properties facilitate their isolation and 
characterization. Depending on the source, about 100 mg of fully active enzyme can be 
recovered from 10 kg of finely chopped and freeze-dried algal material [9].  
The physiological role of VBrPO is assumed to be in the biosynthesis of the 
halogenated marine natural products. These products range from relatively simple 
volatile halomethanes (e.g., CHBr3, CH2Br2, CHBr2Cl) to more complex compounds, 
such as halogenated indoles and terpenes. Halomethanes contribute to the ozone 
degradation and thus, to the global ozone balance. The production of CHBr3 by marine 
algae is ca. 104 tons per year [56]. 
 
Vanadium nitrogenase (VNase) is vanadium-containing bacterial enzyme that promote 
nitrogen fixation. VNases are found in free-living nitrogen-fixing bacteria of the genus 
Azotobacter (chroococcum, vinelandii and amylobacter). Biogenic reductive nitrogen 
fixation occurs when atmospheric nitrogen (N2) is converted to ammonia (NH3) by 
nitrogenases, making nitrogen available for assimilation by plants. The nitrogenases are 
responsible for cycling about 108 tons of nitrogen per year from the atmosphere to the 
soil [57]. 
For many years molybdenum was considered essential for N2 fixation and the majority 
of nitrogenases that have been widely studied contain a molybdenum nitrogenase 
(MoNase) system. In 1930, Bortels in his research of an alternative substitute for Mo, 
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determined that vanadium compounds almost match molybdenum, showing the positive 
effect on N2 fixation by Azotobacter [9]. In 1986, Robson and coworkers (Sussex 
Nitrogen Fixation Group) [58] purified a vanadium-containing nitrogenase from A. 
vinelandii5. Since then, VNases are mostly isolated from A. vinelandii and A. 
chroococcum.  
VNases are considered to be less efficient than MoNase because the reduction 
equivalents used for N2 reduction are 50%, whereas for Mo they are 75%. Generally, 
VNases are less stable, which creates a problematic crystallization (the structural 
information from X-ray diffraction data is not available to date), also it produces some 
hydrazine, whereas no such is observed with MoNases [59]. VNases are expressed in 
case of MoNases deficiency and low temperatures.6  
The main constituents of MoNase/VNase are two metalloproteins, Fe-protein and 
MoFe-protein/VFe-protein, encoded by structural genes (i.e., nif- and vnf-encoded for 
Mo and V, respectively). Both nitrogenases utilize a catalytic mechanism that involves 
ATP-dependent electron transfer from a reductant (i.e., nifH- or vnfH-encoded Fe-
protein) to the catalytic component (i.e., nifDK-encoded MoFe-protein or vnfDGK-
encoded VFe-protein) followed by the reduction of N2 at the cofactor site (i.e., FeMoco 
or FeVco) of the catalytic component. Although, VFe-protein and MoFe-protein are 
biochemically similar, the expression of VNases does not simply occur by substituting 
Mo with V in MoFe-protein. It is because they possess different substructures, α2β2 in 
MoFe-protein and α2β2δ2 in VFe-protein. The α subunits in VNases contain the so-called 
M cluster (termed FeVco for iron–vanadium– cofactor), with the composition of seven 
iron ions, nine bridging sulfide ions (VFe7[μ6-C]S9) [60] and the active centre - 
vanadium, which is bound to a histidine and the vicinal hydroxide and carboxylate of 
homocitrate [13]. This M cluster is responsible for the reductive protonation of N2 to NH4 
(1).  
N2+12e
-+14H
+ 
+ 40 (or 24) MgATP  2NH3
+ + 3H2 + 40  or 24  MgADP + 40  or 24 Pi  (1) 
                                            
5
 Azotobacter vinelandii, member of the family Azotobacteriaceae, contains three genetically distinct nitrogenase 
system, i.e., a Mo-containing nitrogenase, a V-containing nitrogenase and an Fe-only nitrogenase, encoded by 
nitrogen fixation genes. These genes have shown to play roles in the biosynthesis of the Mo- and the V-protein. 
6
 Low temperatures create more effective system for the reductive protonation of nitrogen to the ammonium ion. 
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Recently, Ribbe and co-workers [61] discovered that in a total atmosphere of CO, with 
no nitrogen present, VNases are able to reduce CO (2) with the production of (C2H4), 
(C2H6) and (C3H8). The fact that the reduction of both N2 and CO are industrially 
important processes makes VNases commercially applicable in the future. 
2CO+4H
+
+4e-→C2H4+ 2H2O [+H2      (2) 
 
In the end of the 1990s, Antipov et al. [39] reported the isolation of molybdenum-free 
nitrate reductase from two bacteria, Pseudomonas isachenkovii, which contains 
vanadium, and Thioalkalivibrio nitratireducens which is consistent of vanadium and iron 
(ratio 1:3). The nitrate reductase activity was found to depend on vanadium content in 
P. isachenkovii. The enzyme purified form T. nitratireducens in addition to nitrate 
reduction, reduces nitrite, bromate and selenate. The existence of vanadium-dependent 
nitrate reductase is yet to be confirmed.  
Another biological function of vanadate is to be a primary substrate for electron delivery 
in bacteria such as Pseudomonas vanadium-reductans, P. isachenkovii and Shewanella 
oneidensis. Unlike higher animals and plants, which use oxygen for the respiration, 
bacteria and archaea employs high-valent ions such as Fe3+, Mg3+ and oxometal ions 
such as arsenate(V), selenate(VI), molybdate(VI) and vanadate(V). Most metals in 
aqueous, non-acidic, oxygenated environments such as soil and sea, exist in the form 
of insoluble oxides and hydroxides and thus cannot be utilized by microorganisms. 
Since iron is the most essential in respiration of microbes, they scavenge Fe3+ by 
releasing high-affinity iron compounds (siderophores, i.e., “iron carriers”). Siderophores 
form chelators with Fe3+ in iron-containing minerals, which results into formation of 
soluble iron complexes. The solubility thus makes the metal more bioavailable for 
further uptakes. Siderophores that chelate vanadium (“vanadium carriers”) were named 
vanadophores. More information on vanadium-siderophore complexes can be found in 
[9,31].  
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 Biochemical action I.3.4
The biochemical role of vanadium has been reviewed many times [31,44,45,62,63]. 
Vanadium is likely to be essential considering its various biological functions. Starting 
from 1977, the discovery of the inhibition effect on Na,K adenosine triphosphatases 
(ATPase), vanadium was generally accepted as a bio-metal. The interest in vanadium 
metallobiochemistry is mostly due to structural and chemical similarities of vanadate 
and phosphate, especially in the tetrahedral trianionic forms (VO4
3-
 and PO4
3-
)  One 
difference is that at neutral pH, the V1 exists primarily as a monoanion ([H2VO4]
−), 
whereas phosphate is present in its dianion form ([HPO4]
2−). Another one is that unlike 
H3VO4 which undergoes redox chemistry under physiological conditions, H3PO4 is 
highly stable.  
Being an active competitor of the phosphate, vanadate (four-coordinated) seems to be 
involved in variety of regulations of phosphate-dependent processes. Vanadate mimics 
cellular metabolites because its esters and anhydrites were established as functional 
analogues of those of phosphate. The examples of vanadium-cofactor analogous of 
adenine monophosphate (AMP) [64] and nicotinamide adenine dinucleotide phosphate 
(NADP) such as AMV, ADPV, and NADV [65,66] have been reported. NADV is 
considered to be more potent than NADP since it forms the cyclic derivative for which 
the active enzyme has greater affinity. Both oxidovanadium(V) anion and 
oxidovanadium(IV) cation inhibit phosphorylases such as alkaline, acid and protein 
phosphatases, ribonuclease [67,68] and ATPases.  
One of the prominent functions of vanadium compounds is the insulin-mimetic effect on 
cells, diabetic animals, and humans. Administration of pharmacological doses of 
vanadium to experimentally diabetic animals mimics the effect of insulin and growth 
factor. As a results, glucose tolerance increases, other diabetes symptoms decline; 
DNA synthesis, osteoblast proliferation and collagen formation are induced in bones, 
and along with the rise of vanadium in bone, osteogenesis and bone repair are 
promoted [9].  
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 Toxicity and hazard I.3.5
While no nutritional requirement of vanadium has been established in humans, 
exposures to high level concentrations of any form of the metal are known to be toxic. 
Toxicity can occur via oral administration, intravenous application and inhalation. A dose 
of an immediate danger of vanadium for an average human is 10 mg/kg orally, 7 mg 
intravenously and 35 mg/m3 of inhaled substance. The oral intake is less hazardous due 
to poor absorption of vanadium in the gastrointestinal tract. The main side effects are 
green tongue coloration, weakness, gastrointestinal problems, failure to gain weight. 
Vanadium compounds are encountered relatively rarely by most people. The amount of 
vanadium found in food is out of the hazardous range. In the laboratory, unless known 
otherwise, all vanadium compounds should be regarded as highly toxic. Vanadium 
metal powder is a fire hazard. In some industrial smoke pollution vanadium compounds 
may cause lung cancer. Industrial regulations exist to keep exposure to V2O5 dust under 
control. No studies were located regarding the carcinogenicity in humans after 
inhalation exposure to vanadium [9,16]. 
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 Medicinal interest  I.4
Metal coordination compounds as therapeutics for different medical applications are 
currently one of the most demanding subjects in the biochemical research. More and 
more metal complexes are recognized as effective drugs in diseases such as cancer, 
diabetes, HIV, and malaria. Diabetes mellitus (DM)7 and cancer are among the most 
spread diseases. Metallotherapeutic interest in vanadium rose as early as 1899, when 
Lyonnet and his colleagues first tried sodium metavanadate as a drug in oral uptakes, 
observing the lowering of glucose level in urine of two out of three diabetic individuals. 
However, these studies were left undeveloped due to parallel exploration of constituents 
of pancreas with eventual discovery of insulin (1921-1922). Rapid and successful 
implementation of insulin in the treatment of diabetes eclipsed the research of vanadium 
compounds for the same purpose. This discovery was assigned as miraculous, since 
people with severe diabetes and only days left to live were saved. With daily insulin 
injections into the subcutaneous tissue (in case of Type 1 diabetes) they could live an 
almost normal life. However, the daily injections are painful both physically and 
mentally. To eliminate such undesirable defects, creation and development of new 
therapeutic compounds to replace insulin injections (insulin is a peptide hormone, oral 
application is impossible) and synthetic therapeutics are being explored to improve the 
lives of diabetic patients. The extensive studies of different metals, especially those 
which are essential for humans, such as iron, copper, zinc, selenium, and their 
relationship with numerous diseases, resulted in the development of numerous 
metallopharmaceuticals such as the platinum-containing anticancer drug, cis-platin, and 
the gold-containing rheumatoid arthritis drug, auranofin. That time vanadium was mostly 
explored for its biological effects and functions. After the discovery of high levels of 
vanadium in tunicates in 1911 and its participation in nitrogen fixation (1936), vanadium 
was recognized as a metal with ubiquitous nature. This led to a massive research for 
the significance of vanadium in biological systems and raised question marks around its 
                                            
7
 There are two principal forms of DM: Type I and II DM. Type I, also called insulin-dependent DM (IDDM), results 
from the pancreas failure to produce insulin (e.g., inherited or virus-induced auto-immune reaction or damage of the 
pancreas); most frequently developed in children and adolescents and treated only by daily insulin injections (~10% 
of diabetics). Type II occurs due to the body‟s inability to properly respond to insulin still produced in the pancreas. 
The reason is in the occurring resistance of special receptors, which insulin needs to attack in order to lower the 
glucose. This type of DM most frequently occurs in elderly adults and treated by several types of synthetic therapeutic 
substances together with a controlled diet and physical exercise (~90% of diabetes cases). 
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pharmacological effects. First, it was studied as a potential cholesterol-lowering agent, 
gradually moving to abundant exploration of physiological, metabolic and enzymatic 
effects, stimulatory and inhibitory. The research continued with the studies of anti-
diabetic and anti-cancer agents. Special attention and constant emphasis was paid to 
the solution chemistry in aqua media, precisely, the physiological interconversion of 
vanadium compounds between cationic (VIV) and anionic (VV) species. 
This section will provide a brief introduction into the role of vanadium in medicine, 
namely the main findings for treatment of DM and cancer. Special acknowledge is given 
to the following research groups which contributed into the research of vanadium anti-
diabetic, -cancer and –parasitic effect the most: Cantley; Chasteen; McNeill, Thompson 
and Orvig; Sakurai; Pessoa, Tomaz and Correia; Rehder, Crans, Willsky and Godzala; 
Kiss, Jakusch and Buglyó; Garribba and Micera; Brichard and Reul; Etcheverry, 
Williams and Baran; Gambino. These reviews can be consulted for further reading 
[13,16,31,45,63,69-77,116]. A series of articles about anti-cancer activity of variety 
metal compounds can be consulted in special issue [78].  
 
 Vanadium in diabetes treatment  I.4.1
The interest in the insulin-enhancing8 effect of vanadium received its development only 
in the 1980s, i.e., two decades after the observation of Lyonnet, and has thoroughly 
been explored since. The most important studies are reflected in Table I.3. 
 
                                            
8
 Initially, the effect was called both insulin-enhancing and –mimetic since vanadium compounds were believed to be 
able to mimic the effect of insulin. However, after some studies it became clear that vanadium will never be able to 
substitute insulin but rather works in synergistic way by augmenting the efficiency of insulin. Since then the term 
‟insulin-enhancing‟ was thoroughly used.  
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Table I.3. Development of vanadium and vanadium compounds as anti-diabetic agents, presented chronologically. 
Year Research Ref. Brief description 
1897–98 
Tests of aqueous solutions of 
sodium vanadate on humans in 
the L‟Hôtel-Dieu hospital in Lyon 
9 
The first report on vanadium‟s possible benefits in the treatment of 44 subjects with 
various health problems, including anemia, tuberculosis, rheumatism, arnyotrophia, 
hysteria, neurasthenia and diabetes (three individuals). 
1960s 
Vanadium as potential cholesterol-
lowering pharmaceutical agent 
79 
Despite of modest inhibitory effect on serum cholesterol, no negative side effects were 
observed even at high doses of “di-ammonium vanado-tartrate”. 
Synthesis and characterization of 
numerous V
IV
 and V
V
 complexes, 
particularly VO(acac)2 
80 
Spectral characterization of vanadium(IV) and (V) complexes became possible and the 
characteristic eight-line vanadyl EPR spectrum was described. The coordination 
chemistry of oxidovanadium(IV) was first summarized in 1965. 
Extensive studies on essentiality 
of vanadium 
 
This launched an elaborate study of vanadium‟s metabolism, effect on growth, possible 
deficiency effect and served as a preamble to the studies of vanadium from a medicinal 
point of view. 
1979-1980 
First in vitro studies of the insulin-
mimetic action of vanadate 
81,82 
V
V
 was found to be responsible for glucose oxidation via reduction to V
IV
 which in turn 
inhibits cellular phosphatase. 
mid-1980s 
Recognition of vanadium 
compounds as important metallo-
pharmaceuticals 
 
The potent pharmacological effects and physiological interconversion between cationic 
(V
IV
) and anionic (V
V
) species attracted a great interest which significantly advanced 
research in this field. 
1980-1985 
First reports on vanadium‟s 
insulin-like action in vivo 
83 
Pioneer experiments of Heyliger, McNeill and Meyerovitch‟s groups. Studies on animal 
models of diabetes, namely, alloxan
9
-diabetic and streptozotocin (STZ)
10
-diabetic rats. In 
these assays vanadate was dissolved in the drinking water of animals, where it is 
present at millimolar concentrations as a mixture of      
 ,       
   and 
     
  .Concentrations of vanadium in vivo tissue were found to be in the nanomolar to 
micromolar range. 
Continued on the next page  
                                            
9
 Alloxan is a toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is beta cells) when administered to rodents and many 
other animal species. This causes an insulin-dependent diabetes mellitus (called "Alloxan Diabetes") in these animals, with characteristics similar to type I diabetes 
in humans 
10
 Streptozotocin is an antibiotic that is produced by Streptomyces achromogenes; intravenously applied, it destroys the insulin-producing β-cells in the pancreas 
and thus induces type I diabetes. STZ rats are thus animal models of human type I diabetes. 
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Table 1.3. – Continued 
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 Insulin receptors are receptors with high-affinity cell surface (trans-membrane) that are activated when the insulin is secreted. They belong to the large class of 
tyrosine kinase proteins. By targeting insulin receptors, insulin decreases glucose levels. 
1987 
Peroxovanadate as potential anti 
diabetic drug 
84,85 
First noted in the form of a synergistic effect when incubating adipocytes (fat cells) with a 
combination of vanadate and hydrogen peroxide. Among the effects noted was the 
stimulation of the insulin receptor
11
 tyrosine kinase/inhibition of phosphotyrosine 
phosphatase. Despite a particularly high efficacy, its in vivo applicability is questionable. 
Oral application peroxovanadates will hardly survive the passage through the 
gastrointestinal tract (GIT); in case of intact absorption, will readily be decomposed by 
catalase to form vanadate. 
1988-1995 
Numerous tests of V
IV
 salts as p 
Potent candidates for anti-diabetes 
86-89 
Vanadium salts, at doses ranging from 0.1–0.7 mM/kg/d, in a variety of animal models of 
diabetes, normalized blood glucose and lipid levels, altered thyroid hormone deficiency, 
improved insulin sensitivity, and prevented or reversed secondary complications, such 
as cardiomyopathy, cataract development, impaired antioxidant status and excessive 
food/ fluid intake. 
1989 
Insulin-like activity of V
IV
OSO4 in 
STZ rats 
18,90, 
91 
VOSO4 is advantageous over vanadate because it is sufficiently less toxic. Its drawback 
is a low rate of absorption in the gut, estimated to be 1% or less. 
early 
1990s 
Development and testing of VC 
with organic ligands for anti-
diabetic purposes 
 
Due to potential toxicity of vanadate and the low absorption rate for the less toxic VOSO4 
these inorganic compounds were considered to be excluded from potential use as anti-
diabetic drugs. As an alternative, vanadium coordination compounds containing organic 
ligands began to be tested. This allowed developing vanadium anti-diabetic drugs with 
desired properties which in turn would help to increase their bioavailability. 
1990 
V
IV
O(Cys-Me)2 as promising anti-
diabetic agent 
92 
The efficacy of this complex was found to be equivalent to VOSO4. 
1992 
V
IV
O(malto)2 as a glucose lowering 
agent 
93-96 
Bis(maltolato)oxidovanadium(IV), BMOV, was found to be more effective than VOSO4 as 
a glucose lowering agent. BMOV was better tolerated than inorganic vanadium salts, 
and resulted in reliable glucose-lowering in all animal models of diabetes in which it was 
tested. Also, overall bioavailability of vanadium from BEOV was three times higher than 
from VOSO4. 
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Table 1.3. – Continued 
Continued on the next page   
1995-2009 
Insulin-mimetic V
IV
-picolinate 
complexes 
75, 
97-
102 
After V
IV
O(pic)2 exhibited in vitro insulin-mimetic activity in isolated rat adipocytes and in 
vivo hypoglycemic ability in STZ-rats, many analogues were prepared to mainly study 
relationship between the structure and anti-diabetic activities. Oxidovanadium(IV) 
complexes with picolinato ligands were found to be stable against oxidation in the blood 
and forming the ternary system (oxidovanadium(IV)–LA–LB–Tf, where LA = picolinate or 
picolinate-containing ligand; LB = low molecular mass serum constituents; 
Tf = transferrin). Only systems that contain phosphates or citrate along with picolinato 
ligand were proven to survive to a certain extent in the blood. 
1995 
Tests of vanadate and V
IV
OSO4 on 
humans for insulin-enhancing 
purposes 
 
103,
104 
The second report involving human subjects. The treatment of five type I and five type II 
diabetics with sodium (or ammonium) vanadate and VOSO4 at the Joslin Diabetes 
Center in Boston, MA and at the Diabetes Research Center, Albert Einstein College of 
Medicine, NY. In all cases only a modest improvement in insulin sensitivity and glycemic 
control was observed at the dose of ~1 mM V/d and duration of 6 weeks  
1995-
present 
Studies of the interaction of 
insulin-mimetic vanadium 
compounds with the high (ATP, 
GHS, HAS, Tf) and low (lactate, 
oxalate, phosphate, citrate) 
molecular mass serum 
components 
26,
105-
113 
Vanadium(III,IV,V) undergoes parallel ligand exchange and redox reactions with 
bioligands when given orally. Serum constituents were considered to be potential 
transporters of V
IV
O
2+
 in blood. This field was widely researched and many interesting 
results were obtained. The main finding is that little of the vanadium remains bound to 
the original carrier because citrate and transferrin displace most of the carrier molecules; 
phosphate is able to partially replace of one the functionalities. V
IV
 ions were found to 
bind specifically into two iron biding sites of transferrin and to a histidine of the N-
terminal end of albumin 
1996, 
1999, 
2000, 2005 
VO(acac)2 and derivatives as 
efficient insulin-enhancing 
complexes 
18,
114-
117 
VO(acac)2 and VO(Et-acac)2 were found to have long-term in vivo insulin mimetic 
effects in STZ-diabetic Wistar rats. The effectiveness of these compounds in reducing 
the final glucose levels in STZ-diabetic rats after 12 weeks was compared to the one of 
VOSO4 and VO(malto)2 and was found to be as follows: VO(acac)2 > VO(Et-
acac)2 > VO(malto)2 > VO
2+
. Complex speciation in the aqueous speciation liquid was 
related to its effectiveness in plasma glucose lowering. The concentration of the 1:1 
hydrolysis product (one ligand is substituted with molecules of water) is in the order  
VO(acac)2 > VO(Et-acac)2 > VO(malto)2 > VO
2+
, which is the same order as observed 
for the in in vivo effectiveness, suggesting an active role of this species. Another 
derivative of VO(acac)2, VO(Me-acac)2, had also attracted interest since it as VO(malto)2 
formed similar species when dissolved in water.  
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 FFA (indicator of habitual dietary fat intake in middle-aged adults) increase in patients with uncontrolled type 2 diabetes mellitus and are an indicator of insulin 
resistance. 
1997 
VC with tetradentate salen-type 
ligands as insulin-enhancing agent 
118,
119 
The ability of V
IV
O(salen) to reverse the hyperglycemic condition of alloxan-induced 
diabetic rats to near normal. However, the rats tended to become hypoglycemic, and 
withdrawal of treatment brought an immediate return to hyperglycemia. 
1999, 2003 VO(opt)2 and VO(opd)2 
72,
120,
121 
VO(opt)2 (opt=1-oxy-2-pyridinethiolato) and VO(opd)2 (opd=1-oxy-2-pyridonato) are 
particularly stable complexes that have been shown to lower free fatty acid (FFA)
12
 
levels. When orally administered, VO(opd)2 was more effective at lower doses than 
VO(opt)2 
2000 
Phase I clinical trial using  
V
IV
(Et-maltolato)2 coordination 
complex  
39 
Safety, tolerability, pharmacokinetics and bioavailability of escalating doses of a 
vanadium complex, were possible with bis(ethylmaltolato)oxidovanadium(IV), BEOV in 
treatment of DM. A range of doses from 10 to 90 mg, given orally to 40 non-diabetic 
volunteers, resulted in no adverse effects; all biochemical parameters remained within 
normal limits. The trials were carried out by Medeval Ltd in Manchester, UK. Comparison 
studies revealed that vanadium from VOSO4 was absorbed more slowly than vanadium 
delivered from BEOV. 
2000-2002 
Development of V
III
 and V
V
 
complexes with organic ligands as 
potential anti-diabetic agents 
115, 
11,29,
122,
123 
Most of the active complexes that have been tested over the years contain tetravalent 
vanadium. However, some of V
V
 complexes such as V
V
O2(dipic) and V5dipic-NH2 
exhibited insulin-enhancing activity. Also, some trivalent vanadium complexes were 
found to be as active as pentavalent, e.g., V(maltolate)3. 
2008 Phase II clinical trial with BEOV 77 
The trials were carried out by Akesis Pharmaceuticals, Inc. (La Jolla, CA). Successful 
completion of phase II of human clinical trials made BEOV the benchmark anti-diabetic 
drug candidate; since then the results of vanadium compound newly tested for anti-
diabetic activity are always compared with those of BEOV. First reported by C. Orvig.  
2005-2010 
Tests of V
IV
-allixinate, pyridinone, 
kojicate compounds and 
derivatives; V
III
, V
IV
 and V
V
-malto-, 
allomalto-, and isomaltolate as 
potential drug candidates 
124-
126 
After a successful phase I and II clinical trials with BEOV, these complexes were tested 
assuming their potential anti-diabetic activity due to the structural similarities with BEOV. 
All complexes were found to be active, however none was better than BEVO. 
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Diabetes is a chronic illness, one of the main epidemic challenges of the future. The 
World Health Organization estimated the amount of people worldwide affected by 
diabetes to be around 150 million, forecasting the increment in number of affected 
people (Type II diabetes). DM is a chronic disease, caused by a deficiency or 
insufficient supply of the pancreatic hormone insulin, or resistance of cellular insulin 
receptors to insulin. The lack of insulin results into a failure of glucose balance and lipid 
metabolism, which in turn leads to accumulations of glucose in the blood and urine in 
the first case, and disequilibrium of the acid-base balance of the blood by the 
byproducts of alternative fatty acid metabolism in the second case. Typical 
complications associated with DM are kidney failure, heart diseases, damage of the 
peripheral blood vessels retinopathy and neuropathy. 
Vanadium ions alone and coordinated with variety organic ligands have been 
demonstrated to exert numerous insulin-enhancing and anti-diabetic effects in vitro 
(cells cultures) and in vivo (diabetic animals and sporadically humans) systems. 
Although the mechanism by which metal ion works as insulin-mimetics has yet to be 
established, there is some generally accepted basic understanding of the mode of 
action of vanadium as an insulin-enhancing agent. 
 
I.4.1.1 Mechanism of insulin-enhancing and/or anti-diabetic activity 
Potential mechanisms of anti-diabetic activity of vanadium that have been found and 
investigated to date are stimulation of glucose uptake, glycogen and lipid synthesis in 
muscle, adipose and hepatic tissues, inhibition of gluconeogenesis, and the activation of 
the gluconeogenic enzymes (phosphoenol pyruvate carboxykinase and glucose-6-
phosphatase in the liver and kidney as well as lipolysis in adipocytes). Physiological 
effects of vanadium are expected to result from the structural resemblance between 
phosphate and vanadium, as well as from the fact that vanadium can form cationic and 
anionic compounds.  
Since insulin has only one action site (i.e., insulin receptor), while oxidovanadium(IV) 
ion has been found to have multiple action sites in the adipocytes, the mechanism of 
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action was called an „„ensemble mechanism‟‟ (Figure I.2). Oxidovanadium(IV) and its 
complexes act on at least four sites in this „„ensemble mechanism‟‟. They are the 
tyrosine kinase of the insulin receptors, signal transduction glucose transporter and 
protein kinase B, and phosphodiesterase [75,127].  
A detailed description of the mode of mechanism can be found in [13,63,75,128]. 
 
 
Figure I.2.  Schematic model of absorption, distribution, metabolism and excretion of vanadium 
compounds of the general form VOL2 [63]. I.p. - intraperitoneal and i.v. – intravenous.  
 
Absorption, distribution, metabolism and excretion of vanadium complexes  
Drug delivery to cells and then through the cell membrane can be a problem. 
Bioavailability of vanadium administered orally differs from when the metal is 
internalized intravenously of via inhalation. The distribution of vanadium in a biological 
system is related to aqueous chemistry of VIV and VV at different pH. When vanadium 
complex of VIVOLn (Figure I.2) composition enters a cell, there are four possible 
“transformations” the drug can undergo [9,13,63]: 
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1. Upon complex decomposition of VO2+ cation is freed and oxidized to H2VO4 
which in turn due to structural and chemical similarities with phosphate can use 
phosphate channels to penetrate the membrane; 
2. The complex bind to iron-containing complexes, i.e., transferrin, albumin which 
partly (VO2+(L)nTf/Alb) or completely (VO2+Tf/Alb) substitute the functionalities. 
The latter species is stable and since it contains transferrin, it is assumed to be 
recognized by cellular transferrin receptor and internalized via endocytosis.13  
3. The complex is sufficiently stable to remain intact, and sufficiently lipophilic to be 
able to slowly cross the cellular membrane via diffusion (passive diffusion was 
observed in cells in in vitro studies). 
Unequal exposure time to vanadium and different administered doses in human 
individuals and animals, mainly rats, are the reasons that the effect of vanadium 
observed in humans is not as dramatic as in animals 
 
Many coordination complexes of vanadium, mainly oxidovanadium(IV), have been 
demonstrated as potent insulin-like compounds (Table I.3) and several of them have 
proven to be specially effective. Great efforts have been made to prepare vanadium(IV) 
and (V) complexes of high activity and low toxicity that are readily absorbed. Figure I.3 
presents some complexes with potential anti-diabetic properties. 
 
                                            
13
 Endocytosis is a process of the taking in of matter by a living cell via invagination of its membrane to form a 
vacuole. 
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Figure I.3. Examples of potential anti-diabetic complexes. VO(ema)2, VO(ma)2, VO(ka)2, VO(3hp)2 and VO(alx)2 are BEOV 
derivatives.  
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BEOV to date remains to be the most promising candidate in this field, none of 
vanadium complexes with insulin-mimetic properties so far has surpassed BEOV for 
glucose- and lipid-lowering in an oral administration; however, variety of conditions in 
different studies such as rodent species, levels of glycemia, residues of insulinemia etc., 
make unable a proper comparison of effect of all tested compounds. Since it became 
clear that ligands serve as “delivery system” of oxidovanadium(IV) to the target cells, 
the choice of functionalities became an important task. One of the important 
requirements is a high dissociation degree, since the compounds that do not dissociate 
readily have been found to show no insulin-mimetic effect in vivo [74,129]. Complexes 
BMOV, BEOV, VO(pic)2, VO(6MPA)2, VO(acac)2, and VO(Et-acac)2 seemed to comply 
with such requirement [130]. However, the use of a non-toxic ligands such as maltol or 
ethyl maltol, which are approved in many countries as food additives [131], was given 
preference to the use of ligands with a known problematic toxicity profile, e.g., 
acetylacetonate [132] or picolinic acid [133]. 
 
I.4.1.2 Vanadium in cancer treatment 
According to Domingo [134], metals could be divided into four groups: (1) metals with 
greatest toxicity that are widespread in the environment (arsenic, cadmium, lead, 
mercury, and uranium), (2) essential trace metals (chromium, cobalt, manganese, 
selenium, and zinc), (3) metals with biological importance (nickel and vanadium), and 
(4) metals of pharmacological interest (aluminium, gallium, and lithium). Interestingly, 
some metals being carcinogenic are able to treat cancer and vice versa - some metals 
that are essential micronutrients, can cause cancer directly or indirectly [78]. Both their 
carcinogenicity and aptitude to cure cancer can be explained by their ability to generate 
reaction oxygen species (ROS).14 Vanadium and arsenic are considered to be such 
cases [135-138]. By causing oxidative stress ROS damage macromolecules such as 
nucleic acids, proteins and lipids. As a result, chromosomal instability, variety of 
                                            
14
 Reactive oxygen species OS are oxygen species, by-product of various metabolic processes of molecular oxygen. 
ROS include superoxide anion radical (O
2-
), singlet oxygen (
1
O2), hydrogen peroxide (H2O2), the highly reactive 
hydroxyl radical (•OH) and so-called crypto-radicals. The deleterious effects of oxygen are assumed to result from its 
metabolic reduction to these highly reactive and cytotoxic species which have been implicated in the etiology of a 
wide array of human diseases, including cancer. 
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mutations, loss of organelle functions, damage of cell membrane [139], all of which are 
a straight road to cancer. 
The term „cancer‟ refers to more than 100 forms of this disease and each of these forms 
has unique features. However, the basic process that develops tumours is similar. 
Almost every tissue in the body can spawn malignancies and some can yield several 
types [140]. The development of cancer is mainly triggered by two gene classes, proto-
oncogenes and p53 tumour suppressor genes. In normal conditions, they maintain the 
life cycle of a cell by participating in cell‟s division and proliferation. Proto-oncogenes act 
as stimulators of growth, whereas tumour suppressor genes are inhibiting it. The 
importance of their tandem lies in the regulation of the cell life cycle, namely 
proliferation. Upon mutation, which is most likely to be induced via oxidative stress, the 
loss of regulation in both genes occurs. The mutations induce changes in the protein 
structure of proto-oncogenes thus turning them into carcinogenic oncogenes. This 
modification provokes uncontrolled excessive cell multiplication. Tumour suppressor 
genes, in contrast, contribute to cancer when they are inactivated by mutations. The 
resulting loss of functional suppressor proteins deprives the cell of crucial brakes that 
prevent inappropriate growth. Since cells that actively dividing are in a greater risk for 
acquiring such mutations, tumours generally originate from rapidly proliferating tissues, 
which means that proto-oncogenes are more likely to „host‟ a tumour than tumour 
suppressor genes. 
Cancer tumour development occurs in stages. When normal cells undergo genetic 
mutations, the cell proliferation begins to increase. As a consequence of excessive 
expression, hyperplasia15 (over reproduction) takes place. At this stage these changes 
are not reflected on the appearance of cells. With time, typically of a year scale, some of 
these altered cells undergo secondary mutation. The behaviour of the cells now is 
different because in addition to high-speed division (uncontrolled mitosis16), „new-born‟ 
mutated cells possess abnormal shape and orientation. At this phase dysplasia 
(abnormality of development) occurs. For the cancer to develop to clinical disease, the 
                                            
15
 Hyperplasia is the enlargement of an organ or tissue caused by excessive proliferation; considered as an initial 
stage in the development of cancer. 
16
 Mitosis is a type of cell division that results in two daughter cells each having the same number and kind of 
chromosomes as the parent nucleus, typical of ordinary tissue growth. 
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cells need to suffer another mutation and consequently many others. The affected cells 
become even more abnormal in growth and appearance. This is an early form of 
cancer, and in case of the absence of invasion of tumour cells into the surrounding 
tissue, it is called in situ carcinoma. Numerous attempts have been made to define the 
actual number of mutations that are responsible for cancer. When it became apparent 
that most tumours harbour many mutations, the number was estimated to be from ten to 
tens of thousands [141]. Nevertheless, many of these mutations do not contribute to the 
development of the tumour. In the case when series of mutations actually promote the 
tumour invasion, the mass is considered to have become malignant. Cancer begins to 
penetrate surfaces and barriers of body going through body structures and tissues (local 
invasiveness) and spread to other sites within the body (metastasize) by permeating or 
entering into the lymphatic vessels (regional metastasis)17 and/or the blood vessels 
(distant metastasis). 
Death from cancer worldwide is projected to continue rising, with an estimated 13.1 
million deaths in 2030 [142]. The development of targeted anticancer therapeutics is a 
hot topic in medicinal research. Despite of a great advancement of knowledge towards 
discovery of a cancer cure, the progress in this field has been relatively slow.  
When it comes to designing a drug, many challenges rise instantaneously. The most 
common hurdles in the drug discovery process (in vitro ADME tests) are stability of a 
chosen compound in physiological conditions, toxicity issues, mode of administration to 
a body, drug delivery to tumours, minimal exposure of normal tissue to the drug etc. 
However, one of the main challenges in the design of anti-cancer or any other type of 
drugs is an acute identification of a disease target. In the case of cancer DNA has 
always been considered a common molecular target [143]. Only recently a clinical 
relevance of the insulin-like growth factor has been demonstrated and identified as 
another target [141]. 
Platinum compounds are known for their wide application in cancer chemotherapy, in 
fact they are to date the only ones used in the treatment of patients diagnosed with 
cancer [144]. These pharmaceuticals act by binding to DNA. Cisplatin (square planar 
                                            
17
 Metastasis is the development of secondary malignant growths at a distance from a primary site of cancer. 
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Pt(II) complex (cis-dichlorodiamine platinum(II)) occupies the top position in the 
platinum drug pyramid [145]. Cisplatin was approved in 1978 as the first line therapy 
and clinically used ever since. The main drawbacks of this compound such as high 
toxicity, large volume intravenous infusions, lack of oral bioavailability and inherited or 
acquired resistance of some population of cancer cells, prompted a necessity to start 
searching for alternative drugs. The research led to development of second 
(carboplatin, 1986) and third (satraplatin, has not received an approval, phase III clinical 
trials in 2007) generation of anti-cancer pharmaceuticals. Carboplatin though showing 
similar to cisplatin clinical activity, has lesser effect on cytotoxicity of cancer cells. 
However, higher stability, which allows more time for the drug to reach the target 
molecule in its original form, makes carboplatin advantageous and more desirable for 
the therapy. Satraplatin received a great interest since it is the first orally active 
platinum-based chemotherapeutic drug. In tumour models it was found to behave 
similarly to cis- and carboplatin, and showed the activity against some acquired 
cisplatin-resistant tumour cell lines [143,146]. 
The success of cisplatin and carboplatin stimulated an intense search of other metal-
based cancer drugs with favourable toxicity. A wide range of metals such as ruthenium, 
palladium, gallium, iridium, rhodium, tin, vanadium, titanium, copper and gold are being 
studied as possible candidates in cancer treatment [147,148]. Ruthenium18 complexes 
[149-153] being in the lead are now a proven effective alternative to Pt-based 
complexes, followed by gallium, rhodium, titanium and vanadium compounds [43,154].  
Vanadium, known for possessing insulin mimetic and osteogenic effects [155], has been 
also found to have anti-tumour activity [5]. Moreover, vanadium compounds exhibit 
cytotoxic, mainly due to the generation of oxidative stress that can trigger apoptosis of 
cancer cells, and genotoxic effects [156,157]. Versatility of redox vanadium chemistry, 
i.e., many oxidation states and rapid interconversion between VIV and VV, allows 
vanadium to participate in biological redox chemistry and undergo ligand exchange 
reactions. The ability of vanadium compounds to interact and coordinate with biological 
                                            
18
 From all tested compounds, KP1019 ([IndH]trans-[RuCl4(Ind)2)] (Ind = indazole)) and NAMI-A ([ImH][trans-
RuCl4(DMSO-S)Im] (Im = imidazole)) are in the lead as they have both completed Phase I clinical trials. For more 
information see a detailed review by I. Tomaz and J. Costa Pessoa [43]. Another promising ruthenium anti-cancer 
agent is ONCO4417 has been reported by Antonarakis and Emadi in [152].  
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molecules has awoken a great interest in scientists on their way to „overturn the 
platinum paradigm‟ [143]. The first report on cytostatic effects of vanadate appeared in 
1965 [29]. The anti-tumour potential of organovanadium compounds, namely 
vanadocene Cp2VCl2, was demonstrated on Ehrlich ascites tumour in 1986 [158].  
Discovery of diverse biological effects of vanadium compounds (i.e., insulin-like action 
and reduction of hyperlipidemia and hypertension) established the potential therapeutic 
applications of these compounds. According to Evangelou [5], who wrote the first 
comprehensive review on vanadium in treatment of cancer, in last few decades, 
vanadium compounds have been considered as a new class of metal-based antitumor 
agents and are assumed to act through generation of ROS. Interestingly, Liu et al. [159] 
in their most recent studies of vanadium in the PC-3 human prostate cancer cell line, 
detected and speculated the capability of vanadium to control diabetes and cancer 
simultaneously. They interpreted and related this dual potential of vanadium as a result 
of vanadium-induced ROS generation. 
Vanadium complexes that have been reported to have anti-cancer potential, namely, to 
supress the proliferation of cancer cells, are presented in Figure I.4. Bis(η5-
cyclopentadienyl)vanadium(IV) (vanadocene, Cp2VCl2), derivatives are described in 
[160], bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxidovanadium(IV) (metvan) and 
related compound [5,161-166]. Others compounds reported are vanadate [159]; 
oxidovanadium(IV) silibinin, VO(silibinin)2 [167]; oxidovanadium(IV) oxodiacetate, 
VO(oda) [156]; V-cysteine complex [168], and vanadium(V) complexes with 
salicylaldehyde semicarbozone derivatives [169]. VO(acac)2 was found to block 
permanently the cell cycle in a human hepatoma cell line [170]. This compound was 
also tested as an MRI probe in studies for early detection of cancer [171]. Although the 
majority of tests of vanadium compounds as anti-cancer agents are typically performed 
in vitro, the number of studies in vivo impetuously increases [6,13,143,164,168,172-
175,180]. No tests in humans have been reported to date.  
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Figure I.4. Examples of vanadium compounds with anti-tumour effect. 
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Mechanisms of action of potent vanadium anti-cancer agents 
Cancer conditions vary significantly from case to case. In order to design a proper drug, 
accurate identification of a disease target is required. Most of the chemotherapeutic 
drugs are DNA-targeted thus DNA molecule is often chosen in studies with putative 
anti-cancer compounds. This was the reason for many scientists to study DNA cleavage 
activity of various metal-based compounds (section “Inorganic nucleases”). 
Evangelou in his review [5], highlighted the main capabilities of any designed drug that 
are crucial for achievement of an effective treatment. These properties are 
antiproliferation effect (reduction of cellular growth rate), cytostatic and/or cytotoxic 
effects - inhibition of cell growth and division, necrotic (uncontrolled) or apoptotic 
(programmed) cell death -, antimetastatic effect (reduction and/or inhibition of the 
cancer cells invasion and the metastatic potential), antiresistant effect (a drug should 
possess potency to sensitize drug-resistant cancer cells). Vanadium compounds seem 
to fulfil aforementioned criteria. They can act individually or in tandem with another 
metal-based drug, e.g. cisplatin. Vanadium chelated by EDTA was found to reduce the 
resistance of human ovarian cancer to cisplatin allowing this drug to fully exert its 
cytotoxic effect [176]. 
The main pathways for vanadium compounds to exert antiproliferative and cytotoxic 
effects on normal and malignant cell lines appear to be mainly via cell cycle arrest and 
interactions with DNA. Cell cycle arrest is expected to mediate through the inhibition of 
PTPs, however, it may also be exerted via activation of mitogen activated protein 
kinases (MAPKs superfamily) signalling pathway [5,177]. Metvan was found to induce 
cell apoptosis by inhibiting mitochondrial transmembrane potential, the generation of 
reactive oxygen species and depletion of glutathione [178]. VO(acac)2 was able to block 
the cell cycle permanently at the G1 phase on HepG2 cells in human hepatoma cell line 
[170]. Vanadyl sulfate, cysteine and V(III)-cysteine were found to exert antitumor effects 
on leiomyosarcoma bearing Wistar rats [175]. Also, VOSO4 promoted DNA damage in 
in human lymphocytes and HeLa cells [179]. Treatment with orthovanadate resulted in 
an inhibition of MDAY-D2 lymphosarcoma cells in mice assumed to act through 
generation of ROS [180]. Antitumor activity of vanadocene complexes, namely 
vanadocene dishloride, was found to take place via interaction with DNA‟s nucleotide 
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phosphate groups. As a result, labile vanadocene-DNA complexes form causing 
alterations in nucleic acid metabolism [181]. The mechanism of Cp2VCl2 interaction with 
DNA differs from that of cisplatin which forms covalent DNA adducts that are potentially 
mutagenic [5]. VO(oda) is another compound that exerts cytotoxicity via interaction with 
DNA. It was tested in human colon adenocarcinoma (Caco-2) cells and suggested to 
augment oxidative stress and thus DNA damage of the malignant cells [156].  
Given the increasing number of reports on vanadium anti-cancer activity in the last two 
decades, vanadium compounds have a possibility to become a new class of 
nonplatinum metal antitumor agents. However, more intensive basic and applied 
research is required. 
 
In addition to anti-diabetic and anti-cancer properties, vanadium complexes have shown 
activity against parasitical diseases. Rehder in his recent publication reviewed [13] 
potential vanadium compounds in the treatment of epidemic tropical diseases, which to 
date remain to be a serious problem taking away thousands human lives yearly. While, 
in the past few decades, there has been observable progress with respect to insulin-
enhancing and chemopreventive role of vanadium, little is explored about its effect on 
other diseases. 
Nowadays this gap is slowly becoming filled since many vanadium complexes are being 
investigated and tested as anti-parasitic [182-188], spermicidal [189,190], anti-viral 
[191], anti-HIV [192-195], and anti-tuberculosis agents [196-198].  
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 Vanadium(IV) acetylacetonate I.5
Oxobis(2,4-pentanedionato-O,O´)vanadium(IV) (VO(acac)2,) is a well-known compound 
among vanadium studies [199,200]. Since the discovery of the VO(acac)2 insulin-
mimetic activity in cell cultures [114], the interest to study its behaviour greatly 
increased. The efficiency of VO(acac)2 was found to be superior to that of VOSO4 which 
was intensively investigated for insulin-enhancing potential. VO(acac)2 received the 
attention as a promising anti-diabetic agent in the beginning of this millennium after the 
report of Reul et al. [18]. In this publication VO(acac)2 and VO(Et-acac)2 were shown to 
be more effective in glucose lowering in insulin-deficient diabetic rats than VO(malto)2, 
which was already well known for its insulin-mimetic properties, and by the time being 
had entered phase I clinical trials in humans. This finding allowed investigators to 
assume that VO(acac)2 and its H-acac derivatives may be superior to VO(malto)2 as 
insulin-mimetic agents. This hypothesis has perceptibly triggered new studies on the 
way to understanding the biologically relevant aqueous chemistry of VO(acac)2.  
The first preparation of VO(acac)2 was recorded over a century ago, in 1876 [201]. In 
1914 Morgan et al. [199] reported synthesis and characterization of VO(acac)2 and four 
decades later, in 1961, its crystal structure was published [200]. Since then, the physical 
properties of the compound have been extensively studied [202,203,204]. The IR 
spectrum of VO(acac)2 in the spectral range between 1600-400 cm
-1 was first 
investigated by Nakamoto et al. in 1961 [205] and complete IR and Raman data of the 
complex in the 4000-200 cm-1 range, were reported by Vlčková et al. [206]. The 
characteristic ʋ(V=O) stretch is observed at ca. 1000 cm-1 (often 998 cm-1)  
[207,208,209].  
VO(acac)2 has been used as an oxidizing agent in organic synthesis [210,211,212,213], 
precursor for the synthesis of VC [214,215,216,217,218] and catalyst for selective 
epoxidation of allylic alcohols in combination with terbuthyl hydroperoxide [11,219, 220]. 
The biological significance of vanadium compounds in a wide variety of biological 
systems has augmented also the studies of VO(acac)2 regarding its electrochemical 
behaviour and solution chemistry [115,119,116,209,221-223]. VO(acac)2 acts as 
nonspecific phosphotyrosine phosphatases inhibitor such as PTP1B, exhibits weight 
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and fat-reducing effect by enhancing signal traducer and activator of transcription 3 
phosphorylation induced by centrally administered leptin to normal rats [224]. In 
conjunction with insulin-enhancing activity [117,225], anti-cancer potential of VO(acac)2 
came into focus. The complex was found to inhibit the cell growth in a human hepatoma 
cell line in a dose- and time-dependent manner [170]. As an important part in 
understanding insulin-mimetic behaviour, Costa Pessoa et al. [119]. studied the stability 
and nuclease activity of VO(acac)2 and several oxidovanadium(IV) salen and salan 
complexes, as well as VIVO(phen)2(SO4). A variety of VO(acac)2-type complexes were 
explored on the way of searching new water soluble VO(acac)2-derived complexes for 
biological activity [209,226-229]. Among these derivatives are VO(hd)2, VO(acac-NH2)2 
and VO(acac-NMe2)2 [230,231], VO(Et-acac)2 and VO(Me-acac)2 [116,221]. These 
complexes were synthesized and characterized, and examined as inorganic nucleases 
together with VO(acac)2. VO(Et-acac)2 and VO(Me-acac)2 were also studied as 
potential insulin-mimetic compounds. Another study involving these compounds and 
VO(Cl-acac)2 is desulfurization of fuels with their ionic liquids [232]. Additionally, VO(Et-
acac)2 and VO(Me-acac)2 were tested in inhibition of alkaline phosphatase along with 
VO(acac)2, VO(CF3acac), and VO(Benzac)2 [233]. 
The coordination number and geometry of vanadium is ligand dependent [234]. In the 
solid state and in some non- or weakly-coordinating organic solvents (such as benzene, 
CH3Cl and even in acetonitrile), VO(acac)2 is a pentacoordinate complex [201]. 
However, when placed into aqua media or other polar solvents (such as methanol, DMF 
and pyridine), it becomes six-coordinated [235]. This mononuclear complex is 
coordinated by four oxygen atoms lying in a distorted square pyramidal coordination 
(Figure I.5). The vanadium atom lies above the basal equatorial plane (0.55 Å). The 
V=O bond length measured from the crystal structure is 1.5922 Å [116]. Upon 
dissolution in organic solvents, the vanadium coordinates a donor ligand (L) in the 
vacant site, generating products expressed as [VO(acac)2L] [236,237]. In aqueous 
media VO(acac)2 was determined by EPR and visible spectroscopy to form three 
species (Figure I.6) which are trans-VO(acac)2•H2O (A), cis-VO(acac)2•H2O (B) adducts, 
a hydrolysis product assigned as 1:1 vanadium atom with one acac- group (C), and 
another vanadium(IV) species which is NMR and EPR-silent. In freshly prepared 
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solutions A (85%) and B (5%) species are predominant, whereas the species C is not 
observed; the remaining 10% are assigned to vanadium(IV)-acac complexes with 
strongly antiferromagnetically coupled spins (such as the dimeric VO(acac) complexes). 
Solution of VO(acac)2 recorded after several days, showed significantly higher 
concentrations of C; species A remained relatively intact [116,209]. After 24 days at 
room temperature, the same solution contained about 25% A and 65% C. The species 
C can be observed in the reaction with polydentate ligands, where one acac- group is 
substituted, and the second acac- group remains resistant [238-241]. 
 
 
Figure I.5. Square pyramidal geometry of pentacoordinate VO(acac)2. 
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Figure I.6. Structure and possible isomers of oxobis(2,4-pentanedionato)vanadium(IV). The 
trans (species A) and cis (species B) isomers have the H2O molecule coordinated respectively 
trans and cis to V=O; and the 1:1 hydrolysis product (species C) may contain two or three 
coordinated water molecules and have an overall charge of +1 or neutral. Species A is identified 
to be the major species upon dissolution of VO(acac)2. 
 
The electronic spectra of acetylacetonate are dominated by the n → π* and π → π* 
transitions of the carboxylic groups. The spectra of VO(acac)2 have been intensively 
investigated and it has been shown that they are markedly solvent dependent [242,243]. 
VO(acac)2 spectra, located in the range 380-800 nm, show three bands indicating three 
“d-d” transitions. They were assigned to the b2 → e*, b2 → b1, b2 → a1* transitions [207-
209], following the energy level scheme derived originally by Ballhausen and Gray [244] 
from a molecular orbital study for a square pyramidal structure of C4ʋ symmetry (Figure 
I.7). 
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Figure I.7. Orbital correlation diagram for the transformation of a square pyramid to a trigonal 
bipyramid (C4ʋ  C2ʋ  D3h) and an octahedron to a trigonal prism (D3h ← C4v) under idealised 
local symmetries [9]. 
 
 
 Inorganic nucleases I.6
Nucleases are any enzymes that cleave nucleic acids. Natural nucleases, which belong 
to the class of enzymes called hydrolases, are usually specific in action, ribonucleases 
and deoxyribonucleases acting respectively only upon ribonucleic (RNA) and 
deoxyribonucleic acids (DNA). Some enzymes having a general action (such as 
phosphoesterases, which hydrolyse phosphoric acid esters) can be called nucleases 
because nucleic acids are susceptible to their action. Nucleases are found in both 
mammals and plants [245]. 
Nucleases that cut only those DNA molecules in which they recognize particular 
subunits are called restriction enzymes. Some of them cleave the target DNA molecule 
at random sites (Type I), but others split the molecule only at the recognition site (Type 
II) or at a fixed distance from the recognition site (Type III). Type II and III restriction 
enzymes are powerful tools in the elucidation of the sequence of bases in DNA 
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molecules. They play a fundamental role in the field of recombinant DNA technology, or 
genetic engineering.  
Inorganic nucleases are inorganic compounds which have demonstrated enzyme-
activity towards DNA. They are becoming increasingly important. They may function as 
artificial restriction enzymes offering the possibility for a) designing systems with 
sequence specificities different from those of natural endonucleases, for which inorganic 
nucleases showing site specificity are particularly interesting [246,247]; b) targeting 
DNA sequences to block gene expression at the molecular level in chemotherapy19 
[147]; c) studying nucleic acid conformations. A different and equally important 
motivation to study these compounds comes from predicting a possible undesirable 
DNA damage following the use of metal compounds as new options for therapeutic use 
on other diseases. According to Mancin et al. review [248], the development of these 
synthetic agents is advantageous as they may be even more efficient DNA cleavers 
than natural enzymes. 
Since DNA is sensitive to oxidative cleavage, which is known to be promoted by ROS 
via oxidative stress, many researchers have focused on metallonucleases capable of 
cleaving DNA oxidatively. In spite of their high efficiency and versatility, the products of 
cleavage by these complexes are not readily amenable to further enzymatic 
manipulations, and thus have limited use. Hydrolytic cleaving agents, on the contrary, 
do not possess these drawbacks. Their ability to efficiently cleave nucleic acids in a 
non-degradative manner with different levels of selectivity, made them preferable to 
oxidative agents. The hydrolytic cleavage is targeted at the phosphate ester bonds 
linking the nucleosides. Finding metallohydrolases capable of mimicking the function of 
natural endonucleases is a primary goal in this area of research.  
Transition metal complexes of Fe, Cu, V, Ni and Mn, among others such as Pt, Ru, Rh, 
Cr, Co, Y and Os, have been reported to mediate DNA oxidation in the presence of 
oxidants or reductants or without any assistant agents [246,249,250]. These complexes 
attack the sugar or base moieties of DNA and the mechanism of action often involves 
                                            
19
 Mainly, as potential substitutes for cisplatin in cancer chemotherapy, which is the case of Gallium, Ruthenium, 
Rhodium, Titanium, Tin and Vanadium compounds. 
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generation of reactive oxygen or metal-oxo species (ROS/MROS). Many excellent 
reviews on artificial metallonucleases can be further consulted [194,246,248,249,251-
261], some of which have been recently published [262-264].  
 
 Vanadium nucleases I.6.1
Among several transition metals that have shown nuclease activity, some examples are 
of VC. Some of them are known for their insulin-mimetic properties, and have been 
studied as possible therapeutic agents for diabetes mellitus since the very discovery of 
this disease [75]. 
The first case of nuclease activity by VC was reported in 1985 [265] for bleomycin 
vanadyl(IV) in the presence of hydrogen peroxide. This complex system was found to 
be more effective in attacking G-A (5´→3´) sequences than the bleomycin-iron complex 
system. In 1992, Sakurai et al. [266] tested DNA cleavage by hydroxyl radicals 
generated in a vanadyl ion-hydrogen peroxide system and have found VIVO2+ in the 
form of VOSO4. Another publication [267] reports about [VO(phen)(H2O)2]2
+, a new 
antitumor VC, which showed a strong cleavage towards supercoiled plasmid Col E1 
DNA. A year later [268], VOSO4 was shown to damage DNA which was explained by 
Fenton-like generation of hydroxyl radicals. The interest in V nucleases has since 
increased. In the beginning of this millennium many oxidovanadium(V) and 
peroxidovanadium(V) complexes were investigated as chemical nucleases and were 
found to cleave DNA on photoexposure to UV-A light [269-274]. In 2000, several 
cationic V(III) dimeric complexes with phenanthroline and similar ligands were shown to 
promote nuclease activity. In the same publication, Heater et al. [275] reported a strong 
nuclease activity for the V(IV) complex with phenanthroline. Another publication about 
VOSO4 appeared in 2001 by Stemmler and Burrows [276]; they studied guanine and 
deoxyribose damage in DNA oxidation by vanadyl and vanadate. In 2004, complexes of 
V(IV) with hydroxysalen ligands showed nuclease activity in the presence of an 
activating agent, either a reducing (MPA) or an oxidizing one (oxone) [277]. The authors 
did not establish the actual active vanadium species. Later, several cases were reported 
on photocleavage activity by V(V) complexes with ligands containing polyaromatic 
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groups (either derivatives of phenanthroline or naphthalene) which can dock to DNA. 
The photocleavage activity of phenanthroline peroxovanadate complexes was 
extensively studied by Sam et al. [270] and Chen et al. [274] who observed 
photocleavage activity with site selectivity by a V(V) complex with the Schiff base of 2-
hydroxy-1-naphthaldehyde and L-phenylalanine. Kwong et al. [271] examined another 
example of sequence-specific photocleavage by a V(V) peroxo complex. Since the time 
VO(acac)2 has been proposed as a particularly efficient insulino-mimetic/insulin-
enhancing compound [115], much interest has been focused in its in vivo biological 
behaviour. Costa Pessoa et al. [119], when comparing the nuclease activity of several 
different types of V(IV)Cs with salen-, salan-, and pyran-type ligands for possible 
therapeutic application, also studied VO(acac)2 and VO(phen)2. They found these two 
compounds to be very active towards DNA.  
Most of the DNA-vanadium cleaving agents developed over the past few years promote 
photo-induced DNA cleavage, whereas their “chemical nuclease activity” is relatively 
poor even in the presence of activating agents. Chakravarty‟s group [278-282] greatly 
contributed in the study of photocleavage activity of oxidovanadium(IV) complexes. 
They explored VC with different phenanthroline derivatives and often observed an 
efficient DNA photocleavage activity. In 2009, Leelavathy et al. [283] studies of DNA 
cleavage properties of macrocyclic binuclear VIVO complexes showed a significant 
promotion of oxidative DNA cleavage under physiological conditions in the presence of 
H2O2. Continuing DNA photocleavage activity studies, Du et al. [284] tested two mixed-
ligand (thiosemicarbazones and bipyril) oxidovanadium(IV) complexes. Two novel 
oxidovanadium(IV) complexes of phenanthroline bases investigated by Prasad et al. 
[285] induce a single-strand DNA cleavage under oxidizing conditions (H2O2). Another 
example of oxidative DNA cleavage is found in research by Raman et al. [286]; they 
assumed that the hydroxyl radicals are likely to be the reactive species responsible for 
the cleavage of plasmid DNA by the synthesized complexes containing a pyrazolone 
derivative Schiff base. Recently, Patel et al. [287] synthesized several 
oxidovanadium(IV) complexes with ciprofloxacin and uninegative bidentate ligands such 
as 1-(2-hydroxyphenyl)ethanone, salicylaldehyde, 2-hydroxy-1-naphthaldehyde, 2-
hydroxy-5-methyl-propiophenone, 5-bromosalicylaldehyde, 3,5-dibromosalicylaldehyde 
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and investigated their DNA cleavage without any activating agents. Cationic µ-oxo V(III) 
dimers of the type [V2OL4Cl2]
2+ (L = 1,10-phenanthroline, 3,4,7,8-tetramethyl-1,10-
phenanthroline, 4,7-diphenyl-1,10-phenanthroline, or 2,2´-bipyridine) have been shown 
to bind strongly to DNA and lead to its degradation, assuming the involvement of 
oxidative base loss [275]. Islam et al. [288] have reported the DNA cleavage and the in 
vitro insulin-mimetic activity of four bis(maltolato)vanadium(III)-polypyridyl complexes. 
Two of these complexes (dpq and dppz ligands) have been found to promote DNA 
cleavage, requiring no external additives such as H2O2. They concluded that neither 
hydroxyl nor superoxide radicals are involved. The research group of Parac-Vogt 
[289,290,291] has been thoroughly investigating the hydrolytic cleavage of RNA and 
DNA by polyoxovanadates by NMR spectroscopy using DNA-model substrates, 4-
nitrophenyl phosphate and bis-4-nitrophenyl phosphate. Their two most recent works 
are devoted the hydrolysis of serine-containing peptides by vanadates [292] and the 
mechanism of p-nitrophenyl acetate (pNPA) hydrolysis by vanadate ions [293]. 
Evidently, VCs have been widely explored for their possible nuclease activity. In many 
reported cases the possible DNA damage is evaluated prior to conducting studies on 
insulin-mimetic effect and considering any compound for the treatment of diabetes. 
Typically, nuclease activity studies are performed at micromolar metal ion 
concentrations, at which the metal ion speciation is unknown. This can explain why to 
date it is not yet clear which vanadium species are actually active towards DNA 
breakage.  
 
  Other nucleases I.6.2
Many coordination complexes with metal centres were prepared to serve as nuclease 
mimics. Interest in the development of chemical nucleases is constantly increasing. A 
majority of the metal compounds reported to cleave DNA oxidatively, however a 
considerable progress has been made in the design and study of metal complexes that 
promote phosphodiester hydrolysis.  
Literature survey revealed numerous publications on a variety of transition metal 
complexes with enzyme-like action as well as some articles on some lanthanide 
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complexes tested as nucleic acid cleavage agents. In many cases metal ions, chosen to 
synthesize a compound that will be further tested as a possible nuclease, are divalent. 
Divalent (Cu, Fe, Mn, Zn, Co, Ni, Cd, Cr, Ru and Pt) and some tetravalent metal ions, 
such as V and Cr, are important catalytic centres in a designed metallonuclease [294-
296]. Among such a diversity of metals, copper and iron compounds seem to have 
taken a leading role; they possess the highest number of studies conducted on the way 
to finding efficient artificial nuclease.  
After it has been reported that lanthanide and transition metal ion complexes can 
promote the hydrolysis of DNA [297], a new wave of research on the development of 
artificial metallonucleases, namely synthetic DNA hydrolytic agents containing metal 
ions, grew intensively. It is well known that DNA is particularly resistant to spontaneous 
hydrolysis. Estimated half-life time at 25 ºC and pH 7 is between hundreds of thousands 
to hundreds of millions of years [298]. Although many natural enzymes have metal ions, 
such as Ca(II), Mg(II) and Zn(II), Fe(III) and Fe(II) as their active centres, their synthetic 
analogues, apart from Fe(III), which is a promising candidate, are far from being 
competitive with them. In fact, as shown in the literature, these metal ions are not as 
popular as the others (e.g., Fe(III) and Cu(II)), when it comes to choosing a catalyst for 
designing a nuclease. Synthetic catalysts for DNA hydrolysis with good activity have 
been obtained by using Ce(IV), Cu(II), and Fe(III) complexes, but Zn(II)-based agents 
are generally less efficient [299-301]. 
According to the review of Hegg and Burstyn [247] in order to promote hydrolysis of 
phosphate esters in DNA molecule, a metal ion should possess the following features: 
a) lability to substitution (ability to exchange ligands very rapidly); b) strong Lewis acids 
(ability to polarize carbonyl bonds); c) high charge density (ability to bind to the hard 
oxygen anions of the negatively changed phosphodiester backbone). The combination 
of these characteristics makes a metal a potent candidate for the role of nuclease.  
In accordance with the aforesaid key criteria for effective hydrolytic activity, the most 
effective hydrolytic metal ions have been shown to be lanthanide ions (Ln(III), Eu(III), 
Dy(III), Ce(IV)), as well as Zn(II), Ca(II), Cu(II) and, to some extent, Fe(III) [253]. 
However, literature suggests that metal ions, other than lanthanides, are sporadically 
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effective in DNA hydrolytic cleavage. Indeed, trivalent lanthanides were demonstrated to 
accelerate the hydrolysis of DNA and a number of papers were published on hydrolysis 
of phenyl phosphate esters and DNA by La(III), Er(III), Tm(III), Yb(III) and Lu(III) ions 
[302-309].  
Among transition metals that showed a great merit in cleaving DNA, mainly in a 
oxidative manner, are copper, iron, platinum, ruthenium, zinc, cobalt, manganese and a 
few others. A brief overview of artificial nucleases that most often appear in the 
literature is presented below.  
 
I.6.2.1 Copper nucleases 
Copper complexes have attracted attention due to their redox properties. Countless 
experiments have been carried out testing different copper compounds as enzyme 
mimics. Several well-known and thoroughly studied cleavage agents are [Cu(phen)2]
+ 
(phen = 1,10-phenanthroline)20 [310-323], Cu-BLM (BLM = bleomycin) [324,325], 
metalloporphyrin [326-328], cuprous ion with flavonoids [329] etc. Copper complexes 
are typically used in the development of oxidative-cleaving agents [246,325,330-346]; 
however many examples of Cu(II) complexes promoting hydrolytic mechanism of DNA 
cleavage are also reported [347-357].  
I.6.2.2 Platinum nucleases 
Since platinum compounds were the first metal based complexes used as antitumor 
agents in cancer therapy, they were soon studied as inorganic nucleases. Cisplatin as 
the most effective anti-tumour compound and a representative of all potential platinum 
anti-cancer drugs is known to act via interaction with DNA. However, the acting 
mechanism is not cleaving but rather unwinding. Cisplatin binds to DNA molecules via 
chloride ligand exchange [358]. The planar aromatic cation intercalates between 
adjacent base pairs which leads to unwinding and distortion of the strands 
[359,360,361]. After cisplatin is administered, one of the chloride ligands is slowly 
substituted by water (an aqua ligand), in a process termed aquation. The aqua ligand in 
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 The 1,10-phenanthroline-copper complex was the first synthetic coordination complex demonstrated to have an 
efficient nucleolytic activity 
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the resulting [PtCl(H2O)(NH3)2]
+ is itself easily displaced, allowing the platinum atom to 
bind to bases. Of the bases on DNA, guanine is preferred [362]. 
I.6.2.3 Ruthenium nucleases 
Ruthenium compounds are becoming popular in anti-cancer research, and have gained 
a special attention as inorganic nucleases. The targets of ruthenium based potential 
anti-cancer complexes continue to be debatable [43]. As in the case of platinum 
compounds, the majority of ruthenium complexes promote intercalative binding to DNA 
instead of cleaving it [147,154,363-366]. NAMI-A and KP1019, two important anti-
cancer agents, showed irrevocable coordination with DNA. To date their final targets 
and the mechanism of action are still unclear [367], nevertheless, some tests showed 
that their antitumor activities have stronger effect on plasma proteins and glutathione 
than on DNA [153]. Ruthenium(III) and (II) complexes with phenanthroline, 
phenanthroline-dione, dipyridophenazine [368], diimine, bypiridine, dipyridoquinoxaline, 
nitrofurylsemicarbazone ligands [369] were found to bind to DNA in a non-covalent 
manner prior to the photo- [154] or oxidative cleavage [370]. Ruthenium(II) polypyridyl 
complex was found to hydrolytically cleave DNA in a enzyme-like mode [371]. 
Organomettalic Ru(II)-arene compounds, developed by the groups of Sadler [148,372] 
and Dyson [373], were found to directly coordinate to the DNA bases. 
I.6.2.4 Iron nucleases 
Since the natural antitumor antibiotic iron-bleomycins (Fe-BLMs) [374-376] were found 
to efficiently promote double-strand DNA cleavage, many studies of iron-containing 
complexes have been carried out. Considering that Fe-BLMs, effective chemical 
nucleases, act only in the present of external additives, many attempts have been made 
to develop iron-containing cleaving agents with different functional groups in order to 
augment the cleaving effect. Among many tested complexes, there are examples of 
[Fe(EDTA)]2 [377], methidiumpropyl-EDTA-iron [378], (µ-oxo)diiron(III) complexes [379-
381], and ferrocenes [382]. Compounds reported to date mainly promote oxidative 
breakage [383,384], however, studies of hydrolytic cleavage can also be found 
[385,386]. 
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Other metals such as zinc [337,346,355,387-391], manganese [392-394], nickel 
[337,340,344,355,394-396], cobalt [337,342,344,346,397], chromium [394,398-400,], 
molybdenum [401,402], rhodium(III) [43,403], yttrium(III) [404] gadolinium(III) [405] with 
varying ligands are also reported, though explored to a lesser extent, since their 
compounds are not as effective as those aforesaid.  
It is also important mentioning salen metal complexes, which have been designed as 
nucleic acid reagents to induce specific damage in DNA or RNA. Mn [406], Ni [407], V 
[119,277], Cu [408,409], Co [410], Ru [411], Fe [412] salen-containing complexes [413] 
were demonstrated as effective DNA cleavers. 
Impressive progress towards obtaining efficient metallonucleases has been achieved 
since their first report. However, the successful practical implications are still 
complicated by a number of things, among which are absence of selectivity and 
satisfying cleavage efficiency specified by double strand scission. The design of a really 
effective model of metallonuclease is one of the most demanding tasks in biochemical 
research field. 
 
 Methodologies for studying inorganic nucleases I.6.3
Mechanistic studies of DNA molecule as a substrate are complicated by the 
extraordinary resistance of the phosphodiester bond. Supercoiled plasmid DNA, being a 
more accessible substrate, is typically used for such studies. 
The most common method in efficient evaluations of cleavage reaction of 
metallonucleases is digestion of plasmid DNA in controlled conditions followed by gel 
electrophoresis analysis of the three products of degradation of the pDNA which are Sc, 
Nck and Lin forms. Some of the major methodologies frequently used in the field of 
metallonucleases are listed in Figure I.8. In practical applications it is common to 
combine two or more techniques to get more valuable information.  
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Figure I.8. Methodologies used to study DNA cleavage activity of inorganic nucleases (adapted 
from 246). 
 
 
 DNA and DNA Cleavage I.7
 Briefly about DNA  I.7.1
The nucleus of every cell contains a DNA molecule, a carrier of genetic instructions, 
used in the development and functioning of all known living organisms and many 
viruses. The molecule consists of two strands that wrap around each other to resemble 
a twisted ladder (double-stranded helix), whose sides, made of sugar and phosphate 
molecules, are connected by "rings" of nitrogen-containing chemicals called bases. 
Each strand is a linear arrangement of repeating similar units called nucleotides, which 
are composed of one sugar (deoxyribose), one phosphate (related to phosphoric acid), 
and a nitrogenous base, presented by purine bases (adenine and guanine) and 
pyrimidine (thymine and cytosine) (Figure I.9). Adenine (A) always pairs with thymine 
(T) via two hydrogen bonds. Guanine (G) is connected to cytosine (C) via three 
hydrogen bonds. These four nitrogenous bases of DNA are arranged along the sugar-
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phosphate backbone in a particular order (the DNA sequence), encoding all genetic 
instructions for an organism. The two DNA strands are held together by weak bonds 
between the bases. Each time a cell replicates, DNA molecule undergoes unwinding 
and the breakage of the bonds between the base pairs. 
 
 
Figure I.9. Schematic structure (a) and chemical composition of DNA (b). 
 
DNA molecules are classified into genomic linear (encountered in majority living 
organisms) and plasmid DNA (found mainly in bacteria). DNA molecule in bacteria cells 
is commonly found in the form of cyclic supercoiled double strand. One single strand 
scission unravels the supercoiled DNA (form I) to a relaxed open circular one (nicked, 
form II), while a second scission on the complementary strand, generates a linear DNA 
form (form III). These three DNA forms can be easily separated and quantified by gel 
electrophoresis (Figure I.10) allowing a simple and rapid analysis [246]. 
a b 
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Figure I.10. Cleavage of the plasmid DNA, three form of the DNA molecule.  
 
Due to local deviations in the sugars or the bases, DNA can isomerize into different 
forms. The most important forms are A-DNA, B-DNA (both right handed helices) and Z-
DNA (left handed helix) (Figure I.11) [414]. 
 
 
Figure I.11. Three different forms of DNA; A-DNA (left), B-DNA (center) and Z-DNA (right). 
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 DNA cleavage I.7.2
In all living systems from bacteria to humans, DNA cleavage is a crucial process 
operated by natural enzymes called hydrolases [415]. Since they are ubiquitous in a 
living organism, they function in all situations where partial or complete digestion of 
nucleic acid is required. This is the case of not only degradation and senescence but 
also replication and recombination21. Nucleases that break the phosphodiester bond 
within a polynucleotide chain are named endonucleases, and those that cut at the end 
of the chain bear the name of exonucleases. This type of cleavage, where the 
phosphodiester bond undergoes scission, is recognized as the DNA hydrolysis and is 
encoded in the program of every living cell. The other two types are oxidative and 
photocleavage. In both cases reactive oxygen species (ROS) are responsible for DNA 
damage. Similar reduced oxygen species that are generated as reactive intermediates 
make photochemical and oxidative DNA cleavage almost undistinguishable. However, 
ROS can originate from completely different sources. Development of artificial 
nucleases has shown that most of them cleave DNA molecule mainly via an oxidative 
mechanism [416].  
 
I.7.2.1  Hydrolytic cleavage 
The phosphodiester bonds in biopolymers are cleaved in a base-specific manner by the 
type II restriction endonucleases, which are considered to be the best studied of the 
nucleases to date as to both their in vivo role and their use as tools in the techniques of 
molecular biology. However, the role of their metal centres, particularly ZnII, MgII and 
FeII, in natural hydrolases is yet to be elucidated. This is one of the reasons why 
synthetic metallohydrolases are important to study [247]. The interest in designing 
synthetic systems capable of reproducing the effective activity of natural hydrolases is 
stimulated by the possibility of providing useful alternatives to the restriction enzymes 
currently used as laboratory tools in biotechnology and molecular biology. 
                                            
21
 To date, evidence for the involvement of nucleases in the replication and recombination processes in eukaryotes is 
chiefly circumstantial. 
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Phosphate esters bonds in DNA molecule are remarkably resistant towards hydrolysis22 
[417], nevertheless, natural nucleases are able to cleave them very efficiently with 
impressive rate acceleration [264]. A nucleophilic attack at the DNA phosphate 
backbone is the generally accepted mechanism of the DNA hydrolysis reaction, 
resulting into formation of a five coordinate intermediate (Figure I.12), which can be 
stabilized by the catalyst. Subsequent cleavage of either the 3‟-PO, typical in enzymatic 
systems, or the 5‟-PO results in a strand scission.  
The presence of the metal ions, acting as Lewis acids, always favours the breakage of 
the phosphodiester bonds by 1) activating water or hydroxide as nucleophile;  
2) activating  phosphate group towards nucleophilic attack; and 3) increasing the 
leaving group ability of the departing alcohol (Figure I.12) [247,298,418-420].  
 
 
Figure I.12. Reaction mechanism of the DNA hydrolysis by natural enzymes [416]. The scission 
is shown via activation of water or hydroxide as nucleophile (left), activation the phosphate 
group to facilitate nucleophilic attack (centre) or increment of the leaving group ability of the 
departing alcohol (right). 
 
                                            
22
 The half-life for hydrolysis of phosphodiester bond in DNA at physiological conditions (pH 7 and 25 ºC) has been 
estimated to be 130 000 years [247]. This peculiarity makes it difficult to perform any mechanistic tests using DNA as 
a substrate. 
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Many natural enzymes such as phosphatases23, nucleases or topoisomerases that are 
capable of catalysing the hydrolysis reaction of a phosphate bond, act via a similar 
mechanism.  
 
I.7.2.2  Oxidative cleavage 
Since DNA cleavage under physiological conditions is practically inert toward P–O 
hydrolytic cleavage, spontaneous DNA degradation occurs mainly through different 
pathways, involving C–O cleavage, nucleobase ring opening or radical attack which 
means an oxidative type of cleavage. Numerous amount of reviews have been 
published on this topic [139,421-433]. 
Oxidative DNA damage is involved in diverse biological phenomena and consists of 
several kinds of lesions, mainly, strand breaks, base modifications, and DNA-protein 
crosslinking. However, little is known about the existence of a chemical relationship 
among them or the ratio by which these different types of lesions are produced. 
The oxidation of DNA and its components takes place in the presence of reactive 
oxygen, nitrogen, or chlorine species (ROS/RNS/RCS) such as hydrogen peroxide 
(H2O2), hypochlorous acid (HOCl), hydroxyl radical (
•OH), superoxide (•O2
 
) , singlet 
oxygen (1O2), nitryl chloride (NO2Cl), peroxynitrite (ONOO
-), nitrous acid (HNO2) [423]. 
They are generated in vivo by various exogenous and endogenous mechanisms such 
as aerobic metabolism, mitochondria, peroxisomes, cytochromes P450, xanthine 
oxidase, the neutrophil respiratory burst, other phagocytes, and hypoxia reperfusion 
injury, xenobiotics, ionizing radiation, UV irradiation, ultrasonication etc. [429]. ROS 
normally exist in all aerobic cells in balance with biochemical antioxidants. Oxidative 
stress occurs when this critical equilibrium is disrupted because of excess ROS, 
antioxidants depletion, or both. This leads to a damage of nucleic acids (variety of DNA 
lesions including chemical modification of both purine and pyrimidine bases), proteins 
and lipids [427].  
                                            
23
 The role of phosphatases is to remove a phosphate group from its substrate by hydrolysing phosphoric acid 
monoesters into a phosphate ion and a molecule with a free hydroxyl group. Nucleases, including restriction 
enzymes, protect a cell against virus infection by cleavage of the foreign DNA or by degrading cellular DNA during 
apoptosis (programmed cell suicide) of the affected cell. Topoisomerases resolve topological problems of DNA in 
replication, transcription and other cellular transactions by cleaving one or both strands of the DNA 
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Numerous types of ROS can be formed by all body tissues [427]. Oxygen itself is, 
thermodynamically, a potent oxidizing agent [423]. The most common oxygen centered 
free radicals are as •OH, •O2
 
, H2O2 and 
1O2 [430,432]. An attack of these different 
species on DNA can be distinguished by the pattern of damage that is caused to the 
other DNA bases. For instance, •OH produces a multiplicity of products from all four 
DNA bases, whereas singlet oxygen is selective for guanine, the most oxidisable base 
in DNA [434,435], in fact, 8-hydroxyguanine is the most widely used „„marker‟‟ for 
oxidative DNA damage [436]. 
The hydroxyl radical is a highly reactive species that can cause non-enzymatic 
scission of DNA. Hydroxyl radical is short-lived, but the most damaging radical within 
the body. It is thought to be generated within cells and tissues where it can attack 
proteins, lipids, and DNA, thus initiating secondary radical reactions that can produce 
irreparable cellular damage. This type of free radical can be formed from •O2
 
 and H2O2 
via the Harber-Weiss reaction [437]. The reaction is very slow and is catalysed by iron. 
The first step of the catalytic cycle involves reduction of ferric ion to ferrous: 
Fe3+ + •O2
 
 → Fe2+ + O2 
The second step is the Fenton reaction: 
Fe2+ + H2O2 → Fe
3+ + OH− + •OH 
•O2
 
 + H2O2 → 
•OH + OH- + O2 
 
The interaction of iron with H2O2 produces 
•OH as first observed by Fenton and 
described in 1894 [438]. These reactions are significant as the substrates are found 
within the body and could easily interact [462]. 
Superoxide anions are formed when molecular oxygen (O2) acquires an additional 
electron, leaving the molecule with only one unpaired electron. Within the mitochondria 
•O2
 
  is being formed continuously. The rate of formation depends on the amount of 
oxygen flowing through the mitochondria at any given time and the presence of 
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exogenous components (redox cycling compounds) [439,440]. While superoxide radical 
can be directly toxic [441], in the presence of lipids it has a limited reactivity, raising a 
question about its true toxicity. Thus, its action is frequently considered to result from a 
secondary production of the more reactive •OH species by the iron-catalyzed Haber-
Weiss reaction. As that production may be limited in vivo, it was proposed that nitric 
oxide reacting with •O2
 
 generates secondary cytotoxic species (peroxinitrite anion). 
Superoxide is often cited as the species responsible for the toxicity of oxygen [442]. 
The hydrogen peroxide is produced in vivo by many reactions, mainly by enzymatic 
ones. Corresponding enzymes are located in microsomes, peroxysomes and 
mitochondria. In plant and animal cells, superoxide dismutase is able to produce H2O2 
by dismutation of •O2
 
, thus contributing to the lowering of oxidative reactions [421]. The 
natural combination of dismutase and catalase shows a true cellular antioxidant activity 
by contributing the removal of H2O2 which is also able to diffuse easily through cellular 
membranes. Interestingly, H2O2 is unique in that it can be converted to the highly 
damaging hydroxyl radical or be catalysed and excreted harmlessly as water. H2O2 is 
converted to water during the conversion of glutathione to oxidized glutathione by 
glutathione peroxidase. If H2O2 is not converted into water 
1O2 is formed. 
The singlet oxygen is not a true radical but can be formed during radical reactions and 
also cause further reactions acting as a catalyst for free radical formation. It is reported 
to be an important ROS especially in reactions related to UV exposition [443,444,445].  
 
Another type of radical that has been often mentioned in the past few decades is 
“crypto-  ” radical, so-called “non-free” radical [384,446]. Though the oxygen species 
formed by “crypto-OH” radicals are assumed to mimic those of •OH-radicals, their 
reactions differ since “crypto-OH radical” is expected to form under oxygen limited 
conditions. This type of radicals was found to resist the inhibition by traditional •OH 
radical scavengers [446,447]. Interestingly, many studies on generation of free radicals 
carried out in phosphate buffer, which is a medium widely used in physiological reaction 
systems, obtained results that indicate the formation of “crypto-OH radical” rather than 
of common •OH radical [448-452]. 
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As in the hydrolysis of DNA, the contribution of metal ions is very significant for the 
oxidative cleavage. Due to the ability to participate in one-electron transfer reactions 
redox-active metal ions favour the generation of ROS. These metals are most of 
transition metals. Some of them are found at the active sites of most oxidases and 
oxygenases, again due to their ability to accept and donate single electrons [453]. 
 
Fe(II)\(III) and Cu(I)\(II) are the most common transition metal ions that suggested to 
mediate oxidative damage of DNA via activating ROS and RNS [454-459]. These 
deleterious species are believed to be generated from the less damaging reactive 
oxygen species - superoxide radical anion and hydrogen peroxide - in a Fenton reaction 
catalyzed by iron(II) or cuprous ions (Fenton-like reaction). Interestingly, generation of 
ROS and RNS is suggested to be the unifying factor in determining the toxicity and 
carcinogenicity of metals such as Fe, Cu, Cr, V, Cd, Hg and Ni. The first four metals, 
i.e., Fe, Cu, Cr and V, undergo redox-cycling reactions, while Cd, Hg and Ni, as well as 
Pb, deplete glutathione and protein-bound sulfhydryl groups [431,453]. Mixtures of two 
or five metal ions, FeII, CdII, NiII, CrIII, CuII, results into formation of 8-hydroxy-
deoxyguanosine and strand breaks in DNA by Fenton-type reactions [460]. 
Common mechanisms involving the Fenton reaction, generation of the superoxide 
radical and the hydroxyl radical appear to be also involved for chromium, vanadium and 
cobalt and are primarily associated with mitochondria, microsomes and peroxisomes. 
However, for the Fenton reaction to occur in vivo enough of „catalytic‟ metal should be 
present. As reported by Halliwell and Gutteridge [432,461], despite of high content of 
iron in body fluids, particularly blood, there is no „free‟ iron is available in vivo that would 
be capable of promoting Fenton chemistry as efficiently as in vitro, unless iron ions 
remain unabsorbed after some extra supplementation or in the special case of iron 
overload. [383]. Therefore, iron, being a powerful promoter of free-radicals reaction in 
vitro [462], may not be as powerful in in vivo environment, where it and especially other 
catalytic metal ions seem to be available only to a very limited extent [463]. This means 
that the importance of the Fenton reaction has been proven under in vitro conditions, 
but not under in vivo conditions. On the other hand, if both H2O2 and copper or iron 
catalysts are available in vivo, then •OH will be formed in biologically-significant 
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amounts. The question “Does the Fenton reaction actually produce •OH radicals?” had 
been raised repeatedly in the past few decades [432,447,464]. Despite of increasing 
amount of evidences „against‟ the relevance of Fenton reaction, many scientists 
reported and discussed iron-dependent free-radical reactions insisting on their 
existence in vivo and considering ROS important mediators of oxidative damage 
[429,430,432,451,462, 465,466].  
 
One of the most studied DNA oxidative mechanisms is by natural compound bleomycin 
which is used in the clinical treatment of certain cancers [457]. Its activity is thought to 
rely on its capability to oxidize both strands of the DNA molecule at once - direct double 
strand cleavage. Since bleomycin is such an effective DNA-cleaving agent which can 
damage the DNA of the affected cells triggering apoptosis, many research groups have 
made (synthetic) models of bleomycin, to study various aspects of the DNA cleavage 
process. FeII bleomycin system is well studied (Figure I.13) [374,467]. 
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Figure I.13. Proposed mechanism of oxidative cleavage by bleomycin. 
 
I.7.2.3  Photocleavage 
Photocleavage possesses oxidative mechanism of DNA cleavage by photochemical 
means via 1) generation of ROS by organic compounds or metal complexes [250] and 
2) direct UV-induced DNA damage, which involves a direct UV-promoted dimerization 
reaction between two pyrimidine residues (thymine and cytosine) to form mutagenic and 
cytotoxic DNA lesions [468]. It is important to emphasize that most DNA-cleaving 
agents are not directly responsible for the observed DNA damage but rather create 
labile sites for the further cleavage or more likely – generate highly reactive 
intermediates which affect sugars [467] or nucleobase intermediates [249]. When 
designing systems with photoexcitable or redox active metal centres that bind/cleave 
specific sites of the DNA strand, both direct (oxidation of deoxyribose residues by 
hydrogen abstraction or electron transfer from nucleobases to the metal ion) and 
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indirect mechanisms (generation of reactive species such as the hydroxyl radical or 
singlet oxygen mediated by the metal centre) for DNA cleavage can be included. 
Photochemical DNA damage can be divided into two types (Figure I.14): a one electron 
process (type I) and a pathway involving singlet oxygen (type II). Both processes start 
with the photosensization of the DNA cleavage agent and result in the oxidation of 
guanine base. 
 
Figure I.14. Type I and II photochemical cleavage of DNA. 
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II. Experimental techniques  
In this study agarose electrophoresis was chosen as the main technique to explore DNA 
cleavage properties of vanadium compounds. Circular dichroism was used to study 
DNA-vanadium interactions. These were the only techniques where plasmid DNA was 
used. Other techniques such as cyclic and square wave voltammetry, UV/Vis, 
fluorescence and NMR spectroscopy were employed to examine vanadium solution 
chemistry, i.e., redox reactions, compound stability, possible vanadium species and free 
radicals formation under organic and inorganic buffers. 
In this chapter the principles of each technique is briefly described.  
 
 Electrophoresis. Agarose gel electrophoresis (AGE) II.1
Electrophoresis is the easiest, most popular and important molecular biological 
technique for both analysis and purification of nucleic acids [469]. It is the technique by 
which mixtures of charged macromolecules, including proteins, nucleic acids, and 
carbohydrates, are rapidly resolved in an electric field. When a mixture of different 
nucleic acids is allowed to move through a gel matrix, they can be separated on the 
basis of their shape and size. There are three methods of nucleic acid electrophoresis: 
agarose gel electrophoresis (AGE), polyacrylamide agarose gel electrophoresis (PAGE) 
and capillary electrophoresis (CE). Each type is suited to a particular task. The function 
of both agarose and polyacrylamide matrices is to provide different sized holes in the 
molecular sieve. Therefore, the main difference between these two techniques is the 
size of pores in the gel matrix, which automatically means that the DNA fragments being 
separated are of different size. AGE is useful for the separation of DNA fragments 
ranging from 50 base pair to several millions of bases, while PAGE permits 
conformational analysis of proteins from 5 to 2000 kDa and correspondingly sized DNA 
fragments. Typically, AGE is performed in a horizontal tank, whereas PAGE is run 
vertically. Finally, CE is an increasingly important technique, performing electrophoretic 
separation of biopolymers in narrow buffer-filled capillaries. CE is particularly important 
for protein separation because the charge of proteins at a particular pH depends on the 
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distribution of charged amino acid side-chains, therefore they can be separated 
electrophoretically in liquids. CE can also be carried out in gels as well as in liquids, but 
it is a difficult task to make gels in very fine capillaries. CE is a useful technique for 
determination of diffusion coefficients of small DNA molecules, detection of DNA-buffer 
interactions, and analysis of the sequence dependence of counterion binding in free 
solution (without sieving liquid polymers) [470].  
 
 Theoretical considerations II.1.1
Electrophoresis is a movement of electrically charged particles or molecules in a 
conductive liquid medium, usually aqueous, under the influence of an electric field 
(Figure II.1).  
 
 
Figure II.1. Principles of separation. 
 
When an electric field is applied to the negatively charged nucleic acid, the molecule is 
able to migrate through the gel matrix submerged in a conductive medium. In water, 
poorly conductive medium, only the few positive and negative ions that are present will 
move to the electrodes of opposite sign. However, in a highly conductive aqueous 
medium, an electrical circuit is completed. As current flows, the aqueous part of the 
medium is subjected to electrolysis: the generation of hydrogen gas (H2) and alkali  
(OH-) at the negative electrode (cathode), and oxygen gas (O2) and acid (H3O
+) at the 
positive electrode (anode). This phenomenon is called electrolysis of water:  
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          (eq. II.1) 
 
At the positive electrode, electrons can be removed from water to produce oxygen gas 
and acid: 
      
  
 
 
     
         (eq. II.2) 
 
 
A molecule under an electric field is affected by the force (F) which is dependent on the 
net charge of the molecule (q) and the strength of the field (E/d, V·cm-1) into which it is 
placed: 
 
   
 
 
               (eq. II.3) 
 
where 
E = potential difference between the electrodes (V) 
d = distance between them (cm) 
 
Upon the movement of molecules, a frictional force is initiated that diminishes the 
migration of particles toward an electrode. This force is dependent on the size and 
shape (radius, r) of the molecule and the viscosity of the medium (η, Pa·s = kg/(s·m)), 
through which it passes with a certain velocity (ʋ, cm·s-1). Therefore: 
 
                     (eq. II.4) 
 
By combining eq. II.3 and II.4, we obtain: 
 
 
 
                   (eq. II.5) 
 
Now, when an electrical field is established, and the electrical force equals frictional 
force (     ), the particles move with a terminal velocity that can be expressed as: 
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             (eq. II.6) 
 
Therefore, the velocity at which the molecule moves is proportional to the field strength 
and net charge and inversely proportional to the size of the molecule and the solution 
viscosity (stiffness of the gel). The proportionality constant is called the absolute 
electrophoretic mobility, µ, cm2V-1s-1: 
 
  
 
 
 
 
     
           (eq. II.7) 
 
Two fundamental parameters are important for understanding the mechanism of 
electrophoresis. The first one is described by Ohm‟s law: the voltage (E, volts) is directly 
proportional to the electrical current (I, amperes) and resistance (R, ohms): 
 
                  (eq. II.8) 
 
The second parameter is the power (P, watts), which measures the amount of heat 
produced. It is directly proportional to E and I and can be expressed as: 
 
                  (eq. II.9) 
 
Substitution of E with the product     from eq. II.8 gives the following: 
 
                 (eq. II.10) 
 
 
Agarose and polyacrylamide gel matrices must be as electrically neutral as possible. 
Otherwise a phenomenon known as electroendosmosis (EEO) takes place. It is the 
mass movement of water toward the cathode, against the movement of the 
macromolecules, which is usually towards the anode. The mass flow of water towards 
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the cathode is caused by fixed negative charges in the agarose gel (sulphate and 
carboxyl groups on the agarose). 
Agarose is a polysaccharide extracted from red algae and used for a variety of life 
science applications, especially in gel electrophoresis. The apparatus for conducting 
AGE is relatively simple: an electrophoresis chamber and power supply; gel casting 
trays; sample combs, around which molten agarose forms sample wells in the gel. After 
an agarose gel solidifies, it is placed inside the chamber filled with electrophoresis 
buffer, usually TBE (Tris-Borate-EDTA) or TAE (Tris-Acetate-EDTA), and covered with 
a transparent lid. Before samples are electrophoresed, a loading buffer should be 
added. This buffer consists of glycerol (30%) and bromophenol blue with xylene cyanol 
(0.25% each). Glycerol is important for two reasons: 1) it increases the density of a 
sample to prevent the dissolution in the running buffer and thus ensure its sinking into 
the gel pocket; 2) due to its viscosity the DNA-complex cleavage reaction is believed to 
be diminished or ceased. Bromophenol blue and xylene cyanol serve as tracking dyes 
that allow visual monitoring of migrating samples.  
Another important component in AGE is ethidium bromide (EtBr). It is a fluorescent dye 
that intercalates between bases of nucleic acids and allows very convenient detection of 
DNA fragments in gels. It can be incorporated into agarose gels, or added to samples of 
DNA before loading to enable visualization of the fragments within the gel. As might be 
expected, binding of EtBr to DNA alters its mass and rigidity, and therefore its mobility. 
Supercoiled DNA has a lower ability to bind EtBr, therefore it is important to multiply a 
value obtained from form I DNA by a correction factor [393].  
The separation of the molecules is achieved by the movement of negatively charged 
nucleic acid molecules through an agarose matrix in the formed electric field. The 
movement depends on the length and conformation of the molecule. The main benefit 
of AGE is that it can be a preparative technique as DNA can also be recovered without 
any harm to it at the end of the process. Agarose gel is not supposed to interact with 
DNA samples [471]. 
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DNA strand breaks are quantified by measuring the transformation of the supercoiled 
form into nicked circular and linear forms. After the DNA is cleaved, its integrity is 
impaired and nucleic acid is present in the gel as fragments. The double-stranded 
plasmid DNA exists in a compact supercoiled conformation (Sc, I form). Upon formation 
of strand breaks, the supercoiled form of DNA is disrupted into the nicked circular form 
(Nck, single strand cleavage, II form) and the linear form (Lin, double strand cleavage, 
III form). If one strand is cleaved, the supercoiled form will relax to produce a nicked 
circular form. If both strands are cleaved, a linear form will be produced. Due to 
differences in shape and size, these three forms migrate with different velocities: 
Sc>Lin>Nck [329,460]. Three are different modes of migration: Ogston sieving, 
reptation, rigid rods.  
Ogston sieving  
When nucleic acid fragments are present in the gel as tumbling globules, Ogston 
sieving occurs. The probability of the passage through the matrix depends on the radius 
of gyration24, meaning that molecules can pass if they possess a radius of gyration less 
than that of the matrix pores. On the contrary, when the radius of gyration is significantly 
bigger than the cross-sectional area of a pore, DNA fragments are expected not to 
pass, and thus to not separated. 
Reptation 
It is established that the electric field can deform nucleic acids, which are initially 
present as globules. The reptation mode is a good example since the DNA fragments 
start as molecules with globule-shaped conformation and switch upon electrical supply 
to linear-shaped molecules (coiled or helical) that enter the gel „end-on‟, migrating in a 
reptile-like movement. A larger fragment will therefore migrate with lower mobility than a 
shorter one.  
                                            
24
 The radius of gyration is the average radius of the area swept by a molecule as it undergoes random thermal 
tumbling. 
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Rigid rods 
To separate larger molecules more quickly, it is necessary to increase the strength of 
the electric field. However, this increase influences the coiled or helical shape of DNA 
fragments since the high voltage stretches the molecules towards the positive electrode. 
The stretched molecules thus adopt a rigid, rode-like shape. On one hand, this 
phenomenon progresses the migration through the gel matrix. On the other hand, 
however, the separation of the molecules will be significantly impaired since the rigid 
rod structure of the nucleic acids allows them to proceed through the passage at size-
dependent rates. 
 
 UV-vis spectroscopy II.2
Spectrophotometry is a branch of spectroscopy that measures the radiant energy 
transmitted or reflected by a body as a function of wavelength. Ultraviolet and visible25 
(UV/Vis) spectroscopy is a routine technique in analytical chemistry for analysis of 
clinical samples, environmentally significant pollutants, industrial and forensic samples, 
and the quantitative determination of different analytes, such as transition metal ions 
and highly conjugated organic compounds (e.g., DNA, RNA, proteins). It is particularly 
useful in detecting and quantifying colourless substances in solution; the detection limit 
is 10-5-10-6 mol·L-1. Spectroscopic analysis is commonly carried out in solutions but 
solids and gases may also be studied [472,473].  
Solutions of transition metal ions can be coloured (i.e., absorb visible light) because d 
electrons within the metal atoms can be excited from one electronic state to another. 
Therefore, absorption measures transitions from the ground to the excited state: 
M ground state +hʋ M*(excited state) 
                                            
25
 Ranges of electromagnetic spectrum: ultraviolet (UV, 200-380 nm), visible (Vis, 380-780 nm) and infrared (IR, 780-
3x10
5
 nm) 
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The colour of metal ion solutions is strongly affected by the presence of other species, 
such as certain anions or ligands. This, in turn, changes the wavelength of maximum 
absorption.  
Molecules containing π-electrons or non-bonding electrons (n-electrons) can absorb the 
energy in the form of ultraviolet or visible light to excite these electrons to higher anti-
bonding molecular orbitals. When light of certain intensity (I0), at certain wavelength (λ) 
passes a solution of certain concentration placed into a cuvette, a part of this light will 
be absorbed (Figure II.2) [474].  
 
Figure II.2. Schematic representation of a beam of light (I0) passing through an absorbing 
medium, in a quartz cuvette, and being absorbed (I). The intensity of light is represented by the 
thickness of the arrows. 
 
The absorption or reflectance in the visible range directly affects the perceived colour of 
the chemicals involved. In this region of the electromagnetic spectrum, molecules 
undergo electronic transitions.  
 
 Theoretical considerations II.2.1
According to the Lambert-Beer‟s law, the absorbance of a solution is directly 
proportional to the concentration of the absorbing species in the solution and the path 
length: 
                   (eq. II.11) 
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where  
A = absorbance 
ε = extinction coefficient (M-1cm-1) 
C = concentration of the analyte (M) 
l = optical path length of the cuvette through which the light passes and is absorbed by 
the analyte (cm) 
Absorbance is also expressed as: 
                    (eq. II.12) 
 
Many different types of spectrophotometers have been designed, nonetheless all have 
a similar assembling (Figure II.3), i.e., a light source (often Tungsten filament (300-
2500 nm), a deuterium arc lamp, which is continuous over the ultraviolet region (190-
400 nm), Xenon arc lamp, which is continuous from 160-2000 nm; or more recent - light 
emitting diodes for the visible wavelengths), a monochromator for wavelength 
dispersion, a sample holder, a transparent sample container (typically quartz cuvette), a 
light detector (typically, a photomultiplier tube, a photodiode, a photodiode array or a 
charge-coupled device), and a readout device for measuring output from the detector.  
 
 
Figure II.3. The components of typical absorption elements in a spectrophotometer. 
  
Light source Monochromator Sample 
container 
Detector Read out 
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 UV–vis spectroscopy of VC II.2.2
Unlike vanadium(V), which is a diamagnetic d0 metal, V(IV) is paramagnetic d1 and can 
be conveniently studied using UV-Vis spectroscopy. A square pyramidal V(IV) complex, 
normally containing the VO2+ centre, in ideal conditions26 [244], possesses C4ʋ 
symmetry (dxy ground state, Figure I.7) and therefore, represents an axial system 
(Figure II.4). The electron can be excited into the doubly degenerate e level (dxz, dyz), 
the a1 [d(x
2−y2)] or the b1 [d(z2)] level, consequently giving rise to three bands.  
Under realistic conditions, distortion occurs, which reduces the C4ʋ symmetry to C2ʋ, 
(rhombic system). The degeneracy of the e level is lifted (Figure I.7) and four transitions 
can be observed. Despite the changes caused by distortion, the d-d transition model 
remains. A 3d1 metal ion electronic configuration of vanadium(IV) complexes normally 
give rise to three bands (Table II.1). Band I is the lowest energy band that often appear 
as one broad band but consequently splits in two, IA and IB. Band III is mainly covered 
by the intense charge-transfer (CT) bands or appears just as a shoulder on the low-
energy side of the CT band. This is especially the case if a considerable π interaction 
between vanadium and its ligand system [9]. 
 
                                            
26
 Model of molecular orbital treatment proposed by Ballhausen and Gray for the [VO(H2O)5]
2+
 [244]. 
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Figure II.4. The orientation of d orbitals towards the faces and edges of a cube. 
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Table II.1. Typical ranges of vanadium bands in UV-Vis spectroscopy. 
Bands IA IB II III 
C4ʋ 
b2 → e  b2 → a1 b2 → b1 
d(xy) → d(xz, yz)  d(xy) → d(x2 – y2) d(xy) → d(z2) 
C2ʋ 
a2 → b1 a2 → b2 a2 → a1 a2 → a1 
d(xy) → d(xz) d(xy) → d(yz) d(xy) → d(x2 – y2) d(xy) → d(z2) 
λ, nm 900-620 690-530 480-330 
 
 
 Circular Dichroism II.3
Circular dichroism (CD) occurs in a UV–Vis spectrum if there is a chiral (the one that 
cannot be superposed on its mirror image) element, commonly a centre of chirality, in 
the compound. In substances with optical activity (chiral) the left and right circularly 
polarized beams are traveling at different speeds and are absorbed to a different extent 
[9,414].  
Light is an electromagnetic radiation which has an electrical and a magnetic component. 
These components are perpendicular to each other and to the direction of propagation 
of the light wave (Figure II.5). CD deals with circularly polarized light in which the 
electric field vectors trace out helices. Electrons of a chiral molecule, since it has no 
reflection plane, move in a helical manner. Hence, the interaction between a chiral 
molecule and left- and right-handed photons is different. Therefore, CD is the difference 
in absorption, A, of the left and right circularly polarized light of a chiral molecule (eq. 
II.13). “Dichroism” is used to denote direction-dependent light absorption. 
                   (eq. II.13) 
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Figure II.5. Types of light polarization: linear (electric vector direction constant, magnitude 
varies) and circular (electric vector direction varies, magnitude constant) [414].  
 
The difference between the molar absorption coefficients for left and right circularly 
polarised light,         , is called circular dichroism.    can be calculated from the 
ellipticity27 which emerges from different absorptions of the left and right hand polarized 
                                            
27
 Ellipticity refers to the elliptically polarized light which is the polarization of electromagnetic radiation such that the 
tip of the electric field vector describes an ellipse composed of unequal contributions of right and left circular polarized 
light. Most CD spectropolarimeters, although they measure the changes of intensity (the true differential absorption of 
light), produce a CD spectrum in units of ellipticity, θ. Nowadays this unit is regarded as obsolete. 
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components [414]. Any chiral molecule exhibits both positive and negative CD signals. 
The CD version of the Lambert-Beer‟s law (eq. II.11):  
                    (eq. II.14) 
CD is a very popular technique to study biological systems, much more than non-
biological systems. Due to the large size of biomolecules, detailed structural analysis of 
their CD data is hardly possible. However, changes in the conformation of the 
macromolecule and its interaction with small molecules, especially achiral ones that do 
not solely induce CD, are successfully probed. Many advantages of CD as an 
instrument for high quality analysis of biomolecules have been reported [475]. Using 
CD, it is simple to identify the type of DNA geometry in the tested sample, i.e., A, B or Z-
form (Figure I.11). Since CD spectra is easy to measure, it is often the simplest 
technique to use to probe DNA conformational changes as a function of a wide range of 
variables such as pH, ionic strength, temperature etc., and to obtain information on the 
effect of added ligands and solvent concentration.  
Interestingly, without chirality the biochemical processes in our bodies would not 
function. As nucleotide molecules form the structure of DNA, they develop a twist that 
forms the double helix structure of DNA. It is the chirality or handedness of consisting 
components that gives DNA the spiral shaped helical structure. The chiral part of the 
DNA molecule is composed of ribose sugar units, without which the phosphate and the 
bases are achiral. The moment they are bonded together, the entire molecule becomes 
chiral and their transitions are able to produce CD spectra. Thus, the chirality of DNA 
molecules originates from the ribose sugar, helical structure and supercoiled (double-
stranded DNA) conformation. Single-stranded DNAs are structurally less well defined 
than duplex DNAs and their CD signal is smaller. Measuring CD spectrum means 
probing the asymmetry of the system. The purine bases show a negative CD signal, 
whereas the pyrimidine bases have a positive one.  
CD instruments, known as dichrometer or spectropolarimeter are used to obtain CD 
spectra (Figure II.6). The apparatus typically consists of a xenon lamp (170-1000 nm), a 
source of light which, when passing through the monochromator, becomes left and right 
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circularly polarized light, a monochromator, polariser, photoelastic modulator, emission 
and transition detectors. Since the CD of molecules is generally weak, a polarizer is 
implemented to ensure the induction of circularly polarized light. A photoelastic 
modulator produces alternatively left and right circularly polarized light with a switching 
frequency of 50 kHz, a frequency most commonly employed. This frequency becomes 
significant when an intensity fluctuation (different absorption of left and right circularly 
polarized light) appears after the light of a constant intensity passes through a sample 
and exhibits CD [476,477].  
 
 
Figure II.6. Schematic representation of CD spectropolarimeter [475]. 
 
 
 Voltammetry II.4
In contrast to many chemical measurements, which involve homogeneous bulk 
solutions, electrochemical processes take place at the electrode-solution interface. The 
main types of electroanalytical methods include potentiometric and potentiostatic 
measurements. Both types require at least two electrodes (conductors) that are 
immersed into a sample solution (electrolyte). These components constitute an 
electrochemical cell. The electrode surface is thus a junction between an ionic 
conductor and an electronic conductor. One conductor responds to the target analyte 
and is thus termed the working electrode. The other one, the reference electrode, is of 
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constant potential, i.e., independent of the properties of the solution. Electrochemical 
cells are of two types, electrolytic (when they consume electricity from an external 
source) and galvanic (when they are used to produce electrical energy). 
Voltammetry as one of the controlled-potential (potentiostatic) techniques, concerns the 
study of charge transfer processes at the electrode-solution interface, and is based one 
dynamic (non-zero-current) situations. The electrode potential here is being used to 
derive an electron transfer reaction and the resultant current is measured. The role of 
the potential is analogous to that of the wavelength in optical measurements. This 
parameter “forces” the chemical species to gain or lose an electron (reduction or 
oxidation, respectively). The resulting current reflects the rate at which electrons move 
across the electrode-solution interface. All potentiostatic techniques can measure any 
chemical species that is electroactive. i.e., that can be reduced or oxidized. Controlled-
potential techniques offer a wide range of advantages, from portable low-cost 
instrumentation with variety of electrodes to extremely low detection limits with very 
small (5-20 µL) sample volumes. 
 
 Theoretical considerations II.4.1
The objective of controlled-potential electroanalytical experiments is to obtain a current 
response that is related to the concentration of the target analyte. This can be 
accomplished by monitoring the transfer of electron(s) during the redox process of the 
analyte: 
     ⇌             (eq. II.15) 
where O and R are the oxidized and reduced forms, respectively, of the redox couple. 
This reaction will occur in a potential region that makes the electron transfer 
thermodynamically or kinetically stable. For systems controlled by the laws of 
thermodynamics, the potential of the electrode can be used to establish the 
concentration of the electroactive species at the surface [CO(0,t) and CR(0,t)] according 
to the Nernst equation: 
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        (eq. II.16) 
where Eº is the standard potential for the redox reaction, R is the universal gas constant 
(8.314 JK-1mol-1), T is the Kelvin temperature, n is the number of electrons transferred in 
the reaction, and F is the Faraday constant [96487 C (coulombs)]. On the negative side 
of Eº, the oxidized form thus tends to be reduced, and the forward reaction (reduction) is 
more favourable. The current resulting from a change in oxidation state of the 
electroactive species is termed the faradaic current because it obeys Faraday‟s law, i.e., 
the reaction of 1 moL of substance involves a change of n x 96487 C. The resulting 
current-potential plot, known as the voltammogram, is a display of current signal 
(ordinate) versus the excitation potential (abscissa). The exact shape and magnitude of 
the voltammetric response is governed by the process involved in the electrode 
reaction. The total current is the summation of the faradaic currents for the sample and 
the blank solution as well as the nonfaradaic charging background current [478-480].  
 
 Cyclic voltammetry  II.4.2
Cyclic voltammetry (CV) is one of the most versatile electroanalytical techniques for the 
study of electroactive species. It allows rapid observation of redox behaviour over a 
wide potential range. CV involves the cycling of the potential of an electrode, which is 
immersed in an unstirred solution, and measuring the resulting current. The controlling 
potential applied across these two electrodes is an excitation signal. For CV, the 
excitation signal is a linear potential scan with a triangular waveform (Figure II.7). A 
cyclic voltammogram is obtained by measuring the current at the working electrode 
(often DME – dropping mercury electrode) during the potential scan. The 
voltammogram is a display of current versus potential (Figure II.8). In CV, a potentiostat 
applies a potential to the electrochemical cell and a current to a voltage converter which 
measures the resulting current. The current is displayed on a recorder as a function of 
the applied potential.  
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Figure II.7. Potential time excitation signal in a cyclic voltammetric experiment [478]. 
 
 
Figure II.8. Typical cyclic voltammogram for a reversible O+ne-⇌R redox process [478]. 
 
The utility of CV is highly dependent on the analyte being studied. The analyte has to be 
redox active within the experimental potential window. It is also highly desirable for the 
analyte to display a reversible wave. A reversible wave is obtained when an analyte is 
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reduced or oxidized on a forward scan and is then re-oxidized or re-reduced in a 
predictable way on the return scan as shown in Figure II.8. Even reversible couples 
contain polarization overpotential and thus display a hysteresis between absolute 
potential and the reduction (cathodic peak, Epc) and oxidation peaks (anodic peak, Epa). 
This overpotential emerges from a combination of analyte diffusion rates and the 
intrinsic activation barrier of transferring electrons from an electrode to analyte. 
Reversible couples will display a ratio of the peak currents passed at reduction (ipc) and 
oxidation (ipa) that is near unity (1 = ipa/ipc). Accordingly, when ipa/ipc is less than or 
greater than 1, voltammograms are quasi-reversible or non-reversible [481].  
The method uses a working electrode in conjugation with an auxiliary electrode and 
reference electrode as a three-electrode system (Figure II.9). The working electrode is 
the one on which the reaction of interest occurs. The auxiliary electrode, often referred 
to as counter electrode, is the one in which an electrical current is expected to flow. 
Finally, the reference electrode is an electrode that has a stable and well-known 
electrode potential. Electrolyte is usually added to the test solution to ensure sufficient 
conductivity. The combination of the solvent, electrolyte and specific working electrode 
material determines the range of the potential. Electrodes are static and stay in 
unstirred solutions during CV. This "still" solution method results in cyclic voltammetry's 
characteristic diffusion controlled peaks. This method also allows a portion of the 
analyte to remain after reduction or oxidation where it may display further redox activity. 
Stirring the solution between CV scans is important for supplying the electrode surface 
with fresh analyte for each new experiment. The solubility of an analyte can change 
drastically with its overall charge. Since cyclic voltammetry usually alters the charge of 
the analyte, it is common for reduced or oxidized analyte to precipitate out onto the 
electrode. This layering of analyte can insulate the electrode surface, display its own 
redox activity in subsequent scans, or at the very least alter the electrode surface. For 
this and other reasons it is often necessary to clean electrodes between scans. DME28, 
                                            
28
 DME is a working electrode made of mercury. Like other electrodes this electrode is often used in electrochemical 
experiments. A flow of mercury passes through an insulating capillary producing a droplet which grows from the end 
of the capillary in reproducible way. Each droplet grows until it reaches a diameter of about a millimeter and then is 
releases into the analyte. As the electrode is used mercury collects in the bottom of the cell. Each released drop is 
immediately followed by the formation of another drop. The drops are generally produced at a rate of about 0.2 Hz. In 
addition, the drops growth causes capacitive current and faradaic current. 
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however, does not need to be cleaned or polished due to the self-renewing mercury 
droplets which have a smooth and uncontaminated surface free from any adsorbed 
analyte or impurity. 
Common working electrodes can consists of inert metals such as gold, silver or 
platinum, or inert carbon such as glassy carbon or pyrolytic carbon, DME and film 
electrodes. A regular working electrode has a radius within an order of magnitude of 
1 mm. Having a controlled surface area with a defined shape is important for 
interpreting CV results. To run CV experiments at high scan rates a regular working 
electrode is insufficient. High scan rates create peaks with large currents and increased 
resistances which result in distortions. Ultramicroelectrodes can be used to minimize the 
current and resistance.  
The counter electrode, also known as the auxiliary or second electrode, can be of any 
material that conducts easily and does not react with the bulk solution. Reactions 
occurring at the counter electrode surface are unimportant as long as it continues to 
conduct current well. To maintain the observed current, the counter electrode will often 
oxidize or reduce the solvent or bulk electrolyte.  
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Figure II.9. Schematic diagram of an electrochemical cell with a three-electrode setup. 
 
 Square wave voltammetry II.4.3
Like cyclic voltammetry, square wave voltammetry (SWV) is a derivative of linear sweep 
chronoamperometry technique, often referred as linear sweep voltammetry. However, 
more specifically, SWV is considered to be an improvement of staircase voltammetry. In 
SWV experiments the same three-electrode setup is employed. The current at the 
working electrode is measured while a waveform composed of a symmetric square 
wave is superimposed on the potential staircase sweep (Figure II.10). Oxidation or 
reduction of species is registered as a peak or trough in the current signal at the 
potential at which the species begins to be oxidized or reduced. In staircase 
voltammetry the potential sweep represents a series of stair steps. The current is 
measured at the end of each potential change, right before the next, so that the 
contribution to the current signal from the capacitive charging current is minimized. The 
differential current is then plotted as a function of potential, and the reduction or 
oxidation of species is measured as a peak or trough (Figure II.11) [478,482].  
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Since the SWV waveform diminishes the capacitance current, the detection limits of this 
technique are at concentrations as low as 10 nM [483]. Broader dynamic range and 
higher speed are an advantage of SWV over CV. Frequencies of 1-100 cycles per 
second permit the use of extremely fast potential scan rates due to which the entire 
voltammogram is recorded on a single mercury droplet. 
 
Figure II.10. Square-wave waveform potential sweep [480]. 
 
Figure II.11. Square-wave voltammograms for reversible electron transfer: Forward (A), reverse 
(B) and net (C) are three SWV currents. 
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 Fluorescence spectroscopy II.5
In this work we used fluorimetry, a highly sensitive technique for studying ROS, to 
analyse reaction mixtures of VO(acac)2 with terephthalic acid (TPA) under phosphate 
and MOPS buffers. Hydroxylated aromatic compounds are often used to detect OH 
radicals. The use of terephthalate has been extensively reported for the detection of 
hydroxyl radicals in vitro [484-488] and in vivo studies [489,490,491]. Unlike other 
dosimeters, e.g. salicylate and benzoate [455,492-494], used to detect •OH, the 
hydroxylation of terephthalic acid (TPA) yields only one product, i.e., 2-hydroxyl-
terephtalate (HTPA), which has a strong fluorescent emission around 435 nm when 
excited at 323 nm. Moreover, the efficiency of HTPA is at least three times higher than 
that of salicylate and benzoate [484]. The reaction is very sensitive and the detection 
limit of HTPA is as low as 0.5 nM [433].  
In contrast to absorption, which measures transitions from the ground state to the 
excited state, fluorescence deals with transitions from the excited state to the ground 
state. The significant advantages of fluorescence over absorption spectroscopy are 1) 
the ability to separate compounds on the basis of either their excitation or emission 
spectra, as opposed to a single spectra in UV-Vis; 2) low signal to noise, since emitted 
light is read at right angles to the exciting light; 3) high-sensitivity detection, i.e., 
fluorescence sensitivity is approximately a thousand times greater than in absorption 
spectrophotometric methods; 4) micromolar levels of concentration can be used. A 
major disadvantage of fluorescence is the sensitivity of fluorescence intensity to 
fluctuations in pH and temperature [473].  
Fluorescence occurs when a molecule absorbs photons in the UV/Vis light spectrum 
(200-900 nm) and shifts to a high-energy electronic state, known as excitation, and then 
emits photons as it returns to the ground-state orbital. The lifetime of the fluorescence, 
which is the average time between its excitation and its return to the ground-state, less 
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than 10-9 sec, is affected by temperature, pressure, quenchers29, and the different type 
of matrices used.  
Fluorimetry characterizes the relationship between absorbed and emitted photons at 
specific wavelengths. Emitted energy is less than the exciting energy; correspondingly, 
the emission wavelength is always longer than the excitation wavelength. This 
difference is due to the loss of energy through heat or vibration. Fluorescent compounds 
or fluorophores, commonly aromatic molecules, can be identified and quantified on the 
basis of their excitation and emission properties [495]. Spectral data are generally 
presented as emission spectra. A fluorescence emission spectrum is a plot of the 
fluorescence intensity versus wavelength. 
Once a molecule has absorbed energy in the form of electromagnetic radiation, there 
are a number of routes by which it can return to the ground state (the statistically most 
common energy state for room temperature chemical species). A Jabłoński diagram 
shows a few of these processes. (Figure II.12). The singlet ground, first, second and n 
electronic states are respectively depicted by S0, S1, S2 and Sn. When the light is 
absorbed, several processes occur: 1) a fluorophore is usually excited to some higher 
vibrational level of S2 to possibly Sn (photon absorption, A); 2) molecules in condensed 
phases rapidly relax to the lowest vibrational level of S1. This process is termed internal 
conversion (IC, represented by zigzag arrow), typical lifetime is 10-12 s or less; 3) return 
to the ground state which results into fluorescence emission (F) and occurring on the 
way from the lowest-energy vibrational state of S1 (thermally equilibrated excited state) 
to the ground state of S0. Typically, the emission spectrum is a mirror image of the 
absorption spectrum of the S0 → S1 transition. This implies that the spacing of the 
vibrational energy levels of the excited states is similar to that of the ground state.  
From the S1 level molecules can undergo a spin conversion to the second triplet state, 
T2 via intersystem crossing (ISC). When the S1 → T2 conversion occurs, molecules 
                                            
29
 Quenching is a decrease in the fluorescence intensity. Quenching can occur by a variety of processes. Fluorescent 
compounds can form nonfluorescent complexes with quenchers. This type of quenching occurs in the ground state 
and is considered to be a static one. Another type of quenching occurs via molecular collisions when the excited-state 
fluorophore is deactivated upon contact with some other molecules in solution or air. Among a variety of molecule-
quenchers are examples of oxygen, halogens, amines, acrylamide etc. Molecular oxygen is a good example.If a 
fluorophore in the excited state collides with O2, the former returns to the ground state without emission of a photon, 
i.e. fluorescence does not occur.  
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undergo T2 → T1 IC, followed by emission from T1. This loss of energy, when the spin 
state of the initial and final energy levels is different (e.g. T1 → S0), is called 
phosphorescence. Since fluorescence is statistically much more likely to occur than 
phosphorescence for most molecules, the lifetimes of fluorescent states are very short 
(10-5 to 10-8 seconds) and phosphorescence somewhat longer (from 10-4 seconds to 
minutes or even hours) [473]. 
 
Figure II.12. One form of Jabłoński diagram illustrating the absorption and the emission 
processes. The singlet ground state, first, and second electronic states are depicted by S0, S1, 
and S2, respectively. 
 
The three basic elements of any fluorescence-detecting instrument are a source of light, 
sample holder and detector. The spectrofluorometer (Figure II.13) consists of a light 
source, usually mercury or xenon, two monochromators for operating with the emission 
and excitation wavelength, a sample chamber equipped with working and reference 
cells, photomultiplier tubes as detector and appropriate electronic devices for 
quantifying the fluorescence [495]. 
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Figure II.13. Schematic illustration of a spectrofluorometer. 
 
 Nuclear magnetic resonance spectroscopy (NMR) II.6
In any form of spectroscopy, depending on the case, an electromagnetic field excites 
the molecules, atoms, electrons, or nuclei from the lower energy level to the upper one 
followed by the reversing transition (i.e., from excited to ground state). The intensity of 
the spectroscopic transition is determined by the difference in population of the two 
levels. In nuclear magnetic resonance (NMR) spectroscopy, where the upward 
transitions outnumber the downward ones by only one in 104 - 106, it is as if one detects 
only one nucleus in every 104 - 106. Unlike fluorescence spectroscopy, which allows 
working with micromolar level of concentration, NMR spectroscopy is effective within 
millimolar and molar range. 
All chemical elements possess a nucleus with a mass and charge. Most nuclei have at 
least one naturally occurring magnetic isotope with an intrinsic angular momentum 
known as spin. Since spinning charge creates a magnetic field, there is a magnetic 
moment, µ, associated with the angular momentum. These magnetic properties of 
certain nuclei are exploited using NMR spectroscopy most often to seek structural 
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information of the molecule [473,474]. When a magnetic nucleus is placed in a magnetic 
field, it adopts one of a small number of allowed orientations of different energy. For 
example, the proton has two permitted alignments with respect to the direction of the 
applied field. The nuclei can be aligned either with the field direction, or opposed to it 
(Figure II.14). The two orientations are not equivalent, and separated by an energy     
which depends on the size of the nuclear magnetic moment and the strength of the 
magnetic field [472]. This energy is required to change the more stable alignment to the 
less stable one. By applying electromagnetic radiation of frequency, ʋ, which causes the 
nuclei transition (commonly called as „spin flip‟) from the lower energy level to the upper 
one,     can be measured. The relation between     and ʋ is called the Planck relation 
[496]: 
                 (eq. II.17) 
where h is the Planck constant which is the quantum of action in quantum mechanics. 
Thus, NMR spectroscopy pursuits the measurement of     the energy required to 
change the alignment of magnetic nuclei in the applied magnetic field. 
 
 
Figure II.14. Schematic illustration of possible alignment of magnetic nucleus in an applied 
magnetic field. 
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  Theoretical considerations  II.6.1
When a sample is placed in an external magnetic field, the nuclear spin states come 
into existence; NMR active nuclei such as 1H or 13C absorb electromagnetic radiation at 
a frequency characteristic of the isotope. The NMR phenomenon is based on the nuclei 
that exhibit this phenomenon, their magnetic properties that make it possible, and the 
meaning of resonance [497,498]. 
Nuclei important for NMR are the ones with a fundamental property, i.e. spin. Nuclei are 
either spinning or nonspinning. The angular momentum of the spinning nucleus is 
defined in terms of spin angular momentum quantum number, I (spin quantum number). 
In the case of a nonspinning30 nucleus, I = 0, whereas for the spinning one   = 1/2. The 
magnitude of spin angular momentum |I| of the spinning nucleus is quantized in units of 
         and is related to the spin angular momentum quantum number: 
  √                   (eq. II.18) 
where ħ is the reduced Planck constant which is the quantum of angular momentum in 
quantum mechanics. 
The magnetic moment, μ, of a spinning nucleus is proportional to its spin angular 
momentum, I: 
  
   
  
               (eq. II.19) 
where, gN is called the nuclear g-factor which is characteristic of the particular nucleus, 
e is the charge of a proton and m is the mass of the proton. Altogether, 
   
  
  , which is 
known as the gyromagnetic ratio.  
The magnetic moment vector is in the same direction as the angular momentum vector. 
By substituting the value of the magnitude of spin angular momentum in eq. I.15 from 
                                            
30
 Nuclei with even number of protons and neutrons have I = 0 (e.g., 
4
He, 
12
C and 
16
O) and are spherical nonspinning 
nuclei. Nuclei with odd number of protons and neutrons have integral value of I (e.g. 1, 2) are nonspherical and thus 
nonspinning. Nuclei having odd value for the sum of protons and neutrons have half integral value of I (e.g., 
1
H and 
15
N have I =1/2 and 
17
O has I =5/2). Spherical nonspinning nuclei have a magnetic moment, µ = 0, whereas for 
spherical spinning nuclei µ ≠ 0. 
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eq. I.16 the relationship between the magnitude of magnetic moment and spin angular 
momentum quantum number is expressed: 
 
| |  
   
   
√            √          (eq. II.20) 
where     
 
   
 is called the nuclear Bohr magneton. 
Frequency (ʋ) and magnetic field (B) are principal in the mechanism of resonance. 
Resonance is the condition under which a „spin-flip‟ occurs: the nuclei in the lower spin 
state absorb the radiation and are excited to a higher energy state [474,496]. The NMR 
frequency of the nucleus radiation required for a transition from the lower to the upper 
level is determined by its gyromagnetic ratio γ, and the strength B of the magnetic field 
a nucleus experiences: 
  
  
  
             (eq. II.21) 
For the magnetic fields used in the NMR instruments, this frequency falls in the 
radiofrequency region of the spectrum. In other words, a suitable radiofrequency 
radiation can cause the transition from the lower to the upper spin state. 
The resonance frequency slightly depends on the chemical environment of the nucleus 
in the molecule, an effect known as a chemical shift. It distinguishes, for example, the 
three types of hydrogen atom in ethanol31 and, moreover, gives separately detectable 
signals for the hundreds of protons in a protein. 
Experimentally, there are two different ways to achieve resonance: 1) varying the 
frequency at a fixed magnetic field strength (frequency sweep method), and 2) varying 
the magnetic field strength while keeping the frequency constant [496]. In both setups 
the different protons (nuclei) are brought into resonance one by one by continuously 
varying either the field or the frequency (continuous wave spectrometry). This method, 
being popular to about the end of 1960s, is used nowadays in some lower resolution 
                                            
31
  Liquid ethanol, CH3CH2OH,has three different kinds of H atom which exhibit different resonance frequencies and 
thus give rise to three separate peaks distinguished by their integrated areas reflecting the number of protons of each 
type: OH, CH2, CH3 with corresponding ratio 1 : 2 : 3. 
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instruments. Most modern instruments use pulse Fourier Transform technique (Figure 
II.15). An FT-NMR spectrometer consists of a superconducting magnet, control console, 
detector and amplifier, radiofrequency detector, and a coil of wire that serves as an 
antenna for transmitting and receiving the radiofrequency radiation.  
 
Figure II.15. Schematic illustration of an NMR spectrometer. 
 
  51V NMR II.6.2
The aqueous speciation in some vanadium-organic ligand systems of biochemical 
interest can be determined by 51V NMR spectroscopy. In order to be accessible to 51V 
NMR, a vanadium compound has to be diamagnetic. This is the case for VV(d0), low-
spin VIII (d2), low spin VI (d4), V-I (d6) and V−III (d8). In addition, dinuclear VIV (d1) centres 
with strong anti-ferromagnetic coupling are detectable by NMR [9]. 
The popularity of 1H as an NMR nucleus can be explained by its large gyromagnetic 
ratio and high natural abundance which are favourable for maximizing     Nucleus 51V 
is considered to be unique among the transition metal nuclei with excellent NMR 
properties. High natural abundance and big gyromagnetic ratio, as in the case of the 
proton nucleus, explain its great receptivity32. 
                                            
32
 Receptivity of 
51
V magnetic nucleus relatively to 
1
H is 0.38.  
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Nucleus 50V exhibits less favourable NMR-relevant properties and therefore is not 
commonly employed in analytical NMR spectroscopy. NMR is a powerful tool in 
characterising peroxidovanadium complexes, especially 17O NMR [9]. 
To define 51V NMR chemical shifts, typically, VOCl3 is used as reference. The chemical 
shift of VOCl3 is set to zero. Due to its fast hydrolysis in moist air, the use of others, 
more easily manageable standards is considered. An aqueous solution of 1 M sodium 
metavanadate at pH 12 is sometimes employed, which contains the anions    
   (δ = -
535.7 ppm) and     
    (δ = -535.7 ppm). 
As reviewed in I.2.4, Vi, the monomeric vanadate ion, in solution at millimolar and higher 
concentrations, under different pH, is susceptible to form oligomeric species such as V2, 
V4, V5 and V10. This is well demonstrated by the distribution diagram presented in 
Figure II.16.  
The 51V NMR chemical shifts are presented as a function of pH [9]. Pettersson‟s group 
carried out this investigation [21]. Due to the decavanadate structure which contains 
three structurally different vanadium atoms (two central (Va), four corner (Vb) and four 
capping (Vc)), three resonances with the integral ratio 1:2:2 were obtained. Except for 
the cyclic tetramer, c-V4, and pentamer, V5, the shifts depend on pH, the nuclearity and 
protonation state. The tetrahedral vanadates all resonate in the range −534 to 
−586 ppm. Concentration of ionic medium also plays a significant role, for example, at 
physiological pH, the tetramer is the dominant species in the medium with the highest 
concentration (160 mM), and the monomer dominates in the medium with lowest 
concentration (0.3 mM). 
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Figure II.16. 51V chemical shifts as a function of pH for the H+ - H2VO4
-
 system in the range 
0.3 < V < 160 mM: decavanadate (for the three vanadium sites, Va, Vb and Vc), monovanadate 
[V1 =      
      
 and, below pH ≈ 2,    
 ], divanadate [V2=       
      
], cyclic tetravanadate 
(c-V4 =      
  ), linear tetravanadate (l-V4 =      
  ) and pentavanadate (     
  ) [21]. 
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III. Experimental Part 
All studies were performed with Millipore (MilliQ®) water-purification system of 
conductivity <0.054 µS/cm. All chemicals used were of analytical grade. 
 Synthesis III.1
Chemicals. Vanadium acetylacetonate (VO(acac)2, 98%, Aldrich), vanadium sulphate 
trihydrate (VOSO4•3H2O, 97%, Aldrich), 2,4-pentanedione (Hacac, 99.5%, Merck), 3,5-
heptanedione (Hd, 98+%, Sigma-Aldrich), 3-chloro-2,4-pentanedione (Cl-acac, 97%, 
Aldrich), 3-ethyl-2,4-pentanedione (Et-acac, 98%, Aldrich), 3-methyl-2,4-pentanedione 
(Me-acac, 85%, Aldrich), sodium metavanadate (Riedel-de Haën), sodium acetate 
trihydrate (99.5-100.5%, MERCK), 1,10-phenanthroline (99.5%, Riedel-de Haën) were 
used. 
Characterization. Elemental (C, H, N) analysis was performed by Laboratório de 
Análises at Instituto Superior Técnico, Lisbon. Fourier transform infrared spectroscopy 
(FTIR) spectra in the range of 4000-400 cm-1 were recorded on a Jasco FT/IR-4100 
spectrometer in KBr pellets.  
Procedure. VO(acac)2 1, VOSO4 9, Cu(acac)2 15, and Ni(acac)2 16, are commercially 
available, were used without further purification. Oxidovanadium(IV) complexes 2-5 
were obtained by reaction of vanadyl sulphate trihydrate with a slight excess of ligands 
[116,230]. 
VOSO4·3H2O (1.78 g, 8.21 mM) dissolved in water (25 mL) was placed into a water 
bath at 70 ºC. A 10-mL aqueous solution of sodium bicarbonate (2.30 g, 16.9 mM) was 
added dropwise under constant stirring (pH 4.8). This resulted in a colour change from 
light blue to dark blue-green. To this mixture 3,5-heptanedione (2.21 g, 17.2 mM) was 
added dropwise causing an immediate precipitation of green solid. The mixture was 
stirred at 70 ºC for 35 min and filtered upon cooling to room temperature. The green 
solid was washed with two 5 mL portions of water and dried under vacuum. 
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Oxidovanadium(V) complexes 6-8 were synthesized by three different published 
procedures [226-229]. 
µ-Dioxo-bis[oxo-(acetylacetonato)vanadium(V)], V2O4(acac)2. [226,228]. To a 50-mL 
aqueous solution of sodium monovanadate tetrahydrate (4.8 g, 40 mM) was added 2,4-
pentanedione (4 g, 40 mM). After stirring for 20 min at 50 ºC, the mixture was cooled 
down to room temperature and HCl was added dropwise to lower pH from 8 to 1.5. The 
solution immediately turned from yellow to orange and gradually, with pH decrease, 
became red-brown. To obtain a crystalline product, the mixture was stored at 4 ºC for 
20 h, washed with water and acetone, and dried under vacuum. 
Dioxo(2,4-pentanedionato(1,10-phenanthroline)vanadium(V), VO2(acac)(phen) 
[227]. To a solution of 1 (0.45 g, 1.69 mM) in dichloromethane (18 mL) a solution of 
1,10-phenanthroline monohydrate (2.5 mM) in the same solvent (18 mL) was added. 
The mixture was purged with air for 5 h. Precipitation of red-brown crystals occurred 
after ca. 3 h. To compensate the solution evaporation during the aeration time, 
dichloromethane (8 mL) was added. The crystals were filtered off, washed with diethyl 
ether, and dried under vacuum. Since the solid still contained dichloromethane, 
recrystallization from 1:1 methanol-acetylacetone mixture (v/v) was performed. 
Hydroxomethoxooxo(pentane-2,4-dionato)vanadium(V), VO(OH)(OMe)(acac) [229]. 
A solution of V2O4(acac)2 (0.36 g, 18.6 mM) in methanol (50 mL) was purged with 
nitrogen for 3 h until the volume was reduced by 50%. Obtained red-brown crystals 
were washed with cold methanol (3 mL) and dried under vacuum. 
Complexes 10-14, 22; 17-19; 20, 21, 23-27 and 28-36 were provided by Isabel Cavaco; 
Gisela Gonçalves; Susana Etcheverry and Somnath Roy, respectively. 
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Elemental analysis and IR spectral data.  
Complex 2: dark green solid; 74.7% yield; elemental analysis (%): calculated for 
[VO(C7H11O2)2] (found): C = 52.34 (51.52); H = 6.90 (7.16). IR (KBr, cm
-1): 1552, 1534, 
1411, 1371, 1311, 1248, 1186, 1170, 1076, 1000 (VO), 991, 954, 861, 810, 779. 
Complex 3: light green; 91.6% yield; elemental analysis (%): calculated for 
[VO(C5H6O2Cl)2] (found): C = 35.96 (36.01); H = 3.62 (3.48). IR (KBr, cm
-1): 1576, 1464, 
1424, 1374, 1352, 1298, 1049 (VO) [233], 1024, 1015, 905, 703, 638, 617, 509, 469, 
451. Complex 4: green; 54% yield; elemental analysis (%): calculated for 
[VO(C7H11O2)2] (found): C = 52.34 (52.19); H = 6.90 (7.12). IR (KBr, cm
-1): 1559, 1467, 
1454, 1376, 1331, 1296, 1259, 1173, 1066, 1000 (VO), 958, 916, 790, 780, 722, 686, 
618, 490, 463, 441. Complex 5: green; 70% yield; elemental analysis (%): calculated for 
[VO(C6H9O2)2] (found): C = 49.16 (49.05); H = 6.19 (6.93). IR (KBr, cm
-1): 1563, 1481, 
1429, 1337, 1300, 1178, 998 (VO), 982, 899, 732, 660, 619, 491, 468. Complex 6: 
dark brown; 61% yield; elemental analysis (%): calculated for [V2O4(C5H7O2)2] (found): 
C = 31.03 (30.45); H = 3.65 (3.85). IR (KBr, cm-1): 1580, 1534, 1413, 1384, 1348, 1294, 
1283, 1033, 991 (VO), 983, 949, 934, 818, 790, 775, 672, 604. Complex 7: light brown; 
72% yield; elemental analysis (%): calculated for [VO2(C17H15N2O2)] (found): C = 56.37 
(48.65); H = 4.17 (3.69); N = 7.73 (6.40). IR (KBr, cm-1): 1612, 1515, 1425, 1385, 1263, 
1227, 1189, 1139, 1027, 945, 932, 915 (VO), 889, 868, 852, 777, 736, 728, 703, 669. 
Complex 8: light green; 64% yield; elemental analysis (%): calculated for [VO(C6H11O4)] 
(found): C = 33.66 (26.76); H = 5.18 (4.43). IR (KBr, cm-1): 1590, 1530, 1384, 1360, 
1285, 1045, 1011, 978 (VO), 968, 757. 
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 Nuclease activity studies III.2
  DNA preparation III.2.1
The plasmid DNA (pDNA), used in AGE experiments, was pA1, which consists of a full-
length cDNA from Cytochrome P450 CYP3A1 inserted in the pBS plasmid vector 
(pBluescript33, Stratagene, UK) [499]. The pDNA was amplified in Escherichia coli, 
Mach1, and purified using Nucleobond® AX Anion Exchange Columns34 for quick 
purification of nucleic acids from MACHEREY-NAGEL.  
All manipulations with pDNA were always performed in MilliQ® autoclaved water. 
Chemicals. Tryptone enzymatic (Fluka), yeast extract (Fluka),, MgCl2, MgSO4, glucose, 
ampicillin sodium salt (Sigma-Aldrich), sodium chloride (99.5÷100.5%, Carlo Erba), 
isopropanol (Panreac, 99.8%), 70% ethanol (Panreac, 99,9%), filter Whatman 
polyethersulfone membrane (PuradiscTM 25 AS) were used. 
Instrumentation. BECKMAN AvantiTM CoulterTM Centrifuge J-251 with rotors J-14 and 
J-20, Eppendorf centrifuge 5418 and 5804, incubator, shaking incubator, pH meter from 
HANNA Instruments pH 211 with 7.0 and 4.0 pH standard solutions, autoclave machine 
(20 min, 121 ºC, liquid cycle), vortex were employed. 
Solution preparation. Luria-Bertani (LB) medium was prepared by dissolving under 
constant stirring tryptone enzymatic (10 g), yeast extract (5 g) and sodium chloride (5 g) 
in 1 L of water and after sterilized together with 30 mL open centrifuge tubes, 1000 mL 
Erlenmeyer flasks and 250 mL tapped centrifuge tubes (BECKMAN). 
                                            
33
 The type of plasmid, especially the size and the origin of replication (ori) has a crucial influence on DNA yield. In general, the 
larger the plasmid or the cloned insert is, the lower is the expected DNA yield due to a lower copy number. Plasmids based on, for 
example pBR322 or pACYC, cosmids or BACs are maintained at copy numbers < 20 down to even only 1, whereas vectors based 
on for example pUC, pBluescript or pGEM can be present in several hundred copies per cell [469]. 
34
 Nucleobond® is a patented silica-based anion-exchange resin, developed by MACHEREY-NAGEL. It is developed for routine 
separation of different classes of nucleic acids like oligonucleotides, RNA, and plasmids. NucleoBond® Xtra Silica Resin consists of 
hydrophilic, macroporous silica beads functionalized with MAE (methyl-amino-ethanol). The dense coating of this functional group 
provides a high overall positive charge density under acidic pH conditions that permits the negatively charged phosphate backbone 
of pDNA to bind with high specificity 
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Ampicillin stock (50 mg/mL) solution was prepared by Ana Luisa Ribeiro and Jorge 
Correia (2.5 g in 50 mL of H2O, filter sterilized, divided into 1 mL aliquots per 1.5 mL 
eppendorfs, stored at -20 ºC). 
LB agar solution was prepared by adding 15 g of agar to 1 L of LB, autoclaved. When 
this mixture had cooled down to 50 ºC, ampicillin was added to a final concentration of 
50 µg/mL. Under continuous flame, 30-35 mL of the medium was poured into 85 mm 
petri dishes and set aside until the agar hardened. 
Super optimal broth35 with catabolite repression (SOC) was prepared by adding tryptone 
(2 g), yeast extract (0.5 g), NaCl (1 mL of 1 M) and KCl (0.25 mL of 1 M) to 97 mL 
distilled water, stirred to dissolve, autoclaved and cooled to room temperature. Then, 
1 mL of 2 M Mg2+ stock (1 M MgCl2 ∙ 6H2O, 1 M MgSO4 ∙ 7H2O) and 1 mL of 2 M 
glucose stock36 were added, each to a final concentration of 20 mM. Finally, the 
complete medium was filtered through a 0.2 μm filter unit. 
Procedure. The preparation of pDNA involved four following steps: 
1. Amplification of the pDNA 
2. Growth of the bacterial culture 
3. Harvest of the bacteria 
4. Bacteria lysis and the pDNA purification 
III.2.1.1  Amplification of the pDNA  
The transformation of the competent bacteria started by thawing Mach1 cells on ice 
(5 min), carefully pipetting them up and down. Cells for each transformation were 
aliquoted (50 µL) into a 15 mL conical screw cap tubes (falcon) that had been pre-
chilled on ice. To each tube was added 1 µL (50 ng) of pA1 pDNA, inverting the tubes 
carefully and incubating on ice for 30 min. The tubes were then submerged into 42 ºC 
water bath (heat shock) for 30 sec and places on ice for 2 min. Meanwhile, the SOC 
medium was pre-warmed at 37 ºC and added to each tube (240 µL), inverting carefully. 
                                            
35
 Super optimal broth (SOB) is a nutrient-rich bacterial growth medium used for microbiological culture, generally of Escherichia 
coli. SOC is the SOB with added glucose. 
36
 Mg
2+
 and glucose stock were filter-sterilized 25 mm filter with pores of 0.2 mm. 
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The tubes were positioned horizontally inside of the shaking incubator and left for 1 h at 
37 ºC and 180 rpm (rotations per minute). Each transformation (300 µM) was plated 
onto petri dishes with agar-LB using an L-shaped glass spreader. The plates were left to 
dry and then incubated inverted overnight at 37 ºC. Cells with no plasmid were the 
transformation controls. 
The next morning single colony was picked from agar plate with a disposable 
inoculating loop and transferred into a falcon tube containing 4 mL of SOC with 4 µL of 
ampicillin (50 mg/mL). The mixture was incubated overnight (~ 8 h) at 37 ºC and 
~ 300 rpm. Into 1.5 mL sterile eppendorfs with 70% glycerol (500 µL) was added 500 µL 
of grown culture. The mixtures were gently pipetted up and down and immediately 
placed into a freezer at -78 ºC. Before starting a maxipreparation37, typically, 
minipreparation was performed. 
All manipulations were performed under open flame. 
 
III.2.1.2  Growth of the bacteria culture 
Bacterial cultures were typically grown from a bacteria-glycerol stock stored at -78 ºC 
and sometimes directly from single colony picked from an agar plate. LB broth, 
recommended for standard high-copy plasmids, [469,500] was always chosen as starter 
medium. After sterilization, the broth was cooled down to room temperature and 1 mL of 
ampicillin (50 mg/mL in H2O) was added to ensure plasmid propagation.
38 
The next step was then to divide the medium in four and pour into 1000 mL Erlenmeyer 
flasks39, approximately 200 mL in each. A tube with Mach1 cells was taken out from the 
freezer, placed on ice and left thawing for 5-10 min. Using inoculating loops, the 
bacteria were introduced with LB in each Erlenmeyer, which was immediately tapped 
                                            
37
 Maxipreparation he starting E. coli culture volume is 100-200 mL of LB broth and the expected DNA yield is 500-850 µg, whereas 
in minipreparation DNA yield is 20-30 µg depending from the cell strain. 
38
 Cell cultures should be grown under antibiotic selection. Besides a high probability of contamination in the absence of antibiotics, 
cells tend to lose a plasmid during cell division. 
39
 Using a vessel with a volume of five times greater the volume of the medium is essential for bacteria growth since it ensures a 
better saturation with oxygen. 
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with aluminium foil. Four flasks were placed into a shaking incubator and kept overnight 
(10-16 h) at 37ºC and 220 rpm. Growth was observed by the increasing of the turbidity.  
All manipulations with bacteria were also performed under continuous flame. 
 
III.2.1.3  Harvest of the bacteria 
The bacterial culture was tested for sufficient growth by measuring the optical density 
(OD600) after ~ 12 h of incubation: under open flame a sample of the culture was taken 
from one of the flasks, diluted 1:1040 with fresh LB. Absorbance was measured at 
600 nm with two cuvettes, one contained LB (control) and the other one grown culture 
(working sample). Typically, flasks with the culture were kept incubating for more 2-4 h 
to ensure higher cell masses. However, the incubation longer than 16 h and can lead to 
cells overgrowing which could result into a partial degradation of pDNA or its 
contamination with chromosomal DNA [500].  
The appropriate culture volume, important for obtaining high-copy plasmids, was 
selected according to the OD600 value (Table III.1). 
Table III.1. Recommended culture volume for high-copy plasmids (adapted from 500). 
NucleoBond 
Xtra 
Rec. 
ODV41 
OD600=2 OD600=4 OD600=6 OD600=8 OD600=10 
Maxi prep (mL) 1200 600 300 200 150 120 
 
III.2.1.4  Plasmid DNA purification 
In the Nucleobond® Xtra plasmid purification system the bacterial cells are lysed by a 
set of buffers based on the NAOH/SDS lysis method of Birnboim and Doly [501]. The 
Nucleobond® Xtra Maxi kit contains [500]: 
  
                                            
40
 It is recommended to dilute the culture sample for a correct OD determination, especially if OD600 exceeds 0.5. 
41
 OD volume (ODV) = OD600 x Vol [mL] 
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 RNase A42 
 Resuspension buffer (RES) 
 Lysis buffer (LYS, sodium hydroxide/SDS) 
 Neutralization buffer (NEU, potassium acetate) 
 Equilibration buffer (EQU) 
 Washing buffer (WASH) 
 Elution buffer (ELU) 
 Nucleobond® Xtra Maxi Columns 
 Nucleobond® Xtra Maxi Columns Filters 
The OD600 of E. coli cell mass was typically 2-4, and according to the Table III.1, it 
corresponds to the culture volume 600-300 mL, respectively. For higher yields, the 
volume of the cell culture was usually increased.43 The necessary volumes for the RES, 
LYS and NEU buffers were calculated based to the culture volume and OD600: 
Vol. [mL] = Culture Volume [mL] x OD600 / 50 
For example, for 427 mL of the bacterial culture (OD600 = 2.81), 24 mL of each buffers 
were used. 
After the incubation, the culture was transferred from Erlenmeyer flasks to a 250 mL 
tapped tubes and centrifuged for 15 min at 5524 x G and 4 ºC (rotor ID: JA-14; speed 
(rpm/rce): 6000). Using RES buffer (24 mL), the cell pellet was re-suspended by a slow 
pipetting up and down followed by addition of buffer LYS44 (24 mL). The mixture was 
carefully inverted five times in order not to shear and release contaminating 
chromosomal DNA from cellular debris into the suspension. It was then left incubating 
for 5 min at room temperature. The next step was the equilibration of a Nucleobond® 
Xtra Column Filter inserted in a Nucleobond® Xtra Column with buffer EQU (25 mL). In 
the meantime, buffer NEU (24 mL) was added to the lysate, homogenized by careful 
inverting the tubes, after centrifuged for 10 min at 3836 x G and 4°ºC (rotor ID: JA-14; 
                                            
42
 RNase A was dissolved in buffer RES, when the kit was used for the first time, 
43
 Using too much cell material leads to inefficient cell lysis and precipitation, might reduce the plasmid yield and purity. Therefore, 
lysis buffer volumes was always increased by factor 3-5 when applying larger culture volumes. 
44
 LYS buffer was always checked for precipitated SDS prior to use. In case white precipitate was visible, the buffer was warmed for 
several minutes at 30-40 °C until dissolved completely, cooled down to room temperature before use. 
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speed (rpm/rce): 5000). The cleared lysate was loaded onto the column and left filtering 
by gravity flow. Buffer EQU (15 mL) was applied to the rim of the filter washing out the 
remaining lysate. The filter was then discarded and the buffer WASH (25 mL) was 
applied to the column. To elute the pDNA, the buffer ELU (15 mL) was added. The 
eluate was collected in a 30 mL centrifuge tubes. To precipitate the eluted pDNA, 
isopropanol (10.5 mL) was added; the mixture was vortexed for 2 min and centrifuged 
for 30 min at 15000 x G and 4 ºC (rotor ID: JA-20; speed (rpm/rce): 27216). The 
supernatant was discarded. 
After addition of ethanol (5 mL, 70%), the pellet was centrifuged for 5 min at 15000 x G 
and 24 ºC (rotor ID: JA-20; speed (rpm/rce): 27216). The supernatant was carefully 
removed by pipetting out small quantities. The pellet was left to dry at room temperature 
for 10 min, transferred into a sterile eppendorf with 300 µL of sterile water, and pipetted 
carefully up and down to homogenize.  
The samples of the nucleic acids (aliquots of the cleared lysate, column flow-through, 
wash flow-through and eluate) collected during DNA purification were precipitated by 
adding isopropanol (0.7 volumes), centrifuged for 30 min at 15000 x G and 4 ºC. The 
pellet was washed with 70% ethanol, centrifuged for 10 min at 15000 x G and 25 ºC, 
dried at room temperature (10 min) and dissolved in 100 µL of sterile water. Finally, the 
samples (20 µL) were analysed by AGE. 
 
Determination of plasmid yield. 
The plasmid yield was determined by UV spectrophotometry at 260 nm. DNA stock 
solution was diluted45 1:1000 prior to the measurements. The concentration of pA1 
pDNA was calculated from the obtained value considering that one absorbance 1 (1 cm 
path length) is equivalent to 50 µg DNA/mL. 
                                            
45
 The absolute measured absorbance should lie between 0.1 and 0.7 in order to be in the linear part of Lambert-Beer‟s law. 
Therefore, dilution of DNA sample before UV spectrophotometric measurements is important for the accurate determination of the 
plasmid yield.  
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Plasmid quality and integrity were checked by running a 20 µL sample (18 µL of water 
and 2 µL of diluted to 100 µg/mL pDNA) on a 1% agarose gel in 0.5x TBE. Calculations 
of the pDNA recovery after the precipitation by isopropanol were based on the yield of 
the eluted and precipitated DNA.  
 
 Agarose gel electrophoresis III.3
Chemicals. Trizma® base (≥99.9%, Sigma-Aldrich), phosphate buffered saline (PBS, 
Sigma-Aldrich)46, agarose powder (Type I, low EEO, Sigma-Aldrich), 3-(N-
morpholino)propanesulfonic acid (MOPS, 99.5%, Fluka), di-potassium hydrogen 
phosphate (99%, Panreac), hydrogen peroxide (30%, Panreac), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES, ≥99.5%, Sigma), mercaptopropionic acid (MPA, 
>99%, Acros), potassium peroxomonosulfate compound (oxone, active oxygen, min 
4.5%, Acros), acetylacetone (99.5%, Merck), titriPUR® NaOH solution (Merck), 
suprapur® nitric acid (65%, Merck), ammonium-metavanadate (>99.% Riedel-de Haën), 
boric acid (99.5%, Riedel-de Haën), EDTA (99.5%, AnalaR BDH), ethidium bromide 
powder (EtBr, Sigma), dimethyl sulfoxide (DMSO, ≥99.7%, Fisher Scientific) were used.  
 
Instrumentation. AGE was performed using an electrophoresis chamber and power 
supply (CONSORT E143). AlphaImager from Alpha Innotech was used to visualize and 
photograph the bands of gels under UV light.  
Densitometry. To analyse a gel image after electrophoresis, Lane Densitometry (1-D 
Multi) in AlphaEaseFCTM software (Alpha Innotech) was used. This tool is designed for 
measuring and quantitating the intensity of bands in each lane of the gel image. This 
quantitative estimation can be achieved in two ways, using Auto Lane or Auto Grid 
function. The latter was always used as it allows defining band parameters manually, 
while the Auto Lane is completely automated feature.  
                                            
46
 PBS is a pH 7.4 phosphate buffered medium with controlled ionic strength: 10 mM phosphate buffer, 2.7 mM KCl, 137 mM NaCl=.  
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After bands were visualized under UV light and photographed by AlphaImager, a gel 
image was opened in AlphaEaseFCTM software. The enhancement tools were used to 
modify the image display, e.g., zoom, rotate-flip, annotate. These features allow 
adapting the image only on the monitor47 and do not change the original quantitative 
data. 
To measure the areas of each band, the enhancement function was switched to 
analysis tools, specifically, to 1D-Multi tab (set of densitometry tools,) to display the 
Auto Grid template on the image. After specifying the correct number of lanes (typically 
14-16) and the scan width48, which is the area for measuring the pixel density (defined 
by green lines), the borders of the template (red lines) should be adjusted in such a way 
that they frame the lanes to be scanned and the adjacent lines lie between each of the 
lanes. When these parameters are set and the „AUTOGRID‟ button is clicked, the areas 
of each band are automatically measured. The next important step was checking peaks 
of each lane. Although, 1D-Multi by default identifies the peaks of each band and 
integrates the area - band intensity – correspondingly, often, manual addition/deletions 
of existing peaks or the readjustment of their boundaries is necessary (Figure III.1). The 
data table is automatically updated to reflect the resultant changes. 
 
                                            
47
 To preserve the applied adjustments on the screen, the image was saved as a different file (typically TIF format) and could be 
later opened and viewed/changed with this AlphaEaseFC; however, the modifications, such as annotated information, were never 
displayed when opening the image with Photoviewer, Adobe Photoshop or any other software, able reading TIF files. In such cases, 
“Print” option was used for printing either on paper or as a PDF file. This permitted to check and share the results of any experiment 
when the software was unavailable. 
48
 A proper specification of the scan width is important. A scan width is too narrow may not include enough information and can 
result in a noisy graph with many undesired peaks, while a wide scan can incorporate background pixels that will reduce the pixel 
average and dilute the actual data. 
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Figure III.1. Example of the lane densitometry. Nck (left) and Sc (right) bands of one reaction 
mixture represented by a lane. Areas of each band are adjusted manually if necessary. 
 
After peaks of each lane were detected, the quantitative data were output and saved as 
a text file. From this point the data were managed using Microsoft Excel. 
The values of peak areas for the Sc form were corrected by the factor of 1.47 to account 
for its lower staining capacity by ethidium bromide [393] and used to calculate the 
percentage (%) of each form (Sc, Nck and Lin).  
The variability of results was estimated from the analysis replicate digestions using 
VO(acac)2 as a reference standard metallonuclease. Standard deviation for repeatability 
(sr, measures the random variability within each experiment) for the peak area within the 
same gel was estimated as 8, 6 and 8% for the Sc, Nck and Lin forms, respectively 
[502]. The sr of the whole experimental procedure, including the preparation of solutions 
and incubation was 10, 6 and 3%, for the Sc, Nck and Lin forms, respectively. These 
values were estimated from analysis of variance (single factor ANOVA) of duplicates 
from 11 different runs. sr for the peak area was estimated from duplicates of plasmid 
DNA (not incubated). sr for a whole procedure was estimated from duplicates of 
samples incubated with metal complex. All experiments were done in duplicate, and the 
gel of best quality was presented as example. 
Solutions preparation. Stock solutions of VC were typically prepared by weighing the 
appropriate amount of the compounds (ca. 6 mg) and dissolving in 100 mL of water to 
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obtain a 200 μM solution. The natural uncertainty coming from this procedure is ca. 10% 
due to the small weighted mass. 
When testing the DNA cleavage activity of monovanadates (V1), NH4VO3 was used. 
Most important point in the preparation of the monovanadate solution is to maintain a 
high pH to prevent the formation of decavanadate [503,504]. To prepare V1 solution, 
MilliQ® water was buffered with NaOH (0.1 M) to adjust the pH to 10. This water was 
used to dissolve NH4VO3 to make a 50 mM solution. Water bath (~70 ºC) was used to 
heat up the solution for 10 min. Ready solution was transferred and stored in a plastic 
bottle. 
A 100-mM stock solution of phosphate, HEPES or MOPS buffer was prepared in water. 
The pH was adjusted between 7.0 and 7.4 by adding dropwise nitric acid or sodium 
hydroxide. PBS was prepared by dissolving one tablet in 20 mL of water to obtain a 
100 mM solution; pH (typically 7.39) was verified by a pH meter. 
A 10x stock of TBE (89 mM Tris-borate and 1 mM EDTA, pH 8.0), chosen as 
electrophoresis buffer, was prepared in water at and stored at 4ºC. Typically the buffer 
was freshly diluted to the working concentration of 0.5x prior to a gel preparation.  
Stock solution of EtBr (50 mg/mL) was prepared by dissolving the powder in water and 
was stored at RT in a plastic tube wrapped up in aluminium foil. Loading buffer was 
prepared in water by Professor Isabel Cavaco. Autoclaved MilliQ® water was always 
used in preparation of reaction mixtures with pDNA. 
 
Agarose gel preparation. Agarose gels were typically of 1.0% in 0.5x TBE containing 
ca 3 µg/mL of EtBr. A gel was prepared by adding 150 mL of 0.5x TBE to 1.5 g of 
agarose powder in Erlenmeyer (~5 mm thick gel). The mixture was heated in a 
microwave oven at medium power until no agarose grains were visible. While the gel-
TBE solution was warming up, a gel casting plate, which is composed of UV-transparent 
plastic, was sealed with tape to close the open edges in order to compose a mold, and 
set on the even horizontal surface. A comb with typically 14-16 teeth was chosen to 
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form sample slots in the gel. The comb was positioned 0.5-1 mm above the plate so that 
a complete well is formed when the agarose is added to the mold. 
Upon cooling the mixture to approximately 60 ºC, 10 µL of EtBr was added, swirling the 
Erlenmeyer vigorously to ensure a thorough distribution of DNA dye. Warm agarose 
solution was poured into the mold and left for 1 h at RT to cool and solidify. The gel was 
checked for air bubbles that are likely to form under or between the teeth of the comb or 
anywhere on the surface. In the molten gel these bubbles were easily removed by 
poking them with a pipette tip.  
After the gel hardened, the comb and tape were carefully removed, and the mold with 
the gel was submerged into 0.5x TBE (~ 1 mm depth) in the electrophoresis chamber.  
Procedure. DNA cleavage activity was evaluated by monitoring the conversion of Sc 
plasmid DNA to Nck and Lin DNA. Each reaction mixture was prepared by adding (in 
this order) 6 µL of water, 2 µL of 100 mM buffer solution, 2 µL (100 µg/mL) of 
supercoiled pA1 DNA and 10 µL of the aqueous solution of VC. Phosphate 
(K2HPO4/HNO3) and MOPS/NaOH buffers were used in most experiments
49, unless 
indicated otherwise. Working concentrations of VC were usually 3, 6, 12, 25, 50 and 
100 µM. 
Typical plasmid, purified from E. coli cells, after being cleaved, shows three bands (DNA 
forms) in agarose gel. They are closed circular supercoiled (I, supercoiled, Sc, the 
fastest one), linear (III, Lin, the middle band) and open circular (II, relaxed, nicked, Nck, 
the slowest one). Samples of the DNA control, which always contained only pA1, are 
normally represented by two bands – Sc and Nck, while those of the Lin control, which 
were obtained by digesting pA1 plasmid DNA with HindIII50, show Nck and Lin forms 
(Figure III.2). In most experiments a mixture of 10 mM phosphate buffer and 50 µM of 
VO(acac)2 digested with pA1 was used as a reference of the linearized DNA form. The 
                                            
49
 Initially, HEPES buffer, or sometimes TRIS, was chosen for AGE experiments. When we started to work with cyclic and square 
wave voltammetry, José Paulo Pinheiro, having tested a variety of different buffers from the electrochemical point of view, 
suggested MOPS buffer as non-interactive one, and thus HEPES was substituted with MOPS in electrochemical tests as well as in 
all AGE experiments. 
50
 HindIII is a restriction enzyme (type II site-specific), isolated from Haemophilus influenzae, that cleaves DNA via hydrolysis. This 
endonuclease was used as a reference in our AGE experiments.  
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endonuclease, HindIII, was only employed on the initial stage of our investigation to 
mark the band position of double strand cleavage. 
 
 
Figure III.2. Agarose gel image of the lanes “DNA” – pA1 (plasmid DNA control) and “Lin” – 
pA1digested with HindIII. Bands Sc, Nck and Lin correspond to I (supercoiled), II (nicked) and III 
(linear) forms of DNA. 
 
When the reaction involved addition of activating agents, radical scavengers [462] or 
hydrogen peroxide, the initial volume of water was reduced to 4 µL, and 2 µL of the 
agent/scavenger/H2O2 aqueous solution (NaBz, NaN3 and DMSO
51) were added prior to 
metal complex. MPA and oxone were chosen as reducing and oxidizing agents, 
respectively. The final concentrations of the activating agents and radical scavengers 
were 200 µM and 40 mM, respectively. Their control samples were prepared in the 
absence of metal complex. Stock solutions of ~ 1 mM hydrogen peroxide were freshly 
prepared from 30% H2O2, their concentration was measured spectrophotometrically 
(ε230 nm = 74 M
-1 cm-1) [505] and diluted as needed immediately before addition to the 
reaction mixture. 
The samples were incubated at 37 ºC for 1 h, wrapped in aluminum foil. The reactions 
were quenched by the addition of 5 µL of loading dye and the samples were loaded 
onto 1% agarose gel in a horizontal electrophoresis tank containing 0.5x TBE buffer, 
                                            
51
 NaBz, and DMSO are known hydroxyl radical scavengers, while NaN3 is also recognized as a strong quencher of the singlet 
oxygen reactivity [462]. 
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which served as electrolyte, and subjected to electrophoresis. Controls of supercoiled 
and linearized plasmid were included in both extremes of a 14 or 16-well gel plate.  
Experiments under inert atmosphere were carried out using Schlenk techniques and a 
vacuum and nitrogen line. Solvents for the preparation of VC solutions were degassed 
prior to the dissolution of the complex under nitrogen. Eppendorfs containing the DNA 
and buffer solutions were arranged inside a Schlenk flask. They were submitted to 
vacuum and N2-atmosphere consecutively three times before the careful addition of the 
complex solution using a micropipette and under a continuous flux of nitrogen gas. The 
Schlenk was closed, submitted to vacuum and then nitrogen and left under nitrogen to 
incubate for 1 h at 37 ºC.  
Experiments under UV light were conducted preparing the reaction mixtures as 
described, and incubating them in open Eppendorfs under a 8-W blacklight blue 370 nm 
lamp for 1 h at RT. Experiments in the dark were carried out preparing all solutions in a 
dark room with red light, and incubating the reaction mixtures for 1 h at 37 ºC wrapped 
in aluminum foil.  
 
 Circular Dichroism III.4
Circular dichroism (CD) spectra were recorded at t = (26 ± 1) ºC on a Jasco J-720 
spectropolarimeter with a 180-800 nm photomultiplier using 1 cm path-length cylindrical 
quartz cells.  
Stock solutions of 1 (250 μM) in 100% PBS were freshly prepared prior to each 
measurement. Four independent solutions of 1 with pDNA (ri52 0, 0.3, 0.75 and 1.5) 
were prepared and kept in a water bath during 25 h at 37 ºC stirring sideways (60 rpm). 
After the incubation aliquots of these solutions were collected in a 1.5 mL eppendorfs 
and stored at -20 ºC for analyses by AGE. Spectra were recorded in the 200–400 nm 
range at the time zero (no incubation), 6, 18 and 25 h.  
                                            
52
 „ri‟ is the ratio of the metal concentration to DNA concentration, measured as base pairs per liter. 
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 Solution studies III.5
Chemicals. HEPES (≥99.5%, Sigma), MOPS, (99.5%, Fluka), K2HPO4 (99%, Panreac), 
DMSO (≥99.7%, Fisher Scientific), titriPUR® NaOH solution (Merck), suprapur® nitric 
acid (65%, Merck) were used. In all cases, MilliQ® water (resistivity > 18MΩ.cm) was 
used, unless otherwise mentioned. 
Instrumentation. UV-vis spectra were recorded at room temperature on a Hitachi U-
2000 double beam spectrometer with 1 or 4 cm path-length quartz cell in the 350-
950 nm range. Voltammetric studies were carried out using an Eco Chemie Autolab 
Potentiostat/Galvanostat 12 in conjunction with a Metrohm 663VA stand. A three 
electrode stand with a mercury drop working electrode, a saturated calomel reference 
electrode (SCE) or an Ag/AgCl, and a Pt wire auxiliary electrode.  
 
  UV-vis spectroscopy III.5.1
Visible absorption spectroscopy was employed to analyse the stability of the complexes 
1-5 and 9 in 10 mM PBS and HEPES media at physiological pH. Buffer solutions were 
prepared in deionized water and used as VC solvents. Absorption UV-vis spectra were 
obtained for millimolar solutions for 2, 4, 5 and 9 in 100% PBS (pH 7.4) were 1.2 mM 
concentration; 1 and 3 were of 2 mM in 1 and 100% DMSO, respectively.  
The majority of these complexes are poorly soluble in water, therefore their dissolution 
was complete by sonication (5-10 min). Complex 3 showed a scarce dissolution in 
aqueous medium even with prolonged up to 1 h sonication. 
Spectra were recorded immediately after solution preparation. 
 
  Electroanalytical methods III.5.2
The electrochemical behaviour of 1-6 and 9 was studied by cyclic and square wave 
voltammetry (CV and SWV) in phosphate and MOPS buffers (10, 30 and 100 mM).  
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Cyclic and square wave voltammograms (Cvs and SWvs) were measured at 50 mV/s 
scan rate and 25 Hz, respectively. High-purity N2 gas was used to purge solutions prior 
to each scan for at least 15 min. During all measurement a continuous flow of nitrogen 
passed through an electrochemical cell to ensure a maximum possible removal of 
dissolved oxygen. Typically, measurements started by filling an electrochemical cell with 
a buffer solution (25 mL), purging with nitrogen and measuring the first scan (blank 
voltammogram), followed by addition and scanning of VC solutions. 
Stock solutions of the complexes were always prepared in deionized water immediately 
before use. Complex concentrations were similar to those used in digestion with pDNA, 
i.e., 2, 5, 10, 20 and 50 µM.  
In experiments varying the concentration of phosphate buffer from 1 to 20 mM, the 
measurement started by running a scan of 1 mM buffer (blank), followed by addition of 1 
to a final concentration of 50 µM. The experiment continued with subsequent additions 
of the appropriate volumes of concentrated buffer (100 mM) to 25 mL of solution, thus 
increasing the buffer concentration to 2, 3, 4, 6, 10, 15 and 20 mM. The solution volume 
in the end of the experiment was 30 mL, corresponding to a dilution of VC by maximum 
of 20%.  
Similar procedures were followed in the experiments increasing the concentration of 
phosphate buffer in the presence of MOPS, and vice-versa. Peak potentials and 
currents were determined from the voltammograms using General Purpose 
Electrochemical Chemistry software (GPES, version 4.9, Eco Chemie B.V. Utrecht, the 
Netherlands). 
 
 Mechanistic studies III.6
Chemicals. Terephthalate (disodium salt, 98%, Sigma-Aldrich), 4-nitrophenyl 
phosphate disodium salt hexahydrate (NPP, Sigma), bis-p-nitrophenyl phosphate 
sodium salt (BNPP, Sigma), hydrogen peroxide (30% Panreac), deuterium water (D2O, 
99.9% D, Euriso Top), 4,4-dimethyl-4-silapentano-1-sulfonic acid (DSS) were used. 
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Instrumentation. Fluorescence spectra were recorded on a FluoroMax®-3 
spectrofluorometer in a 3 cm quartz rectangular spectrofluorometer cuvette (Sigma-
Aldrich). NMR measurements were performed using a Bruker Avance 400 spectrometer 
in glass NMR tubes (NORELL® ST500-7). 
 
  Fluorescence spectroscopy III.6.1
Spectrofluorometry was chosen to monitor the formation of ROS in aqueous solutions of 
VC (1, 4 and 9) through the hydroxylation reaction of terephthalic acid (TPA) with a 
single fluorescent product, HTPA.  
Excitation spectra of HTPA were scanned in the 250-400 nm range at emission of 
435 nm, whereas the emission spectra were monitored at excitation of 323 nm in the 
range of 350-500 nm. The slit width was 1 nm (excitation and emission) and the scan 
rate was set on 1 nm/s.  
The stock solutions of TPA, prepared in phosphate or MOPS buffer (solution A), and 1 
in water (solution B) were 400 and 125 µM, respectively. Typically, 10 mL of solution A 
was mixed with 8 mL of solution B and 2 mL of water or H2O2 to a final volume of 
20 mL. Blanks were prepared with 200 µM solution A in phosphate or MOPS buffer 
(pH 7.4). The final buffer concentration varied from 5 to 20 mM. All solutions were kept 
at room temperature between the measurements. TPA is poorly soluble in water and 
the dissolution was complete using water bath (~ 80 ºC) instead of sonication since the 
ultrasound in liquids is known to produce free radicals [487]. 
 
  NMR studies  III.6.2
Hydrolysis of two widely used DNA model substrates, nitrophenyl phosphate (NPP) and 
bis-4-nitrophenyl phosphate (BNPP) (4 mM), by 1 (sat, C≤3 mM) was followed by 1H 
and 51V NMR spectroscopy.  
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The acquisition parameters were 33 KHz spectral width, 25 μs pulse width, 0.5 s 
acquisition time, and 10 Hz line broadening. Solutions were buffered with either MOPS 
or PBS (40 mM) prepared in H2O or D2O (pH 7.2-7.4). Dissolved DSS and a capillary 
containing a saturated solution of metavanadate were used as 1H and 51V references, 
respectively. The reaction mixtures were places in an oil bath, kept at 50 °C and 
followed during 10 days. The 51V NMR chemical shift data of aqueous solutions of 6-8 
were obtained in 10 mM phosphate and HEPES buffers. The NMR signals were 
assigned according to the literature [506]. 
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IV. DNA cleavage activity 
 Results IV.1
This chapter presents the results obtained from AGE technique when studying the 
interaction of plasmid DNA with vanadium compounds (VC) containing acetylacetonate 
ligand. Some results on the interaction of VC with pDNA obtained by Circular Dichroism 
are also demonstrated. 
 
During this work a total of 238 agarose gels were prepared, 115 of which were selected 
for this thesis and can be found in Annex A. Each electrophoresis experiment was 
aimed to show the extent of the DNA cleavage activity of 1-9 mainly. Complexes 10-36 
were tested for comparison purposes and the results are also presented. 
 
We examined different effects on the nuclease activity of VC. Table IV.1 lists the 
complexes with the studied effects. Nuclease activity was measured by the extent of the 
degradation of the supercoiled form of plasmid DNA (Sc) into the nicked form (Nck) and 
the linear form (Lin) after incubation with a metal complex. 
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Table IV.1. Studies of the nuclease activity of vanadium and copper complexes: effect of 1 – complex concentration; 2 – incubation 
time; 3 – excess ligand; 4 – buffer media; 5 – light; 6 – H2O2; 7 – atmosphere (air vs. nitrogen); 8 –activating agents; 9 – radical 
scavengers; 10 – observation of phantom bands. Gel images are presented in Annex 1 numbered as A1, A2, A3…An53. 
                                            
53
 The table demonstrates the numbers of the figures to the complex and studied effect correspondingly. These figures are collected in the Annex A.  in Complex 
1, besides the experiments where it was purposefully tested, is present in every gel at 50 µM concentration digested with pA1 plasmid DNA under phosphate 
buffer, i.e., control ofr the linearized DNA form.  
Complex 
Studied effect 
1 2 3 4 5 6 7 8 9 10 
VO(acac)2 (1) A1-A20, A37-A39, 
A53, A92-A94, A110, 
A111, A113 
A21-
A25 
A27-
A29 
A1-A3, A7, 
A10, A30- 
A37, A94 
A38, 
A39 
A40  A47, A49, 
A50, A58 
 A110, 
A111, 
A113 
VO(hd)2 (2) A7, A11, A13, A19, 
A20 
A26  A7       
VO(Cl-acac)2 (3) A11, A14, A19, A20          
VO(Et-acac)2 (4) A11, A15, A19, A20   A34, A35       
VO(Me-acac)2 (5) A11, A16, A19, A20          
V2O4(acac)2 (6) A46   A34, A35    A33, A47   
VO2(acac)(phen) (7) A46       A47   
VO(OH)(OMe)(acac) (8) A46       A47   
VOSO4 (9) A4, A8-A10, A13, 
A18, A19, A20, A41-
A45, A53, A62-A64, 
A92-A94 
  A10, A31, 
A34, A35, 
A43-A45 
  A41, 
A42 
A66, A98, 
A99 
  
 
 
 
VO(acac-Naf)2 (10) A6, A19, A20          
VO(tmh)2 (11) A11, A17, A19, A20          
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VO(pbd)2 (12) A11, A18, A19, A20          
VO(acac-NH2)2 (13) A19, A20   A27-
A29 
A34, A35       
VO(acac-NMe2)2 (14) A19, A20  A27-
A29 
       
Cu(acac)2 (15) A51, A53, A54, A58   A51, A54    A54, A56, 
A58 
  
Ni(acac)2 (16) A52, A53, A55, A58   A52, A55, A57    A55, A57, 
A58 
  
VO(MPA)2 (17) A59-A61, A111-A112         A110-
A112 
VO(dmpp)2 (18) A59-A61          
VO(PA)2 (19) A62-A64          
VO(oda) (20) A65-A67, A88, A89, 
A110 
  A65, A67, 
A68, A88, A89 
   A66, A67, 
A90, A91 
A32, 
A68 
A110 
VO(oda)phen (21) A69-A75, A88, A89   A69, A70, 
A88, A89 
 A76- 
A79 
 A71-A75, 
A90, A91 
A76- 
A79 
 
VO(phen)2 (22) A71-A75, A110-A112         A110-
A112 
VO(oda)bipy (23) A80, A81, A88, A89   A80-A83, A88, 
A89 
 A84-
A87 
 A82, A83, 
A90, A91 
A84- 
A87 
 
VO(chrysin)2 (24) A92-A94          
VO(morin)2 (25) A92-A96   A97    A97   
VO(clor) (26) A95, A96, A113         A113 
VO(silibinin)2 (27) A98, A99       A98, A99   
Cu(Sal-Gly)(bipy) (28) A100, A101, A107       A103,   
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A105, 
A109 
Cu(Sal-Gly)(phen) (29) A100, A101, A102, 
A107, A108 
      A103, 
A105, 
A109 
  
Cu(Sal-L-Phe)(phen) (30) A100, A101, A102, 
A107, A108 
      A103, 
A105, 
A109 
  
VO(Sal-L-Phe)(bipy) (31) A100, A101, A107       A103, 
A105 
  
VO(Sal-L-Phe)(phen) (32) A100, A101, A107       A103, 
A105 
  
VO(Sal-Gly)(bipy) (33) A100, A101, A107       A104, 
A106 
  
VO(Sal-Gly)(phen) (34) A100, A101, A107       A104, 
A106 
  
VO(Sal-Gly)(H2O) (35) A100, A101, A107       A104, 
A106 
  
VO(Sal-L-Phe)(H2O) (36) A100, A101, A107       A104, 
A106 
  
NH4VO3  A48-A50   A48     A49, A50   
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Normally, the effect of complex concentration is the first step in determining the 
nuclease activity of a metal complex. This effect was studied for all complexes listed in 
Table IV.1 typically at 3, 6, 12, 25, 50 and 100 µM, which corresponds to metal:bp ratio 
(ri) of 0.2, 0.4, 0.8, 1.67, 3.3 and 6.7.  
Except for the complexes 7, 8, 10, 15, 16, 24-36 and NH4VO3 (Figure A46, A6, A51, 
A52, A92, A95 and A48, respectively) nuclease activity of the studied complexes is 
concentration dependent, especially under phosphate buffer.  
Complex 1 is a very active nuclease promoting a strong cleavage, the extent of which is 
directly dependent on the buffer media and complex concentration (Figure A1-A3). 
Figure A11 shows the results of the effect of complex concentration on the nuclease 
activity of 1-5, 9, 11 and 12 at 50 and 100 µM (ri 3.3 and 6.7) under phosphate. All 
complexes are active towards pDNA at these concentration levels. To determine 
whether each of these complexes breaks the DNA strands at lower concentrations, the 
corresponding tests were carried out for 3-100 µM (ri 0.2-6.7) and the images of these 
gels are summarized in Annex in Figures A7, A8, A10, A13-A18.  
VC with ligands composed of oxodiacetate (Figure A65-A91) or picolinic acid (Figure 
A59-A64) were also found to promote a concentration-dependent cleavage.  
A particularly strong concentration effect was observed on the nuclease activity of 
VO(oda)phen, which was found to promote a linearization of the DNA strands even 
under MOPS (Figure A89). 
 
Effect of buffer media was tested using inorganic (phosphate) and organic (HEPES or 
MOPS) buffers. DNA cleavage was found to be usually stronger under phosphate 
buffer. Exception is the complexes containing oxodiacetate ligand (Figure A91). 
Complex 1 can be an excellent example to demonstrate this difference (Figure A1-A3). 
Figure A20 shows the results of the nuclease activity of 1-5 and 9-14 under MOPS 
buffer. No significant change can be observed.  
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Not only was the nature of the buffer found to affect the extent of the DNA cleavage but 
also its concentration (Figure A34). When searching for the optimal buffer media 
concentration, at which the extent of DNA scission would be the highest, different 
concentrations were tested. According to the calculated percentage of each DNA form 
obtained after the cleavage, the most efficient cleavage among 1, 2, 3, 4, 6, 10, 15 and 
20 mM concentration is observed at 6 mM (Figure A33).  
To support the assumption that the activity under organic buffers might be affected due 
to their scavenging effect, the extent of DNA cleavage was tested in the presence of 
both buffers at the ratio 1:1 and 1:2 (Figure A36). The results show that the nuclease 
activity of 1 is stronger under phosphate buffer and the extent of the DNA cleavage 
decreased with addition of MOPS buffer.  
 
The effect of excess ligand was studied by incubating solutions of 1, 13 and 14 with 
an excess of corresponding ligands, i.e., acac, acac-NH2 and acac-NMe2 respectively, 
up to ~160. No increase of nuclease activity was observed. Instead, there is a clear 
decrease in the nuclease activity of 1 when acac is added. In the case of excess ligands 
added to solutions of 13 and 14, the inhibition of the cleavage is considerably smaller 
(Figure A28). 
Ligands of the active complexes were often assumed to be relevant to the extent of 
DNA cleavage. Thus, ligands were typically examined next to the corresponding 
complexes. From Figure A63, A73 and A83 it can be seen that none of the tested 
ligands per se induced the DNA breakage.  
 
To check the effect of light on the nuclease activity of 1, the samples were incubated 
for 1 h at 37 ºC under a 370-nm UV lamp (Figure A38). Although a distinct separation of 
Sc and Lin forms cannot be observed, it is clear that 1 promotes an efficient 
concentration dependent cleavage of both tested plasmids. When the incubation was 
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carried out in the dark (Figure A39), results demonstrate similar behaviour of 1 to that 
observed under natural light or incubated under UV light.  
 
Often, for the DNA cleavage to occur additional stimulating agents are required. MPA 
and oxone were used as reducing and oxidizing activating agents, respectively. These 
agents simulate reducing conditions as may be found inside biological cells, and 
oxidizing conditions as may be found in blood or in contact with the air.  
For most of the tested compounds, the effect of activating agents on their nuclease 
activity was found to be significant. Oxone seemed to always increase the extent of the 
cleavage or, when a complex was initially non-active, to induce it. (Figure A58 and A90). 
MPA, on the other hand, in some cases had no effect on the extent of the cleavage 
(Figure A49 and A97), and many times demonstrated an inhibition effect (Figure A47, 
lane 8; Figure A58, lane 14; Figure A67, lane 9). The results, where MPA increased the 
extent of the cleavage, were also common (Figure A47 lane 7; Figure A99 lane 8). In 
some cases the cleavage in the presence of MPA was much stronger than with oxone 
regardless of the buffer medium (Figure A90 and A91, lane 11).  
Interesting results with MPA were obtained for the compounds containing copper as a 
metal centre: the activity in the presence of the reductant is so strong that the plasmid 
undergoes a complete destruction, once more independently of the buffer medium. As 
the consequence, no bands indicating these samples can be observed in a gel (Figure 
A54).  
Usually, the effect of activating agents was always stronger for more active compounds 
towards DNA cleavage, especially under phosphate buffer. 
 
Assuming that the cleavage is of oxidative nature and that ROS are probably involved in 
the cleavage process, studying the effect of radical scavengers was of a high 
importance. Commonly used scavengers of free radicals (DMSO and NaBz) and singlet 
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oxygen (NaN3), were chosen for these tests. Normally, such experiments were 
conducted with the compounds that demonstrated an efficient nuclease activity. The 
involvement of the reaction oxygen species (ROS) was judged by the decrease in the 
DNA cleavage upon addition of the scavengers. Principally, the cleavage was inhibited 
in the presence of either of the agents (Figure A68 and A86). In some cases the extent 
of the inhibition was higher with NaN3 than with DMSO or NaBz (Figure A76). The 
scavengers under MOPS buffer could have a different effect from that observed under 
phosphate for the same compound (Figure A78). 
 
Experiments related to the effect of atmosphere carried out under inert atmosphere 
gave results similar to those performed under usual conditions, i.e., under air. Though a 
slight decrease in the extent of DNA cleavage is noticeable under N2 (Figure A41 and 
A42), the scission remains significant. 
 
Continuing to study the involvement of OH radicals in the reaction of 1 with pDNA, 
nuclease behaviour of 1 was examined in the presence of H2O2 at physiological 
concentrations. According to the obtained results, a significant effect of hydrogen 
peroxide on the activity of 1 towards DNA cleavage is observed upon addition of ca. 
1 µM and seems to augment with the complex concentration (Figure A40). However, 
further increasing the concentration of H2O2 does not seem to alter the extent of 
scission.  
 
The effect of incubation time on the nuclease activity of 1 was studied with the time 
intervals of 15 or 30 min. A difference in the extent of the cleavage between the sample 
incubated for 5 min and the one digested for 4 hours can be observed (Figure A23). A 
dependence of the intensity of the DNA cleavage on the time digestion does not seem 
to be dramatic. 
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Circular Dichroism studies 
The circular dichroism spectrum of pDNA in PBS buffer shows a negative band with 
max = 246 nm and a positive band at max = 274 nm with zero at 257.5 nm (Figure IV.1, 
A). A slight change is observed between 0 and 6 h, more in the positive than negative 
band. After 25 h of incubation the intensity of both negative positive bands increases. 
The changes in the molar ellipticity of pDNA caused by 1 at 45, 112,5 and 225 µM 
(ri 0.3, 0.75 and 1.5) are shown in Figure IV.1 (B). At the highest ri, the intensity of the 
negative band increases and that of the positive band decreases, both by 6%. At the 
positive band no significant difference in the intensity change is observed between ri 0.3 
and 0.75, whereas at the negative one it is increased by 13%. Some changes can be 
observed in the 220-230 nm range both in the absence and presence of 1. 
 
 
Figure IV.1. Circular dichroism spectra of pDNA in PBS at the time of reaction mixture 
preparation, after 6 and 25 h incubating at 37 °C (A, numbers in the legend present hours) and 
after addition of 1 (B) at different ratios of metal:bp, i.e., 0.3, 0.75 and 1.5; „pA1‟ is pDNA with no 
complex in PBS.  
 
AGE carried out after the CD measurements for the same samples shows significant 
degradation of pDNA (Figure IV.2; A (ri 0.3), B (ri 0.75) and C (ri 1.5), lanes 4, 5 and 6, 
respectively). The increase in the amount of nicked and linear DNA is associated with 
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the increase of metal:bp ratio: the Nck form A – 47%, B – 75% and C – 87%; the Lin 
form 3.9%, 4.8% and C 6.1% respectively, whereas the amounts of these two DNA 
forms for Lin control (pA1 DNA incubated 1 h at 37 ºC with 1, ri 3.3; lane 2 and 7) are 
74% (Nck) and 2.2% (Lin). 
 
 
 
Figure IV.2. AGE of the reaction mixtures used at CD measurements (Figure IV.1, B): pDNA in 
PBS, no complex (D), ri 0.3 (A), ri 0.75 (B), ri 1.5 (C), “DNA” and “Lin” – controls for native and 
linearized plasmid, respectively. Incubation 25 h at 37 ºC. 
 
 
 Discussion IV.2
  Effect of complex concentration IV.2.1
When trying to assess a possible toxic effect of vanadium, namely its effect on plasmid 
DNA (pDNA), which is assumed to occur upon metal penetration into the cells, the 
following questions were of interest: 
1) Does vanadium interact with DNA? Does this interaction lead to a cleavage of DNA 
strands? 
2) Which concentration of vanadium is sufficient for the cleavage to occur? 
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In pilot studies with other vanadium compounds [119] such as VIVO(phen)2, 
VIVO(phen)(SO4), VIVO(salan), VIVO(pyren), complex 1 showed the DNA cleavage in 
the absence of oxidizing (oxone) and reducing (MPA) agents exhibiting different 
behaviour in phosphate and organic (TRIS and HEPES) buffers. Both activating agents 
increased the extent of the cleavage much less in the presence of organic buffers. All 
the experiments on the nuclease activity of VO(acac)2 carried out during the present 
study support these results obtained. 
VO(acac)2
 and its derivatives promote the DNA cleavage with remarkably different 
efficiencies (Figure IV.3). Based on obtained AGE data, two types of nucleases, strong 
and weak, in oxidovanadium(IV) acac family can be distinguished. The least active 
compounds are also less stable ones towards hydrolysis.  
When a complex is active towards DNA, increasing metal:bp ratio “ri” will augment the 
extent of the cleavage. In other words, complexes exhibiting the nuclease activity 
generally induce concentration dependent cleavage. 
Comparison of the DNA degradation by 1 at different concentrations (Figure IV.4) 
demonstrates a strong concentration dependent cleavage. Single-strand cleavage 
occurs at the lowest tested concentration of 6 µM (ri 0.4) and gradually increases up to 
100 µM (ri 6.7), as can be seen from the increase in the percentage of Nck at the cost of 
Sc. Above ri 6.7 a significant decrease in the relative intensity of the Nck band suggests 
further cleavage of this form to produce linear DNA. A tail-like smear observed below 
the Lin bands (Figure A113) is evidence of linear DNA undergoing destruction to form 
shorter strands, indistinguishable by AGE. 
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Figure IV.3. Cleavage of pA1 pDNA by 1-5, 9, 11 and 12 at 0 (DNA control), 3, 6, 12, 25, 50 
and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 and 6.7) under phosphate buffer. Percentage calculated 
from the areas of Sc, Nck and Lin bands vs. complex concentration. Data extracted from the 
gels in Figures A13-A18, A43 and A113. 
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Figure IV.4. Percentage of the Sc, Nck and Lin DNA forms demonstrating the extent of the 
nuclease activity of 1 vs. complex concentration (6, 12, 25, 50, 100, 200 and 400 µM 
corresponding to ri 0.4, 0.8, 1.67, 3.3, 6.7, 13.3 and 26.67) under phosphate buffer. „C‟ indicates 
concentration. Data extracted from the gel in Figure A113.  
 
Complexes 2-5 were synthesized and their nuclease activity was compared with that of 
1. Figure IV.5 presents the results for 1-5 under phosphate buffer at 50 and 100 µM 
(ri 3.3 and 6.7). The presence of both single and double-strand cleavage suggests that 
all complexes are active towards DNA scission. Clearly, complex 1 is the most active; it 
is the only complex that induces a complete degradation of the Sc DNA at ri 6.7 with 
8.6% of the Lin form. Even at ri 3.3 the double-strand cleavage of 1 is higher than that 
of any of complexes at the same or higher ri. The same is observed for single-strand 
cleavage, with the only exception observed in the presence of complex 3 which 
promotes stronger nicking at ri 6.7 (91%) than 1 at ri 3.3 (88%). Considering the fact 
that 3 is scarcely soluble in water, it is likely that its nuclease activity is even stronger 
than that of 1. The absence of the linearization and a scarce change in the relative 
intensity of the Nck band, suggest that 4 and 5 as well as 11 and 12 are weak 
nucleases. The cleavage activity of all seven complexes tested at ri 3.3 and 6.7 seems 
to be concentration dependent. Based on these and other results obtained in the course 
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of this work, the order of activity of 1-5, 11 and 12 under phosphate buffer is assumed to 
be the following: 
3 > 1 ≥ 2 >> 4 ≥ 5 > 12 > 11 
 
 
 
Figure IV.5. Comparison of the nuclease activity of 1-5, 11 (a) and 12 (b) under PBS buffer at 
50 and 100 µM (ri 3.3 and 6.7). “DNA” is the control for native DNA incubated in the absence of 
metal Solutions of 50 and 100 µM of 1, 2, 4, 5 were prepared by dilution from 200 µM stock 
solutions. Due to the scarce solubility of 3, 11 and 12 in water, 1:2 and 1:4 dilutions from a 
saturated solutions (<<200 µM) were used. Error bars represent Sr. Data extracted from the gel 
in Figure A11. 
 
Not all oxidovanadium(IV) complexes with acac ligand show concentration dependent 
activity. Complex 10, for instance, does not seem to promote any cleavage (Figure 
IV.6). This may be due to its poor solubility in water, which is however, not the case of 
the complexes 3, 11 and 12, despite their low solubility, they are active towards pDNA.  
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Figure IV.6. The extent of DNA cleavage promoted by 1 and 10 at 3, 6, 12 and 50 µM under 
phosphate buffer, presented as the percentage of the Nck, Lin and Sc forms vs. complex 
concentration. Data extracted from the gel in Figure A6. 
 
A proper comparison of the efficiency of DNA cleavage by artificial metallonucleases 
measured by different research groups is normally impeded by the large variety of 
reaction conditions used. These can be incubation time, type of buffer media and 
plasmid DNA, concentration of ethidium bromide in a gel, solubility of complexes etc. No 
absolute method is yet established to allow comparison of the efficiency of different 
complexes examined as inorganic nucleases at different conditions.  
According to Cowan [507], a Poisson distribution can be used to describe the cleavage 
process, and the efficiency of a complex can be defined as S/M, where S is the average 
number of strand scissions occurred in each plasmid per micromole of metal complex 
per hour at 37 ºC, and M is the metal concentration in micromole. S equals -ln(fSc) 
where fSc is the fraction of the Sc DNA form (%Sc) in the case only the Nck and Sc 
forms are obtained.  
Figure IV.7 compares the efficiencies of tested complexes with 1 presented as ln (%Sc) 
vs. complex concentration. The ln (%Sc) was calculated from the percentage of the Sc 
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form measured from bands in AGE gel images. The results are displayed as a straight 
line where the slope relates the decrease of the intensity of the Sc band with the 
complex concentration. Supporting earlier conclusion, under phosphate buffer complex 
1 comparing to the derivatives, is the most efficient DNA cleaving agent followed by 2 
and 4. Complex 3 is probably even a stronger nuclease than 1 and 2, however its 
scarce solubility does not allow to accurately estimate the extent of its nuclease activity. 
 
 
Figure IV.7. Comparison of the nuclease efficiencies of 1 and 2, 4 and 5 at 3, 6, 12, 25, 50 and 
100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 and 6.7) under phosphate buffer. Complexes-derivatives 3, 6-8 
and 10-12 are not included for comparison since they do not dissolve completely in H2O, thus 
the concentration might be somewhat different from the expected value.  
 
Quantification of the nuclease activity in phosphate buffer can be observed in Table 
IV.2, ln (%Sc) vs. concentration. Table IV.3 presents the calculations of the absolute 
slope values of the lines for phosphate buffer and the potency order for this activity 
(intervals for 95% confidence).  
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Table IV.2. Values of ln (%Sc) corresponding to 0, 5, 10, 25, 50 and 100 µM complex 
concentration under phosphate buffer. Sampe with complex concentration „0‟ is the the one with 
plasmid DNA and no complex added. 
Concentration, 
µM 
ln (%Sc) 
1 2 4 5 
3 4.169 4.517 4.554 4.462 
6 3.799 4.402 4.484 4.502 
12 3.280 3.919 4.469 4.525 
25 2.800 3.555 4.140 4.484 
50 1.392 3.067 4.091 4.415 
100 * 2.174 3.673 4.382 
* Sc not detected due to complete degradation into Nck and Lin. 
 
Table IV.3. Calculated slopes for –ln (%Sc) vs. complex concentration for 1, 2, 4 and 5 
under phosphate buffer. Intervals for 95% confidence are presented.  
Complex 1 2 4 5 
     -0.056 0.013 -0.023 0.007 -0.009 0.003 -0.001 0.001 
 
VO(acac)2 and derivatives 2-5 including complexes 11 and 12 exhibit different activities 
towards pDNA degradation. This fact suggests an important role of a ligand in the 
complex activity. This assumption was verified by testing the nuclease activity of 9 
which, in aqueous solution, is the oxidovanadium(IV) aqua complex, VO2+. The results 
reveal a strong DNA cleavage activity which, seems to be similar to 1 (Figure IV.8). 
Apparently, some other species are responsible for the efficient DNA degradation, 
different from those formed in aqueous solution of 1. Nonetheless, 1 seems to be a 
stronger nuclease, particularly at 100 µM concentration. 
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Figure IV.8. Comparison of the nuclease activity of 1 and 9 under phosphate buffer at three 
concentration levels. Left: Agarose gel image; samples 1-3 were digested with 1 and samples 4-
6 with 9. Right: Percentage of three DNA forms calculated from the areas obtained by 
densitometry; 1 represents a solid line, while 9 – a dotted one. Data extracted from the gel in 
Figure A10, lanes 8-13. 
 
VOSO4, though commonly reported as an inactive towards DNA degradation [277], in 
the present work shows concentration dependent activity. However, often irreproducible 
behaviour is observed. It can show an activity as high as 1 in some assays, or weaker 
activity in others. This lack of reproducibility may be explained by the hydrolysis and 
precipitation of vanadium hydroxides at neutral pH which occurs more readily for aquo 
complex than for vanadium complexes that are stabilized by bidentate ligands such as 
acac. The precipitation is a very irreproducible process and may affect the DNA 
degradation by itself. The kinetics of the precipitation will depend strongly on factors 
such as the room temperature and the process of mixing the solutions, which were not 
specifically controlled in these experiments. The absence of nuclease activity observed 
in some tests and reported in the literature may be due to extensive precipitation of the 
metal as a hydroxide. When this precipitation is slower or not so extensive, nuclease 
activity can be observed, with a similar behaviour to 1, especially under phosphate 
buffer, since in the presence of organic buffers, HEPES or MOPS, 9 seems to exhibit 
more activity than 1.  
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Similar to 9, the extent of the DNA cleavage was obtained for oxidovanadium(IV) 
perchlorate under MOPS buffer (Figure IV.9), suggesting that the same species are 
responsible for nuclease activity of these complexes. 
 
 
Figure IV.9. Comparison of the nuclease activity of 9 (a) and VIVO(ClO4)2 (b) at 50 µM under 
MOPS buffer. Data extracted from the gels in Figure A32, lanes 8 and 9. 
 
To determine whether the active species in pDNA degradation are products of the 
oxidation of 1, three vanadate (VV) complexes containing acac as a ligand, 6-8, were 
synthesized and digested with pDNA. Comparing the relative intensities of the Nck and 
Sc bands of the DNA control sample (plasmid digested in the absence of metal) with 
those of the samples with complexes, a weak single-strand cleavage by 6 and 7 can be 
distinguished, especially at the highest tested concentration (Figure IV.10).  
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Figure IV.10. Comparison of the nuclease activity of 6-8 under phosphate buffer in the 
presence of activating agents. The complexes did not dissolve completely in water. Their 
concentration is 1:4 of the stock solution, which was prepared to be 200 µM. “DNA” and “Lin” 
are the controls of the Sc (native plasmid DNA) and Lin (50 µM of 1 digested with pA1 pDNA 
under 10 mM phosphate buffer) forms, respectively. Complex 1 with oxone was added for 
comparison. Error bars represent Sr. Data extracted from the gel in Figure A47. 
 
The results of the nuclease of monovanadate, an expected product of oxidation of dilute 
aqueous solutions of VIV-complexes (Figure IV.11), suggest that V1 is apparently not the 
active species either. No DNA cleavage under phosphate buffer even at 200 µM 
(ri 13.3) and merely a moderate single-strand scission in the presence of MOPS are 
observed. A gradual decrease in the intensity of the Sc band under MOPS indicates a 
concentration dependent cleavage. Complex 1 is much more active especially under 
phosphate buffer.  
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Figure IV.11. Extent of the DNA cleavage induced by V1 under phosphate (solid line) and 
MOPS (dashed line) buffers presented as the percentage of the Sc and Nck forms vs. complex 
concentration. Data extracted from the gel in Figure A48. 
 
The effect of complex concentration on the nuclease activity of other complexes, 10-36, 
mainly oxidovanadium(IV) compounds with different ligands was studied in comparison 
with 1 (Figure IV.12–Figure IV.19). None of these complexes demonstrated higher 
activity than that of 1. Exception is VO(oda)phen (21) which exhibits more efficient 
activity than 1 especially under MOPS buffer. In fact, it is the only complex out of total 
36 examined in this work that seems to be a stronger nuclease than 1.  
Two other complexes with oxodiacetate ligand “oda”, VO(oda) (20) and VO(oda)bipy 
(23), are also efficient nucleases (Figure IV.12). The principal complex, 20, has been 
reported as a possible candidate in evaluation related to the search of alternative 
therapeutics in cancer treatment, induces both nicking and linearization. Complexes 21 
and 23, synthesized as VO(oda) derivatives, readily interact with pDNA causing both 
single and double-strand cleavages. However, unlike with phenanthroline (phen), 
addition of bipyridine ligand (bipy) does not increase the reactivity of 20 much, the 
extent of the DNA cleavage seems to be similar. Figure IV.13 compares the nuclease 
activity of 21 and 23 under both buffers. Strong cleavage by 21, including linearization, 
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is observed already at ri 0.3 under phosphate as well as under MOPS. Complete 
conversion of the Sc into Nck and Lin occurs only under phosphate at ri as low as 1.7. 
Complex 23 is much weaker nuclease, linearization takes place also at ri 0.3 but to 
considerably lower extent than observed with 21. The difference in the activities is 
probably due to the binding affinity of phenanthroline which in the series of mononuclear 
mixed ligand copper(II) complexes is stronger than the one of bipyridine [508]. 
In the presence of MOPS a double-strand cleavage occurs only at the highest tested 
concentration, ri 6.7. The difference in the activities is more likely due to the presence of 
phenanthroline (phen). Known for its strong affinity to DNA, this ligand may bind to the 
DNA by intercalating the nucleobases, making it more susceptible to scission.  
 
 
Figure IV.12. Cleavage of pA1 pDNA by 20, 21 and 23 at 5, 10, 25, 50 and 100 µM (ri 0.3, 0.7, 
1.7, 3.3 and 6.7) under phosphate buffer. Data extracted from the gels in Figures A65, A70 and 
A80, respectively. 
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Figure IV.13. Comparison of the nuclease activity of 21 and 23 (black and grey lines, 
respectively) at 5, 10, 25, 50 and 100 µM (ri 0.3, 0.7, 1.7, 3.3 and 6.7) under phosphate and 
MOPS buffers. Data extracted from the gels in Figures A69 and A80. 
 
Figure IV.14 compares the extent of the nuclease activity of 20, 21 and 23 which is 
presented as the slope of the straight lines of ln (%Sc) vs. complex concentration. It is 
clear that the DNA cleavage ability of 23 is similar to that of 20, while 21 has a much 
higher nuclease activity. Quantification of the nuclease activity in phosphate buffer and 
calculated slopes together with the intervals for 95% confidence can be observed in 
Table IV.4 and Table IV.5, respectively. For 21 under MOPS the values of ln (%Sc) vs. 
concentration diverge somewhat from linearity because, simultaneously to the cleavage 
of the Sc, cleavage of the Nck into Lin form also takes place.  
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Figure IV.14. Comparison of the extent of pDNA cleavage by 20, 21 and 23 and 
VO(oda)phen with the one of 1 under phosphate and MOPS buffers, ln (%Sc) vs. 
complex concentration. 
 
Table IV.4. Values of ln (%Sc) corresponding to 0, 5, 10, 25, 50 and 100 µM complex 
concentration under phosphate buffer. Sampe with complex concentration „0‟ is the the one with 
plasmid DNA and no complex added. 
Concentration, 
µM 
ln (%Sc) 
1 20 21 23 
0 4.513 4.571 4.495 4.491 
5 ** 4.105 3.169 4.398 
10 4.168 3.918 1.346 4.248 
25 3.805 3.515 * 4.000 
50 2.808 3.091 * 3.485 
100 1.405 2.299 * 2.733 
* Sc not detected due to complete degradation into Nck and Lin. 
** Not tested 
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Table IV.5. Calculated slopes for ln (%Sc) vs. complex concentration for 20, 21 and 23 and 1 
under phosphate buffer. Intervals for 95% confidence are presented.  
Complex 1 20 21 23 
     --0.031±0.004 -0.021±0.008 -0.3±0.4 0.018±0.002 
 
Other oxidovanadium(IV) complexes that showed a concentration-dependent activity 
are presented in Figure IV.15. Except for VO(clor) (26), all three complexes promote 
single and double-strand DNA scissions at ri 1.7, 3.3 and 6.7. VO(PA)2 (19) is the most 
active followed by VO(MPA)2 (17), VO(dmpp)2 (18). Complex 26 seems to be the least 
active despite similar increase in the percentage of the Nck form as with 18. No 
linearization is observed even at ri 6.7. The cleavage activity of all four complexes is 
considerably lower than that of 1. 
 
 
Figure IV.15. Relation of the nuclease activity of 17-19 and 26 under phosphate buffer with the 
metal:bp ratio presented as the percentage of each DNA form vs. complex concentration. The 
percentage was calculated from the areas measured by densitometry in the gels from Figures 
A60, A62 and A113. 
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Complex 17 and 19 exhibit similar DNA cleavage activity under both buffers (Figure 
IV.16) can be considered for the further studies as potential inorganic nucleases. 
 
 
Figure IV.16. Efficiencies in DNA degradation promoted by 17-19 compared with those 
of 1 and 9 under at 25, 50 and 100 µM (ri 1.7, 3.3 and 6.7) phosphate and HEPES 
buffers. Data extracted from the gels in Figures A59, A60, A62 and A63. 
 
Table IV.6 and Table IV.7 show respectively calculated values of ln (%Sc) and slopes 
for -ln (%Sc) together with the intervals for 95% confidence. According to these results, 
the potency order of activities under phosphate and HEPES buffers are 1>9>17~19>18 
and 9>19>17>1>18, correspondingly. Organic buffers, in this case HEPES, seem inhibit 
the nuclease activity of 1 considerably. 
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Table IV.6. Values of ln (%Sc) corresponding to 0, 5, 10, 25, 50 and 100 µM complex 
concentration under phosphate buffer. Sampe with complex concentration „0‟ is the the one with 
plasmid DNA and no complex added. 
Buffer Concentration, µM 
ln (%Sc) 
1 9 17 18 19 
P
h
o
s
p
h
a
te
 0 4.605 4.562 4.553 4.565 4.567 
25 3.436 3.835 4.102 4.400 4.138 
50 2.737 3.287 3.713 4.396 3.789 
100 * 2.053 3.073 4.365 3.097 
H
E
P
E
S
 
0 4.537 4.554 4.566 4.568 4.556 
25 3.956 3.097 3.954 4.419 4.140 
50 3.895 3.053 3.988 4.453 4.033 
100 3.959 2.813 3.800 4.454 3.754 
* Sc not detected due to complete degradation into Nck and Lin. 
 
Table IV.7. Calculated slopes for –ln (%Sc) vs. complex concentration for 1-9, and 17-19 under 
phosphate buffer. Intervals for 95% confidence are presented.  
     1 9 17 18 19 
Phosphate -0.04 0.07 -0.024 0.003 -0.015 0.004 -0.0017 0.04 -0.015 0.002 
HEPES -0.005 0.02 -0.015 0.03 -0.006 0.01 -0.0008 0.004 -0.007 0.007 
 
VO(chrysin)2 (24) [156], VO(morin)2, (25) [157] and VO(silibinin)2 (27) [167], as the 
complexes that were studied for their antitumor effect by our collaboration group of Dr. 
Susana Etcheverry, in the DNA cleavage activity studies do not show any significant 
activity (Figure IV.17) even after addition of activating agents. Only 27 seems to exhibit 
a weak single-strand cleavage at tested ri 3.3.  
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Figure IV.17. DNA cleavage activity of 24, 25 and 27 under phosphate buffer related to the 
complex concentration. Error bars represent Sr. Data extracted from the gels in Figures A92 and 
A98. 
 
Cu(acac)2 (15) and Ni(acac)2 (16), possessing similar structure to 1, were tested to 
determine the role of the metal center in the DNA cleavage activity of acac-containing 
complexes. Unlike 16, which does not show any nuclease activity, 15 induces nicking 
with no apparent concentration dependence (Figure IV.18). Addition of activating agents 
increases the nuclease activity of 15 significantly, especially in the presence of MPA – 
plasmid seems to undergo a complete destruction. Complex 16 still shows no effect on 
the pDNA.  
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Figure IV.18. Cleavage of pA1 pDNA by 15 and 16 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 
0.8, 1.7, 3.3 and 6.7) under phosphate buffer presented as percentage of the Sc, Nck and Lin 
forms vs. complex concentration. Data extracted from the gels in Figures A51 and A52.  
 
The nuclease activity of six vanadium and three copper complexes containing amino 
acids and phen or bipy as co-ligands, 28-36, is compared in Figure IV.19. These 
complexes are of biological importance and possess therapeutic properties (e.g., anti-
cancer). Except for VO(Sal-L-Phe)(bipy) (31), which exhibits a low single-strand 
cleavage, none of these vanadium complexes induces the cleavage at the tested 
concentration of 50 µM (ri 3.3). Stronger cleavage of pA1 pDNA by copper complexes, 
namely Cu(Sal-Gly)(phen) (29) and Cu(Sal-L-Phe)(phen) (30), could be explained by 
the presence of phen ligand, which, as aforementioned, is a good DNA intercalator able 
to mediate the DNA breakage.  
 
IV. DNA CLEAVAGE ACTIVITY 
 
 
152 
 
Figure IV.19. Cleavage of pA1 pDNA by 28-36 at 50 µM (ri 3.3) under phosphate buffer. All 
complexes were dissolved in 5% EtOH. Error bars represent Sr. Data extracted from the gels in 
Figures A101 and A110.  
 
 
  Effect of buffer media  IV.2.2
To understand the importance of buffer media in the studies of DNA cleavage activity of 
metal complexes, the following questions were of importance: 
Do the concentration and nature of the pH buffer affect the nuclease activity of 
vanadium compounds? Is there any difference in the nuclease activity of 1 when it is 
dissolved in water and in buffer? 
Organic, most often Good‟s buffers54 [469,509-511] such as MOPS, MES, HEPES, are 
common pH buffer media in biochemistry laboratories and are typically reported in the 
studies of the nuclease activity of metal complexes. Considering the fact that these 
organic buffers are weak radical scavengers [462,512], it is not expedient to use only 
them for testing inorganic nucleases, assuming the DNA cleavage is commonly 
                                            
54
 Good buffers (or Good‟s buffers) are twelve buffering agents selected and described by Norman E. Good and 
colleagues in 1966. He developed buffers based on several criteria that made them useful candidates for biochemical 
research: pKa values between 6-8, good solubility in water, cell membrane impremeability, minimal salt, temperature 
and ionic strength effects, well defined or nonexistent interactions with mineral cations, biochemical inertness, 
chemical stability, optical absorbanse (should not absorbe visible or ultraviolet light) purity, non-toxicity, ease of 
preparation and low cost. Tris is not one of the Good’s buffers. It exhibits large shifts in dissociation with temperature 
changes. Tris buffer solution at pH 7 will drop to 5.95 at 37 ºC. Also its pH decreases approximately 0.1 pH unit per 
tenfold dilution. 
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promoted via oxidative mechanism; cases of DNA being cleaved hydrolytically are still 
rare given the stability of DNA towards hydrolysis (half-life is approximately 130 000 
years at neutral pH and 25 ºC). Phosphate buffer is an ideal alternative for such studies. 
Unlike, MOPS, HEPES or TRIS, it does not possess radical scavenging properties, 
moreover it is an important biogenic ligand, one of the major constituents of human 
blood serum and interstitial fluids, where it is present at the approximate concentration 
of 1.1 mM [513]. The choice of phosphate buffer for pDNA digestion studies is not 
random: physiological conditions such as incubation temperature (37 ºC) and buffer pH 
(6.9-7.4) together with the medium itself that is biologically important, allows projecting 
in vitro results for in vivo application. Therefore, complexes were typically studied under 
two buffers – organic (HEPES, MOPS or TRIS) and inorganic (phosphate). 
 
The results in Figure A31–Figure A37 show that the mixture of phosphate buffer with 1 
equals a strong pDNA cleavage, whereas MOPS, HEPES or TRIS buffer do not favour 
this reaction (Figure A1–Figure A3). Figure III.20 compares the extent of the DNA 
cleavage by 1-5 and 9 at 50 µM under MOPS buffer. All complexes promote only single-
strand cleavage and according to the calculated percentage the order of activity can be 
as follows: 1>2>4~9>3~5.  
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Figure IV.20. Left: Agarose gel of pA1 incubated with 1-5, 9 under MOPS buffer (pH 7.0). 
“DNA” - native DNA digested in the absence of metal. Numbers 1-5 and 9 refer to 
corresponding complexes. Complex concentration for 1, 2, 4, 5 was 50 µM (ri 3.3), prepared 
from stock solutions of 100 µM; 3 was diluted 1:2 from a saturated solution at room temperature. 
Right: Percentage calculated by densitometry. Error bars represent Sr.  
 
Results of the nuclease activity of 1 expressed as a slope of the decrease of ln (%Sc) 
related with the increase of complex concentration (Figure IV.21), shows that the 
complex exhibits an insignificant activity in the presence of organic buffers, whereas 
under phosphate the difference is striking. Under TRIS the values of ln (%Sc) vs. 
concentration diverge somewhat from linearity most probably because the cleavage is 
not concentration dependent. 
Complex 9 seems to behave similarly in all tested buffers (Figure IV.22) exhibiting 
stronger DNA cleavage activity under HEPES. Since 9 was found to precipitate under 
phosphate, this could explain the lower activity than under HEPES.  
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Figure IV.21. Comparison of the extent of pDNA cleavage by 1 under phosphate, MOPS, 
HEPES and TRIS buffers, expressed as ln (%Sc) vs. complex concentration. There is no Sc at 
100 µM under phosphate buffer as pDNA was linearized completely.  
 
 
Figure IV.22. Comparison of the extent of pDNA cleavage by 9 under phosphate, MOPS, 
HEPES and TRIS buffers, expressed as ln (%Sc) vs. complex concentration. Data extracted 
from the gels in Figures A44 and A45. 
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Not only was the nature of the pH buffer but also its concentration found to affect the 
extent of the DNA cleavage activity of vanadium complexes. Comparison the DNA 
cleavage activity of 1, 4, 6, 9 and VO(acac-NH2)2 at 12 µM (ri 0.8) and 25 µM (ri 1.7) 
under 10 and 100 mM phosphate buffer (Figure A35 and A36) showed that all 
complexes exhibit stronger DNA cleavage at lower buffer concentration. 
Presuming that the DNA cleavage activity of the majority tested chemical nucleases 
follows oxidative pathways, the possibility that the formation of ROS in the aqueous 
solution of 1 is the culprit of its efficient behaviour towards DNA degradation was 
considered. This hypothesis together with that MOPS can act as a radical scavenger 
was clarified by examining the DNA cleavage by 1 under phosphate buffer with addition 
of MOPS (Figure IV.23). The nuclease activity of 1 is much higher in the absence of 
MOPS, linearization of pDNA 0.8% and 1.6% occurs at 5 and 10 mM of phosphate, 
respectively. On the contrary, the DNA degradation is always inhibited when MOPS is 
added and the extent of the inhibition is higher for higher concentrations of MOPS. 
Apparently, the generation of ROS by 1 is greatly increased in the presence of 
phosphate at millimolar concentrations and is always inhibited with MOPS due to its 
scavenging action. 
 
 
Figure IV.23. Effect of mixtures incubation with DNA buffered with mixtures of MOPS and 
phosphate buffer on the DNA cleavage activity of 1 (50 µM). Left: AGE image. “Lin” and “DNA” 
are the controls for linearized and native DNA. Right: Results obtained from densitometry 
measurements. Error bars represent Sr. 
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As phosphate buffer was found to play a significant role in the nuclease activity of 1, the 
question how exactly arose immediately. According to Saran et al. [447] and Reinke et 
al [449] Fe(II) ions in solutions with neutral pH have a tendency to autoxidize to Fe(III) 
and most likely to precipitate in form of insoluble hydrates. When this solution is 
phosphate medium, the precipitation is prevented by formation of Fe(III)-phosphate 
complex. This could be true for V(IV) ions as well, but in the case of 1 it is less likely due 
to the presence of the ligands coordinated to the complex. However, the assumption 
that phosphate buffer increases the chances of 1 for autoxidation has been made. It is 
reasonable to assume that oxidovanadium(IV) complexes undergo a structural change 
in this medium: phosphate interacts with 1, for example by stabilizing the mono-chelated 
complex, VIVOL+. This assumption could explain the stability of 1 and 2 observed in UV-
vis spectra, taking into account that the compounds were directly dissolved in buffer. 
Since phosphate is an abundant component in physiological buffer system, its possible 
complexation with metal complexes, particularly 1, is crucial for the future in vivo 
studies. 
Reported studies of the interaction of inorganic phosphate with VIVO2+ [34 ,514] show a 
formation of protonated 1:1 and 1:2 complexes in acidic pH range, it then precipitates at 
pH ~4.5, and re-dissolves at pH~8.5, forming mononuclear mixed hydroxo species in 
addition to various poorly characterized oligonuclear hydroxo-bridged complexes. To 
our knowledge, no speciation studies for VO(acac)2 in phosphate media have been 
reported. This has been done for maltolate, a small bidentate ligand with a stability 
similar to VO(acac)2 [28,515]. Above pH 6, when the ratio metal:maltonate:phosphate is 
1:5:5, phosphate cannot compete with maltolate for binding to vanadium. In the 
modelled physiological condition (phosphate and metal concentrations of 1 mM and 
10 µM, respectively), it was predicted that 8% of vanadium forms a binary complex with 
maltolate and phosphate. The stability constant of VO(acac)2 is close to that of 
VO(maltolato)2 (15.6 and 16.3), thus it is possible that a micromolar solution of 
VO(acac)2 in a 10 mM phosphate buffer will also contain a fraction of the ternary 
complex VIVO(acac)-(phosphate). This assumption can be supported by SWV results 
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which indicate a possible formation of at least three different species: 
VO(acac)2(H2PO4)
-, VO(acac)(H2PO4 )2
-
 and VO(H2PO4)2. 
 
  Effect of excess ligand IV.2.3
Assuming that the active species towards DNA cleavage is the one that is stable upon 
formation in an aqueous solution, it is possible that the predominant species is the one 
containing vanadium and at least one functional group as acac coordinated to vanadium 
ensures its stability. 
Considering the importance of ligands in a coordination complex, two following 
questions were of interest: 
1) Do the ligands of the active complexes cause the pDNA degradation per se? In other 
words, can ligands be responsible for the nuclease activity of tested complexes? 
2) Does the increasing of the complex stability by addition of excess ligand mean a 
higher DNA cleavage? 
 
Excess ligand favours the stability of VIVOL2 which is predominant species in an 
aqueous solution of 1. Speciation studies [116] show that when one equivalent of Hacac 
is added to the aqueous solution of VO(acac)2, the 1:2 species, i.e., V
IVOL2, can be 
stable for 7 days. Speciation studies [231] of VO(acac-NH2)2 and VO(acac-NMe2)2 
metal-ligand system showed that at 1:80 metal ion to ligand ratio (L/M), 80% are in the 
VIVOL2 form. Our group tested the effect of excess ligand on the nuclease activity of 
VO(acac-NH2)2, VO(acac-NMe2)2 by incubating the solutions, where the complex at 
50 µM (ri 3.3) under phosphate buffer was stabilized by addition of an excess of ligand 
up to ~300 fold. Following this example, similar experiments with L/M of 1.25, 2.5, 5, 40, 
80 and 160 were carried out (Figure A27-A29). No increase in the DNA cleavage is 
observed up to L/M of 160. Instead, a noticeable decrease in the activity of all three 
complexes is detected upon ligand addition. The inhibition of the DNA cleavage that is 
IV. DNA CLEAVAGE ACTIVITY 
 
 
159 
especially prominent at higher excess of ligands, suggests that stabilization of the 1:2 
species is not a determinant factor in a high nuclease efficiency observed in the 
presence of 1. 
Taking into account that VO(acac)2 was reported [238, 240] to react with polydentate 
ligands having one acac group substituted, with the second acac group remaining 
resistant to substitution, it is likely that upon addition of aqueous solution of 1 to a 
sample containing pDNA and phosphate buffer during 1h incubation at 37 ºC, 
phosphate substitutes one acac- group. As a result VO(acac)(H2PO4)
- species is formed 
which is the one possible responsible for the cleavage we observe. Therefore, there are 
two possible explanations for the inhibition of DNA cleavage upon addition of excess 
ligands. First, stabilization of the complex prevents the species from forming especially 
taking into account the fact that ligands were added before the complex. Second, if the 
species is formed despite the increased amount of ligands and assuming that this 
species favours the formation of ROS, i.e., the mechanism of cleavage is radical, it is 
possible that such high concentration of ligand acts as a radical scavenger. 
  
  Effect of time IV.2.4
Studies of the effect of incubation time allowed answering the following questions:  
1) How does the nuclease activity of VC change with the incubation time?  
2) What is the minimum incubation time necessary for the DNA cleavage to be 
observed?  
The DNA cleavage in the presence of 1 was found to increase with longer incubation 
time. Though no significant change is observed between the results obtained after 15 
and 135 min incubation, a noticeable increase in the percentage of the Nck form at 
3 µM (ri 0.2) and gradual linearization at 25 µM (ri 1.67) (Figure IV.24) suggest that the 
longer the time of pDNA digestion with 1, the higher the extent of strands breaks. 
Nonetheless, it is clear that 15 min of incubation is sufficient for an efficient DNA 
scission, especially at 25 µM. In the experiment, where the lowest amount of time tested 
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was 5 min at 25 µM of 1 (Figure IV.25), the presence of both single and double-strand 
cleavages indicates that the DNA cleavage reaction at 37 ºC is rapid. Most likely that 
with longer incubation time the DNA degradation will continue increasing until 
completely destroyed. This assumption is supported by the calculated percentage of 
DNA forms presented in Figure IV.25. Increased incubation time up to 4 h resulted into 
gradual complete and increasing linearization. 
The fact that the Lin band can be observed at 3 µM in the first 15 min of incubation 
suggests a very strong ability of 1 to cleave DNA. 
Taking into account that the DNA cleavage occurs as early as 5 min of being incubated 
and still continues to be induced after 4 h, chosen incubation time of 1h in a typical AGE 
experiment might be considered as optimal for studies of DNA cleavage by VC.  
 
 
Figure IV.24. Relation of the nuclease activity of 1 and the time of its digestion with pDNA. 
Complex concentrations are 3 (left) and 25 mM (right) under phosphate buffer. Data extracted 
from the gels in Figures A21 and A22, respectively.  
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Figure IV.25. Effect of incubation time on the nuclease activity of 1 (25 µM, ri 1.67) under 
phosphate buffer expressed as the percentage of Sc, Nck and Lin DNA forms vs. time. Data 
extracted from the gel in Figure A23.  
 
  Effect of light IV.2.5
Many chemical nucleases, including VC, have been found to break DNA 
photochemically [278-282].  
Our group previously did some studies of the effect of light on the nuclease activity of 1, 
determining that photocleavage is not an important process in the reaction with pDNA 
Results of the experiments where the incubation was carried in the dark (Figure A40), 
and those where the samples were incubated under a UV lamp at 370 nm (Figure A39), 
do not differ significantly from the experiments where incubation was carried out under 
natural light. Though the complete absence of light could not be guaranteed, it still 
seems like light does not affect the nuclease activity of 1. The progress of the cleavage 
is evident with the increase of complex concentration (Figure IV.26).  
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Figure IV.26. Nuclease activity of 1 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.67, 3.3 and 
6.7, respectively) under phosphate buffer. Left: samples were incubated wrapped in aluminium 
foil to ensure the protection from light. Right: samples were incubated under a 370 nm UV lamp. 
Data extracted from the gels in Figures A38 and A39. 
 
 
  Effect of activating agents  IV.2.6
Our group has previously tested the effect of the presence of an oxidizing and reducing 
agent on the nuclease activity of 1. Oxone enhanced the complex nuclease efficiency, 
and it was observed that supercoiled DNA is totally broken into its Nck and linear forms. 
The activating effect of oxone was found to be similar both under air and inert 
atmosphere. In contrast, the reducing agent MPA inhibited the nuclease activity, 
although some degradation of the Sc form into the Nck form was still observed. This 
inhibiting effect also took place to the same extent under air and under inert 
atmosphere, but it appeared to be less dramatic under N2 because activity is already 
low in the absence of any agent. 
For most of the tested complexes in this work the addition of oxone or MPA ensured a 
significant change in the extent of the DNA cleavage. Such dramatic difference 
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indicates that the oxidation of V(IV) in the presence of oxone greatly affects the DNA 
breakage. Addition of oxone promotes oxidation of V(IV) to V(V) in the process involving 
the formation of ROS. Since oxidovanadium(V) complexes, 6-8, exhibit rather moderate 
DNA cleavage activity, tit is unlikely that V(V)acac species that result from the oxidation 
of 1, are the ones responsible for the strong nuclease activity. On the other hand, the 
role of ROS generated during the oxidation process may be crucial. 
Addition of activating agents, especially oxone, to 6-8 increased the percentage of the 
DNA cleavage significantly. Linearization is observed for all three complexes with the 
higher extent for 7 followed by 6 and 8 (Figure IV.10). Hence, these oxidovanadium(V) 
derivatives of 1, do not promote a significant nuclease activity unless a strong oxidant is 
present.  
Monovanadate on its own has no effect on pDNA (Figure IV.27). The absence of the 
DNA cleavage in the presence of MPA, suggests that no reduction of V(V) took place. 
Upon addition of oxone a slight increase in activity is observed. This is unexpected, as 
V(V) is already in its highest oxidation state and cannot be further oxidized by oxone. 
Nevertheless, some explanation can be found from the reduction potentials of 
monovanadate and oxone. The equilibria for the redox pairs and the standard reduction 
potentials are: 
HSO5 
-
+2H
+
+2e-⇌HSO4 
-
+H
2
O  E0 = 1.44V    (eq.IV.1) 
VO2 
+
+2H
+
+e-⇌VO 
2+
+H
2
O   E0 = 1.00V     (eq.IV.2) 
 
When corrected for pH 7 buffered solutions, the conditional reduction potentials E0‟ 
become 1.03V and 0.17V. The Nernst equation can be used to estimate the reduction 
potential of a redox pair at 25ºC: 
 
Eox/red=E
0 
-
0.05916
n
log (
[red]
[ox]
)         (eq.IV.3) 
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where, for a general redox equilibrium ox + ne– ⇌ red, Eox/red is the reduction potential of 
the redox pair ox/red, E0‟ is the conditional reduction potential for the pair at pH 7, n is 
the number of electrons exchanged and [red] and [ox] are the concentrations of the 
reduced and oxidized species. Applying to the present study, 
 
E
HSO5
-
/HSO4
- =E
0 
-
0.05916
2
log (
[HSO4
-
]
[HSO5
-
]
)      (eq.IV.4) 
E
VO2
+
/VO
2+=E
0 
-0.05916 log (
[VO
2+
]
[VO2
+
]
)       (eq.IV.5) 
 
Oxone is a triple salt 2KHSO5
.KHSO4
.K2SO4 where HSO5 
-
 is the oxidant species 
undergoing the reduction to produce HSO  
-
, already present in solution at an initial 
concentration which is half that of HSO5 
-
. The solution of monovanadate is not expected 
to contain any residues of V(IV), which would make its reduction potential practically 
infinite. It is thus reasonable to expect that vanadate will oxidize oxone (HSO  
-
 to 
HSO5 
-
) to a very small extent. As this process will involve ROS, it may justify the small 
nuclease activity observed when adding oxone to monovanadate. 
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Figure IV.27. DNA cleavage activity of monovanadate at 25, 50 and 100 µM in the presence of 
activating agents under phosphate and MOPS buffers. Data extracted from the gels in Figure 
A49 and A50. The columns “DNA” compare two samples of DNA control from two gels. As 
reaction mixtures for the DNA controls typically do not contain any buffer medium, the columns 
are not filled with colours that were chosen to represent phosphate (black) and MOPS (grey). As 
reactions mixtures for the Lin controls are always prepared with phosphate buffer, both columns 
“Lin” are shown in black.  
 
The effect of activating agents on the nuclease activity of 9 seems to be as significant 
as for 1. There seems to be a difference in the effect of MPA under phosphate and 
MOPS buffers (Figure IV.28). Under MOPS buffer the situation is considerably different: 
in the presence of MPA the extent of the cleavage by 9 is much stronger than with 
oxone. The same behaviour is observed for 21. The most efficient DNA cleavage seems 
to occur in the presence of MPA under MOPS buffer.  
Regarding 20 and 23, under both buffers the extent of the cleavage is affected by MPA 
or oxone but not dramatically (Figure IV.29). Activated by oxone and MPA, the nuclease 
behaviour of 21 is different from what was expected, i.e., being increased with oxone 
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and inhibited by MPA. A complete linearization takes place when the complex is not 
activated by the agents. Interestingly, under MOPS the amount of the Lin (9.6%) is 
considerably bigger than under phosphate (5.5%). Oxone seems to augment a double-
strand cleavage under phosphate (11.3%) and inhibit under MOPS (4.8%). Addition of 
MPA to 50 µM of 21 increases the linearization under both buffers to 13.3% and 33.9% 
in phosphate and MOPS, respectively. Such a high percentage of the Lin form in the 
presence of MPA under MOPS, suggests extremely efficient nuclease ability. Moreover, 
the pDNA degradation seems to still be an on-going process. Clearly, the Lin form is 
increased at the cost of the Nck. A tail-like smear (Figure A91, lane 11) suggests that 
the Lin destruction into smaller fragments. 
Complexes 20 and 23 also seem to cleave pDNA at higher extent under MOPS buffer. 
For 20, the percentage of the Lin form in the absence of activating agents is 2 and 4.3% 
under phosphate and MOPS, respectively. With oxone it is 3 and 4.3%, and with MPA – 
2.9 and 3.8%. 
In the case of 23, the percentage of linearization with no agents is 2.8 and 4.4% under 
phosphate and MOPS, respectively. Upon addition of oxone, it decreased to 2.7 and 
3.9%; in the presence of MPA it is 3 and 3.6%.  
Finding a plausible explanation for an efficient nuclease behaviour under MOPS and 
MPA, it is likely that both 9 and 21 cleave pDNA via mechanism other than radical. 
Another possibility is another type of ROS which are not scaveged by MOPS. 
IV. DNA CLEAVAGE ACTIVITY 
 
 
167 
 
Figure IV.28. Percentage of the Sc, Nck and Lin forms of pDNA after incubating 9 with oxone 
and MPA under phosphate and MOPS buffers. Data extracted from the gels in Figure A98 
(lanes 12-14) and A99 (lanes 7-9). 
 
 
Figure IV.29. Effect of oxone and MPA on the nuclease activity of of 20, 21 and 23 at 50 µM 
(ri 3.3) under phosphate and MOPS buffers. Data extracted from the gels in Figures A90 and 
A91. Error bars represent Sr.  
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The presence of activating agents is expected to intensify the extent of the DNA 
cleavage. It is assumed to be especially true for phen-containing compounds. Due to 
intercalation of phen, the DNA undergoes the strand breakage more readily. Addition of 
activating agents is supposed to augment the strength of the cleavage. The results of 
the effect of activating agents on DNA cleavage activity of phen-containing copper and 
vanadium complexes, Cu(Sal-Gly)(phen) (29), Cu(Sal-L-Phe)(phen) (30), VO(Sal-L-
Phe)(phen) (32) and VO(Sal-Gly)(phen) (34), support this assumption. After a 5h-
digestion, 32 and 34 in the presence of MPA (Figure A105 and A106) promote both 
single and double-strand cleavage, and induced a complete linearization of the Sc DNA 
with oxone (Figure A103 and A104).  
Similarly, in the presence of oxone or MPA, 29 and 30 break the plasmid into very small 
fragments that are possibly eluted in a gel and cannot be detected after visualization by 
UV-light. This is the reason of the missing bands observed in gels (Figure IV.30). These 
results were obtained following a long digestion of 5 h. At was the usual incubation of 
1 h, in the presence of oxone the complexes behaved similarly, i.e., the plasmid 
underwent destruction (Figure A109, lanes 8 and 11). Effect of MPA seems to be less 
dramatic. The bands are well defined but the tail-like smears (lanes 9 and 12) suggest 
that pDNA undergoes the extensive degradation. 
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Figure IV.30. Effect of the reductant on the nuclease activity of 28-32 under PBS. Example of 
the complete breakage of pDNA by copper complexes with MPA. The snip of the gel image is 
from Figure A105. 
 
These are not the only copper complexes that behave in such way towards DNA 
degradation. In fact, all copper complexes that were tested in this work by AGE, 
promoted the destruction of the plasmid in the presence of MPA. A good example is 15. 
Regardless of the buffer medium, the complex seems to completely destroy the plasmid 
that no band can be observed under UV light Figure IV.31). Considering the fact that a 
typical concentration of MPA used in AGE experiment, i.e., 200 µM, might be too high, 
15 and CuCl2 at 50 µM were examined in the presence of 10, 25, 50, 100 and 200 µM 
Of MPA (Figure IV.32). A tail-like smear observed for both complexes at 25 µM (lanes 5 
and 11) suggests that the destruction is taking place and already at 50 µM (lanes 6 and 
12) the plasmid is completely degraded. A plausible reason for this high reactivity is that 
copper(II) is reduced by MPA to copper(I) in a mechanism involving reactive ROS which 
can cleave DNA [331, 516]. 
. 
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Figure IV.31. Extracted from Figure A54. 
 
 
Figure IV.32. Extracted from Figure A56. 
 
Examples of vanadium complexes which were not activated by oxone nor MPA under 
any tested pH buffer are VO(morin)2 (25), VO(clor) (26) and VO(silibinin)2 (27) (Figure 
A96-A98 and A99). This fact allows considering, as already aforementioned, possible 
important role of the ligands in the cleavage activity of VC. In the case of 25 and 26 he 
lack of the DNA cleavage can be explained by their solubility. Although they seem to 
visually dissolve in H2O, DMSO is the solvent that is typically used in their solution 
preparation. 
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  Effect of radical scavengers and H2O2 IV.2.7
The nuclease activity of many inorganic complexes has been attributed to oxidative 
pathways of the cleavage mainly via formation of OH radicals by Fenton-type reactions 
[246]. Literature survey on the reported potential vanadium nucleases points to the 
oxidative mechanism of DNA cleavage. 
The use of known radical scavengers such as NaN3, NaBz, DMSO in the AGE tests with 
active VC helped clarifying the nature of the mechanism of cleavage, which seems to be 
purely oxidative. Our group has previously shown that the pDNA cleavage of 1 is 
completely inhibited in the presence of all scavengers suggesting the involvement of 
activated oxygen species in the degradation process. Addition of sodium azide, a known 
scavenger of singlet oxygen, to the reaction mixture seems to significantly inhibit the 
DNA cleavage, suggesting the involvement of 1O2 in the reaction of pDNA with 1. The 
quenching of the reaction by two other scavengers (NaBz and DMSO) suggests a 
mechanism involving the formation of OH radicals, as intermediates. This assumption 
can be confirmed by the results obtained in the tests of VC with hydrogen peroxide, an 
important constituent of the reactions leading to hydroxyl radical formation. A dramatic 
increase in the DNA cleavage is observed (Figure IV.33). Increasing the concentration 
of H2O2 showed a much less significant effect on DNA degradation than increasing the 
complex concentration. This fact suggests that the oxidative mechanism is not very 
sensitive to the concentration of oxidant. 
VC whether are being introduced intravenously, intramuscularly or orally are expected 
to interact with body‟s fluids. In living systems, H2O2 is formed by dismutation of 
superoxide anions, which are generated in several systems such as xanthine-oxidase, 
NADPH oxidase and NADH-dependent cytochrome P-450 systems and in neutrophils 
[517,518], and which can be generated by the oxidation of the metal centre in the 
presence of molecular oxygen [519]. Hence, addition of oxone or H2O2, most likely, will 
induce the oxidation of V(IV) with the production of ROS such as superoxide O2
-
, which 
may further react with V(V), yielding peroxidovanadium(IV). This product can be the 
cause of the DNA breakage. Liochev and Fridorovich in their numerous publications on 
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vanadate-stimulated oxidation of NAD(P)H [520-522], report the reaction of V(V) with by 
O2
-
, yielding a peroxidovanadium(IV), which is likely to be responsible for the univalent 
oxidation of NAD(P)H. VO2+ is the active form of vanadium that plus H2O2 can could 
oxidize NAD(P)H by a process dependent on hydroxyl radicals [523]. Thus, V(IV) can 
reduce H2O2 yielding •OH in Fenton-like reaction [524] via the same pathway as does 
Fe(II) and Cu(I). 
 
The nuclease behaviour of 20, 21 and 23 in the presence of scavengers is distinctively 
different under phosphate and MOPS buffers. As an example, Figure IV.34 compares 
the efficiency of 21 in the presence of the scavengers under both buffers. Clearly, 
scavenging effect under phosphate buffer is much stronger than under MOPS. This 
difference suggests that in the presence of phosphate buffer, ROS are the cause of the 
remarkable nuclease activity of 21, as in the case of 1.  
Under MOPS buffer all three complexes of oda family (Figure IV.35) cleave pDNA more 
efficiently than 1. Moreover, in the case of 21, the extent of the pDNA cleavage induced 
under MOPS is as high as that with phosphate. Therefore, a mechanism by which 21 
interacts with pDNA in MOPS is rather different from that of 1. The same can be 
assumed under phosphate medium since the DNA degradation by 21 most likely is 
greatly dependent on the binding affinity of phenanthroline.  
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Figure IV.33. Effect of H2O2 on the nuclease activity of 1. (A) Effect of complex concentration 
with constant peroxide content: (♦) no added H2O2 (■) 1 µM (▲) 10 µM (●) 100 µM H2O2. (B) 
Effect of H2O2 with constant complex concentration: (▲) 3 µM (■) 6 µM (♦) 12 µM VO(acac)2. 
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Figure IV.34. DNA cleavage activity of 21 at 100 µM (ri 6.7), under MOPS and phosphate 
buffers in the presence of scavengers. NaN3, NaBz and DMSO are the controls of the 
scavengers. The data are extracted from Figures A77 and A79, respectively. Error bars 
represent Sr. 
 
Figure IV.35. Percentage of the Sc and Nck forms obtained after pDNA cleavage by 20, 21 and 
23 at 50 and 100 µM under phosphate and MOPS buffers. Error bars represent Sr. Data 
extracted from Figure A90.  
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  Effect of atmosphere (air and nitrogen) IV.2.8
Atmospheric oxygen is an important constituent in many chemical and biochemical 
reactions. In the presence of metal cations such as V, Fe(II) Cu(I) it may cause the 
oxidation of the metal centre with the production of superoxide radicals [519].  
The nuclease activity of 1 under inert atmosphere was studied previously in our group. 
The extent of the DNA cleavage decreased but only in a slight manner, a significant 
effect of 1 could still be noticed.  
A slight inhibition of nuclease activity under N2 is also observed for 9 under phosphate 
buffer. In the experiment with HEPES buffer the decrease is higher (Figure IV.36). 
These results, as in the case of 1, indicate that air does not have a primary role in the 
nuclease activity of 9 which is possibly taking place through more than one mechanism 
in parallel, possibly radical, one at least involving atmospheric oxygen. 
 
 
Figure IV.36. DNA degradation induced by 9 in phosphate (black lines) and HEPES buffers 
(grey lines), increasing the concentration of the complex. Samples were prepared and incubated 
under air (A) and nitrogen (B). The percentage of the DNA forms – Sc (●), Nck (▲) and Lin (■) 
was calculated by densitometry. Data extracted from Figure A42 and A43. 
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  „Phantom bands‟ IV.2.9
Interpretation of the results obtained by AGE consists of comparing the working 
samples (i.e., containing metal complexes, the nuclease activity of which is to be 
determined) with the controls for the supercoiled and linear DNA forms. As stated 
earlier, depending on the nuclease efficiency of a tested complex, two (Sc and Nck, 
single-strand cleavage) or three (Sc, Nck and Lin, double-strand cleavage) bands are 
expected to appear and be observed under UV-light on account of EtBr present in a gel. 
However, the data collected as the images of gels during AGE experiments revealed 
the present of some additional bands. They can be observed almost in every image, 
especially in the tests of compounds with a high nuclease activity. As the interest in the 
origin of these extra bands grew, we decided for the time being to call them „phantom 
bands’.  
The intensity of „phantom bands‟ seems to increase with the complex concentration. 
Gels A110- A113 contain the results of experiments specially dedicated to testing these 
bands, which we named as A1, A2, A3 and B1. 
The „phantom bands‟ are absent from the controls of native pDNA and from samples not 
containing metal (see for example samples containing ligand oda in gel A112), but 
always appear in samples containing vanadium. Samples incubated with copper 
complexes also present phantom bands in similar positions (see for example gels A102, 
A103, A109).  
Figure IV.37 compares the percentage of the Sc, Nck and Lin DNA forms with that of 
„phantom bands‟. The intensity of B1 appears to correlate with the intensity of the linear 
form, while A2, and A3 follow the intensity of the Nck form. Band A1 is generally more 
irregular and harder to analyse than the other two. Lin and B1 are purposefully 
presented with the same symbol to better show an assumed relation between them. 
The increase of the B1 band is apparently affected by the intensity of the double-strand 
cleavage. A3 seem to always be present in all samples with pDNA and a complex even 
if no cleavage takes place. In the controls of the Sc DNA form, no „phantom bands‟ can 
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be observed signifying that these bands are the product of the nuclease activity of the 
tested complexes and not just some gel artefacts. 
 
To our knowledge, no information on these extra bands is available in the literature. 
Typically, in scientific reports, a gel image is presented as a snip which is cut right 
above the Nck form and below the Sc or Lin forms; no additional records are usually 
provided. Such bands must represent a fraction of pDNA with a different electrophoretic 
mobility, which can occur due to a change in molecular mass, geometry or electrical 
charge. „Phantom bands‟ can be a result of vanadium causing the distortion of the 
pDNA structure and changing its geometry. Another hypothesis is that vanadium ions 
bind to the phosphate backbone, changing the global charge of the pDNA. This binding 
would lower the overall negative charge of the phosphate backbone and thus lower the 
mobility of the DNA fragments. B1 would correspond to partially neutralized Lin form, 
while A1, A2 and A3 to partially neutralized Sc and Nck forms. ~ 
 
 
Figure IV.37. Change in the percentage of the Sc, Nck and Lin DNA forms (left) and A1, A2, A3, 
B1 (phantom bands; right) vs. concentration of 1. Data extracted from Figure A110. 
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 Variability of gels IV.2.10
The results obtained in AGE can vary from gel to gel. The following are the most 
common problems that were encountered during AGE tests. In such cases an 
experiment was normally repeated:  
1) gel of an inferior quality (e.g., a gel is contaminated or the agarose particles were not 
homogenised) (Figure IV.38);  
2) poor resolution of the gel image (e.g., the bands are non- or only partially visible 
(Figure IV.39) or are not sharp (Figure IV.40)); . 
3) poor separation of the bands (Figure IV.41), especially Lin and Sc (Figure IV.42, 
lanes 11 and 12); 
3) possible contamination of all tested samples (Lin band is present in all lanes 
including references of Sc DNA (Figure IV.43);  
4) significant difference in the percentage of the DNA forms in the bands of the controls 
of native and/or linearized DNA (typically, two controls of Sc and Lin forms of plasmid 
were included in both extremes of a 16/18-well gel plate) (Figure IV.44, lanes 1 and 14).  
As a rule, especially in the beginning of this research, experiments were repeated 
whenever any of the above cases would take place. Later, two replicate gels were run 
on regular basis for purposes of the results reliability. 
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Figure IV.38. Example of a gel contaminated with some external material, small dots are 
probably undissolved particles of agarose. 
 
 
Figure IV.39. Example of the gel with a poor image resolution. 
 
 
Figure IV.40. Example of the gel with distorted bands, low sharpness. 
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Figure IV.41. Example of the gel with a poor separation of the bands. 
 
 
Figure IV.42. Example of the gel with a poor separation of the Lin and Sc bands. 
 
 
Figure IV.43. Example of the gel, where all the samples, including both references of the pDNA 
(first and last lanes), contain a Lin band. 
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Figure IV.44. Example of the gel in which the percentage of the Sc form differs significantly in 
the samples-controls of native pDNA (lanes 1 and 14). 
 
 
 Circular Dichroism studies  IV.2.11
Obtained spectra suggest the CD signature of B-form DNA [322, 525]. A positive band 
(274 nm) is due to the base stacking, while a negative one (264 nm) appear at the cost 
of the DNA helicity. The CD spectra of native pA1 changes with time: the intensity of 
both bands increases by 27% in 25 h (Figure IV.1, A). This is a significant change, when 
compared with the intensity of the same bands in the presence of metal complex - 
maximum change is 20% (Figure IV.1, B). These changes in the 220–230 nm range 
could be due to some degradation of the DNA molecule without extensive change of 
either helix form or base-stacking. 
The changes observed in the pA1 DNA bands are consistent with its degradation. A 
good correlation between the “asymmetry” and the % of linear form can be observed. 
(Figure IV.45). Comparison of the DNA control (native pDNA incubated 1 h at 37 ºC, 
lane 1 and 8) with pA1 used in the CD measurements (D, lane 3, 25 h incubation) 
shows a significant difference in the amount of DNA conformations 3.5% and 12% for 
Nck and 96% and 85% for Sc form, moreover there is a linearization of 3% in the latter. 
This could be due to a long incubation, during which plasmid DNA started to 
decompose. 
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Figure IV.45. Correlation of the “asymmetry” (Δε (+) + Δε (-)) of the DNA bands with the 
degradation of pDNA presented as percentage of the Sc form (A) and as area of the Lin form 
(B). Data extracted from Figure IV.2. 
 
Pure DNA bands are always approximately symmetric. Addition of 1 induces a decrease 
in the intensity of the positive band that is not followed by the negative band, thus 
increasing the “asymmetry” of the two bands. This effect increases with time and with 
DNA concentration. No correlation could be found between DNA degradation and the 
intensity of CD bands (Figure IV.46). 
 
 
Figure IV.46. Effect of the incubation time on the CD intensity of 274 nm (positive band, A) and 
246 nm (negative band, B), with increasing metal:bp ratio. Plasmid DNA at 274 nm(+)/246 nm(-) 
(solid line), ri 0.3 (dashed), ri 0.75 (dot-dashed), ri 1.5 (dotted).  
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V. Solution Studies 
 Results V.1
Solution characterization of 1-5 and 9 involved studies by UV/visible spectroscopy 
(complex stability), cyclic and square wave voltammetry (redox chemistry). In addition, 
51V NMR spectroscopy was used to check for oxidation products of V(IV) complexes.  
 
  Stability studies V.1.1
The electronic absorption spectra of 1-5 and 9 were determined in PBS and HEPES 
buffers at pH 7.4 (Figure V.1 and Figure V.2). The spectrum of 3 was determined in 
100% DMSO due to a scarce solubility of this complex. Solutions of 4 and 5 were 
sonicated for ca. 10 min to ensure a complete dissolution.  
Obtained spectra were identified according to the model of molecular orbital treatment 
proposed by Ballhausen and Gray for the [VO(H2O)5]
2+ described in the Section I.5 
(Figure I.7). The complexes show d-d transitions that within a typical range were 
assigned to the obtained bands are present in Table V.1.  
 
Complex 1 is stable for at least 24 h; no significant changes could be detected during 
this time. A noticeable decrease and a shift in the position are observed after 2 h for the 
band III. In HEPES buffer the intensity of all bands decrease gradually with time, 
especially in the band IA.  
Complex 2 exhibits stability for 2 h and after the intensity starts decreasing. A shift in the 
positions of the bands IA (from 840 to 845 nm) and II (from 585 to 590 nm) is observed. 
There is no difference in the spectra between 2 and 4 h. After 24 h there is still no 
change in the intensity of the band IA. The intensity of the band II, on the contrary,
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continues to decrease and shifts to 580 nm. Under HEPES buffer the intensity 
decreases continuously; the most significant change is observed in the first 2 h. There is 
also a shift in the bands IA (from 830 to 825 nm) and II (from 565 to 570 nm).  
The electronic absorption spectra of 3 changes insignificantly. Only a slight gradual 
decrease can be observed during 24 h. Measurements were performed in 100% DMSO 
since the aqueous solubility of this complex is assumed to be too low for UV-vis studies. 
Attempts to prepare the solution in 5, 10 or 50% of DMSO were unsuccessful as the 
addition of the buffer followed the dissolution in DMSO would cause the turbidity.  
Complexes 4 and 5 upon dissolution in either of the buffers decompose gradually which 
is especially noticeable within the first 2 h. Under HEPES buffer no bands are observed 
even for the freshly prepared solutions (i.e., 0 h). 
In the case of 9, the biggest change is observed also in the first 2 h. Not only is there a 
shift in the band II (from 595 to 590 nm) but also a significant shift in the spectra due to 
which the band II at the time 0 h is not easily identified. Between 2 and 24 h, the 
decrease in the intensity of the bands is gradual. Under HEPES buffer no d-d transitions 
bands are observed, the positions of the spectrum shifts along time. 
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Figure V.1. Time evolution of the UV-vis absorbance spectra of aqueous solutions of 1 (2 mM in 
PBS/1% DMSO; 1.2 mM in HEPES), 2 (1.2 mM) and 3 (1.2 mM in 100% DMSO). Numbers 
indicate time (h) after dissolution: 0, (a spectrum taken immediately after solution preparation) 2, 
4 and 24 h are presented as black, grey, light grey and black dashed lines, respectively. 
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Figure V.2. Time evolution of the UV-vis absorbance spectra of aqueous solutions of 4, 5 and 9 
(1.2 mM) in phosphate and in HEPES buffer. Numbers indicate time (h) after dissolution. 
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Table V.1. Bands in the electronic absorption spectra of 1-5 and 9 identified according to the 
typical range. 
Band C4v C2v 
Typical 
range 
(nm) 
PBS/ 
HEPES 
PBS/ 
HEPES 
DMSO PBS/ 
HEPES 
PBS/ 
HEPES 
PBS/ 
HEPES 
1 2 3 4 5 9 
IA b2-e a2-b1 900-620 820/820 840/830 795 865/- 895/- 895/- 
IB  a2-b2  -/- -/- -/- -/- -/- -/- 
II b2-a1 a2-a1 690-530 570/565 585/565 620 595/- 590/- 595/- 
III b2-b1 a2-a1 480-330 400/400 410/410 435 -/- -/- -/- 
 
 
   Redox chemistry V.1.2
The electrochemical behaviour of 1-5 and 9 under phosphate and MOPS buffers are CV 
measurements were conducted using the potential scan rate of 50 mV/s. This choice 
was preceded by testing 1 at 20 µM in 100 mM phosphate buffer at different scan rates 
(i.e., 25, 50, 100, 150, 200, 250, 300, 350, 400, 450 and 500 mV/s). Though, the scan 
rate affects the shape of a voltammogram, the change is insignificant and behavioural 
pattern remains unaltered. Therefore in Figure V.3, we present only the voltammograms 
taken at 25, 50, 100, 250 and 500 mV/s.  
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Figure V.3. Effect of the scan rate on the electrochemical response of 1 (20 µM) in 100 mM 
phosphate buffer. 
 
The results of all experiments, CV and SWV, are summarized in Annex B. There, 
Figures B1-B4, B11 and B12 show the voltammograms of 1, 2 and 9, respectively, 
under phosphate and MOPS buffers (10, 30 and 100 mM). Results of the redox 
behaviour of 3-5, 13 and 14 under 10 and 100 mM buffer media are presented in 
Figures B5-B10, B13-B16. Figures B17-B18 contain correspondingly cyclic and square 
wave voltammograms (Cvs and SWvs, respectively) of 6, 19, 11 and 12. 
The first measurements of the electrochemical behaviour of 1-5 and 9 were carried out 
under 100 mM phosphate and MOPS buffers. The voltammograms are demonstrated in 
Figure V.4 and Figure V.5. Under 100 mM phosphate buffer complexes 1-3 and 9 show 
quasi-reversible behaviour, whereas 4 and 5 behave irreversibly as well as all 
complexes under MOPS buffer. The cathodic and anodic potentials are given in Table 
V.2. 
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Figure V.4. Evolution of Cvs with increasing concentration of 1, 2 (0, 5, 10 and 20 µM) and 3 in 
phosphate and MOPS buffers (100 mM). Due to a poor solubility, the exact concentrations of 3 
are unknown but lower than the other complexes.  
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Figure V.5. Evolution of Cvs with increasing concentration of 4, 5 and 9 aqueous solutions at 0, 
5, 10 and 20 µM in phosphate and MOPS buffers (100 mM).  
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Table V.2. Summary of electrochemical data for 1-5 and 9 at 20 µM concentration in phosphate 
and MOPS buffers. 
 
Complex 
Phosphate MOPS 
Epc (V) Epa (V) Epc (V) Epa (V) 
1 -0.182 -0.060 -0.056 -0.069 
2 -0.186 -0.072 -0.085 -0.065 
3 -0.186 -0.072 -0.075 -0.087 
4 -0.158 -0.078 -0.098 -0.103 
5 -0.193 -0.096 -0.094 -0.127 
9 -.0.156 -0.065 -0.069 -0.086 
 
Changing concentration of phosphate buffer gave a different electrochemical response 
of 1 (Figure V.6). Progressive changes with increase of the buffer concentration from 1 
to 20 mM are well defined in the SWvs (direct and reverse). Under 1 mM phosphate the 
two bands, A (0.19 V) and B (-0.29 V), can be observed in the reverse scan. Band A 
disappears at 2 mM of buffer, while band B increases progressively with increasing 
buffer concentration, reaching a maximum between ca. 4 and 6 mM.  
CV results of these reaction mixtures are presented in the same Figure. In the reverse 
scan at least three species can be observed, i.e., -0.11 (I), -0.19 (II) and -0.05 V (III). In 
the direct scan there are two species (IV and V). Band IV increases with the 
concentration moving towards more positive potential, -0.22 V at 1 mM changes to -
0.18 V at 20 mM. Band V appears at the lowest concentration, i.e., 1 mM at -0.28 V but 
is almost non-distinguishable even on the zoomed scale. Only at 20 mM it is easily 
noted at more positive potential (-0.23 V). At the lowest buffer concentration species II is 
predominant. Increasing buffer concentration gives a rise to bands I and III. Band II, on 
the contrary, decreases. Significant change in the intensity of the bands is observed 
between 2 and 4, 10 and 20 mM voltammograms. These tests were carried out in 
parallel with AGE experiments (Figure A32 and A33).  
The same experiment was repeated controlling ionic strength with KClO4 (Figure V.7). 
No changes can be observed in either of the scans. Results of the experiments with 2-5 
are presented in Figure B19-B22.  
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Figure V.6. Studies of the electrochemical response and the nuclease activity of 1 under 
increasing concentration of phosphate buffer: 1, 2, 3, 4, 6, 10, 15 and 20 mM. Left: Direct and 
revers SWvs. Top right: Cvs of the same solutions. Bottom right: Results of AGE represented as 
percentage of each DNA vs. buffer concentration extracted from Figure A34. 
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Figure V.7. Square wave voltammetry results of the electrochemical behaviour of 1 changing 
concentration of phosphate buffer (1, 2, 4, 6, 10, and 15 mM) with increased ionic strength 
controlled by KClO4. 
 
 
 Discussion V.2
When studying the biological activity of metal complexes it is important to understand 
whether the complex is stable in solution or if it decomposes with time into different 
species. Upon dissolution in water, vanadium complexes will be hydrated and 
competition of water molecules with the ligand for coordination to the metal may cause 
hydrolysis of the complex and, depending on the pH, oxidation to V(V). Buffer medium 
may compete for coordination positions and cause a degradation of the original 
complexes. Depending on the binding affinities of the ligands as well as their 
concentrations, a mixture of species may be formed in solution including the original 
complex, mixed species with the original ligand and water and/or buffer molecules, aquo 
complexes and vanadates.  
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   Stability Studies V.2.1
According to the obtained electronic spectra (Figure V.8 and Figure V.9), in aqueous 
PBS solution all complexes seem to be more stable than in HEPES. Complexes 1 and 
2, and most likely 3, are the most stable. 
Complex 1 is more stable than 2 in aqueous solution regardless of the pH buffer, but 
both complexes are significantly more stable than complexes 4 and 5. When dissolved 
in HEPES buffer, complexes 4 and 5 do not present absorbance spectra in the visible 
region, suggesting that their hydrolysis is rapid and complete. Under phosphate buffer 
they present weak visible spectra with band II well defined at 595 nm, and band I 
apparently very weak and with maxima above 950 nm. These bands in the visible 
region disappear rapidly with time confirming a fast hydrolysis also in phosphate buffer. 
Complex 9 hydrolyses rapidly in both buffer solutions. Less active complexes, 4 and 5, 
seems to hydrolyse/oxidize significantly in the first 2 h and continued to decompose up 
to 24 h. 
Considering that all tests in the present work were typically performed in phosphate and 
HEPES/MOPS buffers at physiological pH, it is likely that the complex structure upon 
dissolution differs from what has been reported for the solid phase.The stability and 
solution structure of 1 has been previously subjected to extensive studies 
[4,115,116,222,223,231]. According to the studies of Crans [116], freshly dissolved 
VO(acac)2 in aqueous solution is present as VO(acac)2•H2O adduct, i.e., trans (species 
A, 85%) and cis (species B, 5%) isomers (Figure I.6), which remain intact for several 
days. After 24 days at ambient temperature the dominant species (65%) is the product 
of hydrolysis (1:1 complex) is species C in which one acac ligand is replaced with 
molecules of water; species A is reduced to 25%. 
The spectrum of 1 in HEPES buffer presents clearly the bands characteristic of a V(IV) 
complex, 820 nm (band I), 565 nm (band II) which were attributed to species A [116], 
and 400 nm where band III appears as a shoulder of an intense charge transfer band. 
The same complex dissolved in phosphate buffer shows a very similar spectrum with 
the band II shifted to longer wavelengths by 5 nm, but the normalized spectra present 
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some clear differences (Figure V.8). The normalization of spectra to a certain 
wavelength, typically a wavelength of maximum absorbance, allows a better 
comparison of the relative intensities of bands. In this case, the intensities of bands I 
and III relative to band II are lower in phosphate buffer. Evolution with time in both 
buffers shows a slight decrease in the intensity of the absorbance spectra, but no 
change in the position of the bands, suggesting a slow oxidation of the V(IV) complex 
into V(V) along time with disappearance of the bands in the visible region.  
When the spectra of evolution with time are normalized at band I for 1 and 2 (Figure 
V.9), the main change seems to be take place under HEPES buffer after 24 h at the 
change transfer band, i.e., band III. In PBS buffer, the changes can be observed in the 
band II which decreases similarly for 1 and 2. Interestingly, the decomposition of both 
complexes does not progressing equally with time. In the case of 1, there is an increase 
in the intensity of this band between 0 and 2 h. Then, the spectra taken after 2 and 4 h 
are on the same position, while the one after 24 h, demonstrates a significant decrease 
in the intensity which is lower the spectrum “0 h”. The pattern of the complex 
decomposition/speciation is similar for 2. However, the rate of the increase/decrease is 
higher than for 1 and after the intensity of the band increased from after 2 h, the spectra 
after 4 h is no longer on the same position but decreases considerably. Probably, the 
rate of the species formation and their possible further decomposition differs for 1 and 2. 
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Figure V.8. Comparison of the absorption spectra of freshly dissolved 1 and 2 in phosphate and 
HEPES buffers. Spectra have been normalized to the relative maxima at band II (ca. 565 nm). 
 
 
Figure V.9. Comparison of the electronic absorption spectra of 1 and 2 under PBS and HEPES 
buffers along time (0, 2, 4 and 24 h). The spectra are normalized to the relative maxima at band 
I (ca. 820 and 840 nm for 1 for 2, correspondingly). 
 
51V NMR spectrum of 1 freshly dissolved in PBS shows the presence of V1, V2 and V4 
peaks (Figure V.10) suggesting a rapid oxidation and hydrolysis of the complex to some 
extent upon dissolution. No peaks of VV are observed when 1 is prepared in water, 
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which is in agreement with the results presented by Crans [116] that the complex is 
stable in water. 51V NMR spectrum of VV(acac) derivatives, 6-8, presented for 
comparison (Figure V.11), shows peaks only of V1, V2 and V10. Since the complexes did 
not dissolve completely, the absence of the peaks assignable to the complexes 
suggests that the complexes dissolved only to the extent of their hydrolysis, and that 
any solubilized complex was found in concentrations below the detection limit of the 
technique. 
 
Figure V.10. 51V NMR spectrum of 1 (2 mM) under 10 mM of PBS. 
 
 
Figure V.11. 51V NMR spectrum of saturated solutions of 6-8 in 10 mM PBS buffer.  
 
In HEPES buffer the normalized spectrum of 2 is similar to 1. The position and the 
relative intensities of the bands I and II are identical in both complexes (Figure V.12). 
Some differences appear between both complexes when dissolved in phosphate buffer: 
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bands I and II in 2 shift ca. 10 and 20 nm, respectively, to longer wavelengths. The 
relative intensities are also different, with bands I and III much weaker for 2 than for 1. 
 
 
Figure V.12. Comparison the absorption spectra of 1 and 2 in phosphate (left) and HEPES 
(right) buffers. Spectra have been normalized to the relative maxima at band I (ca. 820 and 
840 nm for 1 for 2, respectively). 
 
The solution structure of complexes 1 and 2 is therefore different when dissolved in 
phosphate buffer, but is similar when dissolved in HEPES buffer. 
Figure V.13 compares the normalized spectra of all complexes under phosphate buffer. 
Complexes 4, 5 and 9 show similar spectra which differs greatly from those of 1 and 2. 
It is likely that, like 9, which dissolves as an aquacomplex of V(IV), complexes 5 and 9 
are present in solution as oxidised V(V) and in the form of monomeric VIVO2+ which 
depending, on the pH, can be in the form of [VO(H2O)5]
2+ or [VO(H2O)4(OH)]
+ [115].  
The fact that 1 and 2 are more stable complexes and have similar, much higher DNA 
cleavage efficiencies than 4, 5 and 9 suggests that it is the neat complexes, and not the 
products of their decomposition, that have a relevant role in DNA degradation. 
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Figure V.13. Electronic spectra of 1-5 and 9 at the time of mixing in PBS, normalized to the 
relative maxima at band I ca. 830 nm (left) and II ca. 590 (right). 
 
 
   Redox chemistry V.2.2
Due to the low extinction coefficients associated with the metal d-d electronic 
transitions, UV-vis spectroscopic studies of VC cannot be performed at complex 
concentrations below millimolar. The studies on the speciation of vanadium complexes 
in aqueous solutions that have been published to date are typically conducted at 
millimolar metal concentrations. Studies at micromolar concentrations can be performed 
using mass spectrometry, particularly ESI-MS. This technique, often in combination with 
other spectroscopic techniques like NMR, IR, UV-vis, and theoretical calculations, is 
reported to be a powerful tool for obtaining direct information of the structure and the 
chemistry of peroxo vanadates in solutions [526]. 
The biologically relevant interaction of metal complexes with DNA occurs at micromolar 
levels of concentration, thus the competition of the solvent and buffer molecules for the 
binding sites of the metal can change the metal speciation dramatically. 
In contrast with UV-vis absorption spectroscopy, often employed for monitoring species 
in aqueous solutions, electroanalytical techniques such as cyclic (CV) and square wave 
voltammetry (SWV), allow studying the species formation at much lower detection limits. 
These two methods were chosen to study redox chemistry of complexes 1-5 and 9 in 
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aqueous solutions at concentration level of the metal as low as 2 µM using the dropping 
mercury electrode (DME). Though DME has the advantage of achieving much lower 
detection limits than other electrodes, the available potential window is shifted to more 
negative potentials (+0.4 to -1.3 V) which makes it accessible only for analysis of more 
positive potential range. 
At complex concentrations of 5, 10 and 20 µM, and buffer concentration of 100 mM the 
cyclic voltammograms (Cvs) present a striking pattern that differentiates the group of 
complexes with stronger nuclease activity (1-3, Figure V.4) from the weak ones (4 and 
5, Figure V.5). Under phosphate buffer the first group of complexes exhibits a quasi-
reversible one electron response, with very similar Cvs. Even though complex 3 could 
not be dissolved completely, it exhibits a clear pattern, similar to 1 and 2. The cathodic 
peaks appear at -0.182, -0.186 and -0.186 V (vs. SCE) for 1, 2 and 3, respectively, 
corresponding to V(V)/V(IV) reduction, and the anodic peaks at -0.060, -0.072 and -
0.072 V. The distance between the two peaks for an ideal reversible redox couple at 
25 ºC would be ΔE = 59 mV/n, where n is the number of electrons exchanged. This 
distance is 122 mV for 1 and 114 mV for 2 and 3. The peak intensities ratio is close to 1, 
and the position of the peaks did not change when the scan ratio varied. This is 
consistent with a reversible electrochemical reaction involving dimerization with the 
exchange of one electron: 
2 VVO(L)(P) + e-  ⇌ VVOVIVO(L)(P)-       (eq.V.1) 
 
However, such behaviour is not observed under an organic buffer. Cvs of the same 
complexes under MOPS show an irreversible behaviour, and weaker signals suggesting 
the formation of a mixture of species which probably have sluggish electron exchange.  
 
The Cv of 9 (Figure V.4) in the same conditions shows a pattern similar to 1, however 
the cathodic peak is at a less negative potential, -0.156 V (vs. SCE) while the anodic 
peak maintains a position close to -0.065 V. This suggests that the redox pair formed 
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when dissolving 1, 2 or 3 in phosphate buffer is different from the one obtained when 
dissolving 9, and the difference lays in the stabilization of the reduced form (VIV) by the 
presence of a bidentate acac ligand lowering the reduction potential of the species 
formed from 1 and 2 to more negative values. Phosphate, as a pH buffer ion, is a strong 
competitor for metal binding sites due to the extremely high ligand to metal ratio (>5000) 
and may displace the acac molecules in the physiological pH range [28, 515]. Most 
likely that in the case of 1-3 only one acac- group is being replaced, since the second 
functional group has been found to resist the substitution [238, 239]. It is probable that 
these complexes equilibrate with phosphate ions to form mixed stable species 
VIV/VO(Lx)(Py). Another possibility of phosphate binding to the complexes is via 
replacement of water molecule of trans or cis isomers [223]. 
Complexes 4 and 5 in phosphate present sharp cathodic peaks - characteristic of 
adsorption at the surface of the working electrode. Adsorption significantly affects the 
electrochemical response resulting in Cvs of irreversible shape [478]. In such cases the 
redox processes that take place on the surface of the dropping mercury electrode differ 
greatly from those which involve dissolved species in the bulk and, hence, cannot be 
compared. This suggests the formation of hydrophobic complexes.  
Figure V.14 shows the change accompanying several consecutive scans of 4. The 
intensities of the adsorption anodic peak increase with a shift of potential Epc from -
0.085 to -0.075 V and of the desorption cathodic peak, also shifting from Epa ~ -0.175 to 
-0.146 V. This is consistent with the formation of an adsorbed film promoted by the 
oxidation, and its desorption on reduction. The cathodic peak is sharper than the anodic 
one, suggesting that it is a desorption process. Another, weaker, process can be seen 
at potentials close to -0.4 V. Direct scans start each cycle by lowering the potential 
down to -0.5 V and then increasing it back to +0.05 V. On each consecutive cycle, the 
concentration of adsorbed vanadium species in the mercury drop increases, resulting 
into higher intensity of the cathodic peak. A reverse scan starts at the negative potential 
-0.5 V and moves to +0.05 V before lowering back to -0.5 V. The first reverse scan in 
Figure V.14 shows an oxidation peak at -0.163 V, which disappears with consecutive 
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scans while a second anodic peak appears at -0.08 V, suggesting that a new species is 
formed by the oxidation of the adsorbed film. 
 
 
Figure V.14. Consecutive scans of 4 at 20 µM in 100 mM phosphate buffer. Five consecutive 
forward and one reverse scans. Only the first reverse scan is presented, the subsequent ones 
are similar to the direct scans. 
 
The formation of the adsorbed film could be due to polyoxidovanadium species, 
polymerizing into less soluble, hydrophobic structures.  
 
VIVOL2 → (V
IVOL2)2(PO4) ⇌ (V
IVOL2)(V
VOL2)(PO4) (ads when L=Et, Me) → 
V2O4(L)2(PO4)(ads). 
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Figure V.15 compares the Cv of complex 4 with the one of a vanadium(V) dimer 
complex of acac, complex 6. Both show a similar adsorption-desorption pattern. 
 
 
Figure V.15. Comparison of Cvs of 4 and 6 at 20 µM in 100 mM phosphate buffer. 
 
Summarizing above written, under phosphate buffer all complexes show relatively 
simple quasi-reversible redox behaviour, involving species containing both the original 
ligand and phosphate, probably dimers or polymers bridged by phosphate. The 
voltammograms of complexes 4 and 5 indicate the formation of hydrophobic species 
upon oxidation, due to which different reactions are taking place at the electrode 
surface. This behaviour is similar to complex 6 and it is reasonable to assume that oxo-
bridged vanadium(V) species will form near the surface of the electrode, under the high 
concentrations allowed by the adsorption. In the presence of MOPS buffer all 
complexes behave irreversibly and voltammograms show weak and multiple peaks 
reflecting the formation of multiple electrochemically active species. Cvs of 4 and 5 in 
MOPS are more complex (Figure V.5), showing the cathodic peak at ca. 0.0 - 0.1 V 
increasing with vanadium concentration, and two weaker ones at ~-0.2 and -0.4 V. At 
lower concentrations a sharp anodic peak at ~0.19 V suggests adsorption, but it 
disappears with increasing concentration. 
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To understand whether buffer concentration plays a role in the redox response of the 
complexes, measurements in 10 and 30 mM of phosphate and MOPS buffers were also 
performed (Figures B1-B16).As before, similar electrochemical behaviour was observed 
for complexes 1-3, different from complexes 4-5. The electrochemical behaviour of 1 is 
compared in 10, 30 and 100 mM phosphate and MOPS buffers (Figure V.16). Clearly, 
at lower concentrations of phosphate buffer the system becomes irreversible with more 
peaks and more complex species involved. This suggests that phosphate stabilizes the 
formed species or, more likely, that phosphate is an important part of the species. On 
the other hand, results obtained under 10 mM MOPS buffer show signals as weak as 
observed under 100 mM MOPS. 
 
 
Figure V.16. Cvs of 1 at 20 µM in 10, 30 and 100 mM phosphate (left) and MOPS (right) 
buffers. 
 
Since the AGE studies are typically carried out in the presence of 10 mM phosphate 
buffer, CV results obtained at this concentration were of high interest. Figure V.17 and 
Figure V.18 compare complex 1 as a representative of the strong nucleases, and 4 of 
the weak ones. 
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Figure V.17. Electrochemical behaviour of 1 and 4 at 0, 5, 10 and 20 µM in 10 mM phosphate 
(left) and MOPS (right) buffers.  
 
 
Figure V.18. Comparison of the Cvs of 1 and 4 at 20 µM in 10 mM phosphate (left) and MOPS 
(right) buffers.  
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SWV method was chosen for the studies of electrochemical behaviour due to a much 
broader dynamic range, higher speed and lower detection limits in comparison to CV. 
The concentration at which analytical determinations can be made using SWV can be 
as low as 10 µM [483] which allows studying aqueous solutions of VC at the micromolar 
concentrations, similar to those used in DNA assays.  
In tests of the effect of buffer concentration SWV results (Figures B19-B22) seem to be 
easier to interpret than those obtained from CV. Two observed overlapped bands that 
centered at ca. -0.19 and -0.29 V probably correspond to two different species A and B, 
respectively that are formed in the reverse (oxidative) scan. The reason these bands 
are gradually shifted to more negative potentials with increasing buffer concentration is 
probably due to increasing ionic strength and was not observed in replicate experiments 
where ionic strength was controlled by the addition of excess potassium perchlorate 
(Figure V.7). Species causing bands A and B are expected to be mixed complexes of 
vanadium and phosphate, presumably VO(acac)2(H2PO4)
- (A) and VO(acac)(H2PO4) 
(B), while oxidovanadium phosphate, VO(H2PO4)2 (C), is expected to form only at very 
higher phosphate concentrations. The nuclease activity of 1 was found to depend on the 
concentration of phosphate, showing a maximum at ca. 6 mM phosphate buffer (Figure 
V.19) which is in agreement with the SWV results.  
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Figure V.19. Change in DNA degradation by 1 at 50 µM with increasing concentration of 
phosphate buffer (1, 3, 6, 10 and 15 mM). The right graphic is the replicate with three more 
concentrations, i.e., 2, 4 and 20 mM. Percentage of Sc, Nck and Lin forms is calculated from 
Figure A32 and A33. 
 
Results obtained from the addition of phosphate buffer to a solution of 1 in MOPS 
(Figure V.20) showed the formation of a series of species similar to the ones observed 
in phosphate buffer. On the contrary, adding MOPS to a solution of 1 in phosphate did 
not cause a significant change in the voltammograms, except what was caused by 
dilution. 
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Figure V.20. Changes in redox behaviour of 1 at 20 µM in MOPS buffer (left) with addition of 
phosphate and in vice versa. Numbers indicate concentration (mM). 
 
The electroanalytical results show that speciation of vanadium complexes in media 
buffered by phosphate is affected by small changes in the concentration of buffer. 
These changes in turn affect the nuclease activity of the VC. The nuclease activity of 
the studied complexes increases in the presence of phosphate, and is closely 
dependent on its concentration. 
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VI. Mechanistic Studies 
 Results VI.1
The evaluation of oxidative and hydrolytic mechanisms is presented. The formation of 
ROS in aqueous solutions of the VC was observed by fluorescence spectroscopy, and 
the hydrolysis of DNA phosphoester bond was studied by 1H, 31P and 51V NMR.  
 
 Oxidative cleavage VI.1.1
Generation of ROS that are presumed to be the cause of the cleavage induced by 1 
was assessed through hydroxylation reaction of terephthalic acid (TPA) upon which a 
fluorescent 2-hydroxyl-terephtalate (HTPA) is formed. Fluorescence spectra of HTPA in 
the absence and presence of H2O2 are shown in Figure VI.1 and Figure VI.2, 
respectively. A gradual increase in the intensity is observed with time, i.e., 0, 1, 3, 5 and 
25 h under phosphate buffer. No significant changes seem to occur under MOPS buffer. 
The intensity of the spectra increased considerably upon addition of H2O2 under both 
buffers at the time of mixing, and did not change with time.  
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Figure VI.1. Fluorescence spectra of HTPA resulted from the reaction mixture of TPA (200 μM) 
and 1 (50 μM) under phosphate and MOPS buffers (5 mM) at the time of mixing, after 1, 3, 5 
and 25 h. Excitation spectra (a) were scanned at emission of 435 nm, and emission spectra (b) - 
at 323 nm of excitation.  
VI. MECHANISTIC STUDIES 
 
 
215 
 
Figure VI.2. Fluorescence spectra of the reaction mixture of TPA (200 μM), 1 (50 μM) and 
excess of H2O2 under phosphate and MOPS buffers (5 mM) at the time of mixing, after 1, 3, 5 
and 25 h. 
 
Generation of hydroxyl radicals was also tested in the presence of 4 and 9 (Figure VI.3). 
Under phosphate buffer the formation of HTPA in the reaction with 9 seems to be rapid 
in the first hour, however, the intensity decreased considerably between 5 and 25 h. In 
the presence of 4 the hydroxylation of TPA is also observed, though to a small extent. 
The intensity does not change with time. Under MOPS buffer none of three complexes 
seem to induce the reaction of hydroxylation.  
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Figure VI.3. Fluorescence intensity vs. time. Reaction mixtures containing 200 µM TPA 
prepared in phosphate (black lines) or MOPS (grey) buffers with 1, 4 and 9 (50 µM). 
Measurements were taken at the time of mixing, after 1, 3, 5 and 25 h.  
 
To compare the efficiency of 1 in the formation of HTPA, the experiment in was carried 
out buffering the reaction medium with mixtures of phosphate and MOPS media. The 
reaction is always inhibited in the presence of MOPS even when phosphate is in a two-
fold excess (MOPS/phosphate 5/10 mM) but proceeds with an intense hydroxylation of 
TPA when MOPS is absent (0/5 mM). 
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Figure VI.4. Change in the fluorescence intensity of the reaction mixtures with time (0, 1, 3, 5 
and 25 h). TPA (200 µM) dissolved in MOPS (0, 5 and 10 mM) with addition of 1 (50 µM) 
prepared in 0, 5 and 10 mM of phosphate buffer. MOPS/phosphate buffer concentrations (in 
order of intensity decrease): 0/5, 0/0 (unbuffered), 5/0, 5/10, 5/5, 10/10, 10/5. The inset is the 
same graph with increased X and Y scales. 
 
 
 Hydrolytic cleavage VI.1.2
Hydrolytic cleavage of two DNA model substrates, 4-nitrophenyl phosphate (NPP) and 
bis-4-nitrophenyl phosphate (BNPP), was examined by 1H NMR in PBS and MOPS 
buffers. After mixing solution of 1 with NPP or BNPP, a 1H NMR spectrum was recorded 
at different time increments, i.e., 0, 24, 47, 72, 168 and 240 h. An example of the whole 
spectra is shown in Figure VI.5. The remaining figures focus on the chemical shifts from 
6.5 to 8.5 ppm, where peaks of NPP, BNPP and NP can be found, or from 1 to 4 ppm, 
where the peaks due to acac and MOPS are observed.  
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Figure VI.5. 1H NMR spectrum of NPP hydrolysis in the presence of 1 under PBS buffer. Peak 
at 4.79 ppm is the reference peak of DSS. 
 
1H NMR spectra of 1 in D2O is shown in Figure VI.6. There are four peaks observed: 1) 
a quartet at 3.65 ppm; 2) singlet at 2.07 ppm; 3) singlet at 1.44 ppm after 48 h that can 
be seen only when greatly zoomed; 4) triplet with peaks at 1.20, 1.18 and 1.17 ppm. 
 
 
Figure VI.6. 1H NMR spectra of 1 in D2O along time. Numbers indicate hours after dissolution. 
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The spectra of control blank samples, i.e., NPP and BNPP under PBS and MOPS 
buffers with no added 1, are shown in Figure VI.7. Initially only the two doublets 
characteristic of NPP and BNPP are observed close to 8.5 and 7.5 ppb. After 7 days 
two additional doublet peaks are observed in the spectrum of NPP under both PBS 
(8.21 and 8.19; 6.82 and 6.80 ppm.) and MOPS (8.11 and 8.09; 6.56 and 6.54) buffers. 
In the case of BNPP no changes are observed under PBS buffer, whereas in the 
presence of MOPS two new doublets appeared after 72 h.  
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Figure VI.7. 1H NMR spectra of NPP and BNPP under PBS and MOPS buffers (control 
samples) measured at different times (numbers indicate hours). 
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The results of 1H NMR spectra of NPP and BNPP in the presence of 1 are summarized 
in Figure VI.8. Two doublets of NP, the product of hydrolysis, under PBS occur after 
24 h in the case of NPP (8.26 and 8.24; 6.98 and 6.96 ppm). After 48 h a gradual 
decrease of NPP and increase of NP peaks is observed, until NPP peaks completely 
disappeared after 10 days and only the doublets of NP were left. After 24 h a peak that 
most probably belongs to „free‟ acac is observed indicating a decomposition of 1. In the 
case of BNPP the peaks of NP seems to only appear after 168 h (8.22 and 8.20; 6.93 
and 6.91 ppm), however when zooming the spectrum (Figure VI.9), four doublets can 
be distinguished at the time of 24 h: 1) 8.29 and 8.27; 2) 8.22 and 8.19; 3) 7.40 and 
7.38; 4) 6.93 and 6.91. 
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Figure VI.8. 1H NMR spectra of the reaction of NPP (a) and BNPP (b) with 1 (d) measured at 
different times (numbers indicate hours) under PBS and MOPS buffers. NP (c) is the main 
product of the hydrolysis; „e‟ is acac ligand.  
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Under MOPS, no hydrolysis of NPP or BNPP was observed, except after 7 days which 
can attributed to the natural degradation of NPP also observed in the blank control. 
 
 
Figure VI.9. 1H NMR spectra of the reaction of BNPP (b) with 1 measured at different times 
(numbers indicate hours) under PBS buffer. Zoomed version of the spectra shown in Figure 
VI.8.  
 
Under MOPS buffer (Figure VI.10) peaks are detected after 24 h for both model 
substrates. In case of NPP, two doublets of NP at 8.17 and 8.15, 6.76 and 6.73 
chemical shifts, respectively. In the spectra of BNPP, four doublets, two belong to NPP 
(8.25 and 8.22; 7.34 and 7.32) and two are of NP (8.13 and 8.11; 6.82 and 6.80). The 
resonances though look like doublets possess peaks of a different height: the left hand 
peak is much smaller than the right hand one. Also, there are two new peaks at 8.47 
and 8.06 ppm which are not observed under PBS buffer. 
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Figure VI.10. 1H NMR spectra of the reaction of NPP (a) and BNPP (b) with 1 measured at 
different times (numbers indicate hours) under MOPS buffer. Zoomed version of the spectra 
shown in Figure VI.8. 
 
The same four reaction mixtures, i.e., 1 with NPP/BNPP under PBS/MOPS, were used 
to measure 51V NMR spectra to determine which vanadium species are responsible for 
the hydrolysis of phosphoesters (Figure VI.11). No peaks are observed immediately 
after mixing. Vanadate species are clearly formed after 24 h. Under PBS buffer two 
peaks at similar chemical shifts appeared in the spectra of both NPP (-570.42 and -
578.26) and BNPP solutions (-572.0 and -580.0). Under MOPS buffer more V(V) peaks 
are observed, NPP/BNPP: 1) -548.6/-552.1; 2) -566.4/-567.7; 3) -572.4/-572.7; 4) -
580.6/-581.3. 
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Figure VI.11. 51V NMR spectra of the same solutions presented in Figure VI.7 and Figure VI.8 
for the reaction of NPP and BNPP in solution of 1 under PBS and MOPS buffers.  
 
 
 Discussion VI.2
The DNA cleavage by the metallonucleases typically proceeds via either a radical or a 
hydrolytic mechanism. Unlike the radical attack on the sugar or base moieties mediated 
by inorganic cleaving agents, the hydrolytic cleavage of the phosphodiester bond is 
reversible and is the path followed by natural nucleases. 
Studies of the mechanism of DNA cleavage were to answer the following questions: 
Does ROS form in an aqueous solution of 1? Does the buffer medium influence the 
generation of ROS? Is VO(acac)2 capable of cleaving DNA hydrolytically? What is the 
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possibility of occurrence of mixed oxidative/hydrolytic mechanism during 1h complex-
DNA digestion?  
Based on the previous work of our group and according to the findings obtained by AGE 
in this work, a radical mechanism of DNA cleavage by 1 is considered and can be 
established.  
 
 Oxidative Cleavage VI.2.1
The maximum fluorescence intensity at 323 nm (in excitation spectra) and 435 nm (in 
emission spectra) is interpreted as being proportional to the total number of 
ROS/hydroxyl radicals formed in solution during the experiment time. The interpretation 
of obtained results might be complicated because while the hydroxylation reaction of 
TPA by „free‟ hydroxyl radicals has been a subject of intensive studies, similar reactions 
of TPA with other agents such as metals are not well understood. Oxidovanadium may 
itself be considered a ROS, and it is possible that species such as a metal complex with 
the superoxide anion will promote the hydroxylation of TPA, without the formation of 
„free‟ hydroxyl radicals. For the effects of this study, it is understood that a ROS capable 
of promoting the hydroxylation of TPA is damaging for DNA. 
 
No hydroxylation of TPA is observed in the absence of metal complexes. The situation 
changes dramatically upon addition of 1 and differs with buffer media. Figure VI.12 
compares the fluorescence spectra of HTPA formed upon the addition of 1 under 
phosphate and MOPS buffers. It is clear that 1 induces the hydroxylation to the greater 
extent in phosphate than in MOPS buffer, especially after 25 h. The formation of HTPA 
in these conditions suggests that aqueous solutions of the V(IV) complexes are able to 
generate hydroxyl radicals or ROS in general that are capable of hydroxylating TPA. 
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Figure VI.12. Fluorescence spectra for (a) excitation and (b) emission of HTPA formed in the 
reaction of TPA and 1 in freshly prepared reaction mixture and after 25 h, at neutral pH under 
phosphate or MOPS.  
 
As expected, addition of hydrogen peroxide to solutions of 1 yields a strong formation of 
ROS (Figure VI.13) since in its presence, oxidovanadium(IV) complexes are known to 
produce large amounts of •OH in a Fenton-like reaction [431, 524]. Under both buffers 
the intensity after 25 h is as high as at the time of mixing, suggesting a fast completion 
of the reaction.  
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Figure VI.13. Fluorescence spectra of TPA (200 μM) in phosphate and MOPS buffers (5 mM) in 
the presence of 1 (50 μM) and excess of H2O2. Excitation spectra (a) were scanned at emission 
of 435 nm, and emission spectra (b) - at 323 nm of excitation.  
 
Figure VI.3 compares the evolution of fluorescence intensities of complexes 1, 4 and 9 
with time. The strongest fluorescence is observed under phosphate buffer where the 
intensity of 1 increases along time and seems to stabilize after ca. 20 h, whereas in the 
case of 4 there is a modest increase which stabilizes after 4 h. This is in agreement with 
the nuclease activity results and corroborates the assumption that the DNA cleavage 
caused by these complexes follows a radical mechanism. Complex 4 is the least active, 
and also shows the lowest fluorescence intensity, thus it can be assumed that it 
generates less ROS capable of hydroxylating TPA and cleaving DNA. Complex 1 is the 
most active, and also generates more ROS.  
Though in the presence of 9 the increase in the fluorescence is surprisingly high right 
from the time of mixing, the decrease observed after 3 h suggests low reproducibility 
observed in AGE results. Fluorescence intensities in this figure observed under MOPS 
are insignificant, also reflecting the low nuclease activity observed under organic 
buffers.  
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When dissolving TPA and 1 in solutions buffered by mixtures of MOPS and phosphate 
(Figure VI.4), increasing concentrations of phosphate increase the fluorescence 
intensity when MOPS is kept constant, suggesting that phosphate contributes to the 
generation of ROS, but the most striking results are obtained in the complete absence 
of MOPS, in which case fluorescence jumps to more than 10 fold higher than in its 
presence. This can be explained by the scavenging effect of MOPS on „free‟ radicals 
[462]. 
AGE results of DNA cleavage induced by the same mixtures of buffers and 1 are in 
agreement with those obtained by fluorescence, i.e., the nuclease activity of 1 shows 
the same pattern, i.e. it is strikingly higher in the absence of MOPS (Figure IV.23). 
When MOPS buffer is absent linearization of DNA is observed. On the contrary, the 
DNA degradation is always inhibited when MOPS is added and the extent of the 
inhibition is higher for higher concentrations of MOPS. 
According to the literature precedents, phosphate buffer is often used in the 
experiments involving the generation of „free‟ radicals and is known to increase the rate 
of Fe(II) [447] and V(IV) [522, 523] autoxidation at neutral pH. The reaction products are 
Fe(III) and V(V) and superoxide (eq.VI.1 and VI.2).  
When the reaction involves the addition of H2O2, vanadyl, in the same manner as 
ferrous in the Fenton reaction, appears to reduce it to OH- generating •OH (eq.VI.3 and 
VI.4) in the vanadyl-initiated Fenton-like reaction [524]; formed radicals then rapidly 
react with TPA yielding a fluorescent HTPA. In the absence of H2O2, it is likely that, 
oxidovanadium coordinates to phosphate resulting in a metal-buffer complex, which in 
turn, induces the formation of „non-free‟ („crypto‟) radicals [384, 446, 449], causing the 
hydroxylation. 
 
Fe(II) + O2   → Fe(III) + O2
-
          (eq.VI.1) 
V(IV) + O2   → V(V) + O2
-
          (eq.VI.2) 
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Fe(II) + H2O2 → Fe(III) + OH
- + •OH      (eq.VI.3) 
V(IV) + H2O2 → V(V) + OH
- + •OH       (eq.VI.4) 
 
The effect of phosphate in the biological activity of V has been addressed indirectly by 
Saran, Reinke and Liochev [447,449,522,523]. V(IV) promotes the oxidative stress in 
cells, and in vitro studies show that phosphate buffer increases the activity of ROS 
caused by VC. As an example, an important role of phosphate buffer is described by 
Liochev in the oxidation of NAD(P)H by vanadate [522]. Vanadium(IV) would autoxidize 
rapidly in phosphate buffer at neutral pH with generation of the superoxide anion [the 
reaction in [1a], which would then be the ROS responsible for the oxidation of NAD(P)H. 
On the other hand, in the absence of phosphate the oxidation of V(IV) would normally 
be outrun by the formation of mixed V(V)-V(IV) stable polyacids, which would possibility 
decrease or prevent the production of O2
-
 completely. 
Altogether, the nature of the formed species in phosphate buffer is not clear. Liochev 
[522] explored that phosphate prevents the formation of a stable “green complex” of 
V(V)/V(IV). In this case superoxide formed during oxidation of V(IV) possibly together 
with the metal is likely to play the role of active radical. This is in agreement with 
Saran‟s [447] findings in which the active species in iron Fenton chemistry is not the 
hydroxyl radical, but a metal species with the superoxide ion. Reinke [449] in turn, 
emphasizes the likelihood of „non-free‟ radicals which he describes as an oxidizing 
intermediate formed from a direct reduction of molecular oxygen which is apparently 
different from the hydroxyl radicals.  
The formation of divanadates is usually observed only for vanadium concentrations 
above 100 μM [527]. At the level of concentration of DNA cleavage experiments (ca. 2-
100 μM) the proportion of any eventual vanadium polyacids should be negligible, thus 
Liochev‟s proposal about the formation of oxo-bridged V(V)/V(IV) complexes may not be 
suitable for explaining the observed DNA cleavage activity under either of buffers. It is 
nevertheless reasonable to assume that phosphate-oxidovanadium species could form 
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under of ca. 10 mM phosphate, when phosphate:metal ratios vary from 100 to 5000. 
The results on the electrochemistry of these complexes show that these species are 
formed, and they have a reversible electrochemical behaviour that may facilitate the 
oxidation of V(IV) with generation of ROS in neutral aqueous solutions. 
In summary, the obtained results show that VC can generate ROS in neutral aqueous 
solutions, even in the absence of hydrogen peroxide. Such ROS, possibly a mixed 
radical of superoxide with V or V-PO4 „crypto‟ radical, are capable of hydroxylating TPA 
and are likely to be responsible for the nuclease activity observed in 1 and derivatives. 
The best conditions for hydroxylation reaction are the same as for DNA cleavage, i.e., 
under phosphate buffer. The present work started with VO(acac)2 but in fact can be 
applied to more VC. We observed a similar behaviour for VOSO4, although with low 
reproducibility due to precipitation. V oxidative stress has been clearly described in the 
presence of H2O2, but the results of this work show that it is also important in its 
absence. The oxidation of V(IV) at neutral pH, whether promoted by dissolved oxygen 
or by water itself, will, in the presence of phosphate, generate ROS that can hydroxylate 
TPA and cleave DNA. The oxidative (radical) mechanism can be established. 
 
 
 Hydrolytic cleavage VI.2.2
Nitrophenyl phosphate (NPP) and bis-4-nitrophenyl phosphate (BNPP) are two known 
DNA substrates which are typically used as the models for studying interactions with 
DNA as they have the structure similar to that of phosphoester bonds. The presence of 
an activating nitro group in the structure of NPP and BNPP implies an extreme 
resistance towards P–O bond hydrolysis. The cleavage of both models is expected to 
result into formation of free phosphate, accompanied by the release of p-nitrophenol 
(NP), which is easily detected by 1H NMR due to its characteristic aromatic resonance 
[290]. In the case of hydrolytic cleavage of BNPP, NPP is an intermediate product and 
is supposed to be detected together with NP. Peak assignment is shown in Figure 
VI.14.  
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Figure VI.14. 1H NMR spectra of BNPP in MOPS in the absence (1) and presence (2) of 1, 
incubated at 50 ºC for 168 h. On the left side are the aromatic resonance peaks of BNPP, NPP 
and NP, while the right side are the chemical shifts of MOPS buffer. 
 
The peaks at 1.93 and 5.16 ppm are the resonances due to CH3 and CH protons that 
have been reported in free acetylacetone at 1.99 and 5.54  ppm, respectively [528, 
529]. 
In the course of hydrolysis of both model substrates by 1, the reaction mixture of NPP in 
PBS is the most favourable for the cleavage to occur: the 1H NMR resonances 
attributed to the product of hydrolysis, NP, are easily observed after ca. 24 h increasing 
gradually with time. At ca. 200 h the reaction seems to be completed as at this point the 
1H NMR resonances of the aromatic protons in NPP disappear (Figure VI.3). In 
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agreement with the previously reported studies of this reaction [289], the hydrolysis of 
BNPP into NP is significantly slower than that of NPP. Under PBS, although the first 
signs of hydrolysis are also detected after 24 h, the peaks are too small to be visible in 
the spectrum (Figure VI.4). Also, as the hydrolysis of BNPP is expected to be a two-
stage reaction in which NPP is an intermediate product, this might affect the rates of the 
cleavage. This reason, however, does not seem to be the main one because in the 
studies of this reaction [289], hydrolyses of BNPP is reported to be observed after ca. 
7 h). Thus, the main reason for a very slow hydrolysis of BNPP obtained in our results is 
probably due to the occurred precipitation.  
New peaks, singlets rather than doublets, that appear with time in experiments carried 
out with both substrates under MOPS (Figure VI.3), at chemical shifts 8.47 and 
8.06 ppm are probably due to the degradation of MOPS induced by a reaction with 
ROS. This is the most likely explanation, since no peaks of possible MOPS degradation 
are observed in the control samples (Figure VI.12). The peaks assigned to MOPS in the 
range 2–4 ppm change position in time. This shows that the pH was not completely 
buffered. The concentration of MOPS was 40 mM while the concentration of vanadium 
was ~3 mM. The reason why the MOPS concentration was insufficient to buffer 
changes is the hydrolysis of vanadium. This difference is evidently observed when 
comparing the spectra of the samples with and without 1 in the proton resonances of 
MOPS buffer (Figure VI.14, right plot). 
The phosphoester and phosphodiester hydrolysis is evidently much slower under 
MOPS than in the presence of PBS.  
Except BNPP in PBS where no changes are observed within the timeframe of the 
experiment (i.e., 240 h), in the rest of the control samples some hydrolytic cleavage 
occurred. After ca. 72 h the presence of NP was detected in solutions of NPP both 
under PBS and MOPS; the presence of NPP as well as NP was also detected in 
solutions of BNPP under MOPS. This indicates that 1 is not responsible for the 
hydrolysis in the case of BNPP under MOPS. Nevertheless, under PBS the presence of 
1 is determinant in increasing the rate of the reaction. 
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Regardless of a DNA model substrate and buffer medium, it is apparent that the longer 
the reactions mixtures are kept incubating at 50 ºC the greater the extent of hydrolytic 
cleavage. In fact, temperature is probably playing an important role in the hydrolysis of 
phosphoester structure. However, considering that the half-life of spontaneous cleavage 
for NPP and BNPP at 50 ºC is estimated to be respectively 135 and 27000 days, the 
possibility that the temperature is responsible for the hydrolytic cleavage in the absence 
of 1 is unlikely.  
 
Monitoring the same reaction mixtures by 51V NMR showed that after 24 h 1 has 
hydrolysed completely into inorganic vanadates (Figure VI.11).  
The results show that 1 can promote the hydrolytic cleavage of DNA, but such a 
reaction is too slow to compete with the oxidative cleavage, which is the predominant 
mechanism and most likely the only one occurring during 1 h digestion of DNA.  
It has been previously proven by Steens et al. [289,290] that vanadates can actually 
promote hydrolytic cleavage of the phosphodiester bond [530] – in particular di- and/or 
tetravanadates. It is possible that these species are the ones responsible for the 
observed hydrolytic activity in our experiments.  
Hence, VO(acac)2 induces the hydrolytic cleavage of the phosphoester bond under PBS 
buffer. This occurs more readily with NPP than BNPP. Under MOPS some hydrolysis 
was observed in the presence of VO(acac)2 but it was indistinguishable from what 
occurs in the absence of the complex, suggesting that VO(acac)2 does not play a role in 
this process. The reaction is extremely slow (>24 h at 50°C) comparing to the oxidative 
cleavage of plasmid DNA (<1 h at 37°C) with a completion of approximately 200h for 
NPP. The species responsible for the breakage of the phosphoester bond are probably 
tetravanadates.  
It can be concluded that the hydrolytic mechanism does not play an important role in the 
DNA cleavage activity of VO(acac)2.    
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VII. Conclusions 
The original motivation for this work has been to identify a vanadium complex species 
which would be responsible for the nuclease activity reported for many V(IV) 
complexes. While the search for one “culprit” species has been elusive, the information 
collected and conclusions derived are extremely important when considering the use of 
vanadium complexes in therapeutics. 
The following main conclusions can be drawn from the previous chapters: 
1. All derivatives of VIVO(acac)2 studied, with the exception of V(V) 
derivatives, showed some degree of nuclease activity. Some of these 
complexes (such as VOSO4 and VO(acac)2) have been reported in the literature 
as not showing nuclease activity. We believe the reason is that most research 
groups use commercial plasmid DNA, such as pBR322, which contains EDTA in 
concentrations ranging from 1 to 11 mM. EDTA is a very strong complexing 
agent which will change the metal speciation. All experiments in this work were 
conducted with pA1, a plasmid DNA which was amplified and purified in the 
laboratory, and dissolved in water only.  
 
2. The nuclease activity observed for the complexes under study is mainly 
caused by a radical mechanism. Even though hydrolytic cleavage can occur, it 
is too slow to compete with the radical cleavage. The nuclease activity of these 
VC is indirect, i.e., it is a consequence of the generation of ROS caused by the 
VC. The active ROS are probably hydroxyl radicals, generated in a Fenton-like 
reaction of V(IV) complexes with water. Hence, all discussion on the nuclease 
activity of the complexes under study reflect their capacity of causing oxidative 
stress and is important in other aspects of metals in biological systems besides 
DNA cleavage 
.      
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3. The activity of V(IV) complexes is closely dependent on the nature of the 
ligand. Within the family of VO(acac)2 derivatives, it was found that Cl-acac 
induced the highest activity, followed by acac and hd. Such evolution suggests 
that an electron-attracting group can increase the activity. Other acac derivatives 
substituted in C3 with CH3 and C2H5, as well as amine derivatives, show a much 
lower nuclease activity. These are also much less stable in aqueous solution. 
 
4. The activity of VO(acac)2 derivatives is potentiated by phosphate. As 
phosphate is ubiquitous in biological systems, it is extremely important to 
understand its role in this process. We have found that under phosphate buffer 
the most active and “stable” complexes 1-3 in fact react with phosphate to give a 
species with an electrochemical behaviour which is almost reversible. This is 
probably a mixed complex involving the ligand and phosphate. The less active 
complexes do not form this species, but instead they decompose into hydrolysis 
products. VOSO4 forms a species with a similar reversible electrochemical 
behaviour but showing different reduction potentials. Assuming the 
electrochemical flexibility of these species is important for the oxidative stress, it 
would be expected that VOSO4 would show a significant nuclease activity under 
phosphate buffer. In fact, we have observed that the nuclease activity of VOSO4 
is not very reproducible, but sometimes it is as high as for VO(acac)2. The lack of 
reproducibility can be explained by its prompt precipitation as hydroxide at pH7. 
Cases where no activity of VOSO4 is observed, as often reported in the literature, 
are probably due to a complete precipitation, or to complexation with EDTA when 
using commercial plasmid DNA. 
 
5. Other VC complexes studied do not show a buffer effect and are not 
potentiated by phosphate. Unlike VO(acac)2 derivatives, in the case of VO(oda) 
VO(oda)bipy and VO(oda)phen no significant difference is observed in nuclease 
activities under different pH buffers. The cleavage mechanism involves radicals. 
This is proved by the decreased activity following the addition of radical 
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scavengers. The extent of the decrease indicates that the cause for the buffer 
effect on the nuclease activity of VO(acac)2 derivatives is not the scavenging 
effect of organic buffers, but the involvement of phosphate in the mechanism. 
 
Further considerations 
The reason for the high ROS activity of the mixed ligand – phosphate complexes is not 
clear. Previous studies have reached a similar conclusion and provided a few 
hypothesis. 
The effect of phosphate in the biological activity of V has been addressed in the 1990s 
by Liochev [552,553], who observed a potentiation of the oxidation of NAD(P)H by 
vanadate under phosphate buffer when compared with other buffers. Liochev proposed 
that vanadium(IV) would autoxidize rapidly in phosphate buffer at neutral pH with 
generation of the superoxide anion, which would then be the ROS responsible for the 
oxidation of NAD(P)H. On the other hand, in the absence of phosphate the oxidation of 
V(IV) would normally be outrun by the formation of mixed V(V)-V(IV) stable polyacids, 
which would possibility decrease or prevent the production of superoxide completely. 
Later, other groups [447,449] have described effects of the phosphate buffer on the 
Fenton generation of radicals by iron complexes. It was suggested that the active 
species in iron Fenton chemistry is not the hydroxyl radical, but a metal species 
containing the superoxide ion. 
The formation of divanadates is usually observed only for vanadium concentrations 
above 100 μM [527]. At the level of concentration of DNA cleavage experiments (ca. 2- 
100 μM) the proportion of any eventual vanadium polyacids should be negligible, thus 
Liochev‟s proposal about the formation of oxo-bridged V(V)/V(IV) complexes may not be 
suitable for explaining the observed DNA cleavage activity under either of buffers. It is 
nevertheless reasonable to assume that phosphate-oxidovanadium species could form 
under ca. 10 mM phosphate, when phosphate:metal ratios vary from 100 to 5000. 
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Our results on the electrochemistry of these complexes show that these species are 
formed, and they have a reversible electrochemical behaviour that may facilitate the 
oxidation of V(IV) with generation of ROS in neutral aqueous solutions. 
Based on the proposals by Liochev, Saran and Reinke [447,449,552,553], and on the 
results of this work, a tentative mechanism can be proposed: 
 
 
 
During this work we have tried to detect mixed ligand species containing acac and 
phosphate using Mass Spectrometry (MS-ESI) to analyse solutions of VO(acac)2 under 
phosphate buffer, MOPS buffer and unbuffered solutions (results not shown in this 
thesis). Besides VIVO(acac)(H2O)
+ and VIVO(acac)2.H
+, a species formulated as 
(VO)2(acac)3 (M/z=431) was detected in all solutions.  
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One peak, M/z=449.4, was detected only in phosphate buffered solutions, and may be 
due to the species [VIVO(acac)VVO(acac)PO4] proposed above, ionized with one Na
+. 
Nevertheless, MS-ESI spectra obtained for phosphate buffered solutions was subject to 
high noise due to the interference of refractive phosphate salts, therefore, these results 
must be confirmed.  
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VIII. Annex A 
Images of AGE Gels 
 
VO(acac)2 and derivatives 
 
 
 
 
 
 
 
Figure A1. DNA cleavage activity of 1 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS and TRIS buffers. DNA” is the control for native DNA incubated in the 
absence of metal. „Nck, Lin and Sc‟ indicate the position of the nicked, linear and supercoiled 
form of DNA, respectively. Top: Image of agarose gel. Bottom: graphic of the percentage of 
each DNA form vs. complex concentration  
. 
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Figure A2. DNA cleavage activity of 1 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under HEPES and MOPS buffers. Top: Image of agarose gel. Bottom: graphic of the 
percentage of each DNA form vs. complex concentration. 
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Figure A3. DNA cleavage activity of 1 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS and HEPES buffers. Top: Image of agarose gel. Bottom: graphic of the 
percentage of each DNA form vs. complex concentration. 
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Figure A4. Comparison of the nuclease activity of 1 and 9 at 12, 25 and 50 µM (ri 0.8, 1.7 and 
3.3) under phosphate buffer (pH 7.4) using three plasmids DNA obtained from different batches 
(i.e., DNA H, DNA N and DNA A). 
 
 
 
Figure A5. Comparison of the nuclease activity of 1 at 12, 25, 50 and100 µM (ri 0.8, 1.7, 3.3 
and 6.7) under phosphate buffer (pH 7.4) using three plasmids DNA obtained from different 
batches (i.e., DNA E, DNA G and DNA H).  
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Figure A6. DNA cleavage activity of 1 and 10 under phosphate buffer. Concentration of 1 was 
3, 6, 12 and 50 µM (ri 0.2, 0.4, 0.8 and 1.7). As complex 10 is poorly soluble in H2O, dilutions 
(~1:4, 1:17, 1:33 and 1.67) were made from the stock solution prepared to be 200 µM. „Lin DNA‟ 
is the control for linearized DNA (pA1 plasmid DNA digested with 50 µM of 1 under phosphate 
buffer). Ligand acac-Naf (Naf = naphthalene) was added for comparison.  
 
 
Figure A7. DNA cleavage activity of 1 (A) and 2 (B) 10 and 20 µM (ri 0.7 and 1.33) under 
phosphate and HEPES buffers.  
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Figure A8. DNA cleavage activity of 1 (a) and 9 (b) at 50 and 100 µM (ri 3.3 and 6.7) under 
phosphate buffer using three plasmids DNA obtained from different batches (DNA E, DNA G 
and DNA H). 
 
 
Figure A9. Replicate of the gel in Figure A8. 
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Figure A10. Comparison of DNA cleavage activity of 1 (a) and 9 (b) at 25, 50 and 100 µM 
(ri 1.7, 3.3 and 6.7) under PBS and phosphate buffer. 
 
 
 
Figure A11. Comparison of DNA cleavage activity of 1-5, 11 and 12 at 50 and 100 µM (ri 3.3 
and 6.7) under PBS buffer. As complexes 3, 11 and 12 are poorly soluble in water, a necessary 
amount of the solid was weighed to obtain 200 µM solution and corresponding dilutions 1:2 and 
1:4 were made. 
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Figure A12. DNA cleavage activity of 2 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison. 
 
 
 
Figure A13. DNA cleavage activity of 3 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison. 
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Figure A14. DNA cleavage activity of 4 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison. 
 
 
 
Figure A15. DNA cleavage activity of 5 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison. 
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Figure A16. DNA cleavage activity of 11 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison.  
 
 
 
Figure A17. DNA cleavage activity of 12 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS buffer. Complex 1 and 9 were added for comparison.  
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Figure A18. Comparison of the nuclease activity of 1 (A) at 50 and 100 µM (ri 3.3 and 6.7), 2 
(B), 3 (C), 4 (D), 5 (E), 9 (F), 10 (K), 11 (J), 12 (I), 13 (H), 14 (G) at 50 µM under PBS buffer.  
 
 
Figure A19. Comparison of the nuclease activity of 1 (A) at 50 and 100 µM (ri 3.3 and 6.7) 2 
(B), 3 (C), 4 (D), 5 (E), 9 (F), 10 (K), 11 (J), 12 (I), 13 (H), 14 (G) at 50 µM under MOPS buffer.  
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Effect of incubation time 
 
 
Figure A20. Effect of incubation time on the nuclease activity of 1 at 3 µM (ri 0.2) under 
phosphate buffer. The first sample containing 1 (lane 2) was incubated at 37 ºC for 135 min, the 
last one (lane 10) for 15 min. Interval between introducing samples into incubator was 15 min.  
 
 
Figure A21. Effect of incubation time on the nuclease activity of 1 at 25 µM (ri 1.7) under 
phosphate buffer. The first sample containing 1 (lane 2) was incubated at 37 ºC for 135 min and 
the last one (lane 10) for 15 min with the interval of 15 min. 
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Figure A22. Effect of incubation time on the nuclease activity of 1 at 25 µM (ri 1.7) under 
phosphate buffer. Incubation time is indicated. Interval is 30 min. The first sample (lane 3) was 
incubated at 37 ºC for 4 h and the last one (lane 12) for 5 min. 
 
 
 
 
Figure A23. Replicate of the gel in Figure A22. 
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Figure A24. Effect of incubation time on the nuclease activity of 1 at 25 µM (ri 1.7) under 
phosphate buffer. Incubation interval was 15 min at 37 ºC. The first sample (lane 2) was 
incubated for 180 min and the last one (lane 10) for 15 min. 
 
 
 
Figure A25. Effect of incubation time on the nuclease activity of 2 at 50 µM (ri 3.3) under 
phosphate buffer. Incubation interval was 15 min at 37 ºC. The first sample (lane 2) was 
incubated for 135 min and the last one (lane 10) for 15 min. 
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Effect of excess ligand 
 
Figure A26. Nuclease activity of 1, 13 and 14 affected by addition of excess ligands under 
phosphate buffer. Complex and ligand concentrations are 100 µM (ri 6.7) and 125, 250 and 
500 µM (ri 8.3, 16.7, 33.3), respectively. Ligands were added prior to the addition of the 
complex. Ligand-to-metal (L/M) ratios for the VIVOL2 complex are 1.25 (lanes 4, 8 and 12), 2.5 
(lanes 5, 9 and 13) and 5 (lanes 6, 10 and 14).  
 
Figure A27. Effect of excess ligand on the nuclease activity of 1, 13 and 14 at 100 µM (ri 6.7) 
under phosphate buffer. Ligand concentrations are 100 and 4000, 8000 and 16000 µM. Lane 14 
is the control for acetylacetonate. Ligand-to-metal (L/M) ratios for the VIVOL2 complex are 40 
(lanes 3, 7 and 11), 80 (lanes 4, 8 and 12) and 160 (lanes 5, 9 and 13).  
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Figure A28. Replicate of the gel in Figure A27. 
 
Effect of buffer media 
 
 
Figure A29. Effect of the concentration of phosphate buffer (1, 2, 3, 4, 6, 10, 15 and 20 mM) on 
the nuclease activity of 1 at 20 µM (ri 1.33). 
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Figure A30. Effect of phosphate and MOPS buffers on the DNA cleavage activity of 1 and 9 at 
50 µM (ri 3.3) using two plasmids DNA obtained from different batches. 
 
 
Figure A31. Effect of the concentration of phosphate buffer (1, 3, 6, 10 and 15 mM) on the 
nuclease activity of 1 at 50 µM (ri 3.3; lanes 10-14). Effect of scavengers on the DNA cleavage 
activity of VO(oda) at 100 µM (ri 6.7; lanes 3-7) under MOPS buffer. Complex 9 and VIVO(ClO4)2 
(ri 3.3; lane 8 and 9, respectively) are added for comparison. 
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Figure A32. Effect of the concentration of phosphate buffer (1, 2, 3, 4, 6, 10, 15 and 20 mM) on 
the nuclease activity of 1 at 50 µM (ri 3.3, lanes 8-15). Effect of activating agents (MPA and 
oxone) on the DNA cleavage activity of 6 (ri 3.3, lanes 2-7) under 10 mM phosphate buffer 
Lanes 1, 16 - controls for native DNA; 2 - control for linearized DNA; 3 – 6; 4 - 6 + MPA; 5 – 6 + 
oxone; 6 - control for MPA; 7 - control for oxone.  
 
 
 
Figure A33. Comparison of the DNA cleavage activity of 1 (A), 9 (B), 13 (C), 4 (D) and 6 (E) at 
12 µM (ri 0.8) under 10 and 100 mM phosphate buffer. 
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Figure A34. Replicate of the gel in Figure A33 at complex concentration of 25 µM instead of 12.  
 
 
Figure A35. Nuclease activity of 1 at 50 µM (ri 3.3) in the presence of both phosphate and 
MOPS buffers (pH 7.4). Phosphate/MOPS: 0/5, 0/10, 5/5, 5/10, 10/5, 10/10, 10/0, 5/0 mM.  
 
ANNEX A 
 
 
264 
 
 
Figure A36. Comparison of the activity of 1 at 10, 25, 50, 100 and 200 µM (ri 0.7, 1.7, 3.3, 6.7 
and 13.3) stock solution of which was prepared in PBS buffer (lanes 2-6) and, as typically, in 
water (lanes 8-12). In the latter case PBS was added into each sample before addition of 
plasmid and complex.  
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Effect of light  
 
 
Figure A37. Effect of light on the DNA cleavage activity of 1 at 3, 6, 12, 25, 50 and 100 µM 
(ri 0.2, 0.4, 0.8, 1.7, 3.3 and 6.7) under PBS buffer using plasmids DNA obtained from different 
batches. Closed tubes with the samples were incubated under a 370-nm UV lamp for 1 h at 
37 ºC. 
 
Figure A38. Effect of light on the DNA cleavage activity of 1 at 3, 6, 12, 25, 50 and 100 µM 
(ri 0.2, 0.4, 0.8, 1.7, 3.3 and 6.7) under phosphate buffer using plasmids DNA obtained from 
different batches. Eppendorfs containing sample mixtures were incubated wrapped in aluminium 
foil. 
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Effect of hydrogen peroxide 
 
Figure A39. Effect of hydrogen peroxide on the nuclease activity of 1 at 3, 6 and 12 µM (ri 0.2, 
0.4 and 0.8) under phosphate buffer. Concentrations of hydrogen peroxide are 1, 10 and 
100 µM.  
 
Effect of atmosphere (air and nitrogen) 
 
 
Figure A40. Cleavage of pA1 pDNA by 9 at 5, 10, 20, 50 and 100 µM (ri 0.3, 0.7, 1.7, 3.3 and 
6.7.) under inert atmosphere. Samples were digested under phosphate and HEPES buffers.   
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Figure A41. The cleavage of pA1 DNA by 9 at 5, 10, 20, 50 and 100 µM (ri 0.3, 0.7, 1.7, 3.3 and 
6.7) under air. Samples were digested under phosphate and HEPES buffers.  
 
 
VIVOSO4 (9) 
 
  
Figure A42. DNA cleavage activity of 9 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS and HEPES buffers. 
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Figure A43. DNA cleavage activity of 9 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under PBS and TRIS buffers.  
 
 
 
Figure A44. DNA cleavage activity of 9 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 
and 6.7) under HEPES and MOPS buffers. 
 
 
ANNEX A 
 
 
269 
V(V) derivatives 
 
 
Figure A45. Nuclease activity of 6-8 at 25, 50 and 100 µM (ri 1.7, 3.3, 6.7) under phosphate 
buffer. Complexes 1 (A) and 9 (B) (50 µM, ri 3.3) were added for comparison.  
 
 
 
Figure A46. DNA cleavage activity of 6-8 under phosphate buffer in the presence of activating 
agents (MPA and oxone). Complexes did not dissolve completely and were diluted 1:4 from 
saturated stock solutions prepared to be 200 µM. Lanes 1, 4 and 7 are the complexes alone, 2, 
5 and 8 are with added MPA; 3, 6 and 9 – with oxone; 10 and 11 – controls for MPA and oxone; 
12 – 50 µM of 1 + oxone; 13 and 14 – controls for linearized DNA and native DNA.  
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Monovanadate 
 
Figure A47. Nuclease activity of NH4VO3 (monovanadate, V1) at 12, 25, 50, 100 and 200 µM 
(ri 0.8, 1.7, 3.3, 6.7 and 13.3.) under phosphate and MOPS buffers. Complex 1 (50, ri 3.3) under 
MOPS, HEPES and phosphate buffer was added for comparison.  
 
 
 
Figure A48. Effect of V1 on pA1 DNA cleavage under phosphate buffer after addition of oxone 
and MPA. Lanes 1, 16 – controls for native DNA; 2, 15 – controls for linearized DNA; 3 – 50 µM 
(ri 3.3) of 1 + oxone; 4-6 – 25, 50 and 100 µM (ri 1.7, 3.3 and 6.7, respectively) of V1; 7-9 – 25, 
50 and 100 µM of V1 + oxone; 10-12 – 25, 50 and 100 µM of V1 + MPA; 13 and 14 – control for 
MPA and oxone.  
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Figure A49. Effect of V1 on pA1 DNA cleavage under MOPS buffer after addition of oxone and 
MPA. Lanes 1, 16 – controls for native DNA; 2, 15 – controls for linearized DNA; 3 – 50 µM (ri 
3.3) of 1 + oxone; 4-6 – 25, 50 and 100 µM (ri 1.7, 3.3 and 6.7, respectively) of V1; 7-9 – 25, 50 
and 100 µM of V1 + oxone; 10-12 – 25, 50 and 100 µM of V1 + MPA; 13 and 14 – control for 
MPA and oxone. 
 
 
Cu(acac)2 (15) and Ni(acac)2 (16) 
 
Figure A50. Nuclease activity of 15 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 and 
6.7) under phosphate and MOPS buffers. 
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Figure A51. Nuclease activity of 16 at 3, 6, 12, 25, 50 and 100 µM (ri 0.2, 0.4, 0.8, 1.7, 3.3 and 
6.7) under phosphate and MOPS buffers. 
 
 
 
Figure A52. Comparison of the DNA cleavage activity of 1, 9, 15 and 16 at 25, 50 and 100 µM 
(ri 1.7, 3.3 and 6.7) under phosphate buffer. 
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Figure A53. Nuclease activity of 15 at 50 and 100 µM (ri 3.3 and 6.7) under phosphate and 
MOPS buffers in the presence of MPA and oxone. Samples 7, 8 and 13, 14 are the controls for 
MPA and oxone under phosphate and MOPS buffers, respectively. 
 
 
Figure A54. Nuclease activity of 16 at 50 and 100 µM (ri 3.3 and 6.7) under phosphate and 
MOPS buffers in the presence of MPA and oxone. Samples 7, 8 and 13, 14 are the controls for 
MPA and Ox under phosphate and MOPS buffers, respectively. 
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Figure A55. DNA cleavage activity of 15 and CuCl2, at 50 µM (ri 3.3) under phosphate buffer 
changing the concentration of MPA (10, 25, 50, 100 and 200 µM). 
 
 
 
Figure A56. DNA cleavage activity of 16 at 50 µM (ri 3.3) under phosphate and MOPS buffers 
changing concentration of MPA (0, 100, 200, 300, 400 and 500 µM). 
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Figure A57. Comparison of the nuclease activity of 15 and 16 at 50 and 100 µM (ri 3.3 and 6.7) 
under phosphate buffer in the presence of oxone and MPA. Complex 1 (ri 3.3) is added for 
comparison.  
 
 
Other oxovanadium complexes  
 
VO(MPA)2 (17), VO(dmpp)2 (18), VO(PA)2 (19) 
 
Figure A58. Nuclease activity of 17, 18 and corresponding ligands at 25, 50 and 100 µM (ri 1.7, 
3.3 and 6.7) under phosphate buffer (pH 7.4). 
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Figure A59. Nuclease activity of 17, 18 and corresponding ligands at 25, 50 and 100 µM (ri 1.7, 
3.3 and 6.7) under HEPES buffer (pH 6.97).  
 
 
 
Figure A60. Replicate of the gel in Figure A59. 
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Figure A61. Nuclease activity of 19 and corresponding ligand at 25, 50 and 100 µM (ri 1.7, 3.3 
and 6.7) under phosphate buffer (pH 7.4). Complex 9 at 6, 12, 25, 50 and 100 µM (ri 0.4, 0.8, 
1.7, 3.3 and 6.7) was added for comparison. 
 
 
Figure A62. Nuclease activity of 19 and corresponding ligand at 25, 50 and 100 µM (ri 1.7, 3.3 
and 6.7) under HEPES buffer (pH 6.97). Complex 9 at 6, 12, 25, 50 and 100 µM (ri 0.4, 0.8, 1.7, 
3.3 and 6.7) was added for comparison. 
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Figure A63. Replicate of the gel in Figure A62. 
 
 
VO(oda) (20), VO(oda)phen (21), VO(phen)2 (22) VO(oda)bipy (23) 
 
 
Figure A64. DNA cleavage activity of 20 at 6, 12, 25, 50 and 100 µM (ri 0.4, 0.8. 1.7, 3.3 and 
6.7) under phosphate and MOPS buffers. Complex 9 (A) and VIVO(ClO4)2 (B) at 50 µM under 
phosphate buffer were added for comparison. 
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Figure A65. DNA cleavage activity of 20 and corresponding ligand at 25 and 50 µM (ri 1.7 and 
3.3) under MOPS buffer in the presence of MPA and oxone. Complex 9 at 50 µM was added for 
comparison. “MPA” and “Ox” are the controls for the activating agents with no added complex. 
 
 
Figure A66. DNA cleavage activity of 20 at 50 and 100 µM (ri 3.3 and 6.7) under phosphate and 
MOPS buffers in the presence of MPA and oxone. 
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Figure A67. DNA cleavage activity of 20 at 100 µM (ri 6.7) under phosphate and MOPS buffers 
in the presence of scavengers (NaN3, NaBz and DMSO). Lanes 7-9 present the controls of 
NaN3, NaBz and DMSO in MOPS buffer; lanes 13 and 14 are the controls of NaN3 and NaBz in 
phosphate buffer. 
 
Figure A68. Nuclease activity of 21 at 5, 10, 25, 50 and 100 µM (ri 0.3, 0.7, 1.7, 3.3 and 6.7) 
under phosphate and MOPS buffers.  
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Figure A69. Replicate of the gel in Figure A68. 
 
 
 
Figure A70. Nuclease activity of 1,10-phen (A), 22 (B) and 21 (C) at 25 and 50 µM (ri 1.7 and 
3.3) under phosphate buffer (pH 7.4). Complex 21 is also tested in the presence of oxone and 
MPA. Lanes 13 and 14 are controls for respectively oxone and MPA. 
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Figure A71. Nuclease activity of 1,10-phen (A), 22 (B) and 21 (C), at 25 and 50 µM (ri 1.7 and 
3.3) under MOPS buffer (pH 7.4). Complex 21 is also tested in the presence of oxone and MPA. 
Lanes 13 and 14 are controls for respectively oxone and MPA. 
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Figure A72. Nuclease activity of 1,10-phen (A), 22 (B) and 21 (C), at 25 and 50 µM (ri 1.7 and 
3.3) under HEPES buffer (pH 7.4). Complex 21 is also tested in the presence of MPA and 
oxone. Lanes 13 and 14 are controls for respectively oxone and MPA. Complex 20 (D) at 50 µM 
(ri 3.3) was added for comparison. 
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Figure A73. Replicate of the gel in Figure A70. 
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Figure A74. Replicate of the gel in Figure A71. 
 
 
Figure A75. Nuclease activity of 21 at 100 µM (ri 6.7) under phosphate buffer in the presence 
of scavengers and H2O2. Ligands oda and phen were added for comparison. DNA „N‟ and „K‟ 
are plasmids DNA prepared in different batches.  
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Figure A76. Replicate of the gel in Figure A75. 
 
 
Figure A77. Nuclease activity of 21 at 100 µM (ri 6.7) under MOPS buffer in the presence of 
scavengers and H2O2. Ligands oda and phen were added for comparison. Lanes 3-6 are the 
controls for NaN3, NaBz, DMSO and H2O2 with no added complex. 
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Figure A78. Replicate of the gel in Figure A77. 
 
 
 
Figure A79. Nuclease activity of 23 at 5, 10, 25, 50 and 100 µM (ri 0.3, 0.7, 1.7, 3.3 and 6.7) 
under phosphate and MOPS buffers. 
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Figure A80. Replicate of the gel in Figure A79. 
 
 
 
Figure A81. Nuclease activity of 23 at 50 µM (ri 3.3) under phosphate and MOPS buffers in the 
presence of oxone and MPA. Corresponding ligands, oda and bipy, were added for comparison. 
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Figure A82. Replicate of the gel in Figure A81. 
 
 
 
Figure A83. Nuclease activity of 23 at 100 µM (ri 6.7) under phosphate buffer in the presence of 
scavengers and H2O2. Corresponding ligands, oda and bipy, were added for comparison. 
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Figure A84. Replicate of the gel in Figure A83. 
 
 
 
Figure A85. Nuclease activity of 23 at 100 µM (ri 6.7) under MOPS buffer in the presence of 
scavengers and H2O2. Corresponding ligands, oda and bipy, were added for comparison. 
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Figure A86. Replicate of the gel in Figure A85. 
 
 
 
Figure A87. Comparison of DNA cleavage activity of 20 (1), 21 (2) and 23 (3) at 50 and 100 µM 
(ri 3.3 and 6.7) under MOPS and phosphate buffers.  
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Figure A88. Replicate of the gel in Figure A87. 
 
 
 
Figure A89. Comparison of the nuclease activity of 20 (lanes 3-5), 21 (lanes 9-11) and 23 
(lanes 6-7) at 50 µM (ri 3.3) under phosphate buffer in the presence of oxone and MPA. 
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Figure A90. Comparison of the nuclease activity of 20, 21 and 23 at 50 µM (ri 3.3) under MOPS 
buffer in the presence of oxone and MPA. 
 
VO(crysin)2 (24), VO(morin)2 (25), VO(clor) (26) and VO(silibinin) (27) 
 
Figure A91. DNA cleavage activity of 24, 25 and corresponding ligands at 50 and 100 µM (ri 3.3 
and 6.7) under phosphate buffer. Complexes 1 and 9 were added for comparison.  
 
ANNEX A 
 
 
294 
 
Figure A92. Replicate of the gel in Figure A91. 
 
 
 
Figure A93. DNA cleavage activity of 24, 25 at 50 and corresponding ligands at 50 and 100 µM 
(ri 3.3 and 6.7) under HEPES buffer. Complexes 1 and 9 were added for comparison.  
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Figure A94. DNA cleavage activity of 25 (B) and 26 (D) and corresponding ligands (morin (A) 
and clor (C)) under phosphate buffer. A and B did not dissolve completely; the stock solution 
was prepared to be 200 µM and the corresponding dilutions 1:2 and 1:4 were made. 
 
 
Figure A95. DNA cleavage activity of 25 (B) and 26 (D) and corresponding ligands (morin (A) 
and clor (C)) under MOPS buffer in the absence and presence of activating agents (oxone and 
MPA). A and B did not dissolve completely; the stock solution was prepared to be 200 µM and 
the corresponding dilutions 1:2 and 1:4 were made. 
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Figure A96. DNA cleavage activity of 25 and the corresponding ligand (morin (A)) under 
phosphate and MOPS buffers (pH 7.4). The complex and ligand were dissolved in 5% DMSO 
and in 1% ethanol, respectively. The final concentration for the ligand was 100 µM (ri 6.7). As 
the complex did not dissolve completely, the stock solution was prepared to be 100 µM and 
diluted 1:2 in order to ensure the concentration close to 50 µM (ri 3.3).  
 
 
 
Figure A97. Effect of concentration and activating agents on the DNA cleavage activity of 27 
(Na2[VO(silibinin)2]•6H2O) at 6, 12, 25 and 50 µM (ri 0.4, 0.8, 1.7 and 3.3) under phosphate 
buffer. Complex 9 at 50 µM was added for comparison.  
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Figure A98. Effect of activating agents on the DNA cleavage activity of 27 under MOPS buffer. 
Lanes 1 and 14, 2 and 13 – controls for native and linearized DNA, respectively; 3 – 25 µM of 
27 (ri 1.7); 4 – 50 µM of 27 (ri 3.3); 5 – 50 µM of 27 + MPA; 6 – 50 µM of 27 + oxone; 7 – 50 µM 
of 9; 8 – 50 µM of 9 + MPA; 9 – 50 µM of 9 + oxone; 10 and 11 – controls for MPA; and oxone, 
respectively; 12 – 100 µM ligand silibinin.  
 
Other vanadium and copper complexes: Cu(Sal-Gly)(bipy) (28), Cu(Sal-Gly)(phen) (29), 
Cu(Sal-L-Phe)(phen) (30), VO(Sal-L-Phe)(bipy) (31), VO(Sal-L-Phe)(phen) (32), 
VO(Sal-Gly)(bipy) (33), VO(Sal-Gly)(phen) (34), VO(Sal-Gly)(H2O) (35), VO(Sal-L-
Phe)(H2O) (36) 
 
 
Figure A99. DNA cleavage activity of 28-36 (assigned as 1-9, respectively) at 50 µM (ri 3.3) 
under PBS buffer. The complexes were dissolved in 5% solution of EtOH. “DNA + 5% EtOH” is 
the control for the Sc DNA with 5% solution of EtOH. Reaction mixtures were incubated as 
typically, i.e., 1 h at 37 ºC. 
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Figure A100. DNA cleavage activity of 28-36 (assigned as 1-9, respectively) at 100 µM (ri 6.7) 
under PBS buffer. The complexes were dissolved in 5% solution of EtOH. “Phen” and “bipy” are 
controls for 1,10-phenanthroline and 2,2´-bipyridyne. Reaction mixtures were incubated at for 
5 h 37 ºC.  
 
 
Figure A101. DNA cleavage activity of 29 and 30 at 5, 10, 25, 50 and 100 µM (ri 0.3, 0.7, 1.7, 
3.3 and 6.7) under PBS buffer. The complexes were dissolved in 5% solution of EtOH. Reaction 
mixtures were incubated at 37 ºC for 5 h.  
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Figure A102. Cleavage of pA1 pDNA by 28-32 (assigned as 1-5, respectively) at 50 µM (ri 3.3) 
in the presence of oxone. The complexes were dissolved in 5% EtOH and 20 mM PBS. Final 
PBS concentration in a sample was 10 mM. “Ox” is the control for oxone without a complex. 
Samples were incubated at 37 ºC for 5 h (1-14), and 2 h (15 and 16). 
 
 
 
Figure A103. Cleavage of pA1 pDNA by 33-36 (assigned as 6-9, respectively) at 50 µM (ri 3.3) 
in the presence of oxone. The complexes were dissolved in 5% EtOH and 20 mM PBS. Final 
PBS concentration in a sample was 10 mM. Samples were incubated at 37 ºC for 5 h (1-12), 2 h 
(13-15) and at room temperature for 5 h (16). 
 
ANNEX A 
 
 
300 
 
Figure A104. Cleavage of pA1 pDNA by 28-32 (assigned as 1-5, respectively) at 50 µM (ri 3.3) 
in the presence of MPA. The complexes were dissolved in 5% EtOH and 20 mM PBS. Final 
PBS concentration in a sample was 10 mM. “MPA” is the control for MPA without a complex. 
Samples were incubated at 37 ºC for 5 h (1-14), and 2 h (15 and 16). 
 
 
Figure A105. Cleavage of pA1 pDNA by 33-36 (assigned as 6-9, respectively) at 50 µM (ri 3.3) 
in the presence of MPA. The complexes were dissolved in 5% EtOH and 20 mM PBS. Final 
PBS concentration in a sample was 10 mM. Samples were incubated at 37 ºC for 5 h (1-12), 2 h 
(13-15) and at room temperature for 5 h (16). 
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Figure A106. Cleavage of pA1 pDNA by 28-36 (assigned as 1-9, respectively) at 50 µM (ri 3.3) 
prepared in 20 mM PBS, no EtOH. Final concentration of PBS was 10 mM. “DNA1” is also the 
control for the Sc DNA but is from a different batch. “Phen” and “bipy” are controls for 1,10-
phenanthroline and 2,2'-bipyridyne. Incubation 5 h at 37 ºC.  
 
 
Figure A107. Nuclease activity of 29 and 30 (assigned as 2 and 3) at 10, 25, 50 and 100 µM 
(ri 0.7, 1.7, 3.3 and 6.7) prepared in 5% EtOH and 20 mM PBS. Complexes 32 and 34 
(assigned 5 and 7, respectively) were added for comparison (ri 3.3). Final concentration of PBS 
was 10 mM. “DNA + 5% EtOH” is the control for the Sc DNA with 5% solution of EtOH. Samples 
were incubated at 37 ºC for 5 h (1-12) and 1 h (13-16). 
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Figure A108. Effect of oxone and MPA on the nuclease activity of 28-30 (assigned as 1-3) at 
50 µM (ri 3.3). The complexes were dissolved in 5% EtOH and 20 mM PBS. Final PBS 
concentration was 10 mM. 
 
Phantom bands 
 
 
Figure A109. Understanding „phantom bands‟. Cleavage of pA1 DNA by 1, 17, 20 and 22 under 
phosphate buffer. Tested concentrations are 25, 50, 100 and 200 µM (ri 1.7, 3.3, 6.7, 10 and 
13.3). A1-A3 and B1 are so-called phantom bands detected when a complex promotes the 
scission of both single and double strands.  
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Figure A110. Understanding „phantom bands‟. Cleavage of pA1 DNA by 1, 17, 20 and 22 under 
MOPS buffer. Tested concentrations are 25, 50, 100 and 200 µM (ri 1.7, 3.3, 6.7, 10 and 13.3). 
A1-A3 and B1 are so-called phantom bands detected when a complex promotes the scission of 
both single and double strands. 
 
 
 
Figure A111. Understanding „phantom bands‟. Cleavage of pA1 DNA 17 and 22at 25, 50, 100 
and 200 µM (ri 1.7, 3.3, 6.7 and 13.3) under phosphate buffer (pH 7.4). Oda ligand was added 
for comparison as non-active agent towards pDNA activity. A1-A3 and B1 are observed 
phantom bands.  
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Figure A112. Understanding „phantom bands‟. Cleavage of pA1 DNA by 1 at 6, 12, 25, 50, 100, 
200 and 400 (ri 0.4, 0.8, 1.7, 3.3, 6.7, 13.3 and 26.7) under phosphate buffer (pH 7.4). Complex 
26 (ri 1.7, 3.3 and 6.7), as the one that does not induce significant cleavage, was added for 
comparison. A1-A3 and B1 are the observed phantom bands.  
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IX. Annex B 
Cyclic and Square wave voltammograms of examined complexes
Figure B1. Cyclic voltammograms of 1 in 10, 30 and 100 mM phosphate and MOPS buffers.      
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Figure B2. Square wave voltammograms of 1 in 10, 30 and 100 mM phosphate and MOPS buffers. 
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Figure B3. Cyclic voltammograms of 2 in 10, 30 and 100 mM phosphate and MOPS buffers. 
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Figure B4. Square wave voltammograms of 2 in 10, 30 and 100 mM phosphate and MOPS buffers. 
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Figure B5. Cyclic voltammograms of 3 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B6. Square wave voltammograms of 3 in 10 and 100 mM phosphate and MOPS buffers. 
ANNEX B 
 
 
311 
 
Figure B7. Cyclic voltammograms of 4 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B8. Square wave voltammograms of 4 in 10 and 100 mM phosphate and MOPS buffers. 
ANNEX B 
 
 
313 
 
Figure B9. Cyclic voltammograms of 5 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B10. Square wave voltammograms of 5 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B11. Cyclic voltammograms of 9 in 10, 30 and 100 mM phosphate and MOPS buffers. 
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Figure B12. Square wave voltammograms of 9 in 10, 30 and 100 mM phosphate and MOPS buffers. 
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Figure B13. Cyclic voltammograms of VO(acac-NH2)2 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B14. Square wave voltammograms of VO(acac-NH2)2 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B15. Cyclic voltammograms of VO(acac-NMe2)2 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B16. Square wave voltammograms of VO(acac-NMe2)2 in 10 and 100 mM phosphate and MOPS buffers. 
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Figure B17. Cyclic voltammograms of 6, VO(PA)2, VO(tmh)2 and VO(pbd)2 under 100 mM phosphate buffer. 
 
ANNEX B 
 
 
322 
 
Figure B18. Square wave voltammograms of 6, VO(PA)2, VO(tmh)2 and VO(pbd)2 under 100 mM phosphate buffer. 
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Figure B19. Square wave and cyclic (direct) voltammograms of 2 (50 µM) increasing 
concentration of phosphate buffer (1, 2, 4, 6, 10 and 20 mM). 
 
 
 
Figure B20. Square wave and cyclic (direct) voltammograms of 3 (50 µM) increasing 
concentration of phosphate buffer (1, 2, 4, 6, 10 and 20 mM). 
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Figure B21. Square wave and cyclic (direct) voltammograms of 4 (50 µM) increasing 
concentration of phosphate buffer (1, 2, 4, 6, 10 and 20 mM). 
 
 
 
Figure B22. Square wave and cyclic (direct) voltammograms of 5 (50 µM) increasing 
concentration of phosphate buffer (1, 2, 4, 6, 10 and 20 mM). 
 
 
 
 
 
 
 
 
References 
 
 
 
 
 
 
 
327 
X. References 
                                            
1. Shechter, Y.; Shisheva, A. Endeavour 1993, 17, 27-31. 
2. Orvig, C.; Caravan, P.; Gelmini, L.; Glover, N.; Herring, F.G.; Li, H.; McNeill, J.H.; Rettig, S.J.; 
Setyawati, I.A. J. Am. Chem. Soc. 1995, 117, 12759–12770. 
3. Goldwaser, I.; Gefel, D.; Gershonov, E.; Fridkin, M.; Shechter, Y. Biol. Inorg. Chem. 2000, 80, 21-25. 
4. Rehder, D.; Costa Pessoa, J.; Geraldes, C.F.G.C.; Castro, M.M.C.A.; Kabanos, T.; Kiss, T.; Meier, B.; 
Micera, G.; Pettersson, L.; Rangel, M.; Salifoglou, A.; Turel, I.; Wang, D. Biol. Inorg. Chem. 2002, 7, 384–
396. 
5. Evangelou, A.M. Crit. Rev. Oncol. Hematol. 2002, 42, 249–265. 
6. Kostova, I. Anti-Cancer Agents in Med. Chem. 2009, 9, 827-842. 
7. Weckhuysen, B.M.; Keller, D.E. Catal. Today, 2003, 78, 25-46. 
8. Greenwood, N.N. Catal. Today, 2003, 78, 5-11. 
9. Rehder, D. Bioinorganic Chemistry of Vanadium; John Wiley & Sons, Ltd: The Atrium, Southern Gate, 
Chichester, West Sussex, England, 2008; pp 31-34. 
10. Rychcik M.; Skyllas-Kazacos, M. J. Power Sources, 1988, 22, 59-67. 
11. Ligtenbarg, A.G.J; Hage, R.; Feringa, B.L. Coord. Chem. Rev. 2003, 237, 89-101. 
12. Tracey, A.S.; Crans, D.C. In Vanadium Compounds: Chemistry, Biochemistry, and Therapeutic 
Applications; Tracey, A.S., Crans, D.C., Eds.; ACS Symposium Series 711; American Chemical Society: 
Washington, DC, 1998; pp 2-29. 
13. Rehder, D. Future Med. Chem. 2012, 4, 1823-1837. 
14. Burns, R.G. In Mineralogical Applications of Crystal Field Theory, 2nd ed.; Putris, A., Liebermann R.C. 
Eds.; Cambridge University Press: Cambridge, 1993. 
15. Corathers, L.A., Gambogi, J.; Kuck, P.H.; Papp, J.F.; Polyak, D.E.; Shedd, K.B. In Geological Survey 
Minerals Yearbook: Ferroalloys; U.S. Geological Survey, 2010; pp 25.1-25.16. 
16. Chasteen, N.D. In Copper, Molybdenum and Vanadium in Biological Systems: Structure and Bonding; 
Averill, B.A., Briggs, LeB.R., Chasteen, N.D., Gilbert, T.R., Kustin, K., McLeod, G.C., Penfield, K.W., 
Solomon, E.I., Wilcox D.E., Eds.; Springer: Berlin Heidelberg; 1983; Vol. 53, pp 105-138. 
17. Boas, L.F.V.; Costa Pessoa, J. In Comprehensive Coordination Chemistry: Vanadium; Wilkinson, G., 
Gillard, R.D., McCleverty J.A. Eds.; Pergamon: Oxford, 1987; Vol. 3, pp 453–583.  
18. Reul, B.A.; Amin, S.S.; Buchet, J.P.; Ongemba, L.N.; Crans, D.C.; Brichard, S.M. British J. 
Pharmocol. 1999, 126, 467-477. 
19. Crans, D.C.; Bunch, R.L.; Theisen, L.A. J. Am. Chem. Soc. 1989, 111, 7597-7607. 
20. Selling, A.; Andersson, I.; Pettersson, L.; Schramm, C.M.; Downey, S.L.; Grate, J.H. Inorg. Chem. 
1994, 33, 3141-3150. 
21. Pettersson, L.; Andersson, I.; Gorzsás, A. Coord. Chem Rev. 2003, 237, 77-87.  
22. Gorzsás A.; Andersson, I.; Pettersson, L. J. Inorg. Biochem. 2009, 103, 517-526. 
23. Gorzsás, A.; Getty, K.; Andersson, I.; Pettersson, L. Dalton Trans. 2004, 2873-2882. 
24. Andersson, I.; Gorzsás A.; Pettersson, L. Dalton Trans. 2003, 2503-2511. 
25. Andersson, I.; Gorzsás A.; Kerezsi, C.; Toth, I.; Pettersson, L. Dalton Trans. 2005, 3658–3666. 
26. Kiss, T.; Kiss, E.; Garribba, E.; Sakurai, H. J. Inorg. Biochem. 2000, 80, 65-73. 
27. Crans, D.C.; Jiang, F.; Boukhobza, I.; Bodi, I.; Kiss, T. Inorg. Chem. 1999, 38, 3275-3282. 
28. Kiss, T.; Kiss, E.; Micera, G.; Sanna, D. Inorg. Chim. Acta 1998, 283, 202-210. 
29. Crans, D.C.; Yang, L.; Jakush, T.; Kiss, T. Inorg. Chem. 2000, 39, 4409-4416. 
30. Jakush, T.; Jin, W.; Yang, L.; Kiss, T.; Crans, D.C. J. Inorg. Biochem. 2003, 95, 1-13. 
31. Crans, D.C.; Smee, J.J.; Gaidamauskas, E.; Yang L. Chem. Rev. 2004, 104, 849-902. 
32. Jakush, T.; Costa Pessoa, J.; Kiss, T. Coord. Chem. Rev. 2011, 255, 2218-2226. 
33. Correia, I.; Jakush, T.; Cobbinna, E.; Mehtab, S.; Tomaz, I.; Nagy, N.V.; Rockenbauer, A.; Costa 
Pessoa, J.; Kiss, T. Dalton Trans. 2012, 41, 6477–6487. 
34. Alberico, E.; Micera, G. Inorg. Chim. Acta 1994, 215, 225-227. 
35. Butler, A.; Clague, M.J.; Meister, J.E. Chem. Rev. 1994, 94, 625-638. 
36. Dikanov, S.A.; Liboiron, B.D.; Orvig, C. J. Am. Chem. Soc. 2002, 124, 2969-2978. 
37. Ishii, T.; Nakai, I.; Numako, C.; Okoshi, K.; Otake, T. Naturwissenschaften 1993, 80, 268-270.  
 
 
328 
                                                                                                                                            
38. Kanda, T.; Nose, Y.; Wuchiyama, J.; Uyama, T.; Moriyama, Y.; Michibata, H. Zool. Sci. 1997, 14, 37-
42. 
39. Orvig, C.; Thompson, K.H.; Liboiron, B.D.; McNeill, J.H.; Yuen, V.G. J. Inorg. Biochem. 2003, 96, 14 
(abstr. presented by C. Orvig at ICBIC 11, Cairns, QLD, Australia, 2003). 
40. Antipov, A.N.; Lyalikova, N.N.; Khijniak, T.V.; L‟vov, N. P. FEBS Lett. 1998, 441, 257-260.  
41. Antipov, A. N.; Sorokin, D. Y.; L‟Vov, N. P.; Kuenen, J. G.Biochem. J. 2003, 369, 185-189. 
42. French, R. J.; Jones, P.J.H. Life Science 1993, 52, 339-346. 
43. Costa Pessoa, J.; Tomaz, I. Curr. Med. Chem. 2010, 17, 3701-3738. 
44. Rehder, D. Angew. Chem. Int. Ed. Engl. 1991, 30, 148-167. 
45. Crans, D.C. Pure Appl. Chem. 2005, 77, 1497–1527. 
46. Oltz, E.M.; Bruening, R.C.; Smith, M.J.; Kustin, K.; Nakanishi, K. J. Am. Chem. Soc., 1988, 110, 
6162–6172. 
47. Michibata, H.; Uyama, T.; Kanamori, K. In Vanadium Compounds: Chemistry, Biochemistry and 
Therapeutic Applications; Tracey, A.S., Crans, D.C., Eds.; ACS Symposium Series 711; American 
Chemical Society: Washington, DC, 1998; pp 248-258. 
48. Michibata, H.; Yamaguchi, N.; Uyama T.; Ueki, T. Coord. Chem. Rev. 2003, 237, 41–51. 
49. Treberg, J.R.; Stacey, J.E.; Driedzic, W.R. Comp. Biochem. Physiol. B 2012, 161, 323–330.  
50. Garner, C.D.; Armstrong, E.M.; Berry, R.E.; Beddoes, R.L.; Collison, D.; Cooney, J.J.A.; Ertok, S.N.; 
Helliwell, M. J. Inorg. Biochem. 2000, 80, 17–20. 
51. Matoso, C.M.M.; Pombeiro, A.J.L.; Fraústo da Silva, J.J.R.; Silva, M.F.C.G.; Silva, J.A.L.; Baptista-
Ferreira, J.L.; Pinho-Almeida, F. In Vanadium Compounds: Chemistry, Biochemistry and Therapeutic 
Applications; Tracey, A.S., Crans, D.C., Eds.; ACS Symposium Series 711; American Chemical Society: 
Washington, DC, 1998; Chapter 18, pp 241-247. 
52. Silva, J.A.L.; Frausto da Silva, J.J.R.; Pombeiro, A.J.L. Chem. Commun. 2013, 2388-2400. 
53. Guedes da Silva, M.F.C.; Silva, J.A.L; Fraústo da Silva, J.J.R.; Pombeiro, A.J.L.; Amatore, C.; 
Verpeaux, J.N. J. Am. Chem. Soc.1996, 118, 7568-7573. 
54. Reis, P.M.; Silva, J.A.L.; Palavra, A.F.; Frausto da Silva, J.J.R.; Kitamura, T.; Fujiwara, Y.; Pombeiro, 
A.J.L. Angew. Chem., Int. Ed. 2003, 42, 821-823. 
55. Hubregtse, T.; Neeleman, E.; Maschmeyer, T.; Sheldon, R.A.; Hanefeld, U.; Arends, I.W.C.EJ. Inorg. 
Biochem. 2005, 99, 1264–1267. 
56. Wever, R., Tromp, M.C.M.; Krenn, B.E.; Marjani A.; Van Tol, M. Environ. Sci. Technol. 1991, 25, 446–
449.  
57. Eady, R. R. Coord. Chem. Rev. 2003, 237, 23-30. 
58. Robson, R.L.; Eady, R.R.; Richardson, T.H.; Miller, R.W.; Hawkins M. Postgate, J.R. Nature 1986, 
322, 388–390. 
59. Dilworth, M.J.; Eady, R.R. Biochem. J. 1991, 277, 465–468. 
60. Fay, A.W.; Blank, M.A.; Lee, C.C. J. Am. Chem. Soc. 2010, 132, 12612–12618. 
61. Hu, Y.; Lee, C.C.; Ribbe, M.W. Science 2011, 333, 753–755. 
62. Rehder, D. Inorg. Chem. Comm. 2003, 6, 604–617. 
63. Thompson, K.H., Orvig C. J. Inorg. Biochem. 2006, 100, 1925–1935. 
64. Elvingson, K.; Crans, D. C.; Pettersson, L. J. Am. Chem. Soc. 1997, 119, 7005-7012. 
65. Crans, D.C.; Simone, C.M.; Blanchard, J.S. J. Am. Chem. Soc. 1992, 114, 4926-4928.  
66. Crans, D.C.; Marshman, R.W.; Nielsen, R.; Felty, I. J. Org.Chem. 1993, 58, 2244-2252. 
67. Lindquist, R.N.; Lynn, J.L. Jr.; Lienhard, G.E. J. Am. Chem.Soc. 1973, 95, 8762-8768.  
68. Berger, S.L.; Birkenmeier, C.S. Biochem. 1979, 18, 5143-5149. 
69. Brichard, S.M.; Henquin J.C. Trends Pharm. Sci. 1995, 16, 265-270. 
70. Thompson, K.H.; McNeill, J.H.; Orvig C. Chem. Rev. 1999, 99, 2561-2562. 
71. Sakurai, H. Chem. Records 2002, 2, 237-248. 
72. Sakurai, H.; Tamura, A.; Fugono, J.; Yasui, H.; Kiss, T. Coord. Chem. Rev. 2003, 245, 31–37. 
73. Srivastava, A.K. Mehdi, M.Z. Diabetic Medicine, 2004, 22, 2–13. 
74. Thompson, K.H.; Orvig, C. Met. Ions Biol. Syst. 2004, 41, 221–252. 
75. Sakurai, H.; Katoh, A.; Yoshikawa, Y. Bull. Chem. Soc. Jpn. 2006, 79, 1645–1664. 
76. Goc, A. Centr. Europ. J. Biol. 2006, 1, 314–332. 
 
 
329 
                                                                                                                                            
77. Thompson, K.H.; Lichter, J.; LeBel, C.; Scaife, M.C.; McNeill, J.H.; Orvig, C. J. Inorg. Biochem. 2009, 
103, 554–558.  
78. Desoize, B. Crit. Rev. Oncol. Hematol. 2002, 42, 1-3. 
79. Somerville, J.; Davies, B. Am. Heart J. 1962, 64, 54–56. 
80. Kivelson, D.; Lee, S.L.; J. Chem. Phys. 1964, 41, 1896–1903. 
81. Tolman, E.L.; Barris, E.; Burns, M.; Pansini A.; Partridge, R. Life Sci. 1979, 25, 1159–1164. 
82. Shechter, Y.; Karlish, S.J.D. Nature 1980, 284, 556–558. 
83. Heyliger, C.E.; Tahiliani, A.G.; McNeill, J.H. Science 1985, 227, 1474–1477. 
84. Kadota, S.; Fantus, I.G.; Deragon, G.; Guyda, H.J.; Hersh B.; Posner, B.I. Biochem. Biophys. Res. 
Commun. 1987, 147, 259–266. 
85. Fantus, I.G.; Kadota, S.; Deragon, G.; Foster, B.; Posner, B.I. Biochem. 1989, 28, 8864–8871. 
86. Brichard, S.M.; Pottier, A.M.; Henquin, J.C. Endocrin. 1989, 125, 2510–2516. 
87. Pederson, R.A.; Ramanadham, S.; Buchan, A.M.J.; McNeill, J.H. Diabetes 1989, 38 1390–1395. 
88. Brichard, S.M.; Bailey, C.J.; Henquin, J.-C. Diabetes 1990, 39, 1326–1332. 
89. Thompson, K.H.; Leichter, J.; McNeill, J.H. Biochem. Biophys. Res.Commun. 1993, 197, 1549–1555. 
90. Ramanadham, S.; Mongold, J.J.; Brownsey, R.W.; Cros G.H.; McNeill, J.H. Am. J. Physiol. 1989, 257, 
904–911. 
91. Villani, P.; Cordelli, E.; Leopardi, P.; Siniscalchi, E.; Veschetti, E.;Fresegna, A.M.; Crebelli, R. Toxicol. 
Lett. 2007, 170, 11–18. 
92. Sakurai, H.; Tsuchiya, K.; Nukatsuka, M.; Kawada, J.; Ishikawa, S.; Yoshida, H.; Komatsu, M. J. Clin. 
Biochem. Nutr. 1990, 8, 193–200. 
93. McNeill, J.H.; Yuen, V.G.; Hoveyda, H.R.; Orvig, C. J. Med. Chem. 1992, 35, 1489–1491. 
94. Orvig, C.; Thompson, K.H.; Battell, M.; McNeill, J.H. Met. Ions Biol. Syst. 1995, 31, 575–594. 
95. Caravan, P.; Gelmini, L.; Glover, N.; Herring, F.G.; Li, H.; McNeill, J.H.; Rettig, S.J.; Setyawati, I.A.; 
Shuter, E.; Sun, Y.; Tracey, A.S.; Yuen, V.G.; Orvig, C. J. Am. Chem. Soc. 1995, 117, 12759–12770. 
96. Thompson, K.H.; Yuen, V.G.; McNeill, J.H.; Orvig, C. In Vanadium Compounds: Chemistry, 
Biochemistry and Therapeutic Applications; Tracey, A.S., Crans, D.C., Eds.; ACS Symposium Series 711; 
American Chemical Society: Washington, DC, 1998; pp 329–343. 
97. Sakurai, H.; Fujii, K.; Watanabe, H.; Tamura, H. Biochem. Biophys. Res. Commun. 1995, 214, 1095-
1101. 
98. Fujimoto, S.; Fujii, K.; Yasui, H.; Matsushita, R.; Takada, J.; Sakurai, H. J. Clin. Biochem. Nutr. 1997, 
23, 113-129. 
99. Melchior, M.; Thompson, K.H.; Jong, J.M.; Retting, S.J.; Shuter, E.; Yuen, V.; Zhou, Y.; McNeill, J.H.; 
Orvig, C. Inorg. Chem. 1999, 38, 2288–2293. 
100. Takino, T.; Yasui, H.; Yoshitake, A.; Hamajima, Y.; Matsushita, R.; Takada, J.; Sakurai, H. J. Biol. 
Inorg. Chem. 2005, 6, 133-142. 
101. Esbak, H.; Enyedy, E.A.; Kiss, T.; Yoshikawa, Y.; Sakurai, H.; Garribba. E.; Rehder, D. J. Inorg. 
Biochem. 2009, 103, 590–600. 
102. Willsky, G.R; Chi, L-H.; Godzala, M.; Kostyniak, P.J.; Smee, J.J.; Trujillo, A.M., Alfano, J.A.; Ding, 
W.; Hu, Z.; Crans, D.C. Coord. Chem. Rev. 2011, 225, 2258–2269. 
103. Goldfine, A.B.; Simonson, D.C.; Folli, F.;Patti, M-E.; Kahn, R. J. Clin. Endocrinol. Metab. 1995, 80, 
3311–3320. 
104. Goldfine, A.B.; Willsky, G.R.; Kahn, C.R. In Vanadium Compounds: Chemistry, Biochemistry and 
Therapeutic Applications; Tracey, A.S., Crans, D.C., Eds.; ACS Symposium Series 711; American 
Chemical Society: Washington, DC, 1998; pp 353–368. 
105. Buglyó, P.; Kiss, E.; Fábián, I.; Kiss, T.; Sanna, D.; Garribba, E.; Micera, G. Inorg. Chim. Acta 2000, 
306, 174–183. 
106. Kiss, E.; Garribba, E.; Micera, G.; Kiss, T.; Sakurai, H. J. Inorg.Biochem. 2000, 78, 97–108. 
107. Buglyó, P.; Kiss, T.; Kiss, E.; Sanna, D.; Garribba, E.; Micera, G. J. Chem. Soc., Dalton Trans. 2002, 
11, 2275–2282. 
108. Dörnyei, A.; Marcão, S.; Costa Pessoa,J.; Jakusch, T.; Kiss, T. Eur. J. Inorg. Chem. 2006, 3614–
3621. 
109. Jakusch, T.; Hollender, D.; Enyedy, E.A.; González, C.S.; Montes-Bayón, M.; Sanz-Medel, A.; Costa 
Pessoa, J.; Tomaz, I.; Kiss, T. Dalton Trans. 2009, 13, 2428–2437. 
 
 
330 
                                                                                                                                            
110. Sanna, D.; Bíró, L.; Buglyó, P.; Micera, G.; Garribba, E. J. Inorg. Biochem. 2012, 115, 87–99. 
111. Vincent, J.B.; Love, S. Biochim. Biophys. Acta 2012, 1820 (3), 362–378. 
112. Sakurai, H.; Yoshikawa, Y.; Yasui, H. Chem. Soc. Rev. 2008, 37, 2383–2392. 
113. Delgado, T.C., Tomaz, I.; Correia, I.; Costa Pessoa, J.; Jones, J.G.; Geraldes, C.F.G.C.; Castro, 
M.M.C.A. J. Inorg. Biochem. 2005, 99, 2328-2339. 
114. Li, J.; Elberg, G.; Crans, D.C.; Shechter, Y. Biochem. 1996, 35, 8314-8318.  
115. Crans, D.C. J. Inorg Biochem. 2000, 80, 123–131. 
116. Amin, S.S.; Cryer, K.; Zhang, B.; Dutta, S.K.; Eaton, S.S.; Anderson, O.P.; Miller, S.M.; Reul, B.A.; 
Brichard, S.M.; Crans, D.C. Inorg Chem. 2000, 39, 406-416. 
117. Ou, H.; Yan, L.; Mustafi, D.; Makine, M.W.; Brady, M.J. J. Biol. Inorg. Chem. 2005, 10, 874–886. 
118. Durai, N.; Saminathan, G. J. Clin. Biochem. Nutr. 1997, 22, 31-39.  
119. Costa Pessoa, J.; Cavaco, I.; Correia, I.; Tomaz, I.; Adão, P.; Vale, I.; Ribeiro, V. Castro, M.M.C.A.; 
Geraldes, C.C.F.G. In Vanadium: The Versatile Metal; Kustin, K., Costa Pessoa, J., Crans, D.C., Eds.; 
ACS Symposium Series 974; American Chemical Society: Washington, DC, 2007; Chapter 24, pp 340–
351. 
120. Sakurai, H.; Sano, H.; Takino, T.; Yasui, H. Chem. Lett. 1999, 913-914.  
121. Takeshita, S.; Kawamura, I.; Yasuno, T.; Kimura, C.; Yamamoto, T.; Seki, J.; Tamura, A.; Sakurai, 
H.; Goto, T. J. Inorg. Biochem. 2001, 85, 179-186. 
122. Melchior, M.; Rettig, S.J.; Liboiron, B.D.; Thompson, K.H.; Yuen, V.G.; McNeill, J.H.; Orvig, C. Inorg. 
Chem. 2001, 40, 4686–4690. 
123. Li, M.; Smee J.J.; Ding, W.; Crans, D.C. J. Inorg. Biochem. 2009, 103, 585–589. 
124. Saatchi, K.; Thompson, K.H.; Patrick, B.O.; Pink, M.; Yuen, V.G.; McNeill, J.H.; Orvig, C. Inorg. 
Chem. 2005, 44, 2689-2697. 
125. Adachi,Y.; Yoshida, J.; Kodera, Y.; Kahto, A.; Takada, J.; Sakurai, H. J. Med. Chem. 2006, 49, 
3251–3256. 
126. Hiromura, M.; Adachi, Y.; Machida, M.; Hattori, M.; Sakurai, H. Metallomics 2009, 1, 92–100. 
127. Yoshikawa, Y.; Ueda, E.; Kojima, Y.; Sakurai, H. Life Sci. 2004, 75, 741-751. 
128. Mehdi, M. Z. ; Srivastava, A. K., Arch. Biochem. Biophys 2005, 440, 158–164 
129. Monga, V.; Thompson, K.H.; Yuen, V.G.; Sharma, V.; Patrick, B.O.; McNeill, J.H.; Orvig, C. Inorg. 
Chem. 2004, 44, 2678–2688. 
130. Yasui, H.; Tamura, A.; Takino, T.; Sakurai, H. J. Inorg. Biochem. 2002, 91, 327–338. 
131. Thompson, K.H.; Chiles, J.; Yuen, V.G.; Tse, J.; McNeill, J.H.; Orvig, C. J. Inorg. Biochem. 2004, 98, 
683–690. 
132. Straganz, G.D.; Glieder, A.; Brecker, L.; Ribbons, D.W.; Steiner, W. Biochem. J. 2003, 369, 573–
581. 
133. Beskid, M.; Jachimowicz, J.; Taraszewska, A.; Kukulska, D. Exp. Toxicol. Pathol. 1995, 47, 25–30. 
134. Domingo, J.L. J. Toxicol. Environ. Health 1994, 42, 123–141. 
135. Ding, M.;Li, J-J.; Leonard, S.S.; Ye, J-P.; Shi, X.; Colburn, N.H.; Castranova, V. Vallyathan, V. 
Carcinogenesis 1999, 20, 663–668.  
136. Rojas, E.; Herrera, L.A.; Poirier, L.A.; Ostrosky-Wegman, P. Mutation Res. 1999, 443, 157–181. 
137. Bode, A.M.; Dong, Z. Crit. Rev. Oncol. Hematol. 2002, 42, 5-24. 
138. Chen, F.; Vallyathan, V.; Castranova, V.; Shi, X. Molec. Cellular Biochem. 2001, 222 183–188. 
139. Waris, G.; Ahsan, H. J. Carcinogenesis 2006, 5, 1-8. 
140. Hallenbeck, P.L.; Stevenson, S.C. In Cancer Gene Therapy: Past Achievements and Future 
Challenges. Habib, N.A., Ed.; New York: Kluwer Academic/ Plenum 2000; pp 37-46. 
141. Clemmons, D.R. In Insulin-like Growth Factors and Cancer: From Basic Biology to Therapeutics, 
Cancer Drug Discovery and Development. LeRoith D., Ed.; Springer New York: Humana Press, 2012; 
Chapter 10, pp193-213. 
142. Cancer, fact sheet #297, reviewed January 2013: 
http://www.who.int/mediacentre/factsheets/fs297/en/index.html (last access 24/10/13), part of the World 
Health Organization website. http://www.who.int/en/ 
143. Fricker, S.P. Dalton Trans. 2007, 4903–4917. 
144. Lovejoy, K.S.; Lippard, S. J. Dalton Trans. 2009, 10651–10659. 
145. Lippert, B. BioMet. 1992, 195–208 
 
 
331 
                                                                                                                                            
146. Choy, H.; Park, C.; Yao, M. Clin. Cancer Res. 2008, 14, 1633-1638. 
147. Clarke, M.J.; Zhu, F.; Frasca, D.R. Chem. Rev. 1999, 99, 2511-2533. 
148. Pizarro, A.M.; Habtemariam, A.; Sadler, P.J. Top Organomet. Chem. 2010, 32, 21-56. 
149. Hartinger, C.G.; Jakupec, M.A.: Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zaboras, H.; 
Dyson, P.; Keppler, B.K. Chem.  Biodiver. 2008, 5, 2140-2155. 
150. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Topics in Med. Chem. 2004, 4, 1525-1535. 
151. Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. Chimia 2007, 61, 692–697. 
152. Antonarakis, E.S.; Emadi, A. Cancer Chemother. Pharmacol. 2010, 66, 1-9. 
153. Dyson, P.J.; Sava, G. Dalton Trans. 2006, 1929-1933. 
154. Boerner, L.J.K.; Zaleski, J.M. Curr. Opin. in Chem. Biol. 2005, 9, 135–144. 
155. Cortizo, A.M.; Molinuevo, M.S.; Barrio, D.A.; Bruzzone, L. Intern. J. Biochem. Cell Biol. 2006, 38, 
1171–1180. 
156. Naso, L.; Ferrer, E.G.; Lesama, L; Rojo, T.; Etcheverry, S.B.; Williams, P. J. Biol. Inorg. Chem. 2010, 
15, 889-902. 
157. Naso, L.G.; Lezama L.; Rojo, T.; Etcheverry, S.B.; Valcarcel, M.; Roura, M.; Salado, C.; Ferrer, E.G.; 
Williams, P.A.M. Chem.-Biol. Interact. 2013, 206, 289-301. 
158. Köpf-Maier, P.; Köpf, H. Drugs Future 1986, 11, 297–319.  
159. Liu, T-T.; Liu, Y-J.; Wang, Q.; Yang, X-G.; Wang, K. J. Biol. Inorg. Chem. 2012, 17, 311-320. 
160. Aubrecht, J.; Narla, R.K.; Ghosh, P.; Stanek, J.; Uckun, F.M.. Toxicol. Appl. Pharm. 1999, 154, 228–
235. 
161. Narla, R.K.; Dong, Y.; D‟Cruz, O.J.; Navara, C.; Uckun, F.U. Clinic. Cancer Res. 2000, 6, 1546–
1556.  
162. D‟Cruz, Osmond J.; Uckun, F.M. Toxic. Appl. Pharmac. 2000, 166, 186–195. 
163. D'Cruz, O.J.; Uckun, F.M. Expert Opin. Investig. Drugs, 2002, 11, 1829-1836. 
164. Bishayee, A.; Waghray, A.; Patel, M.A., Chatterjee, M. Cancer Lett. 2010, 294, 1–12. 
165. Fichtner, I.; Claffey, J.; Deally, A.; Gleeson, B.; Hogan, M.; Rivera Markelova, M.; Mueller-Bunz, H.; 
Weber, H.; Tacke, M. J. Organomet. Chem. 2010, 695, 1175–1181. 
166. Gleeson, B.; Deally, A.; Müller-Bunz, H.; Patil, S.; Tacke, M. Aust. J. Chem. 2010, 63, 1514–1520. 
167. Leon, I.E.; Porro, V.; Di Virgilio, A.L.; Naso, L.G.; William, P.A.M.; Bollati-Fogolin, M.; Etcheverry, 
S.B. J Biol. Inorg. Chem. 2013, Manuscript accepted (ID: JBIC-13-06-00093.R2). 
168. Papaioannou, A.; Manos, M.; Karkabounas, S.; Liasko, R.; Evangelou, A.M.; Correia, I.; Kalfakakou, 
V.; Costa Pessoa, J.; Kabanos, T. J. Inorg. Biochem. 2004, 98, 959-968. 
169. Noblía, P.; Vieites, M.; Parajón-Costa, B.S.; Baran, E.J.; Cerecetto, H.; Draper, P.; Gonzalez, M.; 
Piro, O.E.; Castellano, E.E.; Azqueta, A.; Ceráin, A.L.; Monge-Vega, A.; Gambino, D. J. Inorg. Biochem. 
2005, 99, 443-451. 
170. Fu, Y.; Wang, Q.; Yang, X-G.; Yand, X-D.; Wang, K. J. Biol. Inorg. Chem. 2008, 13, 1001-1009. 
171. Mustafi, D.; Foxley, S.; Zamora, M.; Makinen, M.W.; Karczmar, G.S. Proc. Intl. Soc. Mag. Reson. 
Med. 2006, 14, 684. 
172. Barrio, D.A.; Williams, P.A.M.; Cortizo, A.M.; Etcheverry, S.B. J. Biol. Inorg. Chem. 2003, 8, 459–
468. 
173. Bishayee, A.; Roy, S.; Chatterjee, M. Oncol. Res. 1999, 11, 41–53. 
174. Molinuevo, M.S.; Barrio, D.A.; Cortizo, A.M.; Etcheverry, S.B. Cancer Chemother. Pharmacol. 2004, 
53, 163–172. 
175. Liasko, R.; Kabanos, T.A.; Karkabounas, S.; Malamas, M.; Tasiopoulos, A.J; Stefanou, D.; Collery, 
P., Evangelou, A. Anticancer Res. 1998, 18, 3609-3613. 
176. Maier, R.H.; Purser, S.M.; Nicholson, D.L.; Pories, W.J. In Vitro Cell Dev. Biol. Anim. 1997, 33, 218-
221. 
177. Choi, Y-J.; Lim, S-Y.; Woo, J-H.; Kim, Y-H., Kyu Kwon, Y.; Suh, S.; Lee, S-H.; Choi, W-Y.; Kim, J-G.; 
Lee, I-S.; Park, J-W.; Kyu Kwon, T. Biochem. Biophys. Res. Comm. 2003, 305, 176-185.  
178. D'Cruz, O.J.; Uckun, F.M.; Expert Opin. Investig. Drugs. 2002, 11, 1829-1836. 
179. Wozniak, K.; Blasiak, J. Arch Toxicol. 2004, 78, 7-15. 
180. Cruz, T.F.; Morgan, A.; Min, W. Mol. Biochem. 1995, 53, 161-166. 
181. Murthy, M.S.; Rao LN, Kuo LY, Toney JH, Marks TJ. Inorg Chim Acta 1988;152:117-124. 
182. Gambino, D. Coord. Chem. Rev. 2011, 255, 2193–2203. 
 
 
332 
                                                                                                                                            
183. Turner, T.L.; Nguyen, V.H.; McLaughlan, C.C.; Dymon, Z.; Dorsey, B.M.; Hooker, J.D.; Jones, M.A. 
J. Inorg. Biochem. 2012, 108, 96–104. 
184. Benítez, J.; Guggeri, L.; Tomaz, I.; Costa Pessoa, J.; Moreno; Lorenzo, J.; Aviles, F.X.; Garat, B.; 
Gambino, D. J. Inorg. Biochem. 2009, 103, 1386-1394. 
185. Benítez. J.; Guggeri, L.; Tomaz, I. Arrambide, G.; Navarro, M.; Costa Pessoa, J.; Garat, B.; 
Gambino, D.J. Inorg. Biochem. 2009, 103, 609–616. 
186. Maurya, M.R.; Khan, A.A.; Azam, A.; Ranjan, S.; Mondal, N.; Kumar, A.; Avecilla, F.; Costa Pessoa, 
J. Dalton Trans. 2010, 39, 1345-1360. 
187. Maurya, M.R.; Kumar, A.; Bhat, A.R.; Azam, A.; Bader, C.; Rehder, D. Inorg. Chem. 2006, 45, 1260- 
1269. 
188. Maurya, M.R.; Khan, A.A.; Irfan, I.; Azam, A.; Kumar, A.; Costa Pessoa, J. Eur. J. Inorg. Chem. 
2009, 5377-5390. 
189. Ghosh, P.; D'Cruz, O.J.; DuMez, D.D.; Peitersen, J.; Uckun, F.M. J. Inorg. Biochem. 1999, 75, 135-
143. 
190. D'Cruz, O.J.; Waurzyniak, B.; Uckun, F.M.. Toxicol. 2002, 170, 31-43. 
191. Shigeta, S.; Mori, S.; Yamase, T.; Yamamoto, N.; Yamamoto, N. Biomed. Pharmacother. 2006, 60, 
211-219. 
192. D'Cruz, O.J.; Dong, Y.H.; Uckun, F.M. Biochem. Biophys. Res. Commun. 2003, 302, 253-264. 
193. Wong, S.Y.; Sun, R.W.Y.; Chung, N.P.Y.; Lin, C.L.; Che, C.M. Chem. Commun. 2005, 3544-3546. 
194. Wai-Yin Sun, R.; Ma, D-L.; Lai-Ming Wong, E.; Che, C-M. Dalton Trans. 2007, 4884–4892. 
195. Ross, A.; Soares, D.C.; Covelli, D.; Pannecouque, C.; Budd, L.; Collins, A.; Robertson, N.; Parsons, 
S.; De Clercq, E.; Kennepohl, P.; Sadler,P.J. Inorg. Chem. 2010, 49, 1122–1132. 
196. Maiti, A.; Ghosh, S. J. Inorg. Biochem. 1989, 36, 131-139. 
197. David, S.; Barros, V.; Cruz, C.; Delgado, R. FEMS Microbiol. Lett. 2005, 251, 119-124. 
198. da S. Maia, P.I.; Pavan, F.R.; Leite, C.Q.F.; Lemos, S.S.; de Sousa, G.F.; Batista, A.A.; Nascimento, 
O.R.; Ellena, J.; Castellano, E.E.; Niquet, E.; Deflon, V.M. Polyhedron, 2009, 28, 398–406.  
199. Morgan, G.T.; Moss, H.W. J. Chem Soc. 1914, 103, 78-90. 
200. Dodge, R.P.; Templeton, D.H.; Zalkin, A. J. Chem Phys. 1961, 35, 55-67. 
201. Guyard A. Bull. Soc. Chim. 1876, 25, 350. 
202. Taguchi, H.; Isobe, K.; Nakamura, Y.; Kawaguchi, S. Chem. Lett. 1975, 757-760. 
203. Selbin, J.; Manning, H.R.; Cessac, G.J. Inorg. Nucl. Chem. 1963, 25, 1253-1258. 
204. Atherton, N.M.; Gibbon, P.J.; Shohoji, M.C.B. J. Chem. Soc., Dalton Trans. 1982, 2289-2290. 
205. Nakamoto, K.; Morimoto, Y.; Martell, A.E. J Amer. Chem. Soc. 1961, 83, 4533-4536. 
206. Vlčková, B.; Strauch, B.; Horák, M. Collect. Czech. Chem. Comm, 1987, 52, 686-695. 
207. Selbin, J. Coord. Chem. Rev. 1966, 1, 293-314. 
208. Baran, E.J. J. Coord. Chem. 2001, 54, 215-238 
209. Santos Claro, P.C.; González-Baró, A.C.; Parajón-Costa, B.S.; Baran, E.J. Z. Anorg. Allg. Chem. 
2005, 631, 1903–1908. 
210. Kaneda, K.; Jitsukawa, K.; Itoh, T.; Teranishi, S. J. Org. Chem. 1980, 45, 3004-3009. 
211. Conte, V.; Di Furia, F.; Moro. S. J. Phys. Org. Chem. 1996, 9, 329-336. 
212. Hirao, T. Chem. Rev. 1997, 97, 2707-2724. 
213. Wender, P. A.; Rice, K. D.; Schnute, M. E. J. Am. Chem. Soc. 1997, 119, 7897-7898. 
214. Jiang, F.; Anderson, O. P.; Miller, S. M.; Chen, J. Mahroof-Tahir, M.; Crans, D.C. Inorg. Chem. 1998, 
37, 5439-5451. 
215. Rio, D.; Galindo, A.; Tejedo, J.; Bedoy, F.J.; Ienco, A.; Mealli, C. Inorg.Chem. Comm. 2000, 3, 32–
34. 
216. Maurya, M.R. Coord. Chem. Rev. 2003, 237, 163-181. 
217. Jang, Y.J.; Lee, U.; Bon Kweon Koo, B.K. Bull. Korean Chem. Soc. 2005, 26, 72-76. 
218. Sarkar, A.; Pal, S. Inorg. Chim. Acta 2008, 361, 2296–2304. 
219. Itoh, T.; Jitsukawa, K.; Kaneda, K.; Terashini, S. J. Am. Chem. Soc. 1979, 101, 159–169. 
220. Csanyi, L.J.; Jaky, K.; Galbacs, G. J. Mol. Catal. 2002, 179, 65–72. 
221. Nawi, M.A.; Riechel, T.L. Inorg. Chem. 1981, 20, 1974-1978. 
222. Mustafi, D.; Makinen. M.W. Inorg. Chem. 2005, 44, 5580-5590. 
223. Garribba, E.; Micera, G.; Sanna, D. Inorg. Chim. Acta 2006, 359, 4470-4476. 
 
 
333 
                                                                                                                                            
224. Wisley, J.; Michael, K.M.; Philip, J.S. Endocrin. 2006, 147, 493-501. 
225. Makinen, M.W.; Brady, M.J. J. Biol. Chem., 2002, 277, 12215–12220. 
226. Nawi, M.A.; Riechel, T.L. Inorg. Chem. 1982, 21, 2268-2271. 
227. Taguchi, H.; Isobe, K.; Nakamura, Y.; Kawaguchi, S. Bull. Chem. Soc. Jpn. 1978, 51, 2030-2035. 
228. Doadrio, A.; Carro, A.G. An. R. Soc. Esp. Fis. Quim. 1964, 60, 495-504. 
229. Grybos, R.; Samotus, A.; Popova, N.; Bogolitsyn, K. Transit. Met. Chem. 1997, 22, 61-64. 
230. Mahroof-Tahir, M.; Brezina, D.; Fatima, N.; Choudhary, M.; Atta-ur-Rahman J. Inorg. Biochem. 2005, 
99, 589-599. 
231. Crans, D.C.; Khan, A.R.; Mahroof-Tahir, M.; Mondal, S.; Miller, S.M.; Cour, A.; Anderson, O.P.; 
Jakusch, T.; Kiss T. J. Chem. Soc. Dalton Trans. 2001, 3337–3345. 
232. Correia, I.; Mota, A.; Hallett, J.P.; Kuznetsov, M.L. Physical Chemistry Chemical Physics 2011, 13, 
15094–15102. 
233. Ziegler, A.J.; Florian, J.; Ballicora, M.A; Herlinger, A.W. J. Enz. Inhib. Med. Chem. 2009, 24, 22–28. 
234. Holloway, C.E.; Melnik, M. Rev. Inorg. Chem. 1985, 7, 75-159. 
235. Linert, W.; Herlinger, E.; Margl, P.; Boca, R. J.Coord.Chem. 1993 28 1-16. 
236. Carlin, R.L.; Walker, F.A. J. Am. Chem. Soc. 1965, 87, 2128-2133. 
237. Isobe, K.; Nakamura, Y.; Kawaguchi, S. J. Inorg. Nucl. Chem. 1978, 40,607-–611. 
238. Cornman, C.R.; Kampf, J.; Lah, M.S.; Pecoraro, V.L. Inorg. Chem. 1992, 31, 2035-2043. 
239. Schmidt, H.; Bashirpoor, M.; Rehder, D. J. Chem. Soc., Dalton Trans. 1996, 3865-3870. 
240. Crans, D.C.; Keramidas, A.D.; Amin, S.S.; Anderson, O.P.; Miller, S.M. J. Chem. Soc., Dalton Trans. 
1997, 2799-2812. 
241. Kuriakose M.; Kurup P. M.R.; Suresh, E. Polyhedron 2007, 26, 2713–2718. 
242. Barnum, D.W. J. Inorg. Nucl. Chem. 1961, 21, 221-237. 
243. Selbin, J.; Ortolano, T.R. J. Inorg. Nucl.Chem. 1964, 26, 37-40. 
244. Ballhausen, C.J; Gray, J.B. Inorg. Chem. 1962, 1, 111-122. 
245. Barton J.K. In Bioinorganic Chemistry. Bertini, I., Eds.; Sausalito, California: University Science 
Books, 1994; pp. 455-503. 
246. Jiang, Q.; Xiao, N.; Shi, P.; Zhu, Y.; Guo, Z. Coord. Chem. Rev. 2007, 251, 1951–1972. 
247. Hegg, E.L.; Burstyn, J.N. Coord. Chem. Rev. 1998, 173, 133–165. 
248. Mancin, F.; Scrimin P.; Tecilla P.; Tonellato U. Chem. Commun. 2005, 2540-2548. 
249. Burrows, C.J.; Muller, J.G. Chem. Rev. 1998, 98, 1109-1151. 
250. Armitage, B. Chem. Rev. 1998, 98, 1171-1200. 
251. Sigman, D.S.; Bruice, T.W.; Mazumder, A.; Sutton, C. Acc. Chem. Res. 1993, 26, 98-104. 
252. Erkkila, K.E., Odom, D.T. Barton J.K. Chem. Rev. 1999, 99, 2777-2795. 
253. Cowan, J. A. Curr. Opin. in Chem. Biol. 2001, 5, 634–642. 
254. Sigman, D.S.; Mazumder, A.; Perrin, D.M. Chem. Rev. 1993, 93, 2295-2316. 
255. Liu, C.; Wang, M.; Zhang, T.; Sun, H. Coord. Chem. Rev. 2004, 248, 147–168. 
256. Morrow, J.R.; Iranzo, O. Curr. Opin. Chem. Biol. 2004, 8, 192–200. 
257. Sigman, D.S. Biochem. 1990, 29, 9097-9105. 
258. Dupureur, C.M. Curr. Opin.  Chem. Biol. 2008, 12, 250–255. 
259. Livieri, M.; Mancin, F.; Saielli, G.; Chin, J.; Tonellato, U. Chem. Eur. J. 2007, 13, 2246-2256. 
260. Liu, C.; Wang, L. Dalton Trans. 2009, 227-239. 
261. Zhang, J.J; Shao, Y.; Wei, L.; Li, Y.; Sheng, X.; Liu, F.; Lu, G.Y. Sci. China Ser. B-Chem. 2009, 52, 
402-414 
262. Crespy, D.; Landfester, K.; Schubert, U.S.; Schiller, A. Chem. Commun. 2010, 46, 6651-6662. 
263. Gyurcsik, B.; Czene, A. Future Med. Chem. 2011, 3, 1935-1966. 
264. Mancin, F.; Scrimina, P.; Tecilla, P. Chem. Commun. 2012, 48, 5545–5559. 
265. Kuwahara, J.; Suzuki, T.; Sugiura, Y. Biochem. Biophys. Res.Commun. 1985, 129, 368-374. 
266. Sakurai, H.; Nakai, M.; Miki, T.; Tsuchiya, K.; Takada, J.; Matsushita, R. Biochem. Biophys. Res. 
Commun. 1992, 189, 1090-1095. 
267. Sakurai, H.; Tamura, H.; Okatani, K. Biochem. Biophys. Res.Commun. 1995, 206, 133-137. 
268. Shi, X.; Jiang, H.; Mao, Y.; Ye, J.; Saffiotti, U. Toxicol. 1996, 106, 27-38. 
269. Hiort, C.; Goodisman, J.; Dabrowiak, J.C. Mol. Cell. Biol. 1995,153, 31-36. 
270. Sam, M.; Hwang, J.H.; Chanfreau, G.; Abu-Omar, M.M. Inorg.Chem. 2004, 43, 8447-8455. 
 
 
334 
                                                                                                                                            
271. Kwong, D.W.J.; Chan, O.Y.; Shek, L.K.; Wong, R.N.S. J. Inorg. Biochem. 2005, 99, 2062-2073. 
272. Kwong, D.W.J.; Chan, O.Y.; Wong, R.N.S.; Musser, S.M.; Vaca, L.; Chan, S. I. Inorg. Chem. 1997, 
36, 1276-1277. 
273. Hiort, C.; Goodisman, J.; Dabrowiak, J.C. Biochem. 1996, 35, 12354-12362. 
274. Chen, C.-T.; Lin, J.-S.; Kuo, J.-H.; Weng, S.-S.; Cuo, T.-S.; Lin, Y.-W.; Cheng, C.-C.; Huang, Y.-C.; 
Yu, J.-K.; Chou, P.-T. Org. Lett. 2004, 6, 4471-4474. 
275. Heater, S.J.; Carrano, M.W.; Rains, D.; Walter, R.B.; Ji, D.; Yan, Q.; Czernuszewicz, R.S.;. Carrano, 
C.J. Inorg. Chem. 2000, 39, 3881-3889. 
276. Stemmler, A.J.; Burrows, C.J. J. Biol. Inorg. Chem. 2001, 6, 100-106. 
277. Verquin, G.; Fontaine, G.; Bria, M.; Zhilinskaya, E.; Abi-Aad, E.; Aboukais, A.; Baldeyrou, B.; Bailly, 
C.; Bernier, J.-L. J. Biol. Inorg. Chem. 2004, 9, 345-353. 
278. Sasmal, P.K; Saha, S.; Majumdar, R.; Dighe, R.R.; Chakravarty, A.R. Chem. Comm. 2009, 1703-
1705. 
279. Sasmal, P.K; Saha, S.; Majumdar, De, S.; Dighe, R.R.; Chakravarty, A.R. Dalton Trans. 2010, 39, 
2147–2158. 
280. Sasmal, P.K; Saha, S.; Majumdar, R.; Dighe, R.R.; Chakravarty, A.R. Inorg. Chem. 2010, 49, 849-
859. 
281. Prasad, P.; Sasmal, P.K; Majumdar, R.; Dighe, R.R.; Chakravarty, A.R. Inorg. Chim. Acta 2010, 363, 
2743–2751. 
282. Prasad, P.; Sasmal, P.K.; Khan, I.; Kondaiah, P.; Chakravarty, A.R. Inorg. Chim. Acta 2011, 372, 79-
87. 
283. Leelavathy, L.; Anbu, S.; Kandaswamy, M.; Karthikeyan, N.; Mohan, N., Polyhedron 2009, 28, 903-
910. 
284. Du, Y.F.; Lu, J.Z.; Guo, H.W.; Ping, J.J.; Chen, C.F.; Pan, J.M. Trans. Met. Chem. 2010, 35, 859–
864. 
285. Prasad, K.S.; Kumar, L.S.; Shekar, S.C.; Prasad, M.; Revanasiddappa, H.D. Chem. Scien. J. 2011, 
12, 1-10. 
286. Raman, N.; Jeyamurugan, R.; Subbulakshmi, M.; Boominathan, R.; Yuvarajan C.R. Chem. Papers 
2010, 64, 318-328.  
287. Patel, M.N.; Patel, S.H.; Chhasatia, M.R.; Desai, C.R. Nucleos. Nucleot. Nucl. Acids 2010, 29, 200-
215. 
288. Islam, M.N.; Kumbhar, A.A.; Kumbhar, A.S.; Zeller, M.; Butcher, R.J.; Dusane, M.B.; Joshi, B.N. 
Inorg. Chem. 2010, 49, 8237-8246. 
289. Steens, N.; Ramadan, A.M.; Parac-Vogt, T.N. Chem. Commun. 2009, 965-967. 
290. Steens, N.; Ramadan, A.M.; Absillis, G.; Parac-Vogt, T.N. Dalton Trans. 2010, 39, 585-592. 
291. Ho, P.H., Breynaert, E.; Kirschhock, C.E.A.; Parac-Vogt, T.N. Dalton Trans. 2011, 40, 295-300. 
292. Ho, P.H.; Mihaylov, T.; Pierloot, K.; Parac-Vogt, T.N. Inorg. Chem. 2012, 51, 8848-8859. 
293. Mihaylov, T.; Parac-Vogt, T.N.; Pierloot, K. Inorg. Chem. 2012, 51, 9619-9628. 
294. Ren, Y.-G.; Kirsebom, L.A.; Virtanen, A. J. Biol. Chem. 2004, 279, 48702-48706. 
295. Robertazzi, A.; Platts, J. A. J Biol. Inorg. Chem. 2005, 10, 854–866. 
296. Casellato, U.; Tamburini, S.; Tomasin P.; Vigato, P.A. Inorg. Chim. Acta 2004, 357, 4191-4207. 
297. Takenaka, S.; Ihara, T.; Takegi, M. J. Mol. Recognit. 1990, 3,156–162. 
298. Williams, N.H.; Takasaki, B.; Wall M.; Chin, J. Acc. Chem. Res. 1999, 32, 485–493. 
299. Komiyama, M.; Takeda, N.; Shigekawa, H. Chem. Commun. 1999, 1443–1451.  
300. Niittymaki, T.; Lonnberg, H. Org. Biomol. Chem. 2006, 4, 15–25. 
301. Mancin, F.; Tecilla, P. New J. Chem. 2007, 31, 800–817. 
302. Roigk, A.; Hettich, R.; Schneider, H. Inorg. Chem. 1998, 37, 751-756. 
303. Takasaki, B.K.; Chin, J. J. Am. Chem. Soc., 1994, 116, 1121–1122. 
304. Morrow, J. R.; Buttrey, L.A.; Shelton, V. M.; Berback, K.A. J. Am. Chem. Soc. 1992, 114, 1903-1905. 
305. Matsumoto, Y.; Komiyama, M. Nucleic Acids Symp. Ser. 1992, 27, 33-34. 
306. Komiyama, M. J. Biochem. 1995, 118, 665-670. 
307. Jurek, P.E.; Jurek, A.M.; Martell, A.E. Inorg. Chem. 2000, 39, 1016–1020. 
308. Komiyama, M.; Shiiba, T.; Kodama, T.; Takeda, N.; Sumaoka J.; Yashiro, M. Chem. Lett. 1994, 23, 
1025–1028. 
 
 
335 
                                                                                                                                            
309. Sumaoka, J.; Igawa, T.; Furuki, K.; Komiyama, M. Chem. Lett. 2000, 29, 56–57. 
310. Sigman, D.S. Graham, D.R.; D‟Aurora, V.; Stern, A.M. J. Biolog. Chem. 1979, 254, 12269-12272. 
311. Pope, L.M.; Reich, K.A.; Graham, D.R. Sigman, D.S. J. Biolog. Chem. 1982, 257, 12121-12128. 
312. Sigman, D.S. Acc. Chem. Res. 1986, 19, 180-186. 
313. Chen. C.B. Sigman, D.S. J. Am. Chem. Soc. 1988, 110, 6570-6572. 
314. Oyoshi, T.; Sugiyama, H. J. Am. Chem. Soc. 2000, 122, 6313-6314. 
315. Lu, L-P.; Zhu, M-L.; Yang, P. J. Inorg. Biochem. 2003, 95, 31–36. 
316. Zhang, S.; Zhu, Y.; Tu, C.; Wei, H, Yang, Z.; Lin, L.; Ding, J.; Zhang, J.; Guo, Z. J. Inorg. Biochem. 
2004, 98, 2099–2106. 
317. Pitie, M.; Croisy, A.; Carrez, D.; Boldron, C.; Meunier, B. ChemBioChem. 2005, 6, 686–691. 
318. Thomas, A.M.; Nethaji, M.; Chakravarty, A.R. J. Inorg. Biochem. 2004, 98, 1087–1094. 
319. Hirohama, T.; Kuranuki, Y.; Ebina, E.; Sugizaki, T.; Arii, H.; Chikira, M.; Selvi, P.T.; Palaniandavar, 
M. J. Inorg. Biochem. 2005, 99, 1205–1219. 
320. Reddy, P.R.; Shilpa, A. Polyhedron 2011, 30, 565–572. 
321. Chen, C-H.B.; Milne, L.; Landgraf, R.; Perrin, D.M.; Sigman, D.S. ChemBioChem 2001, 2, 735-740. 
322. Ramakrishnan, S.; Palaniandavar, M. J. Chem. Sci. 2005, 117, 179–186. 
323. Patra, A.K.; Bhowmick, T.; Ramakumar, S.; Nethajia, M.; Chakravarty, A.R. Dalton Trans. 2008, 
6966-6976. 
324. Zuber, G.; Quada, J.C.; Hecht, S.M. J. Am. Chem. Soc. 1998, 120, 9368-9369. 
325. Dhar, S.; Nethaji M.; Chakravarty, A.R. Dalton Trans. 2004, 4180-4184. 
326. Ward, B.; Skorobogaty, A.; Dabrowiak, J.C. Biochem. 1986, 25, 6875-6883. 
327. Le Doan, T.; Perrouault, L.; Helene, C.; Chassignol, M.; Thuong, N.T. Biochem. 1986, 25, 6136-
6739. 
328. Groves, J.T.; Farrell, T P. J. Am. Chem. Soc. 1989, 111, 4998-5000. 
329. Yoshino, M.; Haneda, M.; Naruse, M.; Murakami, K. Molec. Genet. Metab. 1999, 68, 468-472. 
330. Macías, B.; Villa, M.V.; Sanz, F.; Borras, J.; Gonzalez-Alvarez, M.; Alzuet, G. J. Inorg. Biochem. 
2005, 99, 1441-1448. 
331. Ueda, J.; Takai, M.; Shimazu, Y.; Ozawa, T. Arch. Biochem. Biophys. 1998, 357, 231-239. 
332. Reddy, P.A.N.; Santra, B.K.; Nethaji, M.; Chakravarty, A.R. J. Inorg. Biochem. 2004, 98, 377-386. 
333. Zan, J.; Yan, H.; Guo, Z.-f.; Lu, Z.-L. Inorg. Chem. Comm. 2010, 1054-1056. 
334. McMillin, D.R.; McNett, K.M. 1998, 98, 1201-1219. 
335. Patra, A.K.; Dhar, S.; Nethaji, M.; Chakravarty, A.R. Dalton Trans. 2005, 896-902 
336. He, J.; Hu, P.; Wang, Y.-J.; Tong, M.-L.; Sun, H.; Mao, Z.-W.; Jia, L-N. Dalton Trans. 2008, 3207-
3214. 
337. Kirin, S.I.; Happel, K.M.; Hrubanova, S.; Weyhermüller, T.; Klein, C.; Metzler-Nolte, N. Dalton Trans. 
2004, 1201–1207. 
338. Das, S.; Madhavaiah, C.; Verma, S.; Bharadwaj, P.K. Inorg. Chim. Acta 2005, 358, 3236-3240. 
339. Li, L.; Karlin, K.D.; Rokita, S.E. J. Amer. Chem. Soc. 2005, 127, 520-521. 
340. Kong, D.; Reibenspies, J.; Mao, J.; Clearfield, A.; Martell, A. E. Inorg. Chim. Acta 2003, 342, 158-
170. 
341. Macías, A.; Villa, M.V.; Salgado, M.; Borras, J.; Gonzalez-Alvarez, M.; Sanz, F. Inorg. Chim. Acta 
2006, 359, 1465-1472. 
342. Jimenez-Garrido, N.; Perello, L.; Ortiz, R.; Alzuet, G.; Gonzalez-Alvarez, M.; Canton, E.; Liu-
Gonzalez, M.; Garcıa-Granda, L.; Perez-Priede, M. J. Inorg. Biochem. 2005, 99, 677–689. 
343. Chetana, P.R; Rao, R.; Roy, M.; Patra, A.K. Inorg. Chim. Acta 2009, 362, 4692-4698. 
344. Krishnamoorthy, P.; Sathyadevi, P.; Cowley, A.H.; Butorac, R.R.; Dharmaraj, N. Europ. J. of Med. 
Chem. 2011, 46, 3376-3387. 
345. Li, D.-D.; Tian, J.-L.; Gu, W.; Liu, X.; Yan, S-P.; Eur. J. Inorg. Chem. 2009, 5036-5045. 
346. Raman, N.; Selvan, A. J. Coord. Chem. 2011, 64, 534-553. 
347. Modak, A.S.; Gard, J.K.; Merriman, M.C.; Winkeler, K.A.; Bashkin, J.K.; Stern, M.K. J. Am. Chem. 
Soc. 1991, 113, 283-291. 
348. Burstyn, J.N.; Kim A.D. Inorg. Chem. 1993, 32, 3585-3586. 
349. Deal, K.A.; Burstyn, J.N. Inorg. Chem. 1996, 35, 2792–2798. 
350. Hegg E.L.; Burstyn, J.N. Inorg. Chem. 1996, 35, 7474-7481. 
 
 
336 
                                                                                                                                            
351. Deck, K.M.; Tseng, T.A.; Burstyn, J.N. Inorg. Chem. 2002, 41, 669–677. 
352. Reddy, P.R.; Shilpa, A. Indian J. Chem. 2010, 49A, 1003-1015. 
353. Sissi, C.; Mancin, F.; Gatos, M.; Palumbo, M.; Tecilla, P.; Tonellato, U. Inorg, Chem. 2005, 44, 2310-
2317. 
354. Anbu, S.; Kandaswamy, M.; Kamalraj, S.; Muthumarry, J.; Varghesec, B. Dalton Trans. 2011, 40, 
7310–7318. 
355. Subat, M.; Woinaroschy, K.; Gerstl, C.; Sarkar,B.; Kaim, W.; Konig, B. Inorg. Chem. 2008, 47, 4661-
4668. 
356. Desbouis, D.; Troitsky, I.P.; Belousoff, M.J; Spiccia, L., Graham, B. Coord. Chem. Rev. 2012, 256, 
897–937. 
357. Roy, M.; Dhar, S.; Maity, B.; Chakravarty, A.R. Inorg. Chim. Acta 2011, 375, 173–180. 
358. Zhang, C.X.; Lippard, S.J. Curr. Opin. Chem. Biol. 2003, 7, 481-489. 
359. Malinge, J-M.; Giraud-Panis, M-J.; Leng, M. J. Inorg. Biochem. 1999, 77, 23-29. 
360. Jamieson, E.R.; Lippard, S.J. Chem. Rev. 1999, 99, 2467-2498. 
361. Mounir, M.; Lorenzo, J.; Ferrer, M.; Prieto, M.J.;Rossell, O.; Aviles, F.; Moreno, V. J. Inorg. Biochem. 
2007, 101, 660–666. 
362. Lippard, S.J. In Bioinorganic Chemistry. Bertini, I., Gray, H.B., Lippard, S.J., Valentine, J.S., Eds.; 
Mill Valley: University Science Books, 1994; Chapter 9; pp 505-583. 
363. Vashisht Gopal, Y.N.; Jayaraju, D.; Kondapi, A.K. Biochem. 1999, 38, 4382-4388. 
364. Neyhart, G.A.; Grover, N.; Smith, S.R.; Kalsbeck, W.K.; Fairley, T.A.; Cory, M.; Thorp, H.H. J. Amer. 
Chem. Soc. 1993, 115, 4423-4428. 
365. Janaratne, T.K.; Yadav, A.; Ongeri, F.; MacDonnell, F.M. Inorg. Chem. 2007, 46, 3420-3422. 
366. Ghosh, A.; Mandoli, A.; Kumar, K.; Singh Yadav, N.; Ghosh, T. Jha, B.; Thomas, J.A.; Das, A. Dalton 
Trans. 2009, 9312–9321. 
367. Bicek, A.; Turel, I.; Kanduser, M.; Miklavcic, D. Bioelectrochem. 2007, 71, 113–117. 
368. Arounaguiri, S.; Easwaramoorthy, D.; Ashokkumar, A.; Dattagupta, A.; Maiya, B.G. Proc. Indian 
Acad. Sci. (Chem. Sci.) 2000, 112, 1–17. 
369. Tan, C.; Liu, J.; Chen L.; Shi, S.; Ji, L. J. Inorg. Biochem. 2008, 1644-1653. 
370 Otero, L.; Smircich, P.; Vieites, M.; Ciganda, M.; Severino, P.C.; Terenzi, H.; Cerecetto, H.; Gambino, 
D.; Garat, B. J. Inorg. Chem. 2007, 101, 74-79. 
371. Deshpande, M.S.; Kumbhar, A.A.; Khumbar, A.S. Inorg. Chem. 2007, 46, 5450-5452. 
372. Yan, Y.K.; Melchart, M.; Habtemariam, A.; Salder, P.J. Chem. Commun. 2005, 2764-4776. 
373. Vock, C.A.; Ang, W.H.; Scolaro, C.; Phillips, A.D.; Lagopoulos, L.; Juillerat-Jeanneret, L.; Sava, G.; 
Scopelliti, R.; Dyson, P.J. J. Med.Chem. 2007, 50, 2166-2175. 
374. Burger, R.M. Chem. Rev. 1998, 98, 1153-1169. 
375. Claussen, C.A.; Long, E.C. Chem. Rev. 1999, 99, 2797-2816. 
376. Hecht, S.M. J. Nat. Prod. 2000, 63, 158-168. 
377. Pogozelski, W.J.; McNeese, T.J.; Tullius, T.D. J. Am. Chem. Soc. 1995, 117, 6428-6433. 
378. Hertzberg, R.P.; Dervan, P.B. Biochem. 1984, 23, 3934-3945. 
379. Chen, X.; Wang, J; Sun, S.; Fan, J; Wu, S.; Liu, J.; Ma, S.; Zhang, L.; Peng, X.; Bioorg. Medic. 
Chem. Lett. 2008, 18, 109–113. 
380. Roy, M.; Santhanagopal, R.; Chakravarty, A.R. Dalton Trans. 2009, 1024–1033. 
381. Roy, M.; Bhowmick, T.; Santhanagopal, R.; Ramakumarb, S.; Chakravarty, A.R. Dalton Trans. 2009, 
4671–4682. 
382. Kowalski, K.; Suwaki, N.; Zakrzewski, J.; White, A.J.P.; Long, N.J.; Mann, D.J. Dalton Trans. 2007, 
743–748. 
383. Proteggente, A.R.; England, T.G.; Rice-Evans, C.A.; Halliwell, B. Biochem. Biophys. Res. Comm. 
2001, 288, 245-251. 
384. Flemming, J.; Arnhold, J. Eur Biophys J. 2007, 36, 377–384. 
385. Liu, C.; Yu, S.; Li, D.; Liao, Z.; Sun, X.; Xu, H. Inorg. Chem. 2002, 41, 913-922. 
386. Neves, A.; Terenzi, H.; Horner, R.; Horn Jr., A.; Szpoganicz, B.; Sugai, J. Inorg. Chem. Comm. 2001, 
4, 388-391. 
387. Livieri, M.; Mancin, F.; Tonellato, U; Chin, J. Chem. Commun. 2004, 2862–2863. 
 
 
337 
                                                                                                                                            
388. Boseggia, E.; Gatos, M.; Lucatello, L.; Mancin, F.; Moro, S.; Palumbo, M.; Sissi, C.; Tecilla, P.; 
Tonellato, U.; Zagotto, G. J. Am. Chem. Soc. 2004, 126, 4543-4549. 
389. Penkova, L.V.; Macia, A.;  Rybak-Akimova, E.V.; Haukka, M.; Pavlenko, V.A.; Iskenderov, T.S.; 
Kozlowski, H.; Meyer, F.; Fritsky, I.O. Inorg. Chem. 2009, 48, 6960–6971. 
390. Qian, J; Wang, L; Gu, W; Liu, X; Tian, J.; Yan, S. Dalton Trans., 2011, 40, 5617-5624. 
391. Jun, T.; Bochua, W.; Liancai, Z.; Bioorgan. Medic. Chem. Lett. 2007, 17, 1197–1199. 
392. Qian, J.; Ma X.-F.; Xu, H.-Z.; Tian, J.-L.; Shang, J.; Zhang, Y.; Yan, S.-P. Eur. J. Inorg. Chem. 2010, 
3109–3116. 
393. Bernadou, J.; Pratviel G.E; Bennis, F.; Girardet, M.; Meunier, B. Biochem. 1989, 28, 7268-7275. 
394. Mandal, S.S.; Kumar, K.V.; Varshney, U.; Bhattacharya, S. J. Inorg. Biochem. 2006, 63, 265-272. 
395. Oikawa, S.; Hiraku, Y.; Fujiwara, T.; Saito, I.; Kawanishi, S. Chem. Res. Toxicol. 2002, 15, 1017-
1022. 
396. Anbu, S.; Shanmugaraju, S.; Kandaswamy, M. RSC Adv. 2012, 2, 5349–5357. 
397. Qian, J.; Ma, X.; Tian, J.; Gu, W.; Shang, J.; Liu, X.; Yan, S. J. Inorg. Biochem. 2010, 104, 993–999. 
398. Levina, A.; Lay, P.A.; Dixon, N.E. Inorg. Chem. 2000, 39, 385-395.  
399. Vijayalakshmi, R.; Kanthimathi, M.; Subramanian, V.; Unni Nair, B. Biochem. Biophys. Comm. 2000, 
271, 731-734. 
400. Kawanishi, S.; Inoue, S.; Sano, S. J. Biol. Chem. 1986, 261, 5952-5958. 
401. Absillis, G.; Van Deun, R; Parac-Vogt, T.N. Inorg. Chem. 2011, 50, 11552-11560. 
402. Ho, P.H.; Stroobants, K.; Parac-Vogt, T.N. Inorg. Chem. 2011, 50, 12025-12033. 
403. Uchida, K.; Pyle, A.M.; Morii, T.; Barton, J.K., Nucleic Acids Res. 1989, 17, 10259-10279. 
404. Gómez-Tagle, P. Yatsimirsky, A.K. J. Chem. Soc. Dalton Trans. 2001, 2663–2670. 
405. Camargo, M.A.; Neves, A.; Szpoganicz, B.; Bortoluzzi, A.J.; Fischer, F.L.; Terenzi, H.; Castellano, 
E.E. Inorg. Chem. 2010, 49, 3057–3063. 
406. Gravert, D.J.; Griffin, J.H. Inorg. Chem. 1996, 35, 4837-4847. 
407. Burrows, C.J.; Rokita, S.E. Acc. Chem. Res. 1994, 27, 295-301. 
408. Routier, S.; Bernier, J.-L.; Waring, M.J. Colson, P.; Houssier, C.; Baily, C. J. Org. Chem.1996, 61, 
2326-2331. 
409. Lamour, E.; Routier, S.; Bernier, J.-L.; Catteau, J.-P.;Baily, C.; Vezin, H. J. Amer. Chem. Soc. 1999, 
121, 1862-1869. 
410. Mandal, S.S.; Varshney, U.; Bhattacharya, S. Bioconjugate Chem. 1997, 8, 798-812. 
411. Cheng, C-C.; Lu, Y.-L. J. Chinese Chem. Soc.1998, 45, 611-617. 
412. Routier, S.; Vezin, H.; Bernier, J.-L.; Catteau, J.-P.;Baily, C. Nucleic Acids Res.1999, 27, 4160-4166 
413. Clever, G.H.; Sçltl, Y.; Burks, H.; Spahl, W.; Carell, T. Chem. Europ. J. 2006, 12, 8708-8718  
414. Rodger. A.; Norden, B. In Circular Dichroism and Linear Dichroism. Oxford University Press: Oxford; 
1997. 
415. Pingoud, A.; Alves J.; Geiger, R. In Enzymes in Molecular Biology. Method in Molecular Biology. 
Burrell, M.M., Ed.; Totowa, NJ: Humana Press Inc.; 1993; Vol, 16, Chapter 8, pp 107-200. 
416. Mancin, F.; Teclilla, P. In Metal Complex-DNA Interactions, Hadjiliadis, N.; Sletten E., Eds.; UK: 
Willey, Blackwell Publishing Ltd.; 2009; pp 369-394. 
417. Radzicka, A.; Wolfenden, R.; Science 1995, 267, 90-93. 
418. Hendry, P.; Sargeson, A.M. Prog. Inorg. Chem. 1990, 38, 201-258. 
419. Cowan, J.A. Chem. Rev. 1998, 98, 1067-1087. 
420. Blasko, A.; Bruice, T.C. Acc. Chem. Res. 1999, 32, 475-484. 
421. Hirt, H.; Apel, K. Annu. Rev. Plant. Biol. 2004, 55, 373-399. 
422. Halliwell, B.; Gutteridge, J.M.C. Molec. Aspects. Med. 1985, 8, 89-193. 
423. Halliwell, B. Mutation Res. 1999, 443, 37–52. 
424. Valko, M.; Leibfritz, D.; Moncola, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. The Intern.J. Biochem. Cell 
Biol. 2007, 39, 44–84. 
425. Wiseman, H.; Halliwell, B. Biochem. J. 1996, 313, 17-29. 
426. Halliwell, B. Plant Physiol. 2006, 141, 312-322. 
427. Valko, M.; Rhodes, C.J.; Moncola, J.; Izakovic, M.; Mazur. M. Chemico-Biolog. Interac. 2006, 160, 1-
40. 
428. Halliwell, B. Drugs Aging 2001, 18, 685-716. 
 
 
338 
                                                                                                                                            
429. Kuznetsova, A.A.; Knorre, D.G.; Fedorova, O.S. Russian Chem. Rev. 2009, 78, 659-678. 
430. West, J.D.; Marnett, L.J. Chem. Res. Toxicol. 2006, 19, 173-194. 
431. Valko, M.; Morris, H.; Cronin, M.T.D. Curr. Medic. Chem. 2005, 12, 1161-1208. 
432. Halliwell, B.; Gutteridge, J. M. C. Meth.Enzymol. 1990, 186, 1-85. 
433. Freinbichler, W.; Colivicchi, M.A.; Stefanini, C.; Bianchi, L.; Ballini, C.; Misini, B.; Weinberger, P.; 
Linert, W.; Vareslija, D.; Tipton, K.F.; Corte, L.D. Cell. Mol. Life Sci. 2011, 68, 2067–2079. 
434. Rehmana, A.; Nourooz-Zadehb, J.; Moëllerc, W.; Tritschlerc, H.; Pereirad, P.; Halliwell, B. FEBS 
Lett. 1999, 448, 120-122. 
435. Floyd, R.A. Carcinogenesis 1990, 11, 447–1450. 
436. Whiteman, M.; Hong, H.S.; Jenner, A.; Halliwell, B. Biochem. Biophys. Res. Commun. 2002, 296, 
883-889. 
437. Haber, F.; Weiss, J. Proc. R. Soc. Lond. A 1934, 147, 332-351. 
438. Fenton, H.J.H. J. Chem. Soc. Trans. 1894, 65, 899-910. 
439. Sawyer, D.T.; Valentine, J.S. Acc. Chem .Res. 1981, 14, 393-400. 
440. Bielsky, B.H.J.; Cabelli, D.E.; Ravindra, L.A. J. Phys. Chem. Ref. Data 1985, 14, 1041-1100. 
441. Fridovich, I. Arch. Biochem.Biophys. 1986, 247, 1-11. 
442. Hassan, H.M.; Fridovich, I. J. Biol. Chem. 1978, 253, 8143-8148. 
443. Kearns, D.R. Chem. Rev. 1971, 71, 395-427. 
444. Basu-Modak, S.; Tyrrell, R. M. Cancer Res. 1993, 53, 4505-4510. 
445. Schweitzer, C.; Schmidt, R. Chem. Rev. 2003, 103, 1685-1757. 
446. Youngman, R.J.; Elstner, E.F. FEBS Lett. 1981, 129, 265-268. 
447. Saran, M.; Michel, C.; Stettmaier, K.; Bors, W. Free Rad. Res. 2000, 33, 567-579. 
448. Gutteridge, J.M.C. Biochem. J. 1984, 224, 761-767. 
449. Reinke, L.A.; Rau, J.M.; MacCay, P.B. Free Rad. Biol. Med. 1994, 16, 485-492. 
450. Tadolini, B. Free. Rad. Biol. Med. 1987, 4, 149-160. 
451. Burkitt, M.J.; Gilbert, B.C. Free Rad. Res. Commun. 1991, 14, 107-123. 
452. Tero-Kubota, S.; Ikegami, Y.; Kurokawa, T.; Sasaki, R.; Sugioka, K.; Nakano, M. Biochem. Biophys. 
Res. Commun. 1982, 108, 1025-1031. 
453. Koppenol, W.H.; Butler, J. Adv. Free Rad. Biol. Med. 1985, 1, 91-131.   
454. Makrigiorgos, G.M.; Bump, E.; Huang, C.; Baranowska-Kortylewicz, J.; Kassis, A.I. Free Radic. Biol. 
Medicin. 1995, 18, 669-678. 
455. Gutteridge, J.M.C. Biochem. J. 1987, 243, 709-714. 
456. Inoue, S.; Kawanishi, S. Canc. Res. 1987, 47, 6522-6527. 
457. Evans, P.J.; Halliwell, B. Methods in Enzym. 1994, 233, 82-92. 
458. Fisher, A.E.O.; Maxwell, S.C.; Naughton, D.P. Biochem. Biophys. Res. Commun. 2004, 316, 48-51. 
459. Anipsitakis, G.; Dionysiou, D.D. Environ. Sci. Technol. 2004, 38, 3705-3712. 
460. Moriwaki, H.; Osborne, M.R.; Phillips, D.H. Toxicol. in Vitro 2008, 22, 36–44. 
461. Halliwell, B.; Gutteridge, J.M.C. FEBS 1992, 307, 108-112. 
462. Halliwell, B.; Gutteridge, J.M.C. Free Radicals in Biology and Medicine. Oxford University Press: 
Oxford; 2007.  
463. Sawyer, D.T.; Sobkowiak, A.; Matsushita, T. Acc. Chem. Res. 1996, 29, 409-416. 
464. Kremer, M.L. J. Inorg. Biochem. 2000, 78, 255–257. 
465. Halliwell, B.; Gutteridge, J.M.C. Arch. Biochem. Biophys. 1986, 246, 501-514. 
466. Halliwell, B.; Guttcridge, J.M.C. Arch. Biochem. Biophys. 1990, 280, 1-8. 
467. Pogozelski, W.K; Tullius, T.D. Chem.l Rev. 1998, 98, 1089-1107. 
468. Sinha, R.P.; Häder, D.-P. Photochem. Photobiol. Sci. 2002, 1, 225-236. 
469. Sambrook, J.; Russel, D.W. Molecular Cloning, A laboratory Manual; 3rd Ed. Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, New York, 2001; Vol. 1, pp 1.1-1.170. 
470. Villareal, V.; Zhang, Y.; Zurita, C.; Moran, J.;Silva, I.; Gomez, F.A. Anal.Lett. 2003, 36, 451–463.  
471. Stellwagen, N.C. Electrophoresis 2009, 30, S188-S195. 
472. Silverstein, R.M.; Webster, F.X. Spectrometric Identification of Organic Compounds, 6th Ed. John 
Wiley & Sons, Inc: USA; 1997; pp 144-216.  
473. Handbook of Spectroscopy. Gauglitz, G., Vo-Dinh, T., Eds.; WILEY-VCH Verlag GmbH & Co. KGaA: 
Weinheim; 2003; Vol. 1. 
 
 
339 
                                                                                                                                            
474. Pavia, D.L.; Lampman, G.M.; Kriz, G.S.; Vyvyan, J.A. Introduction to Spectroscopy, 4th Ed.; 
Brooks/Cole, Cengage Learning Publishers: Belmont, CA, USA; 2009; pp 381-417. 
475. Sutherland, J.C. In Modern Techniques for Circular Dichroism and Synchrotron Radiation Circular 
Dichrosim Spectroscopy. Wallace, B.A., Janes, R.W., Eds.; IOS Press: Amsterdam; 2009; Vol. 1, pp 19-
72. 
476. Kelly, S.M.; Price, N.C. Biochim. Biophys Acta 1997, 1338, 161-185. 
477. Kelly, S.M.; Jess, T.J; Price, N.C. Biochim. Biophys Acta 2005, 1751, 119-139. 
478. Bard, A.J.; Faukner, L.R. Electrochemical methods: Fundamentals and applications, 2nd Ed.; John 
Wiley & Sons, Inc: Republic of Singapore; 2001.  
479. Brett, C.M.A.; Brett, A.M.O. Electrochemistry: Principles, Methods, and Applications, Oxford 
University Press: Oxford; 1993. 
480. Wang, J. Analytical electrochemistry, 2nd Ed.; John Wiley & Sons, Inc: New York; 2001; pp 28-39. 
481. Christensen, P.A.; Hamnett, A. Techniques and Mechanisms in Electrochemistry. Blackie Academic 
& Professional, an imprint by Chapman & Hall: Glasgow; 1994; pp 55-66. 
482. O‟Dea, J.J.; Wojciechowski, M.; Osteryoung, J.G. Anal. Chem. 1985, 57, 954-955. 
483. Helfrick Jr, J.C.; Bottomley, L.A. Anal. Chem. 2009, 81, 9041–9047. 
484. Saran, M.; Summer, K.H. Free Rad. Res. 1999, 31, 429-436. 
485. Linxiang, L.; Abe, Y.; Nagasawa, Y.; Kudo, R.; Usui, N.; Imai, K.; Mashino, T.; Mochizuki, M.; Miyata, 
N.; Biomed. Chromatogr. 2004, 18, 470-474. 
486. Freinbichler, W.; Bianchi, L.; Colivicchi, M.A.; Ballini, C.; Tipton, K.F.; Linert, W.; Corte, L.D. J. Inorg. 
Biochem. 2008, 102, 1329-1333. 
487. Mason, T.J.; Lorimer, J.P.; Bates D.M.; Zhao Y. Ultrason. Sonochem. 1994, 1, S91-S95. 
488. Barreto, J.C.; Smith, G.S.; Strobel, N.H.; McQuillin, P.A.; Miller, T.A. Life Sci. 1995, 56, PL-89–PL-
96. 
489. Yan, E.B.; Unthank, J.K.; Castillo-Melendez, M.; Miller, S.L.; Langford, S.J.; Walker D.W. J. Appl. 
Physiol. 2005, 98, 2304–2310. 
490. Mishin, V.M.; Thomas, P.E. Biochem. Pharmacol. 2004, 68, 747–752. 
491. Dai, G.D.; Cui, L.B.; Song, L.; Zhao, R.Z.; Chen, J.F.; Wang, Y.B.; Chang, H.C.; Wang, X.R. Biomed. 
Environ. Sci. 2006, 19, 8–14. 
492. Montgomery, J.; Ste-Marie, L.; Boismenu, D.; Vachon, L. Free Rad. Biol. Med. 1995, 19, 927-933. 
493. Teismann, P.; Ferger, B.; Brain Res. Protoc. 2000, 5, 204-2010. 
494. Luo, H.; Lehotay, D. Clinic. Biochem. 1997, 30, 41-46. 
495. Lakowicz, J.R. Principles of Fluorescence Spectroscopy; 3rd Ed.; Springer, 2006; pp 1-60. 
496. Hore, P.J. Nuclear Magnetic Resonance Oxford University Press: Oxford; 1995. 
497. Roat-Malone, R.M. Bioinorganic chemistry. A Short Course, 2nd Ed.; John Wiley & Sons, Inc., 
Hoboken: New Jersey; 2007, 98-122.  
498. Lambert, J.B.; Mazzola, E. Nuclear Magnetic Resonance Spectroscopy: An Introduction to 
Principles, Applications, and Experimental Methods Pearson Education Ins.: New Jersey; 2004.  
499. Fisher, M.B.; Thompson, S.J.; Ribeiro, V.; Lechner, M.C.; Rettie, A. Arch. Biochem. Biophys. 1998, 
356, 63-70. 
500. Plasmid DNA Purification User Manual NucleoSpin® Plasmid 2009 Macherey-Nagel. 
501. Birnboim, H.C.; Doly, J. Nucl. Acids Res. 1979, 7, 1513-1523. 
502. Nigam, S. Validation of methods for measuring efficiency of inorganic nucleases, MSc Thesis 
(European Master in Quality in Analytical Laboratories), University of Algarve, Faro, 2011. 
503. Aureliano, M.; Gândara, R.M.C. J. Inorg. Biochem. 2005, 99, 979-985. 
504. Aureliano, M.; Crans, D.C. J. Inorg. Biochem. 2009, 103, 536-546. 
505. Mueller, S.; Riedel, H.-D.; Stremmel, W. Anal. Biochem. 1997, 245, 55–60. 
506. Slebodnick, C.; Pecorraro, V.; Inorg. Chi. Acta 1998 283, 37-43 
507. Sreedhara, A.; Freed, J.D.; Cowan, J.A. J. Am. Chem. Soc. 2000, 122, 8814–8824. 
508. Loganathan, R.; Ramakrishnan, S.; Suresh, E.; Riyasdeen, A.; Akbarsha, M.A.; Palaniandavar, M. 
Inorg Chem. 2012, 51, 5512-5532. 
509. Good, N.E; Winget, G.D.; Winter, W.; Connolly, T.N.; Izawa, S.; Sing, R.M.M. Biochem 1966, 5, 467-
477. 
510. Good, N.E.; Izawa, S. Meth. Enzymol. 1972, 24, 53-68. 
 
 
340 
                                                                                                                                            
511. Ferguson, W.J.; Braumschweiger, K.L.; Braumscheiger, W.R.; Smith, J.R.; McCormick, J.J.; 
Wasman, C.C.; Jarivis, N.P.; Bell, D.H.; Good, N.E. Anal. Biochem. 1980, 104, 300-310. 
512. Haveles, K.S.; Georgakilas, A.G.; Sideris, E.G.; Sophianopoulou, V. Int. J. Radiat. Biol. 2000, 76, 
51–59. 
513. Harris, W.R. Clinic. Chem. 1992, 38, 1809-1818. 
514. Buglyó, P.; Kiss, T.; Alberico, E.; Micera, G.; Dewaele, D. J. Coord. Chem. 1995, 36, 105–116. 
515. Kiss, T.; Kiss, E.; Garribba, E.; Sakurai, H. J. Inorg. Biochem. 2000, 80, 65–73. 
516. Veal, J.M.; Merchant, K.; Rill, R.L. Nucleic Acids Res. 1991, 19, 3383-3388. 
517. Fridovich, I. Meth. Enzymol. 1984, 105, 59-61.  
518. Ohno, Y.; Gallin, J.I. J. Biol. Chem. 1985, 260, 8438-8446. 
519. Szczepanik, W.; Kaczmarek, P.; Jezowska-Bojczuk, M. J. Inorg. Biochem. 2004, 98, 2141–2148. 
520. Liochev, S.I.; Fridovich, I. Arch. Biochem. Biophys. 1986, 250, 139-145. 
521. Liochev, S.I.; Fridovich, I. Arch. Biochem. Biophys. 1989, 275, 40-43.  
522. Liochev, S.I.; Fridovich, I. Arch. Biochem. Biophys. 1990, 279, 1-7. 
523. Liochev, S.I.; Fridovich, I. Arch. Biochem. Biophys. 1987, 255, 274-278. 
524. Carmichael, A.J. FEBS 1990, 261, 165-170. 
525. Rajendiran, V.; Karthik, R.; Palaniandavar, M.; Stoeckli-Evans, H.; Periasamy, V.S.; Akbarsha, M.A.; 
Srinag, B.S.; Krishnamurthy, H. Inorg. Chem. 2007, 46, 8208–8221. 
526. Bortolini, O; Conte, V. Mass Spectrom. Rev. 2006, 25, 724–740. 
527. Larson, J.W. J. Chem. Eng. Data 1995, 40, 1276-1280. 
528. Smith, J.A.S. Wilkins, E.J. J. Chem. Soc. 1966, 1749. 
529. Straganza, G.; Breckerb, L.; Weberb, H-J.; Steinera, W.; Ribbons D.W. Biochem. Biophys. Res. 
Comm. 2002, 297, 232-236. 
530. Crans, D.C.; Trujillo, A.M.; Pharazyn, P.S.; Cohen, M.D. Coord. Chem. Rev. 2011, 255, 2178-2192. 
